

CASE NUMBER: 034252/2022

EXHIBIT(S) - A (Motion #003) - Amended Verified Complaint 1-5-2023 (with exhibits)Document prepared for:
kevin barlow**CASE NAME**Rosemarie Mckinnis Est Of, Kathleen Mckinniss, Carin
Rosado, James Finn Est Of, Geraldine Finn Exr v. Ecohealth
Alliance Inc, Peter Daszak, Janet D Cottingham Aka, Janet
Dasz...**DOCUMENT FILED DATE**

Feb. 21st, 2023

CASE FILING DATE

Oct. 5th, 2022

COUNTY

Rockland county, NY

JUDGE

Sherri L Eisenpress

CATEGORY

Torts - Environmental (SARS-COV-2)

STATUS

Active

EXHIBIT A

SUPREME COURT OF THE STATE OF NEW YORK.
COUNTY OF ROCKLAND

-----X
IN RE SARS-CoV-2;

INDEX NO. 034252/2022

KATHLEEN MCKINNISS, PROPOSED REPRESENTATIVE OF
THE ESTATE OF ROSEMARIE MCKINNISS, DECEASED;
CARIN ROSADO, individually; GERALDINE FINN, AS
EXECUTOR OF THE ESTATE OF JAMES FINN, DECEASED;
DAVID CADDOD, EXECUTOR OF ESTATE OF PATRICIA
MARIE CADDOD, DECEASED; MELANIE SMITH,
EXECUTRIX OF ESTATE OF ROBERT SENDZISCHEW,
DECEASED; KIMBERLY J. LEWIS, EXECUTRIX OF ESTATE
OF ROBERT F. LEWIS, DECEASED; LISA PETER, PROPOSED
REPRESENTATIVE OF ESTATE OF PATRICIA A. CHISLETT,
DECEASED; and ROXANNE JONES, PROPOSED REPRESENTATIVE
OF ESTATE OF DALE JONES, DECEASED

**AMENDED
VERIFIED COMPLAINT
JURY TRIAL DEMANDED**

Plaintiffs,

-against-

ECOHEALTH ALLIANCE, INC., PETER DASZAK,
JANET D. COTTINGHAM a/k/a JANET DASZAK,
RALPH BARIC, WALTER IAN LIPKIN, and JOHN
AND JANE DOES 1-1000;

Defendants.
-----X

Plaintiffs, by and through their undersigned attorneys, respectfully allege as
follows:

I. INTRODUCTION

1. These are personal injury actions and tort claims against Defendants and their affiliates, subsidiaries, alter-egos, named and unnamed co-conspirators, and/or joint venturers who were responsible for creating, financing, designing, researching, developing, testing, manufacturing, and releasing SARS-CoV-2 into the environment, directly and proximately causing the Covid-19 pandemic and plaintiffs' injuries.

2. The above-identified Plaintiffs allege claims for negligence, strict liability, negligent failure to warn, intentional infliction of emotional distress, negligent infliction of emotional distress, assault and battery, medical monitoring fear of contracting illness, civil conspiracy, wrongful death, survival and breach of warranty.
3. The Covid-19 pandemic could have been avoided.
4. Plaintiffs allege Defendants caused the Covid 19 pandemic injuring them by engaging in *Gain of Function* (“**GOF**”) research and virus manipulation, whereby, a virus is transformed and genetically altered to become more transmissible and/or virulent to humans creating the SARS-CoV-2 virus that causes Covid 19.
5. Defendants alleged illegal acts caused for the **GOF** SARS-CoV-2 manipulated virus to be released into the environment directly and proximately causing Plaintiffs’ injuries.
6. Defendants engaged in dangerous **GOF** research despite a federal moratorium on such research, and ultimately exposed the world to a manipulated, highly transmissible and deadly lab-made virus and global pandemic, directly and proximately causing Plaintiffs’ injuries.
7. On March 13, 2020, then President Donald Trump stated: “In December 2019, a novel (new) coronavirus known as SARS-CoV-2 (‘the virus’) was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.” 85 Fed. Reg. 15337 (“Proclamation 9994”) (March 18, 2020).¹

¹ See also 85 Fed.Reg. 17060, 17062 (March 26, 2020) (“COVID-19 is a communicable disease caused by a novel (new) coronavirus, SARS-CoV-2, that was first identified as the cause of an outbreak of respiratory illness that began in Wuhan, Hubei Province, People’s Republic of China (China).” 85 Fed.Reg. 17335 (March 27, 2020) (“involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV). The virus is now named SARS-CoV-2, which causes the illness COVID-19.”).

8. In April 2020, President Trump proclaimed that SARS-CoV-2, also known as the Covid 19 virus, was released from a Level-4 Bio Safety Laboratory (“BSL-4”) in Wuhan, China.
9. This dangerous Covid 19 virus was manufactured by and through Defendants at the Wuhan Institute of Virology (“WIV”), at Level-2 (“BSL-2”) and Level-3 (“BSL-3”) Bio Safety Laboratories that were less secure than required by law.² See Exhibit “1” to Complaint (“Compl.”), *Photos of the Wuhan Institute of Virology*.
10. WIV’s failed safety and lax security, as well as its ties to the Chinese military, were well known to Defendants who disregarded the risks of **GOF** work it was subcontracting to WIV in violation of federal law.
11. Defendants disregarded WIV failed safety and lax security, and created the SARS-CoV-2 virus at the WIV that directly and proximately injured Plaintiffs.
12. Since the release of the **GOF** SARS-CoV-2 virus into the environment, Defendants thereafter engaged in a cover-up with respect to the origins of SARS-CoV-2, impeding effective countermeasures and strategies to control the release, mutation, and spread of SARS-CoV-2, that directly and proximately caused Plaintiffs’ injuries.
13. The mounting credible evidence showing that SARS-CoV-2 had escaped from WIV was initially denigrated as a baseless conspiracy theory through the concerted, intentional actions of the Defendants.
14. Today, much of the scientific community accepts the “lab leak” theory origin of SARS-CoV-2.

² See, e.g., **Error! Main Document Only.** “An Analysis of the Origins of the COVID-19 Pandemic, Interim Report”, October, 2022 Senate Committee on Health Education, Labor and Pensions, Minority Oversight Staff: https://www.help.senate.gov/imo/media/doc/report_an_analysis_of_the_origins_of_covid-19_102722.pdf

15. An October, 2022, Interim Report issued by the US Senate Minority Oversight Staff the report concluded it was now “more likely than not” that the Covid-19 pandemic was “the result of a research-related incident.”³ See Exhibit “13” to Compl.: The U.S. Senate Minority Interim Report “*An Analysis of the Origins of the Covid-10 Pandemic*,” Senate Committee on Health Education, Labor and Pensions Minority Oversight Staff, October 2022.
16. Plaintiffs allege the above-mentioned “research-related incident” was the caused by Defendants’ illegal acts at the WIV, and directly and proximately caused Plaintiffs’ injuries.
17. Defendants **GOF** SARS-CoV-2 virus was designed and created at WIV, made possible through the research, development, and funding support by the named Defendants, acting individually and in concert.
18. Each Plaintiff, or the Decedent they represent, named herein, was exposed to SARS-CoV-2 and suffered injuries and/or death.
19. SARS-CoV-2 is an abnormally dangerous, genetically manipulated coronavirus that was financed, designed, manufactured and released into the environment by the Defendants through their carelessness and reckless subcontracting to WIV, directly and proximately causing Plaintiffs’ injuries.

II. CPLR ARTICLE 16

20. If it is deemed by this Court that Article 16 of the CPLR applies to this action, the Plaintiffs assert this action falls within one or more of the exceptions set forth in CPLR § 1602

³ **Error! Main Document Only.** “An Analysis of the Origins of the COVID-19 Pandemic, Interim Report”, October 2022 Senate Committee on Health Education, Labor and Pensions, Minority Oversight Staff: https://www.help.senate.gov/imo/media/doc/report_an_analysis_of_the_origins_of_covid-19_102722.pdf, at 26.

including, but not limited to, the exception for cases where a person is held liable for causing the claimant's injury by having acted with reckless disregard for the safety of others [CPLR § 1602(7)]; the exception for cases involving any person held liable for causing claimant's injury by having unlawfully released into the environment a substance ultra-hazardous to public health, safety or the environment [CPLR § 1602(9)]; the exception for any parties found to have acted knowingly or intentionally and in concert to cause the acts or failures upon which liability is based [CPLR § 1602(11)]; the exception based upon Defendants' non-delegable duty to warn of the health hazards of genetically manipulated viruses [CPLR § 1602(2)(iv)]; and the exception for persons held liable in a product liability action where the manufacturer of the product is not a party to the action and jurisdiction over the manufacturer could not with due diligence be obtained [CPLR § 1602(10)].

III. PARTIES

A. PLAINTIFFS

1. Kathleen McKinniss, on behalf of the Estate of Rosemarie McKinniss, Deceased

21. Plaintiff Kathleen McKinniss ("Plaintiff McKinniss") is a resident of Worthington, Ohio, County of Franklin, and is the surviving daughter and former caregiver of Rosemarie McKinniss, a decedent who was killed as a result of the SARS-CoV-2 virus.
22. Rosemarie McKinniss was infected with SARS-CoV-2 while in a nursing home in Franklin County, Ohio, and died from exposure to SARS-CoV-2 on April 24, 2020 at the age of 85.
23. Plaintiff Kathleen McKinniss is pending an appointment as the personal representative of the Estate of Rosemarie McKinniss by the State of Ohio.

24. Plaintiff Kathleen McKinniss brings this action on her own behalf, on behalf of the Estate of Rosemarie McKinniss, and on behalf of all heirs of Rosemarie McKinniss, in their own right and in their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

2. *Carin Rosado*

25. Plaintiff Carin Rosado (“Plaintiff Rosado”) is a resident of Rocky Point, New York, County of Suffolk, and suffered injuries alleged in this Complaint as a direct and proximate result of the Defendants’ individual, and collective, unlawful and tortious conduct.
26. Plaintiff Rosado was a front-line worker with the NYC Fire Department (FDNY) as an emergency medical technician (EMT) and deemed to be an essential worker required to work during the early stages of Covid 19, when its consequences were then unknown.
27. Plaintiff Rosado brings this action on her own behalf to recover damages personal to her.

3. *Geraldine Finn, on behalf of the Estate of James Finn, Deceased*

28. Plaintiff Geraldine Finn (“Plaintiff Finn”) resides in New York, County of Rockland, and is the surviving spouse of Decedent James Finn, who died at Montefiore Nyack Hospital on April 18, 2021, at the age of 90 as a result of the exposure to SARS-CoV-2 virus as a direct and proximate result of Defendants’ unlawful and tortious conduct.
29. Plaintiff Finn was appointed the Executor of the Estate James Finn.
30. Plaintiff Finn brings this action on her own behalf, on behalf of the Estate of James Finn, and on behalf of all heirs of James Finn, and in their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified Amended Complaint.

4. *David Caddoo, on behalf of Estate of Patricia Marie Caddoo, Deceased*

31. Plaintiff David Caddoo (“Plaintiff Caddoo”) is a resident of Lewisville, Texas, and the son of Patricia Marie Caddoo, a decedent who was killed as a result of the SARS-CoV-2 virus at the age of 85.
32. Patricia Marie Caddoo died at a nursing home in Lewisville, Texas, on December 9, 2020, as a result of exposure to SARS CoV-2 and as a direct and proximate result of Defendants’ unlawful and tortious conduct.
33. The Estate of Patricia Marie Caddoo is being administered in Denton County, Texas. Plaintiff Caddoo brings this action on his own behalf, on behalf of the Estate of Patricia Marie Caddoo, and on behalf of all heirs of Patricia Marie Caddoo in their own right and in their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

5. *Melanie Smith, on behalf of Estate of Robert Sendzischew, Deceased*

34. Plaintiff Melanie Smith (“Plaintiff Smith”) resides in Valley Village, California, and is the surviving wife of Robert Sendzischew, and the Executrix of the Estate of Robert Sendzischew, who died at the age of 48 at a long-term rehabilitation facility named Five Towns Premier Rehabilitation and Nursing Center in Nassau, New York on December 13, 2021, as a result of exposure to SARS CoV-2 and as a direct and proximate result of Defendants’ unlawful and tortious conduct.
35. Plaintiff Smith is pending an appointment as the personal representative of the Estate of Robert Sendzischew being administered in Nassau County, New York.
36. Plaintiff Smith brings this action on her own behalf and on behalf of the Estate of Robert Sendzischew and on behalf of all heirs of Robert Sendzischew in their own right and in

their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

6. Kimberly J. Lewis, on behalf of Estate of Robert F. Lewis, Deceased

37. Plaintiff Kimberly J. Lewis (“Plaintiff Lewis”) resides in Alden, New York, and is the surviving wife of Robert F. Lewis, who was hospitalized on December 28, 2021 as a result of COVID 19 at Mercy Hospital in Buffalo, New York, and died at the age of 60 on January 15, 2022 as a result of exposure to SARS CoV-2 and as a direct and proximate result of Defendants’ unlawful and tortious conduct.
38. Plaintiff Lewis is pending an appointment as the personal representative of the Estate of Robert F. Lewis being administered in Erie County, New York, and brings this action on her own behalf and on behalf of the Estate of Robert F. Lewis and on behalf of all heirs of Robert Lewis in their own right and in their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

7. Lisa Peter, on Behalf of the Estate of Patricia A. Chislett, Deceased

39. Plaintiff Lisa Peter (“Plaintiff Peter”) is a resident of East Aurora, New York and the daughter of Patricia A. Chislett, who was hospitalized as a result of COVID 19 at Sisters of Charity Hospital in Buffalo, New York, on November 24, 2021 and died on December 18, 2021, at the age of 75, as a result of exposure to SARS CoV-2 and as a direct and proximate result of Defendants’ unlawful and tortious conduct.
40. Plaintiff Peter is pending an appointment as the personal representative of the Estate of Patricia A. Chislett, being administered in Erie County, New York.
41. Plaintiff Peter brings this action on her own behalf and on behalf of the Estate of Patricia A. Chislett and on behalf of all heirs of Patricia A. Chislett in their own right and in their

capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

8. *Roxanne Jones, on behalf of the Estate of Dale Jones, Deceased*

42. Plaintiff Roxanne Jones (“Plaintiff Jones”) is a resident of Cheektowaga, New York and the surviving spouse of Dale Jones, who was hospitalized as a result of COVID 19 at Mercy Hospital in South Buffalo, New York, on July 30, 2021 and died on September 2, 2021, at the age of 62, as a result of exposure to SARS CoV-2 and as a direct and proximate result of Defendants’ unlawful and tortious conduct.
43. Plaintiff Jones is pending an appointment as the personal representative of the Estate of Dale Jones being administered in Erie County, New York.
44. Plaintiff Jones brings this action on her own behalf and on behalf of the Estate of Dale Jones and on behalf of all heirs of Dale Jones in their own right and in their capacities as beneficiaries of the Wrongful Death, Survival, and other claims pled in this Verified First Amended Complaint.

B. DEFENDANTS

1. *Defendant EcoHealth Alliance*

45. Defendant ECOHEALTH ALLIANCE, Inc. (“Defendant EcoHealth”) is a 501 (c)(3), non-governmental organization, with a street address of 520 8th Avenue, Ste. 1200, New York, NY 10018, registered in New York State as a foreign not-for-profit corporation, and is authorized to transact business in New York State as a “global environmental health nonprofit corporation.” Its principal place of business is in the City of New York, County of New York.

46. Upon information and belief, Defendant EcoHealth, formerly “Wildlife Trust,” was initially organized under the laws of the Commonwealth of Massachusetts on or about July 20, 2000, and registered by Application for Authority with the State of New York, as a foreign corporation filed with the Department of State on or about July 27, 2000.
47. Defendant EcoHealth, through the above-captioned Defendants, and named and unnamed co-conspirators, has engaged in the oversight, direction, control, funding, research and development, and manufacture of the genetically modified coronavirus, a.k.a., SARS-CoV-2 virus using **GOF** and other techniques, with full knowledge of its abnormally dangerous propensities and lethality, directly and proximately causing Plaintiffs’ damages from the release of their lab-made, ultra-hazardous SARS-CoV-2 virus into the environment.
48. Defendant EcoHealth expected or should have expected their acts to have consequences within each of the States and Territories of the United States.

2. Defendant Peter Daszak

49. Defendant PETER DASZAK is the President of Defendant EcoHealth, transacts business in the State of New York, resides in Suffern, New York, County of Rockland, and owns real property there. Pursuant to CPLR § 503(c), venue in Rockland County is appropriate.
50. Upon information and belief, Defendant Peter Daszak holds a doctorate in infectious diseases awarded in the United Kingdom.
51. Defendant Peter Daszak receives a salary for his work and is not subject to the protections of Not-for-Profit Corporations Law § 720-a and the pleading requirements of CPLR § 3016(h).

52. At all times relevant, Defendant Daszak, individually, and acting in concert with the other above-captioned Defendants, known and unknown co-conspirators, engaged in the oversight, direction, control, funding, research, development and creation of the genetically modified coronavirus using **GOF** and other techniques, resulting in the SARS-CoV-2 global pandemic, directly and proximately causing Plaintiffs' injuries and Decedents' deaths.
53. At all times relevant, Defendant Daszak engaged in a cover-up with the other named Defendant co-conspirators to conceal the origins of SARS-CoV-2, to mislead the public and health officials as to the origin of SARS-CoV-2, and the lethality, virulence and transmissibility of the ultra-hazardous lab-made virus released by Defendant Daszak into the environment.
54. Defendant Peter Daszak expected or should have expected his acts to have consequences within each of the States and Territories of the United States.

3. Defendant Janet D. Cottingham-Daszak

55. Defendant JANET D. COTTINGHAM, also known as JANET DASZAK, ("Cottingham- Daszak") is an immunologist, and the wife of Defendant Peter Daszak.
56. Defendant Cottingham- Daszak was and is providing input, advice and service to Defendant EcoHealth, that transacts business in the State of New York with her co-defendant husband PETER DASZAK, both of whom reside in Suffern, New York, County of Rockland, where they own real property. Pursuant to CPLR § 503(c), venue in Rockland County is appropriate.
57. Upon information and belief, Defendant Cottingham- Daszak works along with Daszak to aid and abet his goals, including the cover up of the cause and origin of the SARS-CoV-2

- virus and the COVID-19 pandemic, while handsomely profiting economically and in professional reputational respect, etc.
58. Upon information and belief, by, amongst other things, Defendant Cottingham provided input, advice and support to Eco Health and Daszak, by aiding in seeking and securing the subject federal research grants, performing research, monitoring grant applications, monitoring receipt and expenditure of funds, and improperly monitoring and supervising grant activities and compliance.
59. Upon information and belief, Defendant Cottingham aided and abetted Daszak and EcoHealth Alliance's acts and omissions in securing grants under false pretenses; in creating, making, engineering and altering coronaviruses, including SARS-CoV-2; in making and covering up falsehoods and fraud; in failing to maintain proper biosafety and biosecurity with respect to their subject coronavirus experimentation; in failing to comply with grant restrictions, limitations, terms, and conditions; in failing to properly monitor and supervise the Wuhan Lab concerning the subject coronavirus experimentation; in failing to safeguard and secure SARS-CoV-2, and, inter alia, in causing and originating the COVID-19 pandemic.
60. At all times relevant, Defendant Cottingham-Daszak, along with her husband Peter Daszak and Eco Health Alliance engaged in a cover-up of the origins of SARS-CoV-2 to mislead the public and health officials, as to her alleged role in the origin of SARS-CoV-2, and the lethality, virulence and transmissibility of the ultra-hazardous lab-made virus released into the environment by Defendants.
61. Defendant Cottingham-Daszak expected or should have expected her acts to have consequences within each of the States and Territories of the United States.

4. *Defendant Ralph Baric*

62. Defendant RALPH BARIC (“Baric”) is a Professor in the Department of Epidemiology and the Department of Microbiology and Immunology at the University of North Carolina, Chapel Hill, North Carolina.
63. At all times relevant, Defendant Baric, individually and acting in concert with the other above-captioned Defendants, and now unknown co-conspirators, engaged in the oversight, direction, control, research, development and creation of the genetically modified coronavirus, resulting in the SARS-CoV-2 global pandemic and Plaintiffs’ and their Decedents’ injuries and/or deaths.⁴
64. Defendant Baric expected or should have expected his acts to have consequences within each of the States and Territories of the United States.

5. *Defendant Walter Ian Lipkin*

65. Defendant WALTER IAN LIPKIN (“Lipkin”) is the John Snow Professor of Epidemiology at the Mailman School of Public Health at Columbia University, with his principal place of employment and business in the State of New York. He lives and works in the State of New York.
66. Defendant Lipkin was listed as a member of EcoHealth’s advisory board from 2012 to 2014.
67. Defendant Lipkin has co-authored at least 15 scientific papers with Defendant Daszak between 2010 and 2020:

(a) “Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (*Pteropus giganteus*) in Bangladesh.”

⁴ **Error! Main Document Only.** “The Origins of COVID-19: An Investigation of The Wuhan Institute of Virology,” August, 2021 Report of House Foreign Affairs Committee Report Minority Staff: <https://gop-foreignaffairs.house.gov/wp-content/uploads/2021/08/ORIGINS-OF-COVID-19-REPORT.pdf> (accessed 12/30/2022).

- (b) “Zoonotic viruses associated with illegally imported wildlife products.”
 - (c) “The search for meaning in virus discovery.”
 - (d) “Prediction and prevention of the next pandemic zoonosis.”
 - (e) “Ebola virus antibodies in fruit bats, Bangladesh.”
 - (f) “Bats are a major natural reservoir for hepaciviruses and pegiviruses.”
 - (g) “Identification of a novel cetacean polyomavirus from a common dolphin (*Delphinus delphis*) with Tracheobronchitis.”
 - (h) “A strategy to estimate unknown viral diversity in mammals.”
 - (i) “Middle East respiratory syndrome coronavirus in bats, Saudi Arabia.”
 - (j) “Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia.”
 - (k) “Middle East respiratory syndrome coronavirus quasi species that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia.”
 - (l) “Reply to ‘Concerns about misinterpretation of recent scientific data implicating dromedary camels in epidemiology of Middle East respiratory syndrome (MERS)’”.
 - (m) “Non-random patterns in viral diversity.”
 - (n) “Viral Diversity, Prey Preference, and Bartonella Prevalence in *Desmodus rotundus* in Guatemala.”
 - (o) “Nipah virus dynamics in bats and implications for spillover to humans” (edited by Dr. Anthony Fauci).
68. In early 2020, certain media sources were reporting the conclusions of other specialists suggesting that WIV had created the coronavirus and it had escaped from that facility, either by accident or design.
69. In April of 2020, for his own interest and to assist the other named Defendants, Defendant Lipkin and several others published an article titled “The Proximal Origin of SARS-CoV-

2” in an effort to conceal his involvement in the creation SARS-CoV-2 to convince the public that the coronavirus had natural origins, stating in relevant part: “Although the evidence shows that SARSCoV-2 is not a purposefully manipulated virus, it is currently impossible to prove or disprove the other theories of its origin described here. However, since we observed all notable SARS-CoV-2 features, including the optimized RBD and polybasic cleavage site, in related coronaviruses in nature, we do not believe that any type of laboratory-based scenario is plausible.”⁵

70. At all times relevant, Defendant Lipkin engaged in a cover-up of the origins of SARS-CoV-2 to mislead the public and health officials as the origin of SARS-CoV-2, and the lethality, virulence and transmissibility of the lab-made virus released into the environment by Defendants.
71. Defendant Lipkin knew the origins of SARS-Cov-2 was manmade, and he later admitted to having knowledge that SARS-Cov-2 was manmade after publishing the misleading Proximal Origins to conceal the “lab leak” theory.
72. Defendant Lipkin expected or should have expected his acts to have consequences within each of the States and Territories of the United States.

6. Unidentified Defendants John Does/Jane Does 1-1000

73. Defendants JOHN DOES/JANE DOES 1-1000 are those persons, agents, employees, representatives, affiliates, subsidiaries, alter-egos, joint venturers, and/or other unnamed co-conspirators of the Defendants whose conduct described herein caused or contributed to the damages of Plaintiffs, all of whose names and legal identities are unknown to

⁵ **Error! Main Document Only.** Andersen, K.G., Rambaut, A., Lipkin, W.I. *et al.* The proximal origin of SARS-CoV-2. *Nat Med* 26, 450–452 (2020). <https://doi.org/10.1038/s41591-020-0820-9>

Plaintiffs at this time, but will be substituted by amendment when ascertained, individually and jointly.

74. Defendants Unknown Individuals, Businesses and/or Corporations 1-1000 are unknown entities whose conduct as described herein caused or contributed to the damages of Plaintiffs, all of whose names and legal identities are unknown to Plaintiffs at this time, but will be substituted by amendment when ascertained, individually and jointly.

IV. JURISDICTION AND VENUE

75. Pursuant to CPLR § 301, the Supreme Court of the State of New York may properly exercise jurisdiction over Defendants EcoHealth, Peter Daszak, Cottingham-Daszak, Lipkin, and any unknown John Doe/Jane Doe Defendants, given that at all relevant times they resided, were formed, and/or maintained the principal places of business within the State of New York.
76. Pursuant of CPLR § 302(a), the Supreme Court of the State of New York may properly exercise jurisdiction over any parties that may be a non-domiciliary of the State of New York given that at all relevant times, they committed dangerous and/or tortious acts within the State of New York; or alternatively they committed dangerous and/or tortious acts outside the State of New York, causing damages sustained by Plaintiffs within the State; and/or they regularly transact business within the state or contract anywhere to supply goods or services in the state; and/or they possess real property in New York State.
77. Defendants Peter Daszak and Cottingham-Daszak own, use and possess real property in New York State, and, upon information and belief, Defendant EcoHealth uses and possesses real property in New York State.

78. Defendants regularly solicited business, engaged in other persistent courses of conduct, derived substantial revenue from services rendered in the State of New York, derived substantial revenue from interstate commerce, derived substantial revenue from international commerce, and expect and/or should reasonably expect that their improper acts would have consequences in the State of New York.
79. Pursuant of CPLR §503 (a), venue is properly fixed in the Supreme Court, Rockland County as it is the County in where a substantial part of the events or omissions giving rise to Plaintiffs' claims occurred and it is the domiciliary residence of Defendants Daszak and Cottingham-Daszak and Plaintiff Geraldine Finn.

V. FACTUAL ALLEGATIONS

A. Background on Gain of Function Research

80. The United States Government describes **GOF** as follows:

“Gain of function” refers to any modification of a biological agent that confers new or enhanced activity. Typically, researchers mutate or alter genes and examine the impact of these modifications on a particular property or trait of the organism. For example, some investigators can modify influenza viruses in ways that enhance pathogenicity and/or transmissibility in order to better understand the origins and nature of these traits at the molecular level, as well as their pathogenesis in susceptible hosts. Since influenza viruses constantly evolve in nature, these gain-of-function studies may help predict whether these viruses could evolve naturally over time to acquire these new or enhanced traits, and if so, how the viruses might affect hosts and the kinds of medical countermeasures that might be most effective. **Some gain-of-function studies may entail biosafety and biosecurity risks that require unique risk assessment and mitigation measures.**⁶ (Emphasis added).

⁶ US Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), November 2014 Report, *U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses*, “Frequently Asked Questions.” <https://www.phe.gov/s3/dualuse/Documents/GOF-qanda.pdf>.

81. A chimera, or chimeric virus, is a virus that contains genetic material from two or more distinct viruses.
82. Chimeric viruses have been considered potential bioweapons with increased lethality that can result from combining pathogens in a lab. See Exhibit “14” to Compl., *Answering Crucial Questions About Sars-CoV-2*, authors Thomas Renz, attorney at law and Pamela A. Popper, *Make Americans Free Again*, dated September 12, 2022 at pg. 10, 41, 55.
83. **GOF** research is controversial due to the risk that a mutated virus might develop and/or be released, causing harm of immeasurable proportions. *Id.* at 8.

B. The Scientific Community Knew GOF Research Was Abnormally Dangerous

84. In 2012, Dutch scientist Ron Fouchier conducted **GOF** experiments designed to make a highly lethal avian influenza virus, H5N1, more transmissible. After several attempts, the team was successful. Live ferrets were used and H5N1 acquired mutations resulting from serial passage in ferrets. The result: lab created H5N1 was transmissible between mammals without requiring recombination in an intermediate host.
85. H5NI “gained” this “function” described above alarming Government Officials and Scientists, which led to the 2014 **GOF** moratorium that paused **GOF** research involving influenza, SARS, and MERS until a new regulatory framework could be developed. *Id.* at pg. 8.

C. EcoHealth’s Background and Mission

86. Defendant EcoHealth, formerly Wildlife Trust, is a nonprofit organization that at one time focused on wildlife conservation and matters like habitat loss, pollution, and environmental issues. In 2010, EcoHealth rebranded itself to focus on “global health,” and the relationships between ecosystems and animal and human health.”

87. EcoHealth purports to be “dedicated to protecting wildlife and public health from the emergence of disease.”⁷ “Building on over 45+ years of groundbreaking science, EcoHealth Alliance is a global environmental health nonprofit organization dedicated to protecting wildlife and public health from the emergence of disease.”⁸
88. On its website, Defendant EcoHealth lists many partners, including the U.S. Centers for Disease Control and Prevention (“CDC”); the NIH; the New York City Department of Health; University of California, Davis; University of Pittsburgh, School of Public Health; Columbia University; Princeton University; Johns Hopkins, Bloomberg School of Public Health; and Johnson & Johnson, among others.
89. The Vice Chair of Defendant EcoHealth’s Board of Directors, Carlota Vollhardt, previously “held positions of increasing responsibility at Pfizer Inc. in global talent, organizational development, and knowledge management as part of the R&D, commercial and corporate divisions.”⁹
90. Starting in 2008, Defendant EcoHealth received funding specifically related to **GOF** research from two U.S. government sources: the U.S. Agency for International Development (“USAID”) through a 5-year program called “PREDICT,” and the National Institutes of Health (“NIH”).
91. Defendant EcoHealth also received grants from the National Institute of Allergy and Infectious Diseases (“NIAID”), including a \$3.7 million grant in 2014 entitled, “Understanding the Risk of Bat Coronavirus Emergence.”^{10,11} The grant “proposed to

⁷ <https://www.ecohealthalliance.org/about> (accessed 12.16.22).

⁸ *Id.* (accessed 12.16.22).

⁹ <https://www.ecohealthalliance.org/2016/12/carlota-vollhardt-board-directors> (accessed 12.16.22); <https://www.ecohealthalliance.org/board-of-directors> (accessed 12.16.22).

¹⁰ https://www.usaspending.gov/award/ASST_NON_R01AI110964_7529

¹¹ <https://www.vanityfair.com/news/2022/03/the-virus-hunting-nonprofit-at-the-center-of-the-lab-leak-controversy> (accessed 12.16.22).

- screen wild and captive bats in China, analyze sequences in the laboratory to gauge the risk of bat viruses infecting humans, and build predictive models to examine future risk.”¹²
92. The USAID’s “PREDICT” was “[a]n epidemiological research grant program funded by the [USAID]. PREDICT provided funding for biological sampling aimed at virus identification and collection. The program provided grant funding to EcoHealth Alliance.”¹³
93. During an interview on December 19, 2019, Defendant Daszak stated that SARS likely originated from bats, which prompted researchers to find more SARS-related coronaviruses. Eventually, over one hundred were found.¹⁴
94. In the same interview, Defendant Daszak reported that some coronaviruses can “get into human cells in the lab,” and others can cause SARS disease in “humanized mouse models.” He warned that such coronaviruses are “untreatable with therapeutic monoclonals [antibodies] and you can’t vaccinate against them with a vaccine.”
95. Defendant Daszak claimed that his team’s goal was trying to find the next “spillover event” that could cause the next pandemic.
96. At the 29:54 mark of the video recording, Defendant Daszak is asked what can be done to deal with coronaviruses given that there are no therapeutics or vaccines for them.
97. Defendant Daszak discusses that the goal of his **GOF** (gain-of-function) research was to develop a universal vaccine that could be used for many different types of coronaviruses.

¹² *Id.*

¹³ **Error! Main Document Only.** “The Origins of COVID-19: An Investigation of The Wuhan Institute of Virology,” August 2021 Report of House Foreign Affairs Committee Report Minority Staff: <https://gop-foreignaffairs.house.gov/wp-content/uploads/2021/08/ORIGINS-OF-COVID-19-REPORT.pdf>

¹⁴ Keoni Everington. WHO inspector caught on camera revealing coronavirus manipulation in Wuhan before pandemic. Taiwan News Jan 18, 2021. <https://www.taiwannews.com.tw/en/news/4104828> (accessed 12.16.2022).

98. Referring specifically to bat coronaviruses, Defendant Daszak said, “[y]ou can manipulate them in the lab pretty easily.” He then mentioned the most unique characteristic of SARS-CoV-2 (which had not yet been named at the time of this podcast), the spike protein, and stated “[s]pike protein drives a lot of what happens with the coronavirus, zoonotic risk.”
99. Defendant Daszak also talked about inserting the spike protein “into a backbone of another virus” and then doing “some work in the lab.”
100. Defendant Daszak further acknowledged collaboration with Defendant Baric: “and we work with Ralph Baric at UNC [University of North Carolina] to do this.”
101. Defendant Daszak also admitted the creation of chimeras in order to investigate vaccines: “Now, the logical progression for vaccines is, if you are going to develop a vaccine for SARS, people are going to use pandemic SARS, but let’s try to insert these other related diseases and get a better vaccine.”¹⁵
102. Defendant EcoHealth collaborated with a consortium of entities and named and unnamed co-conspirators to study SARS-related coronaviruses in humans. One of these entities was the subcontractor Wuhan Institute of Virology (“WIV”).¹⁶

D. The Wuhan Institute of Virology (“WIV”)

103. The WIV was founded in 1956 as the Wuhan Microbiology Laboratory and has operated under the administration of the Chinese Academy of Sciences since 1978.
104. The WIV hosts labs ranging from BSL-2 to BSL-4, which is the highest level of biosafety containment. According to HHS:

¹⁵ *Id.*

¹⁶ *An Analysis of the Origins of the COVID-19 Pandemic, Interim Report*, October 2022 Senate Committee on Health Education, Labor and Pensions, Minority Oversight Staff: https://www.help.senate.gov/imo/media/doc/report_an_analysis_of_the_origins_of_covid-19_102722.pdf at 15.

Biosafety Level 4 is required for work with dangerous and exotic agents that pose a high individual risk of aerosol-transmitted laboratory infections and life-threatening disease that is frequently fatal, for which there are no vaccines or treatments, or a related agent with unknown risk of transmission.

105. The Wuhan National Biosafety Laboratory (“WNBL”), along with WIV Headquarters, are two of the WIV’s campuses. WNBL’s BSL-4 space did not become operational until early 2018.
106. The WIV was a key collaborator of Defendant EcoHealth and received approximately \$600,000 in subawards from them.¹⁷
107. WIV and Defendant EcoHealth sought to collaborate on the Defense Advanced Research Projects Agency’s (“DARPA”) “Project DEFUSE” to “search for SARS-related coronaviruses with potential to bind to human ACE2 receptors and that have naturally-occurring furin cleavage sites in Yunnan Province, China.”
108. Defendant EcoHealth’s made a funding request to DARPA that was declined.

1. Background and Purpose of WIV BSL-4 Labs

109. BSL-4 labs are used for research with dangerous agents and substances.
110. The WIV BSL-4 lab at issue in this matter was developed by the People’s Republic of China (“PRC”) in partnership with France following the 2003 SARS pandemic.
111. Almost immediately after the project was undertaken, French officials expressed discomfort because it was suspected that the PRC had an ongoing biological warfare program, and the BSL-4 lab might be used for the purpose of developing biological weapons.

¹⁷ Eban, Katherine. “‘This Shouldn’t Happen’: Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy.” *Vanity Fair*, 31 Mar. 2022, <https://www.vanityfair.com/news/2022/03/the-virus-hunting-nonprofit-at-the-center-of-the-lab-leak-controversy>.

112. To mitigate the concern of French Researchers, the parties agreed that all PRC/French research projects would be conducted under the supervision of French researchers on site at the lab, but this did not resolve the concerns.

2. Shi Zheng-Li's Research and Collaboration with EcoHealth, Daszak, Baric, and DARPA

113. The WIV is headed by Dr. Shi Zheng-Li, who is known as China's "Bat Woman" because she has spent a significant portion of her career collecting and studying bat viruses, ostensibly to facilitate the development of effective vaccines.¹⁸
114. Dr. Shi's colleagues include scientists and physicians who have close ties to both the political and military leadership of the PRC. An example is Guo Deyin, who has conducted research on AIDS and hepatitis vaccines, as well as genetic recombination methods.
115. Dr. Shi's lab at WIV is/was unencumbered by any **GOF** restrictions, and **GOF** continued at the WIV while the U.S. moratorium existed.
116. Dr. Shi and her colleagues researched how spike proteins in both natural and chimeric SARS-like viruses bind to the ACE2 receptors in the cells of humans, bats, and animals.¹⁹
117. In a 2010 paper, Dr. Shi and her colleagues reported the results of their research on angiotensin-converting enzyme II (ACE2) protein, which is a known SARS-CoV receptor.
118. Dr. Shi's group looked at ACE2 molecules from seven bat species and tested the interaction of the ACE2 receptor with the human SARS-CoV spike protein. They used HIV-based pseudo type and live SARS-CoV infection assays.

¹⁸ Qiu, Jane. "How China's 'Bat Woman' Hunted down Viruses from SARS to the New Coronavirus." *Scientific American*, Scientific American, 1 June 2020, <https://www.scientificamerican.com/article/how-chinas-bat-woman-hunted-down-viruses-from-sars-to-the-new-coronavirus1/>.

¹⁹ See, e.g., Ren W, Qu X, Wendong L et al. "Difference in Receptor Usage between Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-Like Coronavirus of Bat Origin." *J Virol* 2008 Feb;82(4):1899-1907.

119. Spike proteins are structures that allow coronaviruses to bind to the receptor sites on human cells.
120. The researchers found that the ACE2s of two bat species – *Myotis daubentoni* and *Rhinolophus sinicus* – were susceptible to SARS-CoV and might be candidates as the natural host of the SARS-CoV progenitor viruses.²⁰
121. Dr. Shi was also a member of the research team that was involved in the controversial **GOF** research financed by the NIH and Defendant EcoHealth and conducted in partnership with a research team led by Defendant Baric at the University of North Carolina Chapel Hill.
122. In a paper published in 2015 in *Nature Medicine*, the research was characterized a chimeric virus with the spike protein SHC014 that was able to use multiple genes of the SARS receptor human angiotensin-converting enzyme II (ACE2) and “replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-Cov.”
123. In other words, this virus could infect humans and quickly replicate. The article specifically stated, “... we synthetically re-derived an infectious full-length SHC014 recombinant virus and demonstrate robust viral replication both *in vitro* and *in vivo*.”²¹
124. The team also reported replication of the chimeric virus in the lungs of mice.
125. Most important, Defendants knew therapies typically used to treat SARS patients were found to be ineffective for treating the chimeric virus and vaccines did not prevent “infection with CoVs using the novel spike protein.”²²

²⁰ Hou Y, Peng C, Yu M et al. “Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry.” *Arch Virol* 2010 Oct;155(10):1563-1569.

²¹ Menachery VD, Yount BL, Debbink K et al. “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.” *Nat Med* 2015 Nov; 21:1508-1513.

²² *Id.*

126. Dr. Shi further conducted research on a virus called “WIV1” with clones of spike proteins and then tested the creation in humanized mice. The viruses quickly replicated, and the mice showed signs of severe pathogenesis.
127. A peer-reviewed article reporting the results of this research listed Defendant Peter Daszak as a co-author.²³
128. This work was especially risky as WIV1 was already known to be potentially dangerous to humans. Defendant Baric had made this clear in an article titled “SARS-Like WIV1-CoV Poised for Human Emergence.”²⁴
129. Researchers at the WIV, in partnership and collaboration with U.S. scientists including Defendants EcoHealth, Daszak, Baric, and others, were conducting dangerous research on bat viruses, and admitted they were successful on at least one occasion in developing a virus that could infect humans and was resistant to treatment and/or prevention with vaccination.
130. In an e-mail to NIAID, Defendant Daszak listed several “Senior/Key Personnel” involved in his projects, including Defendant Baric and Dr. Shi Zhengli, along with several other scientists at WIV.²⁵
131. According to the October 2022 Senate Interim Report:

WIV researchers and their collaborators undertook large scale virus collection expeditions to Southern China and Southeast Asia, where bats naturally harbor SARS-related viruses, on an annual basis from 2004 onwards. During these expeditions, scientists collected bat blood, saliva, and urine samples. The WIV collected

²³ Zeng LP, Gao YT, Ge XY et al. “Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response.” J Virol 2016 Jun;90(14):6573-6582.

²⁴ Menachery VD, Yount BL, Sims AC et al. “SARS-like WIV10CoV poised for human emergence.” PNAS 2016 Mar;113(11):3048-3053.

²⁵ See **Error! Main Document Only**.<https://theintercept.com/2021/11/03/coronavirus-research-ecohealth-nih-emails/>

more than 15,000 bat-related samples around the time the pandemic began. Of these, the WIV had identified more than 220 SARS-related coronaviruses, at least 100 of which have not been made public.

By 2018, the WIV showed interest in finding SARS-related coronaviruses that used human ACE2 receptors to enter cells in order to determine whether SARS antibodies would effectively neutralize those viruses. This research effort is described in a March 2018 grant proposal submitted to the Defense Advanced Research Projects Agency (DARPA) by a consortium of research entities, including the WIV, led by the U.S.-based non-governmental organization EcoHealth Alliance. The group proposed to collect and conduct genetic recombination experiments on SARS-related coronaviruses possessing specific traits making them “high-risk” for zoonotic spillover into animals and humans.

3. Extensive Safety Concerns at WIV Were Well-Known in China and U.S.

132. It is well-documented that WIV has a history of biosafety failures and problems.
133. In 2004, the WHO voiced concerns about laboratory security, particularly Chinese labs.
134. According to the WHO, a SARS outbreak in 2003 during research using both live and inactivated samples of SARS-CoV infected nine people, one of whom died. This was the third outbreak of SARS that had been traced to a lab, and the WHO indicated that a better containment policy might be necessary, as well as a reduction in the number of labs that handled SARS viruses.^{26, 27}

²⁶ Parry J. “Breaches of safety regulations are probable cause of recent SARS outbreak, WHO says.” BMJ 2004 May;328(7450):1222.

²⁷ The Origins of the COVID-19 Global Pandemic, Including the Roles of the Chinese Communist Party and the World Health Organization. House Foreign Affairs Committee Minority Staff Interim Report. <https://gop-foreignaffairs.house.gov/wp-content/uploads/2020/08/Interim-Minority-Report-on-the-Origins-of-the-COVID-19-Global-Pandemic-Including-the-Roles-of-the-CCP-and-WHO-8.17.20.pdf> (accessed 12.16.2022).

135. Approximately two (2) years before the release of SARS-CoV-2, U.S. Embassy officials visited the Wuhan Lab, and reported that safety in the lab was inadequate.
136. One U.S. Embassy official specifically warned about the lab's experiments on bat viruses and the potential for human transmission and the risk of a SARS pandemic, and this information was known, or should have been known, to Defendants' prior to subcontracting their *Gain of Function* research to the Wuhan Lab and Dr. Zheng-Li.²⁸
137. A former employee at Defendant EcoHealth – Dr. Andrew Huff – informed Defendant Peter Daszak and other members of the EcoHealth executive team of “biosafety and biosecurity risks in contract laboratories.”
138. According to Dr. Huff, “Daszak refused to mitigate the risks without any objection or discussion from the other executives. In my opinion, Daszak was dismissive of my concerns.” See Exhibit “3” to Compl., Andrew Huff Declaration dated September 14, 2022 at pg. 4 -5.
139. The U.S. Senate October 2022 Minority Interim Report “*An Analysis of the Origins of the Covid-10 Pandemic*” points out recent activity at the WIV suggesting evidence of biosafety failures:

²⁸ https://scholar.harvard.edu/files/kleelerner/files/20200414_wapo_-_state_department_cables_warned_of_safety_issues_at_wuhan_lab_studying_bat_coronaviruses_-_the_washington_post.pdf

b. Evidence of Biosafety Failures at the WIV

WIV patents and procurements suggest that the WIV experienced persistent biosafety problems relevant to the containment of an aerosolized respiratory virus like SARS-CoV-2.

- April 24, 2019: Auxiliary exhaust patent
- August 14, 2019: Environmental air disinfection system procurement
- September 16, 2019: Central air conditioning
- November 19, 2019: Sole source procurement for air incinerator
- December 11, 2019: Biocontainment transfer cabinet HEPA filter failure patent
- November 13, 2020: Disinfectant formulation patent

See Exhibit “13” to Compl.: The U.S. Senate Minority Interim Report “*An Analysis of the Origins of the Covid-10 Pandemic*,” Senate Committee on Health Education, Labor and Pensions Minority Oversight Staff, October 2022 at pg.17 - 19.

140. Sir Jeremy Farrar, head of the Wellcome Trust, privately condemned the “Wild West” research being done at WIV.²⁹
141. A tweet by Alina Chan, Scientific Advisor at the Broad Institute of MIT and Harvard, and co-author of VIRAL: the search for the origin of Covid-19, stated “[i]t’s clear from the emails that the leaders of funding agencies that had funded the Wuhan Institute of Virology were concerned that risky SARS-like virus work had been performed at low biosafety levels in Wuhan. Farrar described it as the ‘Wild West’. [sic]”³⁰

²⁹ <https://www.dailymail.co.uk/news/article-11465573/Top-British-scientist-privately-condemned-Wild-West-research-carried-Wuhan.html> (accessed 12.1.2022).

³⁰ <https://twitter.com/Ayjchan/status/1595401489337417728> (accessed 12.1.2022)

From: Jeremy Farrar
Sent: Tue, 4 Feb 2020 20:26:23 +0000
To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Wild West.....

From: Francis Collins (b) (6)
Date: Tuesday, 4 February 2020 at 20:23
To: Jeremy Farrar (b) (6), "Fauci, Anthony (NIH/NIAID) [E]"
 (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Surely that wouldn't be done in a BSL-2 lab?

From: Jeremy Farrar (b) (6)
Sent: Tuesday, February 4, 2020 9:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Collins, Francis (NIH/OD) [E]
 <(b) (6)>
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Exactly!

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Date: Tuesday, 4 February 2020 at 13:18
To: Francis Collins (b) (6), Jeremy Farrar (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

?? Serial passage in ACE2-transgenic mice

3. Other U.S. Collaborators

142. James LeDuc, Director of the Galveston National Laboratory ("GNL") at the University of Texas, frequently collaborated with Defendants and co-conspirators at the WIV and elsewhere on risky GOF research. See Exhibit "8" to Compl.: Galveston emails\invitation November 2, 2017.
143. A November 2, 2017, e-mail shows that the U.S. National Academy of Sciences (NAS) and GNL hosted a "meeting of U.S. and Chinese experts working to counter infectious disease and improve global health."

144. Upon information and belief, Defendant Baric received the invitation to meeting the above-mentioned meeting and attended.

E. The United States Funded GOF and other Risky Research with Grants to EcoHealth

145. Beginning in 2008, EcoHealth received funding from two U.S. government sources related to **GOF** research.

146. First, the U.S. Agency for International Development (USAID) funded a five-year program called PREDICT.

147. In addition, the NIH and NIAID funded research related to “Understanding the Risk of Bat Coronavirus Emergence.” See Exhibit “14” to Compl. at 17 -18.

148. Between 2002 and 2021, EcoHealth received approximately \$16,874,314 in grant money from NIH/NIAID to research **GOF**. *Id.* Some of the grants awarded are listed herein:

- number 5R01AI079231-05, Risk of Viral Emergence from Bats (\$518,980).³¹ 2008 NIH/NIAID Project number 1R01AI079231-01, Risk of Viral Emergence from Bats (\$534,989). *Id.*
- 2009 NIH/NIAID Project number 5R01AI079231-02, Risk of Viral Emergence from Bats (\$535,156). *Id.*
- 2010 NIH/NIAID Project number 5R01AI079231-03, Risk of Viral Emergence from Bats (\$480,423). *Id.*
- 2011 NIH/NIAID Project number 5R01AI079231-04, Risk of Viral Emergence from Bats (\$510,005). *Id.*
- 2012 NIH/NIAID Project. *Id.*

³¹ *Id.* (citing source).

149. According to a press release dated November 21, 2014, Defendant EcoHealth announced their participation in the second phase of the PREDICT project which would develop initiatives to help prepare the world for emerging infectious diseases like pandemic influenza, SARS, and Ebola. See Exhibit “3” to Compl., at 6.
150. Defendant EcoHealth, in the same announcement, confirmed it was partnering in this project with the University of California-Davis, Metabiota, Smithsonian Institution, Wildlife Conservation Society, Columbia University, Boston Children’s Hospital, International Society for Infectious Disease, and University of California – San Francisco.³²
151. As a result, EcoHealth and its co-conspirators’ **GOF** research led to the creation and release of the ultra-hazardous SARS-CoV-2 virus, causing a worldwide pandemic, as alleged herein, which was the direct and proximate cause of Plaintiffs’ injuries.

F. EcoHealth and Co-Defendants Conspired with WIV Researchers to Continue GOF and Other Risky Coronavirus Research Before the COVID-19 Pandemic Began

152. During the relevant time, Defendants EcoHealth, Peter Daszak, and Baric regularly conspired with WIV to conduct risky research on viruses, including coronaviruses.
153. Defendant EcoHealth provided funding to the WIV to conduct dangerous **GOF** research prior to the COVID-19 pandemic. While the NIH informed Defendant EcoHealth that the NIH was “pursuing suspension of Wuhan Institute of Virology from participation in federal programs[,]” the damage had been done.

³² USAID Announces Second Phase of Predict Project with Global Partners. Nov. 24, 2014. <https://www.ecohealthalliance.org/2014/11/usa-id-announces-second-phase-of-predict-project-with-global-partners>

154. Scientists at WIV and their collaborators, including Defendants EcoHealth, Peter Daszak, and Baric, had conducted the risky research in unsafe environments, which led to the COVID-19 pandemic.
155. The House Committee investigating the origins of COVID-19 described Defendant Peter Daszak as the “CEO of EcoHealth Alliance as a longtime collaborator of [WIV bat virus researcher Dr.] Shi [Zheng-Li] and others at the WIV. The Committee described Defendant Baric as a “[r]esearcher at the University of North Carolina at Chapel Hill who **has** collaborated with Shi and other WIV researchers on coronavirus research.”
156. The House Committee described Dr. Shi Zheng-Li of WIV as a “Senior scientist” that “[s]erves as Director, Research Center for Emerging Infectious Diseases; Director, Chinese Academy of Sciences Key Laboratory of Special Pathogens; Director, Biosafety Working Committee; and Deputy Director of the Wuhan National Biosafety Laboratory’s Biosafety-Level 4 lab.”³³
157. Defendants Peter Daszak and Baric regularly collaborated with “Bat Woman” Shi Zhengli on research related to SARS-like coronaviruses between 2004 and 2017.
158. At all times relevant hereto, and in furtherance of its conspiracy, Defendant EcoHealth funneled to the WIV sub-grants and other U.S. taxpayer funds awarded to it by NIH in violation of specific safety conditions of the prime contract awarded to EcoHealth.
159. The above-described sub- grants were used for **GOF** research enabled by Defendant EcoHealth after receiving an NIH “exemption” from a 2014 moratorium restriction placed on **GOF** funding and research.

³³ *Id.*

160. Defendant EcoHealth provided direct funding and resources to perform **GOF** research to WIV researcher Dr. Zheng-Li, consequently violating the terms of the grant funding for which the exemption to the **GOF** Moratorium was obtained, specifically, prohibiting outsourcing of **GOF** research by EcoHealth to the Wuhan Lab and Dr. Zheng-Li.
161. In 2010, the WIV bat virus researcher Dr. Shi Zheng-Li, in partnership with Defendant Peter Daszak and EcoHealth, conducted research on a virus called “WIV1” with clones of spike proteins and then tested the creation in humanized mice.
162. Upon exposure to the virus, the mice showed signs of severe pathogenesis. All of the Defendants knew or should have known that WIV1 was potentially dangerous to humans.³⁴
163. In its 2014 NIH Notice of Award grant to EcoHealth, Dr. Zheng-Li and the Wuhan Lab were listed by Peter Daszak as one of the collaborating institutions that were specifically allocated funds for “subcontract/consortium activity with the Wuhan Institute of Virology” and were engaged in **GOF** research.³⁵
164. In the 2014 NIH Notice in the “accomplishments” section of the Award, Defendant Peter Daszak reported that EcoHealth had collected 121 bat fecal samples in Laos to test for viruses by Dr. Zheng-Li.
165. The viruses collected from the aforementioned bat fecal samples were genetically manipulated by Defendant EcoHealth and their co-conspirators through **GOF** mechanisms, creating a lab-made, SARS-CoV-2 virus that causes Covid-19. SARS-CoV-2 is transmitted

³⁴ Menachery, V. D., Yount Jr, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., ... & Baric, R. S. (2016). SARS-like WIV1-CoV poised for human emergence. *Proceedings of the National Academy of Sciences*, 113(11), 3048-3053.

³⁵ Notice of Award. Grant Number 1R01AI110964-01

<https://www.nih.gov/sites/default/files/institutes/foia/20211214-foia-log-2021.pdf>

from person to person predominantly through droplets and/or aerosols and has directly and proximately caused Plaintiffs' injuries.³⁶

166. Dr. Zheng-Li at the Wuhan Lab, working in partnership with Defendants EcoHealth, Peter Daszak, and Ralph Baric, was successful in developing a dangerous, genetically modified coronavirus SARS-CoV-2 that could jump species, and could infect humans, and seemed to be resistant to treatment and prevention with vaccines.³⁷

G. Moratorium on GOF Research

1. Background

167. In announcing the **GOF** Moratorium in 2014, the government stated:
168. Gain-of-function studies, or research that improves the ability of a pathogen to cause disease, help define the fundamental nature of human-pathogen interactions, thereby enabling assessment of the pandemic potential of emerging infectious agents, informing public health and preparedness efforts, and furthering medical countermeasure development.
169. Gain-of-function studies may entail biosafety and biosecurity risks; therefore, the risks and benefits of gain-of function research must be evaluated, both in the context of recent U.S. biosafety incidents and to keep pace with new technological developments, in order to determine which types of studies should go forward and under what conditions:

“In light of recent concerns regarding biosafety and biosecurity, effective immediately, the U.S. Government (USG) will pause new USG funding for gain-of-function research on influenza, MERS or SARS viruses, as defined below. This research funding pause will be effective until a robust and broad deliberative process is completed that results in the adoption of

³⁶ <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted>

³⁷ Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., ... & Baric, R. S. (2015). A SARS-like cluster of circulating bat coronaviruses show potential for human emergence. *Nature medicine*, 21(12), 1508-1513

a new USG gain-of-function research policy 1. Restrictions on new funding will apply as follows:

‘New USG funding will not be released for gain-of-function research projects that may be reasonably anticipated to confer attributes to influenza, MERS, or SARS viruses such that the virus would have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route. The research funding pause would not apply to characterization or testing of naturally occurring influenza, MERS, and SARS viruses, unless the tests are reasonably anticipated to increase transmissibility and/or pathogenicity.’

In parallel, we will encourage the currently funded USG and non-USG funded research community to join in adopting a voluntary pause on research that meets the stated definition.” See Exhibit “14” to Compl. at 9 -10. fn. 4.”

170. Elsewhere, the government explained:

Why is the U.S. government¹ [sic] pausing the funding of certain types of gain-of-function studies at this time?

The occurrence this year of laboratory biosafety incidents at U.S. government research facilities have caused the federal government to re-assess the risk/benefit calculus underpinning funding decisions for a certain subset of gain-of-function research involving agents that pose a significant risk to public and animal health. The pause will allow the U.S. government, in partnership with the life sciences community, to conduct a comprehensive assessment of gain-of-function research with the explicit goal of developing a new policy framework to guide future funding decisions.³⁸

171. It should have been clear to Defendants – that **GOF** research is extremely risky, and abnormally dangerous and posed a significant risk to Plaintiffs.
172. Defendant Baric, who was at the time conducting **GOF** research in partnership with Dr. Shi Zhengli of WIV, petitioned the NIH biosecurity board for an exemption from the pause on **GOF** research. It was subsequently granted.

³⁸ See <https://www.phe.gov/s3/dualuse/Documents/GOF-qanda.pdf> (accessed 12.19.22)

173. At all relevant times, Defendants knew or should have known that **GOF** research is extremely risky and abnormally dangerous.
174. Defendants and their co-conspirators were aware that in October 2014, the NIH stated that the moratorium on **GOF** research “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy” and understood that NIH “suspend[ed] funding for **GOF** studies involving influenza, MERS-CoV, and SARS-CoV.”³⁹
175. On February 23, 2016, the New York Academy of Medicine hosted an event entitled, “Where Will The Next Pandemic Come From?”⁴⁰ Defendant Peter Daszak was a member of the panel at this event.
176. At the above-mentioned event Defendant Daszak presciently explained exactly how the Covid-19 pandemic would come about less than four years later: “We found other coronaviruses in bats, a whole host of them; some of them looked very similar to SARS. So we sequenced the spike protein, the protein that attaches to cells; then we – I didn’t do this work, my colleagues in China did this work – you create pseudo-particles, you insert the spike proteins from those viruses, see if they bind to human cells, each step of this you move closer and closer to this virus [...] could really become pathogenic in people.”⁴¹
177. Defendant Daszak’s statement (admitting “we” did this work) demonstrates his and co-Defendant EcoHealth’s culpability in working to develop and unleash the ultrahazardous SARS-CoV-2 that caused Plaintiffs’ injuries.

³⁹ Burki, Talha: *Ban on gain-of-function studies ends*, *The Lancet, Infectious Diseases* (Vol. 18, Issue 2, P. 148-49, Feb. 1, 2018). [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(18\)30006-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30006-9/fulltext) (accessed 12.19.22).

⁴⁰ <https://www.nyam.org/events/event/where-will-next-pandemic-come/> (accessed 12.19.2022)

⁴¹ Daszak C-SPAN video (See <https://twitter.com/i/status/1463673517501816840>) (accessed 12/19/2022).

178. Nonetheless, Defendant EcoHealth, collaborating with co-conspirators, facilitated and was responsible for the **GOF** research that resulted in the creation and release of SARS-CoV-2 at the WIV that caused Plaintiffs' injuries.
179. Defendant EcoHealth had knowledge of the potential risks involved in such research but proceeded anyway.
180. Defendants EcoHealth, Peter Daszak, and Baric and other name and unnamed defendants collaborated with Shi and others at WIV to collect, identify, genetically modify, and manufacture the novel coronaviruses adversely effecting the human immune systems.

2. Moratorium on GOF Research Ends in 2017

181. In December of 2017, federal policy changed to permit federal funding of **GOF** research following the **GOF** Moratorium.
182. The original **GOF** framework established in 2017 required that any federal funding sought for **GOF** research be subject to enhanced oversight given the "biosafety and biosecurity risks associated with undertaking such research."⁴²
183. Pursuant to the guidelines, a "Potential Pandemic Pathogen" ["PPP"] is "likely highly transmissible and likely capable of wide and uncontrollable spread in human populations" and "likely highly virulent and likely to cause significant morbidity and/or mortality in humans."⁴³
184. Moreover, "[a]n enhanced PPP is defined as a PPP resulting from the enhancement of the transmissibility and/or virulence of a pathogen.

⁴² <https://www.phe.gov/s3/dualuse/Documents/p3co.pdf>

⁴³ *Id.*

185. Enhanced PPPs do not include naturally occurring pathogens that are circulating in or have been recovered from nature, regardless of their pandemic potential.”⁴⁴
186. Given the risks associated with enhanced PPP, the guidelines require that proposed **GOF** research that may be funded by a federal agency be subjected to additional review by the Department of Health and Human Services.⁴⁵
187. SARS-CoV-2 is an enhanced PPP because it is an alleged, lab creation with enhanced transmissibility and virulence.

H. EcoHealth/DARPA DEFUSE Project

188. After the moratorium on **GOF** research was lifted in 2017, on January 19, 2018, DARPA issued a “Broad Agency Announcement” publishing a funding opportunity entitled “Preventing Emerging Pathogenic Threats” (PREEMPT).⁴⁶

DARPA is soliciting innovative proposals for research to develop new tools and models to quantify the likelihood of a virus to jump from an animal host into humans, and to develop and validate new scalable technologies to target potential human-capable viral pathogens in wild reservoirs and/or mosquito vectors to prevent transmission to humans.⁴⁷

DARPA made the following statement regarding **GOF** research:

⁴⁴ *Id.*

⁴⁵ *Id.*

⁴⁶ <https://drasticresearch.files.wordpress.com/2021/09/prempt-background-hr001118s0017.pdf>

⁴⁷ *Id.* at 4.

1.4. PROTECTION OF SENSITIVE INFORMATION

PREEMPT is a 6.1 fundamental research program aimed at enhanced biosurveillance and novel approaches to preempt viral pathogens in animal reservoirs from jumping into human populations. DARPA follows current DoD policy for contracted fundamental research. DARPA recognizes, however, that PREEMPT program components aimed at understanding and quantifying mechanisms for viral zoonotic spillover could potentially generate sensitive information that could be misused. Since this is a fundamental research program, the risk of misuse currently cannot be reasonably evaluated. However, proposers are notified that during proposal evaluation and/or program performance, when such a risk reasonably can be evaluated, DARPA may determine that risk of misuse creates exceptional circumstances, compelling reasons, and/or national security reasons under current DoD policy for contracted fundamental research. DARPA therefore expects that proposers to this program understand and will comply with various government guidance regarding potential gain-of-function research of concern (GOFROC)⁸ and dual use research of concern (DURC)^{9,10,11,12,13}. See <https://www.phe.gov/s3/dualuse/Pages/default.aspx> for further information.


⁸ Gain-of-Function Research (GOFROC) refers to studies with the potential to generate pathogens with pandemic potential exhibiting high transmissibility and high virulence.

189. Defendants EcoHealth and Peter Daszak subsequently applied for a \$14,209,245 grant from the DARPA PREEMPT Committee in late March 2018.⁴⁸
190. Defendants EcoHealth and Daszak, in conjunction with Defendant Baric, and other co-conspirators, sought to use this money for “Project Defuse: Defusing the Threat of Bat-Borne Coronaviruses.”⁴⁹
191. Defendants proposed to make infectious clones with chimeric spike genes and SARS coronaviruses with Furin cleavage sites at WIV.
192. On the title page of the Project Defuse Proposal, the “LEAD ORGANIZATION” was listed as “EcoHealth Alliance (Other Nonprofit)” while “OTHER TEAM MEMBERS” included Duke NUS Medical School (Other Educational), University of North Carolina (Other

⁴⁸ <https://drasticresearch.files.wordpress.com/2021/09/main-document-preempt-volume-1-no-ess-hr00118s0017-ecohealth-alliance.pdf> at 2.

⁴⁹ *Id.*

Educational), Wuhan Institute of Virology (Other Educational), USGS National Wildlife Health Center (Other Nonprofit), and Palo Alto Research Center (Large Business).”




193. The “Project Defuse” proposal explains in detail how Defendants ultimately caused the COVID-19 pandemic. “In TA1 [Technical Area 1] we will intensively sample bats at our field sites where we have identified high spillover risk SARSr-CoVs. We will sequence their spike proteins, reverse engineer them to conduct binding assays, and insert them into

bat SARSr-CoV (WIV1, SHC014) backbones... to infect humanized mice and assess capacity to cause SARS-like disease.”⁵⁰

194. Defendants would then evaluate two approaches to reduce SARSr-CoV shedding in cave bats via “Broadscale immune boosting” and “Targeted immune boosting” where they would “inoculate bats with novel chimeric polyvalent recombinant spike proteins plus the immune modulator to enhance innate immunity against specific, high-risk viruses.”⁵¹

195. The “Executive Summary” for Project Defuse was encapsulated in the following chart:



⁵⁰ <https://drasticresearch.files.wordpress.com/2021/09/main-document-preempt-volume-1-no-ess-hr001118s0017-ecohealth-alliance.pdf> at 3.


⁵¹ *Id.*

196. Defendant EcoHealth was the “lead organization” behind the Project Defuse proposal, and would “oversee all work[,]” with “subcontract[ing] to the following organizations:

- [Defendant] Prof. [Ralph] Baric, Univ. N. Carolina, will lead targeted immune boosting work, building on his two-decade track record of reverse-engineering CoV and other virus spike proteins.
- Prof. [Linfa] Wang, Duke-Natl. Univ. Singapore, will lead work on broadscale immune boosting, building on his group’s pioneering work on bat immunity.
- Dr. Shi [Zhengli], Wuhan Institute of Virology will conduct viral testing on all collected samples, binding assays and some humanized mouse work.
- Dr. [Tonie] Rocke, USGS National Wildlife Health Center will optimize delivery of immune modulating biologicals, building on her vaccine delivery work in wildlife, including bats.
- Dr. [Jerome] Unidad, Palo Alto Research Center will lead development of novel delivery automated aerosolization mechanism for immune boosting molecules.⁵²

The “Program Administration” as supplied by Defendants in their proposal was as follows:

⁵² <https://drasticresearch.files.wordpress.com/2021/09/main-document-preempt-volume-1-no-ess-hr00118s0017-ecohealth-alliance.pdf> at 3.



197. Regarding some of the names in the chart, above, Defendants noted that “Dr. Karesh has 40+ years’ experience leading zoonotic and wildlife disease projects... Dr. Epstein, with 20 years’ experience working emerging bat zoonoses will coordinate animal trials across partners. Drs. Olival and Ross will manage modeling approaches for this project.” In addition, Defendants acknowledged that Defendant EcoHealth “has worked extensively with other collaborators: Prof. Wang (15+ yrs); Dr. Shi [Zhengli] (15+ yrs; [Defendant] Prof. Baric (5+ yrs) and Dr. Roche (15+ yrs).”⁵³
198. Defendants claimed in their Project Defuse proposal that viruses identified in China had produced SARS-like disease in humanized mice, which do not respond to antibody treatment or vaccination, and argued “[t]hese viruses are a clear and present danger to our military and to global health security because of their circulation and evolution in bats and periodic spillover into humans.”⁵⁴ Defendant EcoHealth further touted that it “leads the

⁵³ *Id.*, Defuse Proposal at 22. *See also* “Biographies” at page 24 of the Proposal.

⁵⁴ *Id.* Defuse Proposal at 2 (emphasis in original).

world in predictive models of viral emergence[]” and would use their expertise to minimize hazards.⁵⁵

199. Defendants explained their strategy in detail, including “using data from >10,000 previously collected bat samples from 6 Asian countries under our USAID-funded PREDICT project.”⁵⁶ Continuing: “[t]he Univ. N. Carolina (UNC) team will reverse-engineer spike proteins of a large sample of high- and low-risk viruses for further characterization... [t]hese QS₀ strain viral spike glycoproteins will be synthesized, and those binding to human cell receptor ACE2 will be inserted into SARSr-CoV backbones (non-DURC, non-GOF), and inoculated into humanized mice to assess capacity to cause SARS-like disease... or vaccines against SARS-CoV.”⁵⁷ Continuing, Defendants stated: “[w]e will test these previously collected human sera (n>2000) for presence of antibodies to the high- and low-risk SARSr-CoVs identified by our modeling, using Luciferase immunoprecipitation system (LIPS) assays we design against the SARSr-CoVs identified in this project.”⁵⁸
200. In explaining “Technical Area 2,” Defendants highlight their plans to use CRISPR technology at Duke-NUS and their plans to develop recombinant chimeric spike proteins at UNC.⁵⁹

201. The chimeric spike proteins would contain a Furin cleavage site.

⁵⁵ *Id.*

⁵⁶ *Id.* at PDF Pg. 5.

⁵⁷ *Id.* at PDF Pg. 5 (grant proposal at 3).

⁵⁸ *Id.* (internal citation omitted).

⁵⁹ *Id.* at PDF Pg. 6

202. Defendants – recognizing the extreme risks of their proposed project, highlighted the fact that their “team has more than 50 years collective experience in safe and humane handling of bats for biological sampling.”⁶⁰
203. Defendants and their co-conspirators proposed to make new, chimeric coronaviruses at WIV, by swapping spike proteins with infectious clones from related viruses, inserting Furin cleavage sites: “we will introduce appropriate human specific cleavage sites and evaluate growth potential in Vero cells and HAE [Human Airway Epithelial] cultures.”⁶¹
204. The Furin cleavage site allows a virus to bind more efficiently, and to release genetic material into human cells, allowing for easier viral transmission between humans.
205. The researchers funded by EcoHealth would then test the altered viruses in human respiratory cells and humanized mice at WIV. (“*In vivo*, we will evaluate pathogenesis in transgenic hACE2 mice.”).⁶² In the words of one researcher: “Find, engineer, and evolve human-infectious viruses capable of causing a pandemic...”⁶³
206. In the “Capabilities” section of its Defuse proposal, Defendants describe a few of their partner labs, including:
- **“University of North Carolina Medical School (UNC).** The Baric Laboratory in University of North Carolina at Chapel Hill comprise biosafety level two facilities equipped to perform basic virology, immunology, and molecular biology as well as university space for breeding mice for the proposed studies. The Baric BSL-3

⁶⁰ *Id.* at PDF Pg. 10.

⁶¹ *Id.* at PDF Pg. 13. *See also* Exhibit “13” – Senate Minority Interim Report October 2022 at 15 (“[I]f WIV researchers were unable to find a SARS-related virus with these traits ... they then proposed to manipulate the ACE2 receptors of SARS-related coronaviruses to increase binding affinity to human lung tissue and to insert furin cleavage sites at the same location where one appears in SARS-CoV-2.”). Notably, DARPA did not ultimately fund this proposal. *Id.*

⁶² *Id.* at PDF Pg. 13 (proposal Pg. 11).

⁶³ <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (last accessed 11.21.22).

laboratories are approved and have the required equipment to perform all of the chimeric virus recovery and characterization and ventilated rodent caging to examine the bat coronaviruses within this proposal.”

- **“Wuhan Institute of Virology:** includes BSL3, BSL-3, and BSL-4 laboratories, animal feeding rooms and other supporting facilities. The Biosafety Laboratory will carry out CoV research, sample testing, sequencing, binding assays, *in vitro* and *in vivo* work.”⁶⁴

207. In Section II, Part J of their Defuse proposal, Defendants laid out their “PREEMPT RISK MITIGATION PLAN” where they listed **“Risks: Personnel safety, biosafety, mitigation of risks to public health and animal safety.”**⁶⁵ Defendants further stated:

Section II

J. PREEMPT RISK MITIGATION PLAN

Risks: Personnel safety, biosafety, mitigation of risks to public health and animal safety

Animal Use & safety: All work with wild bats will be conducted in China by EcoHealth Alliance staff and Wuhan Institute of Virology. Capture and sampling techniques have been previously approved by Tufts University School of Veterinary Medicine IACUC under our NIH NIAID award (Daszak, PI). Experimental work using bats and or transgenic mice will be conducted at the BSL-3 lab in WIV, Duke-NUS, UNC, or NWHC. Each partner institute will apply for and procure animal research approval from its respective IACUC. All animal work conducted by EcoHealth Alliance in China will be overseen by both the IACUC at WIV and the IACUC at Tufts. Each partner institute will be responsible for ensuring the training and safety of its laboratory personnel, which will be documented by EcoHealth Alliance, and each partner has extensive experience and a record of safety with the techniques and procedures for lab animal experiments described in this protocol. **Field safety:** Free-ranging bats will be captured using either a mist

208. Notably, Defendants planned to conduct experimental work using bats and transgenic mice in less than BSL-4 labs, while acknowledging that “[e]ach partner institute would be responsible for ensuring the training and safety of its laboratory personnel[.]”⁶⁶

⁶⁴ *Id.*, Proposal at 25.

⁶⁵ <https://drasticresearch.files.wordpress.com/2021/09/main-document-preempt-volume-1-no-ess-hr00118s0017-ecohealth-alliance.pdf> at Pg. 35 of PDF, Pg. 33 of Proposal.

⁶⁶ *Id.*

209. The subsection “*Risks to general public*” was apparently cut short at the bottom of page 33 of the Defuse proposal. The text as written states: “The proposed work has minimal risk to the general public, as sampling will be done near the cave sites and not in populous areas. Our team has extensive experience...”
210. A “Summary of Proposed Costs” for Project Defuse details exactly how Defendants and their co-conspirators planned to carry out their research experiments that ultimately led to the COVID-19 pandemic.⁶⁷ This document also shows that substantial travel between the United States and Wuhan was planned.⁶⁸
211. DARPA ultimately turned down the Defendants’ “Project Defuse” proposal.^{69,70}
212. In the “PM Summary Sheet” rejecting Defendants’ request for funding, PM James Gimlett, Ph.D., Program Manager, Biological Technologies Office gives the following reasons:

[L]ack of detail regarding data, statistical analyses and model development and how prior work will be leveraged and extended. Proposal also lacks clear decision points to assess the deployment and how prior work will be leveraged and extended. Proposal also lacks clear decision points to assess the deployment and validation of TA2 preemption methods in the wild. Regulatory ELSI issues are not discussed. Variability of vaccine dose due to variability in delivery mechanisms is also not discussed. In addition, there is concern that vaccine approaches may lack sufficient epitope coverage to effectively protect against the diverse and evolving quasispecies of the many coronaviruses found in the bat caves.

Notably, Dr. Gimlett pointed out that Defendants:

[Did] not mention or assess **potential risks of Gain of Function (GOF) research** and DURC [dual use research of concern]. **Given the team’s approach does potentially involve GOF/DURC research** (they aim to synthesize spike glycoproteins that may bind to human cell receptors and insert them into SARSr-CoV backbones to assess capacity to cause SARS-like disease), if selected for

⁶⁷ <https://drasticresearch.files.wordpress.com/2021/09/wiv-budget-packet-hr001118s0017-ecohealth-alliance-defuse.pdf>

⁶⁸ *Id.*

⁶⁹ See Exhibit “14” to Compl., (*Answering Crucial Questions...*) at 19-20 (citing sources).

⁷⁰ <https://drasticresearch.files.wordpress.com/2021/09/hr001118s017-preempt-fp-019-pm-summary-selectable-not-recommended.pdf>

funding an appropriate DURC risk mitigation plan should be incorporated into contracting language that includes a responsible communications plan.

213. As such, Defendants were unambiguously put on notice that their proposed research involved dangerous **GOF** experiments that must be addressed if they were to proceed.
214. Nevertheless, Defendants' Defuse proposal shows a clear aspiration to create SARS coronaviruses not yet found in nature.
215. Rutgers University Chemistry and Chemical Biology Board of Governors Professor Richard Ebright explained, "SARS-CoV-2 ... is the only virus in its entire genus of SARS-related coronaviruses that contains a fully functional cleavage site at the S1, S2 junction. And here is a proposal from the beginning of 2018, proposing explicitly to engineer that sequence at that position in chimeric lab-generated coronaviruses."⁷¹
216. Scientist Alex Washburne notes that "SARS-CoV-2 has a Furin cleavage site (FCS), **and it is the only SARS coronavirus with one.**"⁷² He continues:

Prior to SARS-CoV-2, we had discovered as many Furin cleavage sites in SARS coronaviruses as we had discovered winged primates or flying penguins: zero. Other mammals have wings (bats) and other birds fly, but the lineages of interest don't. Similarly, despite extensive wildlife sampling, SARS coronaviruses were not known to have Furin cleavage sites. The exact FCS of SARS-CoV-2 is not found in any other coronavirus and in fact it contains specific RNA sequences - CGG CGG - that are almost nonexistent in bats but are optimized for humans. Not only are FCS's nonexistent in other SARS coronaviruses, but this specific FCS is particularly anomalous in its optimization for humans. From an evolutionary standpoint, the FCS is a massive anomaly in nature, yet it is exactly what was proposed in the DEFUSE grant.

Recall the language of the DEFUSE grant:

"... we will introduce appropriate human specific cleavage sites and

⁷¹ Sharon Lerner, Maia Hibbet. Leaked Grant Proposal Details High Risk Coronavirus Research. The Intercept Sept 23, 2021, <https://theintercept.com/2021/09/23/coronavirus-research-grant-darpa/> (accessed 9.10.2022).

⁷² <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (accessed 12.1.2022) (emphasis added).

evaluate growth potential in Vero and HAE (Human Airway Epithelial) cell cultures.'

The evolutionary anomaly of the FCS must be impressed upon the lay reader, so I'll repeat it here. The FCS of SARS-CoV-2 is the first FCS of any SARS coronavirus. It is an uncommonly human-specific cleavage site for what's otherwise a lineage of bat coronaviruses. The SARS-CoV-2 FCS has not one but two CGG codons appropriate for humans and it mimics a particular protein (ENaC) found in humans.

217. Elsewhere, Washburne observed:

The motives and intentions to create such a virus did not die with the rejection of DEFUSE. While not funded by DARPA, similar research proposals were funded by NIAID and others prior to and during the emergence of SARS-CoV-2, and may easily have provided enough discretionary funding to support the inexpensive research proposed in DEFUSE. **The DEFUSE grant is the letter proposing the crime: catch wild bat coronaviruses, send them to Wuhan, assemble infectious clones *in vitro* with a specific method, swap Spike genes and add Furin cleavage sites**, all to find an extremely human-infectious coronavirus against which we could produce vaccines.⁷³

I. NIH Funded EcoHealth's Research Despite DARPA Grant Proposal Rejection, Leading to the Creation of SARS-CoV-2

218. NIH funded research on SARS viruses, including but not limited to **GOF** research such as the 2014 \$3.7 million grant entitled, "Understanding the Risk of Bat Coronavirus Emergence."⁷⁴ This included various "sub-awards" to WIV and the Wuhan University School of Public Health.⁷⁵

⁷³ <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (last accessed 11.21.22).

⁷⁴ https://www.usaspending.gov/award/ASST_NON_R01AI110964_7529 (accessed 12.2.2022); <https://reporter.nih.gov/search/xQW6UJmWfUuOV01ntGvLwQ/project-details/9491676> ("Understanding the Risk of Bat Coronavirus Emergence") (accessed 12.2.2022).

⁷⁵ *Id.*

Award History



Transaction History 12

Sub-Awards 7

Federal Account Funding 6

Total Count of Sub-Award
Transactions: 7Total Amount of Sub-Awards:
\$799,717Percent of Prime Award Obligated
Amount: 21.3%

Sub-Award ID	Recipient Name	Action Date	Amount
1R01AI110964-01	WUHAN UNIVERSITY SCHOOL OF PUBLIC HEALTH	05/31/2017	\$159,342
1R01AI110964-01	WUHAN UNIVERSITY SCHOOL OF PUBLIC HEALTH	05/31/2016	\$41,875
1R01AI110964-01	WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES CAP...	05/31/2019	\$66,500
1R01AI110964-01	WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES CAP...	05/31/2017	\$133,000
1R01AI110964-01	WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES CAP...	05/31/2018	\$133,000
1R01AI110964-01	WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES CAP...	05/29/2015	\$133,000
1R01AI110964-01	WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES CAP...	05/31/2016	\$133,000

NIH suspended the grant in July 2020.⁷⁶

219. As noted by Washburne, *supra*, the DARPA rejection did not deter the Defendants' quest to research bat coronaviruses using **GOF** and/or other dangerous research methods. Defendants EcoHealth and Peter Daszak applied for a grant from the NIH to do exactly that, and NIH awarded the requested grant to Defendants EcoHealth and Peter Daszak.⁷⁷ As scientist Alex Washburne explained in a blog post:⁷⁸

The DEFUSE proposal was not accepted as DARPA saw major risks that the proposed recombinant viruses might gain functions like enhanced infectivity or lethality in humans. However, the grant reveals the clear desire of this group to conduct such research and the intention to make a very unusual set of SARS coronaviruses not found in nature. While their intentions were not funded by DARPA, the proposed research is relatively

⁷⁶ <https://www.vanityfair.com/news/2022/03/the-virus-hunting-nonprofit-at-the-center-of-the-lab-leak-controversy> ("But the work there had been controversial enough that the NIH suspended the grant in July 2020.") (accessed 12.2.2022).

⁷⁷ https://reporter.nih.gov/search/sizVvtAps0O7_3-grB_8Bw/project-details/9819304 (accessed 12.1.2022).

⁷⁸ <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (accessed 12.1.2022).

inexpensive and EcoHealth and the Wuhan Institute of Virology had funding from other sources that could finance their proposed work. Their alternative sources of funding include an NIAID biodefense grant proposing extremely similar S-gene chimeras made with infectious clones.⁷⁹ In fact, the NIAID grant was cited as a funding source in the construction of a novel infectious clone at the Wuhan Institute of Virology, rWIV1.⁸⁰ The DEFUSE grant proposed to make infectious clones with chimeric Spike genes, SARS coronaviruses with furin cleavage sites, all at the Wuhan Institute of Virology.

220. As laid out in detail in a June 10, 2021 letter from Congress’s Energy and Commerce Committee to Dr. Francis Collins, Defendant EcoHealth worked hand-in-glove with WIV using grant money from NIH to study bat coronaviruses, among other things, in Wuhan.⁸¹
221. Congress criticized NIH’s oversight of its grants to Defendant EcoHealth and subgrants to WIV, among other issues.
222. According to a more recent letter to the NIH, the agency still has not responded to the June 10, 2021 letter.⁸² Exhibit “25”.
223. In a Senate hearing on November 4, 2021, Senator Rand Paul asked Dr. Anthony Fauci: “Will you today finally take some responsibility for funding **GOF** research in Wuhan?” Fauci responded by asserting that **GOF** is a “very nebulous term...” and would not admit that NIH funded **GOF** research according to the operative NIH definition.⁸³
224. Many scientists believe this is untrue, and at the very least, Defendant EcoHealth was conducting risky research at WIV using NIH funds, which ultimately led to the SARS-CoV-2 lab leak.

⁷⁹ See https://reporter.nih.gov/search/sizVvtAps0O7_3-grB_8Bw/project-details/9819304 (accessed 12.1.2022).

⁸⁰ See <https://pubmed.ncbi.nlm.nih.gov/27170748/> (accessed 12.1.2022).

⁸¹ See Exhibit “25” June 10, 2021 Letter from Congress to Dr. Francis Collins

⁸² See Exhibit “20”, November 30, 2022 Letter from Energy and Commerce Committee to Dr. Lawrence A. Tabak.

⁸³ <https://www.washingtonexaminer.com/policy/healthcare/rand-paul-accuses-fauci-of-trying-to-cover-your-ass-over-gain-of-function> (accessed 12.2.2022).

J. Release of the Ultra-Hazardous SARS-CoV-2 Virus Into the Environment and Early Investigations Into Its Origin

225. As alleged herein, there has been a coordinated effort to suppress any suggestion that SARS-CoV-2 was created in a lab and released on the global population.
226. It is unclear when exactly SARS-CoV-2 was released into the world.
227. The first official announcement from the government of the People's Republic of China ("PRC") concerning SARS-CoV-2 was issued on December 30, 2019, when the Wuhan Municipal Health Commission ("WMHC") reported that "cases of pneumonia of unknown cause" were linked to the Huanan Seafood Market.
228. The first official announcement would come to be known as the "natural origin" or "wet market" theory and is Defendant Peter Daszak and his co-conspirators' chief alibi.
229. The WMHC stated there was no evidence of "obvious human to human transmission and no infection among medical personnel." See Exhibit "14" to Compl. at 22.
230. Defendant Daszak's program officer at NIAID, Erik Stemmy, asked Daszak on January 7, 2020, what his China contacts were saying about "Wuhan pneumonia cases" and Daszak promised to tell him "off the record."⁸⁴
231. Dr. Anthony Fauci's senior adviser, David Morens, asked Defendant Daszak on January 9, 2020 for "any inside info" on the new virus. Daszak responded that he had been "talking to reporters today" and would share with Morens as well.⁸⁵
232. Before China or the WHO made an official statement on the nature of SARS-CoV-2, Defendant Baric in a January 13, 2020 email to Defendant Peter Daszak referred to the

⁸⁴ <https://justthenews.com/government/federal-agencies/major-funder-wuhan-lab-told-faucis-agency-covid-would-end-20000-cases> (accessed 11.30.22).

⁸⁵ *Id.*

coronavirus as “*our* highly variable SARS-like COV!” See Exhibit “4” to Compl.: January 13, 2020 email exchange between Baric and Daszak; Source Goa Chronicle: re: “*Looks like we found our Highly Variable SARS-like COV: Ralph Baric to Peter Daszak*” by Savio Rodrigues⁸⁶.

233. In mid-January 2020, virologist Robert Redfield – then director of the CDC – voiced concern to Dr. Anthony Fauci, Wellcome Trust Director Jeremy Farrar, and WHO Director-General Tedros Ghebreyesus that a lab accident occurred at WIV.⁸⁷ “Farrar noticed email chatter among credible scientists ‘suggesting the virus looked engineered to infect human cells’ in the last week of January, according to his memoir Spike.⁸⁸ Farrar obtained a “burner phone” and suggested they avoid discussing SARS-CoV-2 in e-mails.⁸⁹
234. In a January 27, 2020 e-mail among NIH/NIAID members, Dr. Fauci is informed that NIH had been funding work on coronaviruses at WIV through EcoHealth Alliance.⁹⁰

⁸⁶ <https://goachronicle.com/looks-like-we-found-our-highly-variable-sars-like-cov-ralph-baric-to-peter-daszak>

⁸⁷ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/#fauci-alerted>

⁸⁸ *Id.*

⁸⁹ *Id.*

⁹⁰ *Id.*

From: Folkers, Greg (NIH/NIAID) [E]
To: Routh, Jennifer (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: For review (due to HHS for White House by 8:30 tonight): press conference talking points
Date: Monday, January 27, 2020 6:24:59 PM
Attachments: Talking Points for NIAID Director Dr. Fauci.docx

As a place folder looks good to me.

+ Andrea who is the lead on a CoV talk ASF is giving on Tuesday

Also --- when talking about CoV (not necessarily in this venue) we have on our team (Vincent and folks we fund, Peter Daszak, Ralph Baric, Ian Lipkin, etc.) probably the world's experts non-human coronaviruses.

From David M -- EcoHealth group (Peter Daszak et al), has for years been among the biggest players in coronavirus work, also in collaboration with Ralph Baric, Ian Lipkin and others.

NIAID has funded Peter's group for coronavirus work in China for the past 5 years through R01 1R01AI110964: "Understanding the Risk of Bat Coronavirus Emergence". That's now been renewed, with a specific focus to identify cohorts of people highly exposed to bats in China, and work out if they're getting sick from CoVs. Erik Stemmy is the Program Officer. Collaborators include Wuhan Institute of Virology (currently working on the nCoV), and Ralph Baric. The results of the work to date include:

- (b) (5)
- Discovered Swine Acute Diarrheal Syndrome Virus (SADS-CoV) killing >25,000 pigs in Guangdong Province (Published in *Nature*)
 - Found SARS-related CoVs that can bind to human cells (Published in *Nature*), and that cause SARS-like disease in humanized mouse models.

235. This e-mail makes clear that Defendants EcoHealth, Peter Daszak, and Ralph Baric were collaborating with WIV, via funding from NIAID, and “[f]ound SARS-related CoVs that can bind to human cells... and that cause SARS-like disease in humanized mouse models.”⁹¹

236. On January 29, 2020, Scripps Research virologist Kristian Andersen “became alarmed that a bat coronavirus may have been engineered to infect humans, pointing to the receptor binding domain and furin cleavage site.”⁹² He further noted a **GOF** study that showed how

⁹¹ *Id.*

⁹² *Id.* (citing Farrar memoir, Spiked).

- to build the Wuhan coronavirus in a lab, according to Farrar.⁹³ “Andersen found a scientific paper where exactly this technique had been used to modify the spike protein of the original SARS-CoV-1 virus, the one that had caused the SARS outbreak of 2002/3... [t]he pair knew of a laboratory where researchers had been experimenting on coronaviruses for years: the Wuhan Institute of Virology, in the city at the heart of the outbreak.”⁹⁴
237. Upon information and belief, Andersen informed University of Sydney virologist Edward Holmes about a concerning part of the SARS-CoV-2 genome: the furin cleavage site between the S1 and S2 junctions, with two restriction sites (BamHI) around it, which appeared to have reduced variation. In short, the furin cleavage site – a feature of SARS-CoV-2 that makes it unusually infectious – had features characteristic of genetic engineering.⁹⁵ “F*ck, this is bad,” Holmes allegedly said.⁹⁶
238. On January 30, 2020, the WHO designated SARS-CoV-2 a “Public Health Emergency of International Concern (PHEIC).” The WHO advised at that time that “further international exportation of cases may appear in any country.”⁹⁷
239. The next day, January 31, 2020, HHS Secretary Alex Azar declared a public health emergency for the United States.⁹⁸

⁹³ *Id.*

⁹⁴ *Id.*

⁹⁵ *Id.*

⁹⁶ *Id.*

⁹⁷ [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)) (accessed 1.2 2023).

⁹⁸ <https://aspr.hhs.gov/legal/PHE/Pages/2019-nCoV.aspx> (accessed 1 2 2023).

240. That same day, Dr. Fauci received an email from Greg Folkers of the National Institutes of Health.⁹⁹ The email included no text, but an article published in *Science* was attached.¹⁰⁰
241. This article reported that scientists were sharing and reviewing a growing number of genetic sequences of the virus obtained from infected patients. These had been posted in the Global Initiative on Sharing All Influenza Data database.¹⁰¹
242. The author of the above-mentioned article reported that there was some doubt as to whether the virus originated in the wet market, which was the story promoted by U.S. and Chinese authorities at the time.
243. The same author also reported in the article that many scientists had been expressing concerns for many years about experiments conducted at the Wuhan Institute and cited the gain-of-function research fully described in the above-mentioned article in *Nature Medicine* in 2015.¹⁰²
244. The *Nature Medicine* article referenced above included a disclosure that the research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), the division of the NIH headed by Fauci, along with the NIH and Defendant EcoHealth.
245. Further on January 31, 2020, Wellcome Trust's Jeremy Farrar requested a phone call with Dr. Fauci, in which he asked Fauci to call Andersen.
246. In the meantime, Fauci forwarded to Farrar and Andersen an article published in *Science Magazine* quoting Holmes, Andersen, and Rutgers Professor Richard Ebright concerning

⁹⁹ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3229 (accessed 9.10.2022).

¹⁰⁰ Jon Cohen. Mining coronavirus genomes for clues to the outbreak's origins. *Science* Jan 31 2020. <https://www.science.org/content/article/mining-coronavirus-genomes-clues-outbreak-s-origins>

¹⁰¹ <https://gisaid.org/database-features/flusurver-mutations-app> (accessed 1 2 2023).

¹⁰² Menachery VD, Yount BL, Debbink K et al. "A SARS-like cluster of circulating bat coronaviruses shows great potential for human emergence." *Nature Medicine* 2015 Nov;21:1508-1513. <https://pubmed.ncbi.nlm.nih.gov/26552008/> (accessed 1.2.2023).

the origins of SARS-CoV-2. Fauci noted the article was “of interest to the current discussion.”¹⁰³

247. At this point, Andersen was fairly convinced that SARS-CoV-2 was not of natural origin, noting to Fauci that he and other scientists “all find the genome inconsistent with expectations from evolutionary theory” and highlighting “[t]he unusual features of the virus...”¹⁰⁴

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:43:31 +0000
To: Kristian G. Andersen
Subject: RE: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Thanks, Kristian. Talk soon on the call.

From: Kristian G. Andersen (b) (6) >
Sent: Friday, January 31, 2020 10:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Jeremy Farrar (b) (6) >
Subject: Re: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Hi Tony,

Thanks for sharing. Yes, I saw this earlier today and both Eddie and myself are actually quoted in it. It's a great article, but the problem is that our phylogenetic analyses aren't able to answer whether the sequences are unusual at individual residues, except if they are completely off. On a phylogenetic tree the virus looks totally normal and the close clustering with bats suggest that bats serve as the reservoir. The unusual features of the virus make up a really small part of the genome (<0.1%) so one has to look really closely at all the sequences to see that some of the features (potentially) look engineered.

We have a good team lined up to look very critically at this, so we should know much more at the end of the weekend. I should mention that after discussions earlier today, Eddie, Bob, Mike, and myself all find the genome inconsistent with expectations from evolutionary theory. But we have to look at this much more closely and there are still further analyses to be done, so those opinions could still change.

Best,
Kristian

248. Following his call with Andersen, Dr. Fauci sent the 2015 *Nature* paper by Defendant Baric and WIV's Shi Zhengli entitled “A SARS-like cluster of circulating bat coronaviruses

¹⁰³ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/>

¹⁰⁴ *Id.*

shows potential for human emergence” to a principal deputy director at NIAID, Hugh Auchinloss, with instructions: “You will have tasks today that must be done.” Fauci further said “[i]t is essential that we speak this AM. Keep your cell phone on.”¹⁰⁵ The file name attached to the e-mail included the words “SARS Gain of function.”

249. The *Nature Medicine* paper supra had shown that Defendant Baric, Shi, and colleagues had spliced the spike protein of one coronavirus into a SARS-CoV backbone, but that future experimentation with such viruses “may be too risky to pursue.”¹⁰⁶
250. NIH had funded this study through a grant to Defendant EcoHealth. The NIH deputy director later responded to Fauci that the work was reviewed and approved by NIH but had not undergone the “P3 framework[.]”¹⁰⁷
251. On February 1, 2020, Farrar set up a teleconference with Dr. Fauci and others, including Andersen, Bob Garry of Tulane University, German virologist Christian Drosten, Dutch virologist Ron Fouchier, Holmes, Dutch Virologist Marion Koopmans, Patrick Vallance – Chief Scientist UK, German virologist Stefan Pohlmann, Wellcome’s deputy chair and biochemist Mike Ferguson, and Wellcome’s Paul Schreier. “My preference is to keep this [a] really tight group... obviously ask everyone to keep in total confidence,” wrote Farrar.¹⁰⁸ CDC Director Robert Redfield was excluded from the meeting.¹⁰⁹
252. Following the meeting, on information and belief, Holmes was “80 percent sure” SARS-CoV-2 originated in a lab, while Andersen was 60 to 70 percent sure. Andersen later told Farrar: “I was battling with the idea that, having raised the alarm, I might end up being the

¹⁰⁵ *Id.*

¹⁰⁶ *Id.*

¹⁰⁷ *Id.* The “P3 framework” is a reference to regulations put in place to regulate “pandemic potential pathogens” after a temporary pause on GOF research related to SARS viruses. *Id.*

¹⁰⁸ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/#fauci-alerted>

¹⁰⁹ *Id.*

person who proved this new virus came from a lab... I didn't necessarily want to be that person."¹¹⁰

253. On February 2, 2020, Farrar e-mailed Fauci, Collins, and others at NIH with a summary of thoughts from others at the meeting, including concern about the furin cleavage site. "He [Mike Farzan, discoverer of SARS receptor] is bothered by the furin site and has a hard time explain [sic] that as an event outside the lab (though, there are possible ways in nature, but highly unlikely)... Instead of directed engineering, changes in the RBD and acquisition of the furin site would be highly compatible with the idea of continued passage of virus in tissue culture... Acquisition of the furin site would likely destabilize the virus but would make it disseminate to new tissues." Farrar concluded that SARS-CoV-2's origin could have occurred from passage in tissue culture on human cell lines in a BSL-2 lab for an extended period; accidentally creating a virus primed for rapid transmission between humans via gain of furin site (from tissue culture) and adaptation to human ACE2 receptor via repeated passage.¹¹¹

254. Dr. Garry of Tulane University said:

"I really can't think of a plausible natural scenario where you get from the bat virus or one very similar to it to nCoV where you insert exactly 4 amino acids 12 nucleotide that all have to be added at the exact same time to gain this function – that and you don't change any other amino acid in S2? I just can't figure out how this gets accomplished in nature."¹¹²

255. University of Edinburgh virologist Andrew Rambaut agreed: "From a (natural) evolutionary point of view the only thing here that strikes me as unusual is the furin

¹¹⁰ *Id.*

¹¹¹ *Id.* (citing <https://s3.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf#page=3126>)

¹¹² <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/>

- cleavage site. It strongly suggests to me that we are missing something important in the origin of the virus.¹¹³ Dr. Fouchier’s position was that debating natural versus lab-leak origin “would unnecessarily distract top researchers from their active duties and do unnecessary harm to science in general and science in China in particular.”¹¹⁴
256. Francis Collins agreed with this sentiment: “a swift convening of experts... is needed, or the voices of conspiracy will quickly dominate, doing great potential harm to science and international harmony.”¹¹⁵
257. In an e-mail to Fauci and Collins, Farrar wrote: “Tedros and Bernhard have apparently gone into conclave... they need to decide today in my view. If they do prevaricate, I would appreciate a call with you later tonight or tomorrow to think about how we might take forward [sic].”¹¹⁶
258. In this email, Farrar expressed concern about an article published by ZeroHedge which discussed the potential lab release as the origin of the virus. Id.
259. ZeroHedge was thereafter banned from Twitter.
260. On February 4, 2020, Farrar sent an early draft of what would come to be a seminal article concerning the origins of SARS-CoV-2 – *The Proximal Origin of SARS-CoV-2* (“*Proximal Origin* paper”) – published on March 17, 2020 in *Nature Medicine*. In his e-mail regarding the early draft, Holmes noted they “[d]id not mention other anomalies as this will make us look like loons” even though the group of scientists *did* discuss such “anomalies” (i.e., the furin cleavage site). Similarly, Andersen shared his concerns about “conspiracy theorists”

¹¹³ Id.

¹¹⁴ Id.

¹¹⁵ Id.

¹¹⁶ <https://s3.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf#page=3126> (accessed 1.2.2023)

and wrote to Fauci regarding the *Proximal Origin* paper: “If one of the main purposes of this document is to counter those fringe theories, I think it’s very important that we do so strongly and in plain language... ‘consistent with [natural evolution] is a favorite of mine when talking to scientists, but not when talking to the public – especially conspiracy theorists[.]”

261. In response to one of the drafts of the *Proximal Origin* paper, on February 4, 2020 Francis Collins stated: “Very thoughtful analysis. I note that Eddie [Holmes] is now arguing against the idea that this is the product of intentional human engineering. But repeated tissue culture passage is still an option – though it doesn’t explain the O-linked glycans.”¹¹⁷
262. Farrar responded: “Being very careful in the morning wording. ‘Engineered’ probably not. Remains a very real possibility of accidental lab passage in animals to give glycans. Will forward immediately or if you want to give Eddie [Holmes] a ring. Eddie would be 60:40 lab side. I remain 50:50...”¹¹⁸ Collins responded: “Yes, I’d be interested in the proposal of accidental lab passage in animals (which ones?).”¹¹⁹ Fauci responded to Collins’s e-mail later that day: “?? Serial passage in ACE2-transgenic mice” to which Farrar replied, “Exactly!”¹²⁰ Collins then replied: “Surely that wouldn’t be done in a BSL-2 lab?” to which Farrar replied, “Wild West.....” referring to the WIV.¹²¹
263. On February 11, 2020, Defendant Lipkin made the following observation about the draft *Proximal Origin* paper:¹²²

¹¹⁷ <https://www.documentcloud.org/documents/23316400-farrar-fauci-comms> at 93 (accessed 11.23.22).

¹¹⁸ *Id.*

¹¹⁹ *Id.*

¹²⁰ *Id.* at 92.

¹²¹ *Id.*

¹²² *Id.* (citing https://media.vanityfair.com/photos/625450eee8cd707c14c24ee9/master/pass/eban-email.jpg?_ga=2.257946248.283059975.1661889230-1462471727.1645214664)

On 11 Feb 2020, at 9:01 am, Ian Lipkin <[REDACTED]> wrote:

It's well reasoned and provides a plausible argument against genetic engineering. It does not eliminate the possibility of inadvertent release following adaptation through selection in culture at the institute in Wuhan. Given the scale of the bat CoV research pursued there and the site of emergence of the first human cases we have a nightmare of circumstantial evidence to assess.

Ian

264. Defendant Lipkin's admission that there was "a nightmare of circumstantial evidence" apparently refers to the fact that risky, abnormally dangerous research on SARS coronaviruses was taking place at WIV, the precise city of the eventual SARS-CoV-2 outbreak.
265. In or around February 2020, as the debate about COVID-19's origins began in earnest, Defendant Peter Daszak coordinated the drafting and signing of a group letter to *The Lancet*, a well-known international medical journal ("*Lancet* Letter").¹²³ The authors of the *Lancet* Letter argued – without support – that the COVID-19 pandemic occurred naturally, despite facts suggesting it was actually developed in a lab.¹²⁴
266. Defendant Peter Daszak's motive was obvious: "The *Lancet* statement, signed by 27 prominent scientists, has been influential in tamping down suspicions by some scientists that COVID-19 could have ties to China's Wuhan Institute of Virology, which has a research affiliation to the EcoHealth Alliance."¹²⁵

¹²³ Calisher, et al., "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19," *The Lancet*, Vol. 395, Issue 10226, March 7, 2020. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30418-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30418-9/fulltext) (last accessed 1 2 2023).

¹²⁴ Emails show scientists discussed masking their involvement in key journal letter on COVID origins. US Right to Know Feb 15, 2021, <https://usrtk.org/covid-19-origins/scientists-masked-involvement-in-lancet-letter-on-covid-origin/> accessed 1 2 2023; Also see Exhibit "3" to Compl.: Huff Declaration.

¹²⁵ *Id.*

267. The authors of the *Lancet* Letter – which include Defendant Daszak – wrote: “[t]he rapid, open, and transparent sharing of data on this outbreak is now being threatened by rumours and misinformation around its origins. We stand together to strongly condemn conspiracy theories suggesting that COVID-19 does not have a natural origin.” There is evidence that Defendant Daszak was in fact the primary author of the *Lancet* Letter.¹²⁶ Exhibit “21” Daszak-Baric email February 6, 2022.
268. In addition, five of the signatories of the *Lancet* Letter were directly affiliated with Defendant EcoHealth,¹²⁷ and two were partners there.¹²⁸
269. Further proof of Defendant Peter Daszak’s motive can be gleaned from an e-mail exchange between him and Defendant Baric, and others, on February 6, 2020, entitled “No need for you to sign the ‘Statement’ Ralph!!” sent with “high importance.” There, Defendant Peter Daszak wrote:

“I spoke with Linfa [Wang] last night about the statement we sent round. He thinks, and I agree with him, that you, me and him should not sign this statement, so it has some distance from us and therefore doesn’t work in a counterproductive way.

Jim Hughes, Linda Saif, Hume Field, and I believe Rita Colwell will sign it, then I’ll send it round some other key people tonight. We’ll then put it out in a way that doesn’t link it back to our collaboration so we maximize an independent voice.” See Exhibit “21” Baric – Daszak email exchange, February 6, 2020.

270. In response, Defendant Baric wrote:

“I also think this is a good decision. Otherwise it looks self-serving and we lose impact.”

¹²⁶ https://usrtk.org/wp-content/uploads/2021/02/Maryland-Lancet-emails_Feb_6_draft.pdf

¹²⁷ Sainath Suryanarayanan. EcoHealth Alliance orchestrated key scientists’ statement on “natural origin” of SARS-CoV-2. USRTK Nov 18 2020 <https://usrtk.org/covid-19-origins/ecohealth-alliance-orchestrated-key-scientists-statement-on-natural-origin-of-sars-cov-2/> (accessed 1 2 2023).

¹²⁸ <https://www.ecohealthalliance.org/partners> (accessed 1 2 2023).

271. Thus, while Defendant Peter Daszak organized the Lancet letter, he purposefully omitted Defendant EcoHealth's partnership with WIV and Defendant Baric's name in order to feign impartiality.¹²⁹ The letter publicly called upon the WHO to discount the lab leak theory.¹³⁰
272. The *Lancet* letter further included this statement: "*We declare no competing interests.*"¹³¹ Daszak also told the *Washington Post* that he had no conflicts of interest concerning his work with Shi Zhengli at the Wuhan Institute of Virology.¹³²
273. Defendant Daszak further tried to cover his tracks when he agreed to be part of a team sent to China by the WHO in February 2021 to investigate the origin of SARS-CoV-2.
274. Not surprisingly, the team reported it was "extremely unlikely" that the virus has been released from a lab.¹³³
275. Team members were asked to sign a declaration of interest and according to the report, "[a]ll declared interests were assessed and found not to interfere with the independence and transparency of the work."¹³⁴
276. Defendant Daszak could not have disclosed his connection to the WIV and prior **GOF** research and met the criteria for "independence and transparency."

¹²⁹ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/>

¹³⁰ Calisher, et al., "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19," *The Lancet*, Vol. 395, Issue 10226, March 7, 2020. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30418-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30418-9/fulltext) (accessed 11.21.22).

¹³¹ Calisher C, Carroll D, Colwell R et al. "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19." *The Lancet* 2020 Mar;395(10226):E42-E43

¹³² Josh Rogin. Opinion: the coronavirus shows he risks of scientific collaboration with China. *Washington Post* Apr 23 2020 https://www.washingtonpost.com/opinions/global-opinions/the-coronavirus-crisis-shows-the-risks-of-scientific-collaboration-with-china/2020/04/23/4ccd5850-85a8-11ea-878a-86477a724bdb_story.html (accessed 1 2 2023)

¹³³ WHO-convened Global Study of the Origins of SARS-CoV-2: China Part. <https://www.who.int/publications/i/item/who-convened-global-study-of-origins-of-sars-cov-2-china-part> (accessed 1 2 2023)

¹³⁴ *Ibid.* at 12.

277. Defendant Daszak also hid his conflicts of interest concerning his research and his ties to the Wuhan Institute of Virology from Jeffrey Sachs, chair of the *Lancet* COVID-19 Commission.
278. Defendant Daszak had been asked by Sachs to head a Task Force to look into the origins of COVID-19. According to Sachs, “*It is clear that the NIH co-funded research at the Wuhan Institute of Virology that deserves scrutiny under the hypothesis of a laboratory-related release of the virus.*”¹³⁵ Sachs ended the task force’s work after more information became public that questioned the veracity of statements made by Daszak.¹³⁶
279. On February 17, 2020, a preprint of the *Proximal Origin* paper was published.¹³⁷
280. On March 6, 2020, Andersen thanks Fauci, Collins, and Farrar for their “advice and leadership” on the *Proximal Origin* paper, which had just been accepted for publication in *Nature Medicine*. Fauci responds thanking Andersen and commenting, “[n]ice job on the paper.”
281. On March 17, 2020, the *Proximal Origin* paper is officially published in the journal by five authors: Andersen, Rambaut, Defendant Lipkin, Holmes, and Garry.
282. The media promptly accepted the paper’s conclusion that SARS-CoV-2 was not lab-made,¹³⁸ and branded anyone that argued otherwise “conspiracy theorists.” For example,

¹³⁵ Jeffrey Sachs. Finding the Origins of the COVID-19 and Preventing Future Pandemics.

<https://www.jeffsachs.org/newspaper-articles/cp24mtcpswgyty5st4pm29mwh6dt2d> (accessed 9.10.2022)

¹³⁶ COVID-19: Lancet investigation into origin of pandemic shuts down over bias risk. BMJ 2021;375:n2414 <https://www.bmj.com/content/375/bmj.n2414> (accessed 1.2.2023).

¹³⁷ <https://web.archive.org/web/20200217170645/http://virological.org/t/the-proximal-origin-of-sars-cov-2/398>

¹³⁸ See, e.g., <https://www.foxnews.com/science/the-coronavirus-did-not-escape-from-a-lab-heres-how-we-know> (last accessed 1.2.2023); <https://www.vice.com/en/article/xgqkn4/the-novel-coronavirus-was-not-made-in-a-lab-nature-medicine-study-confirms> (1.2.2023).

an article published on the ABC News website announced: “Sorry, conspiracy theorists. Study concludes COVID-19 ‘is not a laboratory construct.’”¹³⁹

283. The *Proximal Origin* paper proposed “two scenarios that can plausibly explain the origin of SARS-CoV-2: (i) natural selection in an animal host before zoonotic transfer; and (ii) natural selection in humans following zoonotic transfer.”¹⁴⁰ The authors also wrote that “[i]t is improbable that SARS-CoV-2 emerged through laboratory manipulation of a related SARS-CoV-like coronavirus” and provided the following analysis:

[T]he RBD of SARS-CoV-2 is optimized for binding to human ACE2 with an efficient solution different from those previously predicted. Furthermore, if genetic manipulation had been performed, one of the several reverse-genetic systems available for betacoronaviruses would probably have been used. However, the genetic data irrefutably show that SARS-CoV-2 is not derived from any previously used virus backbone.¹⁴¹

284. In their Conclusions section, the authors stated: “Although the evidence shows that SARS-CoV-2 is not a purposefully manipulated virus, it is currently impossible to prove or disprove the other theories of its origin described here.”¹⁴²
285. In mid-April, Francis Collins voiced his concern about the lab leak theory gaining widespread momentum and wondered if NIH can do anything “to help put down this very destructive conspiracy[.]”¹⁴³ Fauci tells Collins to stand down, as COVID-19 “is a shiny object that will go away in times.”¹⁴⁴
286. In an April 18, 2020 e-mail, Defendant Daszak thanked Dr. Anthony Fauci for “publicly standing up and stating that the scientific evidence supports a natural origin for COVID-

¹³⁹ <https://abcnews.go.com/US/conspiracy-theorists-study-concludes-covid-19-laboratory-construct/story?id=69827832> (accessed 1.2.2023).

¹⁴⁰ <https://www.nature.com/articles/s41591-020-0820-9> (accessed 1.2.2023).

¹⁴¹ *Id.*

¹⁴² *Id.*

¹⁴³ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/>

¹⁴⁴ *Id.*

- 19 from a bat-to-human spillover, not a lab release from the Wuhan Institute of Virology.”¹⁴⁵ See Exhibit “5” to Compl., Daszak to Fauci email exchange April 18- 19, 2022, re: thank you Dr. Fauci.
287. The above email was in response to Fauci’s statement at a White House press conference on April 17, 2020, where Fauci cited the *Proximal Origin* paper and told reporters the virus’s genome was “totally consistent with a jump of species from an animal to a human.”¹⁴⁶
288. In response to a White House press corps reporter’s inquiry, Fauci attached a copy of the *Proximal Origin* paper along with *A Genomic Perspective on the Origin and Emergence of SARS-CoV-2*.¹⁴⁷
289. Members of the Chinese Communist Party affiliated with Defendant Lipkin expressed pleasure with the efforts by scientists to dispel the lab leak theory.
290. On May 5, 2020, Defendant Lipkin wrote to Fauci: “*We deeply appreciate your efforts in steering and messaging.*”¹⁴⁸
291. As part of his message to Fauci, Defendant Lipkin forwarded an e-mail from China’s former Minister of Health, Chen Zhu, the current vice-chairperson of the Standing Committee of the National People’s Congress of China (headed by Li Zhanshu, a prominent CCP figure and top advisor to Chinese President Xi Jinping). While most of Zhu’s e-mail is redacted, he thanks Defendant Lipkin and promises to keep him “informed

¹⁴⁵ April 18, 2020, e-mail from Peter Daszak to Anthony Fauci, et al.:

<https://www.thegatewaypundit.com/2021/06/caught-top-official-thanks-dr-fauci-email-april-2020-insisting-covid-19-naturally-occurring-men-knew-lie/>

¹⁴⁶ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/> (accessed 1.2.2023).

¹⁴⁷ *Id.* (citing <https://pubmed.ncbi.nlm.nih.gov/32220310/> (accessed 1.2.2023)).

¹⁴⁸ <https://www.foxnews.com/politics/columbia-professor-lipkin-fauci-wuhan-lab-china> (accessed 11.21.22).

of any progress in the coming weeks.”¹⁴⁹ Zhu’s e-mail came in response to Defendant Lipkin’s e-mail to Zhu, in which Lipkin discusses the “[u]ncertainty about the origin of COVID-19 pandemic [] causing friction worldwide, particularly between China and the United States” and assures Zhu “[t]here is agreement that the causative agent, SARS-CoV-2 originated in a bat.” Lipkin also referenced “a high level of confidence that the virus was not deliberately modified in any laboratory[.]”¹⁵⁰

292. On March 30, 2021, the WHO released a report on the origins of SARS-CoV-2.¹⁵¹

293. Defendant Peter Daszak and Professor Koopmans (who had an undisclosed role in drafting the *Proximal Origin* paper) were members of the WHO team.

294. While WHO Director-General Ghebreyesus noted the investigation was still incomplete, the report dismissed a lab origin as “extremely unlikely[.]”¹⁵²

295. In records released by investigative reporting group Project Veritas, Major Joe Murphy USMC – who had previously worked at DARPA – made the following allegations:

“I’m reaching out to communicate some information relative to COVID that I don’t believe or your director is aware of. You probably saw earlier this week that more official documents linking NIH and EcoHealth Alliance to the Wuhan Institute of Virology were published by The Intercept. I came across additional incriminating documents and produced an analysis shortly after leaving DARPA last month. This report was routed to the DOD IG office.

I’m unsure whether the significance of what I communicated is understood by those that received the report. Decisions with regards to the vaccines do not appear to be informed by analysis of the documents. The main points being that SARS-CoV-2 matches the SARS vaccine variants the NIH-EcoHealth program was making in Wuhan; that the DOD rejected the program proposal because vaccines would be ineffective and because the spike proteins being inserted into the variants were deemed too dangerous (gain-of-function); and that the DOD

¹⁴⁹ <https://www.documentcloud.org/documents/20793561-leopold-nih-foia-anthony-fauci-emails-at-706-707> (accessed 11.21.22).

¹⁵⁰ *Id.* at 707.

¹⁵¹ <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/origins-of-the-virus> (accessed 11.21.22).

¹⁵² <https://www.theguardian.com/world/2021/feb/09/wuhan-laboratory-leak-covid-origin-theory-unlikely-says-who-team> (accessed 11.21.22).

now mandates vaccines that copy the spike protein previously deemed too dangerous. To me, and to those who informed my analysis, the situation meets no-go or abort criteria with regards to the vaccines until the toxicity of the spike protein can be investigated.”

296. Major Murphy further asserted:

“SARS-CoV-2 is an American-created recombinant bat vaccine, or its precursor virus. It was created by an EcoHealth Alliance program at the Wuhan Institute of Virology (WIV), as suggested by the reporting surrounding the lab leak hypothesis. The details of this program have been concealed since the pandemic began. These details can be found in the EcoHealth Alliance proposal response to the DARPA PREEMPT program Broad Agency Announcement (BAA) HR00228S0017, dated March 2018...

The contents of the proposed program are extremely detailed. Peter Daszak lays out step-by-step what the organization intends to do by phase and by location...

When synthesized with the EcoHealth Alliance proposal, US collections confirm EcoHealth Alliance was performing the work proposed...

DARPA rejected the proposal because the work was too close to violating the gain-of-function (GOF) moratorium, despite what Peter Daszak says in the proposal (that the work would not). As is known, Dr. Fauci with NIAID did not reject the proposal. The work took place at the WIV and at several sites in the US, identified in detail in the proposal.

SARS-CoV-2, hereafter referred to as SARSr-CoV-WIV, is a synthetic spike protein chimera engineered to attach to human ACE2 receptors and inserted into a recombinant bat SARSr-CoV backbone... It leaked and spread rapidly because it was aerosolized so it could efficiently infect bats in caves...”¹⁵³ ¹⁵⁴

297. In 2021, the WHO created the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), an international team of 26 people. SAGO issued reports on April 13, 2022, May 15, 2022, and June 9, 2022.

¹⁵³ https://assets.ctfassets.net/syq3snmxcl9/2mVob3cl1aDd8CNvVnyci6n/95af7dbfd2958d4c2b8494048b4889b5/JAG_Docs_pt1_Og_WATERMARK_OVER_Redacted.pdf (accessed 12.2.2022)

¹⁵⁴ <https://www.vanityfair.com/news/2022/03/the-virus-hunting-nonprofit-at-the-center-of-the-lab-leak-controversy-add-additional-facts>.

298. In the June 9, 2022 *Preliminary Report of the SAGO*, the group discussed the “[p]ossibility of introduction of SARS-CoV-2 to the human population through a laboratory incident[.]”¹⁵⁵
299. SAGO determined they could not make a conclusive recommendation on this issue until additional information can be obtained, noting “it is not common practice to publish the institutional implementation of biosafety and biosecurity practices of individual laboratories in peer-reviewed scientific journals[.]”¹⁵⁶ In other words, WIV’s cooperation is essential.
300. In the Summer of 2022, a connection between Holmes and WIV was uncovered – specifically related to work on RaTG13. “One hundred and sixty-three partial sequences describing SARS-like coronaviruses appeared on an NIH database, **but quickly disappeared from the database’s search results**... Two of the authors are Shi, senior scientist at the [WIV], and Holmes, a coauthor of the ‘proximal origin’ paper.”¹⁵⁷
301. Holmes said in a September 2022 interview that “[t]he really shocking thing about these submissions was that my name was on them... I thought, ‘why am I on this?’ Then I looked back, and it turns out there was this paper that was never published.”¹⁵⁸
302. Upon information and belief, Holmes had helped write a paper about bat coronaviruses in January 2018 at the request of a Chinese scientist, Jie Cui. The paper investigated where SARS1 bat viruses are found in Guangdong and Yunnan Provinces, and sought to discern whether there is a lineage that goes along that southern part of China.¹⁵⁹

¹⁵⁵ https://cdn.who.int/media/docs/default-source/scientific-advisory-group-on-the-origins-of-novel-pathogens/sago-report-09062022.pdf?sfvrsn=42b55bbc_1&download=true (accessed 11.21.22).

¹⁵⁶ *Id.*

¹⁵⁷ <https://usrtk.org/covid-19-origins/timeline-the-proximal-origin-of-sars-cov-2/#genbank> (emphasis added).

¹⁵⁸ *Id.*

¹⁵⁹ *Id.*

303. The partial sequence of the SARS-Cov-2 virus are missing from the NIH database and is highly concerning.
304. As Defendant Peter Daszak stated on Chinese state-affiliated television in 2018: “The work we do with Chinese collaborators is published jointly in international journals and the sequence data is uploaded onto the Internet free for everyone to read, very open, very transparent, and very collaborative... Science is naturally transparent and open... You do something, you discover something, you want to tell the world about it. That’s the nature of scientists.”¹⁶⁰, ¹⁶¹
305. In October 2022, the Senate Committee on Health Education, Labor and Pensions (Minority Oversight Staff) issued *An Analysis of the Origins of the COVID-19 Pandemic* (“Senate Minority Interim Report”). See Exhibit “13” to Compl. ¹⁶²
306. Senator Richard Burr explained in the October 2022 Senate Interim Report that the effort sought to clarify the origin of the COVID-19 pandemic so as “to address pandemic preparedness and response programs... to be better prepared to respond to future public health threats.”¹⁶³ *Id.* at 3.
307. The October 2022 Senate Interim Report acknowledged the challenges in establishing the origins of SARS-CoV-2, including efforts by the PRC to stonewall and prohibit transparency.¹⁶⁴ *Id.* at 4.

¹⁶⁰ <https://www.vanityfair.com/news/2022/03/the-virus-hunting-nonprofit-at-the-center-of-the-lab-leak-controversy> (accessed 1 2 2023).

¹⁶¹ <https://usrtk.org/covid-19-origins/scientists-masked-involvement-in-lancet-letter-on-covid-origin>

¹⁶² https://static1.squarespace.com/static/61910a2d98732d54b73ef8fc/t/635d0e2c7d58c0223ff8ac02/1667042865326/report_an_analysis_of_the_origins_of_covid-19_102722.pdf

¹⁶³ *Id.* at 3.

¹⁶⁴ *Id.* at 4.

308. The October 2022 Senate Minority Interim Report begins with an *Analysis of Natural Zoonotic Origins Hypothesis*.¹⁶⁵ *Id.* at 5. While recognizing natural zoonotic spillover might plausibly explain the Covid-19 outbreak, the Senate Interim Report also points to several “anomalies in the SARS-CoV-2 outbreak and the early COVID-19 pandemic compared to the emergence of past natural zoonotic spillovers...”¹⁶⁶
309. For example, assuming the virus began in a horseshoe bat residing in Southern China or Southeast Asia, the authors of the October 2022 Senate Interim Report question how the virus could have traveled over 1,000 miles before emerging in Wuhan. *Id.*
310. The October 2022, Senate Interim Report questions how there is still no evidence of an animal infected with SARS-CoV-2 or a related virus, despite being approximately three years into the pandemic.¹⁶⁷ *Id.*
311. The October 2022 Senate Interim Report recounts:
- “[a] number of epidemiologists and virologists – and, at first, the Chinese government – have asserted that the COVID-19 pandemic originated from a natural zoonotic transmission occurring at the Huanan Seafood Market. Government officials in China have subsequently also postulated the theory that SARS-CoV-2 arrived in China on the surface of imported frozen seafood or was brought into China by infected people or animals after being created by the U.S. military. Support for these alternative theories is limited to government-controlled publications in China and is not credible absent independent corroboration.”*¹⁶⁸ *Id.*
312. The October 2022 Senate Minority Interim Report further notes the lack of published genetic evidence that SARS-CoV-2 was circulating in animals prior to the start of the

¹⁶⁵ *Id.* at 5.

¹⁶⁶ *Id.*

¹⁶⁷ *Id.* at 6-7.

¹⁶⁸ *Id.* at 8 (citing Cohen, Jon. (Aug. 18, 2022). Where did the pandemic start? Anywhere but here, argue papers by Chinese scientists echoing party line. *Science*. 2022: 377 (6608). <https://www.science.org/content/article/pandemic-start-anywhere-but-here-argue-papers-chinese-scientists-echoing-party-line>; and Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). (June 9, 2022). Preliminary Report. World Health Organization. <https://cdn.who.int/media/docs/default-source/scientific-advisory-group-on-the-origins-of-novel-pathogens/sago-report-09062022.pdf>

pandemic. The authors also point to “the genomes of early COVID-19 cases” which did not show genetic evidence that SARS-CoV-2 recently circulated in species other than humans.¹⁶⁹ Id.

313. The October 2022 Senate Minority Interim Report concludes, in part, it appears likelier that the virus bound at the Huanan Seafood Market was shed by infected humans, rather than by infected animals.¹⁷⁰ Id.

314. The October 2022 Senate Minority Interim Report added:

“[t]here... do not appear to have been subsequent spillovers of the virus that generated sustained transmission in humans, or any other independent spillovers of SARS-CoV-2, from the immediate host animal(s) to humans since the pandemic started. It is also noteworthy that the earliest variants of SARS-CoV-2 were well-adapted for human-to-human transmission.”¹⁷¹

315. The October 2022 Senate Minority Interim Report concludes that the natural zoonotic hypothesis is unlikely to explain the origins of SARS-CoV-2 for the following reasons:

- The intermediate host species for SARS-CoV-2, if one exists, remains unidentified;
- Unlike SARS, the genomes of early COVID-19 cases from the first months of the pandemic do not show genetic evidence of SARS-CoV-2 having circulated in another animal species other than humans;
- SARS-CoV-2’s high binding affinity for human ACE2 receptors suggests that it is possible for it to directly infect humans without needing a period of adaptation in an intermediate host;
- Based on the available evidence, Wuhan is the only location where SARS-CoV-2 spilled over into humans; and
- The low genetic diversity of the earliest SARS-CoV-2 samples suggests that the COVID-19 pandemic is most likely the result of a single successful spillover of SARS-CoV-2.¹⁷² Id. at 12.

¹⁶⁹ *Interim Report* at 8 (citing sources).

¹⁷⁰ *Id.* at 8-9 (citing sources).

¹⁷¹ *Id.* at 9 (citing sources).

¹⁷² *Id.* at 12 (citing sources). Calisher, et al., “Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19,” *The Lancet*, Vol. 395, Issue 10226, March 7, 2020. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30418-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30418-9/fulltext) (last accessed 1 2 2023).

316. Despite Defendants' and their co-conspirators' efforts to bolster the "wet market" origin theory, published research showed that the market could *not* have been the source of the outbreak.
317. Indeed, the co-authors of the article published in the *Lancet*, including experts from Wuhan's leading infectious disease hospital, reported that among the first 41 patients identified in Wuhan, the first patient to show symptoms (on December 1, 2019) had no exposure to the market. "No epidemiological link was found between the first patient and later cases," wrote the researchers. Thirteen of the patients had no link to the wet market.¹⁷³ See Exhibit "14" at 24.
318. The authors of the October 2022 Senate Interim Report separately analyzed whether SARS-CoV-2 could have resulted from a "research-related incident." They noted that a lab release could result from "human errors, mechanical failure, animal bites, animal escapes, inadequate training, insufficient funding, and pressure for results," among other things.¹⁷⁴
319. Further, they observed that "[t]he WIV is an epicenter of advanced coronavirus research that was designed to predict and prevent future pandemics by collecting, characterizing, and experimenting on 'high-risk' coronavirus with the potential to spill over into humans."¹⁷⁵
320. The abnormally dangerous activity undertaken through WIV include:
- In the aftermath of the 2002-2004 SARS epidemic, WIV researchers undertook annual virus collection expeditions to Southern China and Southeast Asia, where bats naturally harbor SARS-related viruses, from 2004 onward.¹⁷⁶

¹⁷³ Huang C, Wang Y, Li X et al. "Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China." *Lancet*, 2020 Feb;395(10223):P497-506

¹⁷⁴ *Id.* at 13.

¹⁷⁵ *Id.* at 23.

¹⁷⁶ *Id.* at 23 (citing Qiu J. (June 1, 2020). How China's "Bat Woman" Hunted Down Viruses from SARS to the New Coronavirus. *Scientific American*. 322, 6, 24-32. doi:10.1038/scientificamerican0620-24, <https://www.scientificamerican.com/article/how-chinas-bat-woman-hunted-down-viruses-from-sars-to-the-new-coronavirus1/> (accessed 11.15.22)).

- WIV researchers actively sampled bats in Southern China and Southeast Asia where the SARS-related coronaviruses most similar to SARS-CoV-2 have been collected and identified.¹⁷⁷
- The WIV had collected more than 15,000 samples from bats, from which they had identified more than 1,400 bat viruses, including an estimated 100 unpublished sequences of SARS-related coronaviruses – the genre of coronaviruses to which SARS-CoV-2 belongs. The database containing the sequences of viruses collected by the WIV, including unpublished SARS-related coronaviruses, was taken offline starting in September 2019.¹⁷⁸
- Following field collection, samples were transported to Wuhan, where they were screened for the presence of coronaviruses. WIV researchers performed animal and human cell-related research using recombinant genetic techniques with the express goal of discovering human adapted SARS- like chimeric viruses. The WIV conducted these experiments in BSL2 and BSL3 laboratories.¹⁷⁹
- Senior coronavirus researcher Shi Zhengli disclosed that in 2018-2020, her team infected civets and humanized mice that expressed human ACE2 receptors with chimeric SARS-related coronaviruses. The results of these experiments have never been published.¹⁸⁰
- The EcoHealth Alliance NIH grants and DARPA grant proposals, in partnership with the WIV, sought to collect and conduct genetic recombinant experiments on SARS-related coronaviruses with specific traits that made those viruses a “high risk” for zoonotic spillover into animals and humans. SARS-CoV-2 shares many of the traits these researchers were interested in finding in SARS-related coronaviruses or interested in engineering such traits if they were not found naturally.¹⁸¹

¹⁷⁷ *Id.* at 23 (citing BurNIH-00000483-495 (on file with staff)).

¹⁷⁸ *Id.* at 23 (citing Editorial Board. We’re still Missing the Origin Story of this Pandemic. China is Sitting on the Answers. The Post’s View. Washington Post. <https://www.washingtonpost.com/opinions/2021/02/05/coronavirus-origins-mystery-china/>; see also Contributor, Anonymous & Bostickson, Billy & Demaneuf, Gilles. (2021). An Investigation into the WIV Databases that were Taken Offline. DOI: [10.13140/RG.2.2.28029.08160](https://doi.org/10.13140/RG.2.2.28029.08160) - https://www.researchgate.net/publication/349073738_An_investigation_into_the_WIV_databases_that_were_taken_offline

¹⁷⁹ *Id.* at 23 (citing Cohen J. (Jul. 31, 2020). Wuhan Coronavirus Hunter Shi Zhengli speaks out. Science. 369(6503), 487–488. <https://doi.org/10.1126/science.369.6503.487>).

¹⁸⁰ *Id.* at 24 (citing Cohen J. (Jul. 31, 2020). Wuhan Coronavirus Hunter Shi Zhengli speaks out. Science. 369(6503), 487–488. <https://doi.org/10.1126/science.369.6503.487>).

¹⁸¹ *Id.* at 24 (citing Cohen J. (Jul. 31, 2020). Wuhan Coronavirus Hunter Shi Zhengli speaks out. Science. 369(6503), 487–488. <https://doi.org/10.1126/science.369.6503.487>).

321. The October 2022 Senate Minority Interim Report further noted evidence of biosafety failures at the WIV, management and training concerns at the WIV, and anomalies in epidemiology of SARS-CoV-2 outbreak as supporting the lab-leak origin.¹⁸²
322. SARS-CoV-2 was created in a lab and developed in collaboration with other entities. “BLAST” is an acronym for “Basic Local Alignment Search Tool.” It’s a computer algorithm available for use at the National Center for Biotechnology Information (NCBI) website.
323. The above-described algorithm allows scientists to quickly query a DNA sequence to find matches or regions of similarity between protein sequences.
324. Scientists worldwide deposit their sequences when they make new discoveries.
325. A distinguishing feature of SARS-CoV-2 is the furin cleavage site and the 12-nucleotide insertion in the spike protein, particularly its two consecutive CGG codons. Researchers conducted a BLAST search and found a 100% reverse match in a proprietary U.S. patent filed on February 4, 2016 (US patent 9,587,003).¹⁸³
326. According to the researchers, statistical analysis shows that the probability of this sequence randomly being present in a 30,000-nucleotide viral genome is 3.21×10^{-11} (less than one in one billion). The owner of the patent is Moderna, which makes COVID-19 vaccines using mRNA technology.¹⁸⁴

¹⁸² See Exhibit 13, Senate Minority Interim Report October 2022 at 24-25.

¹⁸³ Bancel S, Chakraborty T, De Fougerolles A, Elbashir SM, John M, Roy A, et al. Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides. Cambridge, MA: United States Patent. (2016). <https://pubchem.ncbi.nlm.nih.gov/patent/US-9587003-B2> (accessed 1.2.2023)

¹⁸⁴ Ambati BK, Varshney A, Lundstrom K et al. “MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site.” Frontiers Virol 2022 Feb; <https://doi.org/10.3389/fviro.2022.834808> (accessed 9.10.2022).

327. On October 20, 2022, Bruttel and colleagues issued a pre-print entitled, “*Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2.*” (“*Endonuclease Fingerprint Paper*”).¹⁸⁵
328. After reviewing the evidence, the authors concluded that “SARS-CoV-2 likely originated from a reverse genetics system.” They explained that “[t]he BsaI/BsmBI map of SARS-CoV-2 is anomalous for a wild coronavirus and more likely to have originated from an infectious clone designed as an efficient reverse genetics system.”¹⁸⁶
329. The above-mentioned authors further noted their evidence “is independent of other genomic evidence suggestive of a lab origin of SARS-CoV-2, such as the furin cleavage site (FCS) found in SARS-CoV-2 yet missing from all other known sarbecoviruses.”¹⁸⁷ And they advise that “[t]he probable laboratory origin suggested by our findings motivates improvements in global biosafety.” *Id.*
330. Further evidence suggests that SARS-CoV-2 has the restriction map of an infectious clone. According to scientist Alex Washburne:¹⁸⁸

“Valentin Bruttel, Tony VanDongen and I examined all infectious clones of coronaviruses made from 2000-2019 by type II directional assembly.”¹⁸⁹ We found that 8 out of 10 infectious clones, including the single CoV infectious clone made in the Wuhan Institute of Virology, used the specific type II directional assembly method cited in the DEFUSE grant. We uncovered a fingerprint of this particular method of *in vitro* viral assembly: due to bioengineering constraints, the cutting/pasting sites researchers choose end up being unusually regularly spaced compared to the random spacing of cutting/pasting sites in non-engineered viruses.

SARS-CoV-2 has that exact fingerprint.¹⁹⁰ In our preprint, we examined a wide range of other coronaviruses and SARS-CoV-2 has the most extreme

¹⁸⁵ Bruttel, et al., *Endonuclease Fingerprint Indicates a Synthetic Origin of SARS-CoV-2*. See <https://www.biorxiv.org/content/10.1101/2022.10.18.512756v1.full.pdf>

¹⁸⁶ *Id.*


¹⁸⁷ *Id.*

¹⁸⁸ <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (accessed 12.1.2022)

¹⁸⁹ See <https://alexwasburne.substack.com/p/the-synthetic-origin-theory-of-sars> (accessed 12.1.2022)

¹⁹⁰ See <https://alexwasburne.substack.com/p/a-synthetic-origin-of-sars-cov-2> (accessed 12.1.2022)

infectious-clone-like type II restriction map of all the natural coronaviruses we analyzed.¹⁹¹ The FCS of SARS-CoV-2 is anomalous among sarbecoviruses, and the type II restriction map of SARS-CoV-2 is the most extreme type II restriction map of any coronavirus we analyzed.”



(A) The BsaI/BsmBI restriction maps of CoVs, with the unusual even-spacing of SARS-CoV-2 BsaI/BsmBI sites in vertical dashed lines. (B) In the number of fragments & length of the longest fragment, SARS-CoV-2 is right within the idealized range of the proposed efficient reverse genetic system. (C) The BsaI/BsmBI map of SARS-CoV-2 is an anomaly among natural coronaviruses and a midpoint of engineered coronaviruses.

331. Washburne further argues that:

“...animal trade outbreaks look a lot different from SARS-CoV-2 emergence... While the animal trade and Huanan wet market are proposed as the proximal origins of SARS-CoV-2 under the zoonotic theory, the earliest cases may not have been associated with the wet market and SARS-CoV-2 lacks a broader geographic fingerprint characteristic of our prior experience with SARS-CoV outbreaks caused by animal trade networks.”¹⁹²

¹⁹¹ <https://www.biorxiv.org/content/10.1101/2022.10.18.512756v1> (accessed 12.1.2022)

¹⁹² <https://alexwasburne.substack.com/p/the-totality-of-the-circumstances> (accessed 12.1.2022)

K. Dangerousness of SARS-CoV-2

1. Background Facts

332. SARS-CoV-2 is undeniably dangerous, which is why a pandemic was declared. At all times relevant hereto, SARS-CoV-2 (the virus that causes COVID-19) has been listed pursuant to 42 C.F.R. §73.3(b) as one of what is categorized as “Select Agents” because HHS has determined it “ha[s] the potential to pose a severe threat to public health and safety.” 42 C.F.R. § 73.3(a).¹⁹³
333. Pursuant to 42 C.F.R. §73.12, research involving “Select Agents” is subject to strict biosafety and containment procedures because of the severe threat they pose to public health and safety.¹⁹⁴
334. According to the CDC, there are “a wide range of symptoms reported” for COVID-19, including fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea.¹⁹⁵
335. The CDC also addresses “Post-COVID Conditions” on its website, which “is an umbrella term for the wide range of physical and mental health consequences experienced by some patients that are present four or more weeks after SARS-CoV-2 infection...”¹⁹⁶ CDC also acknowledges that Post-COVID conditions are referred to as: Long COVID, Post-acute COVID-19, Long-term effects of COVID, Post-acute COVID syndrome, Chronic COVID, Long-haul COVID, and others. **“Although standardized case definitions are still being developed, in the broadest sense, post-COVID conditions can be considered a lack of**

¹⁹³ <https://www.ecfr.gov/current/title-42/chapter-I/subchapter-F/part-73/section-73.3>

¹⁹⁴ <https://www.ecfr.gov/current/title-42/chapter-I/subchapter-F/part-73/section-73.12>

¹⁹⁵ <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html> (accessed 12.1.2022).

¹⁹⁶ <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html> (accessed 1.2.2023).

return to a usual state of health following acute COVID-19 illness.”¹⁹⁷ The CDC further describes debilitating results of COVID-19, including multiorgan system effects.

2. The Virus That Injured Plaintiffs

336. In early 2020, the daily death toll of COVID-19 was harrowing, as the medical journals and media frequently reported.¹⁹⁸
337. Video footage from China claimed to show people collapsing in the streets of Wuhan, sending shockwaves of fear across the world.¹⁹⁹
338. In Italy, “hysteria over coronavirus... [was] reminiscent of the black death.”²⁰⁰ SARS-CoV-2 was a virus that shut down the world.
339. On March 11, 2020, the WHO declared that COVID-19 was a “pandemic.”²⁰¹
340. SARS-CoV-2 has been designated by the Department of Health and Human Services (“HHS”) as a biological agent or toxin with “potential to pose a severe threat to public health and safety.”²⁰²
341. In the first quarter of 2020, officials from around the world took unprecedented steps to combat the emerging pandemic and the novel pathogen that caused it. The risks from SARS-CoV-2 were so severe that entire countries forced their citizens into “lockdowns,” whereby people could not freely leave their homes, travel, go to work, attend school, or meet in groups.²⁰³

¹⁹⁷ *Id.* (emphasis in original).

¹⁹⁸ See, e.g., <https://www.nature.com/articles/d41586-020-01008-1> (accessed 1.2.2023).

¹⁹⁹ <https://www.dailymail.co.uk/news/article-7923981/Coronavirus-Disturbing-videos-claim-people-collapsing-Wuhan.html> (accessed 12.1.2022).

²⁰⁰ <https://sg.news.yahoo.com/hysteria-over-coronavirus-italy-reminiscent-165558650.html> (accessed 1 2 2023)

²⁰¹ <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>

²⁰² CFR § 73.3(a) and (b).

²⁰³ See, e.g., <https://www.reuters.com/article/us-health-coronavirus-italy/italy-to-extend-coronavirus-lockdown-until-easter-as-new-cases-fall-idUSKBN21H2EH>; <https://www.politico.com/news/2020/03/22/germany-merkel-bans-meetings-two-people-142283>;

342. On widely viewed television channels such as CNN, a Coronavirus Pandemic case and death count was perpetually displayed on-screen, per below:²⁰⁴



343. As such, SARS-CoV-2 came to be known as “the virus that shut down the world.”²⁰⁵

3. EcoHealth Award Terminated

344. In an October 20, 2021, letter (“Tabak Letter”), NIH Deputy Director Lawrence Tabak wrote to Representative James Comer (R-KY) that the NIH had given a grant to EcoHealth Alliance, Inc., which then awarded a subgrant to the Wuhan Institute of Virology, and that EcoHealth had failed to submit reports as required under the terms of the grant.²⁰⁶ See Exhibit “7” to Compl.: Tabak letter to Comer dated October 20, 2021.

345. Tabak’s letter stated that EcoHealth’s “limited experiment” looked at whether spike proteins from naturally occurring bat viruses circulating in China were capable of binding

<https://www.cnn.com/2020/04/16/new-york-and-other-east-coast-states-extend-shutdown-of-nonessential-businesses-to-may-15-gov-cuomo-says.html>

²⁰⁴ https://edition.cnn.com/world/live-news/coronavirus-pandemic-03-31-20/h_3253ec4c79b62eef1cc7024e18a16f0

²⁰⁵ <https://www.washingtonpost.com/graphics/2020/world/coronavirus-pandemic-globalization/>

²⁰⁶ <https://int.nyt.com/data/documenttools/niH-eco-health-alliance-letter/512f5ee70ce9c67c/full.pdf> (accessed 11/16/2022).

- to the ACE2 receptor in a mouse model. Tabak stated that mice infected with the modified virus became sicker than those who were infected with the unmodified virus. Tabak also wrote, “[a]s sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do.”²⁰⁷ *Id.*
346. Tabak explained that while the NIH determined the research did not involve enhanced pathogens of pandemic potential, it nevertheless required “an additional layer of oversight” as a condition for the grant.
347. Specifically, EcoHealth was required to “report immediately a one log increase in growth” which would then prompt a secondary review to determine whether the research aims should be re-evaluated, or new biosafety measures should be enacted.”²⁰⁸ *Id.*
348. Defendant EcoHealth allegedly failed to report this finding immediately as required by the terms of the grant, they were given five days to submit to NIH all unpublished data from the experiment and work conducted under the award.²⁰⁹ *Id.*
349. In an October 20, 2021 tweet, Oversight Committee Republicans (@GOPoversight) said the following regarding the Tabak Letter, specifically calling out Defendants Peter Daszak and EcoHealth:²¹⁰

²⁰⁷ *Id.*

²⁰⁸ *Id.*

²⁰⁹ *Id.*

²¹⁰ <https://twitter.com/GOPoversight/status/1450934193177903105> (accessed 1.2.2023).



Oversight Committee Republicans
@GOPoversight




July 28th NIH says “no NIAID funding was approved for Gain of Function research at the WIV.”

Obviously, they were lied to.

NIH confirmed today EcoHealth and the WIV conducted GOF research on bat coronaviruses.

@PeterDaszak with EcoHealth hid it from the USG.



5:17 PM · Oct 20, 2021

350. A former member of a WHO advisory committee, Jamie Metzl, tweeted in response that it is “[d]eeply concerning Peter Daszak & @EcoHealthNYC violated terms of their @NIH grant by not reporting the increased ability of the genetically altered bat coronaviruses to infect human cells. We need a full investigation w/access to all relevant data, samples & personnel in #China.”²¹¹ Separately, Rutgers Professor Richard H. Ebright tweeted his own response:

²¹¹ <https://twitter.com/JamieMetzl/status/1450949931305422851> (accessed 12.1.2022)



Richard H. Ebright ✓ @R_H_Ebright · Oct 20, 2021

...

Replying to @GOPoversight and @PeterDaszak

The NIH received the documents in 2018 and reviewed the documents in 2020 and again in 2021.

The NIH--specifically, Collins, Fauci, and Tabak--lied to Congress, lied to the press, and lied to the public. Knowingly. Willfully. Brazenly.

351. On January 6, 2022, Dr. Michael Lauer, NIH Deputy Director for Extramural Research wrote to Defendant EcoHealth Alliance – specifically Drs. Aleksei Chmura and Defendant Peter Daszak. Exhibit “22” to January 6, 2022, Letter from Michael S. Lauer, MD, HIH Deputy Director for Extramural Research to Daszak, *et ano*.
352. In the above-mentioned letter, Dr. Lauer informed Defendants EcoHealth and Peter Daszak that “NIH is imposing specific award conditions on EcoHealth’s active awards, U01AI151797 and U01AI153420. **EcoHealth has demonstrated a history of failure to comply** with several elements of the terms and conditions of grant awards not only for these active awards, but also for the suspended award, R0AI110964.” (Emphasis added). *Id.* See Exhibit “16” to Compl.: Lauer letter to Chmura and Daszak, July 23, 2021.
353. Dr. Lauer outlined Defendant EcoHealth’s failures to comply in detail. *Id.* at 24.
354. As a result, NIH imposed specific award conditions (SAC), and required Defendant EcoHealth to successfully implement a Corrective Action Plan (CAP).
355. On August 19, 2022, NIH terminated a sub-award to WIV that had been part of an earlier grant to Defendant EcoHealth due to “failure to meet award terms and conditions requiring provision of records to NIH upon request.”²¹² (Emphasis in original). Exhibit “23” Letter from Lauer to Comer August 19, 2022.

²¹² https://republicans-oversight.house.gov/wp-content/uploads/2022/08/NIH-Letter-to-Congress-regarding-EHA_Comer.pdf

356. On August 19, 2022, that same day, NIH informed Defendants EcoHealth and Peter Daszak that, “NIH is terminating the subaward from EcoHealth Alliance (EHA) to the Wuhan Institute of Virology (WIV) due to material non-compliance with terms and conditions of award that cannot be remedied by specific award conditions.” According to NIH, Defendant EcoHealth failed to provide NIH the laboratory notebooks and original electronic files from the research conducted at WIV. “To date, WIV has not provided these records” either.²¹³
357. NIH further explained that “WIV’s refusal to provide the requested records, and EHA’s failure to include the required terms in WIV’s subaward agreement represent material failures to comply with the terms of award.”²¹⁴ While NIH noted that the partial termination is appealable, there is no evidence EcoHealth appealed the termination. The NIH advised that Defendant EcoHealth could potentially renegotiate the grant without involvement of the WIV.²¹⁵

L. Congressional Investigations Into the Origins of SARS-CoV-2 Are Continuing Amid NIH’s Stonewalling

358. On November 30, 2022, members of Congress²¹⁶ sent another letter to Dr. Lawrence Tabak at the NIH: “We write to urge the [NIH] to respond to our longstanding requests to provide us information related to the origins of the COVID-19 pandemic, including matters related to [NIAID’s] grant to EcoHealth Alliance and subgrant to [WIV], and other subjects.”²¹⁷
- Exhibit “20”: House letter to Tabak, November 30, 2022.

²¹³ *Id.* at 3.

²¹⁴ *Id.*

²¹⁵ <https://theintercept.com/2022/10/04/ecohealth-alliance-lab-leak-nih-grant/>

²¹⁶ Representatives Rodgers (Committee on Energy and Commerce), Guthrie (Subcommittee on Health), and Griffith (Subcommittee on Oversight and Investigations) issued the letter.

²¹⁷ <https://republicans-energycommerce.house.gov/wp-content/uploads/2022/11/11.30.22-Letter-to-Dr.-Tabak.pdf> (accessed 12.2.2022).

359. The House members expressed concern that NIH has continuously failed to address their correspondence, and summarized the twelve letters sent between March 18, 2021 through October 31, 2022:

- a. a. March 18, 2021, Letter to Dr. Francis Collins – Congressional members sent a letter “requesting information related to where SARS-CoV-2 originated and how NIH grant dollars at the WIV were used.” NIH has not provided written responses. Exhibit “29”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Feb. 14, 2022) (internal footnotes omitted).
- b. June 10, 2021, Letter to Dr. Francis Collins – Congressional members “wrote to strongly express support for a ‘comprehensive investigation into the origins of the COVID-19 pandemic, including the possibility of an accidental laboratory leak.’ We identified several concerns related to the financial management and oversight of the NIH grant to EcoHealth Alliance and its subaward recipient, the WIV.” NIH has not provided responses.²¹⁸ Exhibit “24”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (March 18, 2021).
- c. July 21, 2021, Letter to Dr Francis Collins – Congressional members asked for more information regarding “NIH-supported gain-of-function research

²¹⁸ Exhibit “25”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (June 10, 2021) (internal footnotes omitted).

involving ‘humanized mice’ as well as briefings from NIAID officials related to a grant award to EcoHealth Alliance, and an NIAID’s official [sic] visit to WIV.” Exhibit “26”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (July 21, 2021) (internal footnotes omitted).

- d. August 24, 2021, Letter to Dr. Francis Collins – Congressional members followed up concerning “NIAID’s coronavirus grant to EcoHealth Alliance[]” including inquiries about Defendant EcoHealth’s “oversight of its subgrantee WIV’s experiments to ensure compliance with biosafety requirements.” NIH has not provided a written response to date. Exhibit “27”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Aug. 24, 2021) (internal footnotes omitted).
- e. October 27, 2021, Letter to Dr. Francis Collins – “Based on documents the Department of Health and Human Services arranged for the Committee to review *in camera*, we highlighted in an October 27, 2021, letter our concerns about NIH’s oversight of EcoHealth Alliance’s research proposal that purported it was not conducting gain-of-function research. In addition, the letter raised concerns EcoHealth Alliance failed to comply with NIH’s grant terms yet continued to receive millions of dollars in grant funds. NIH was asked to reply to our questions by November 10, 2021, but to date, NIH has not submitted a written response to this letter.” Exhibit “28”, Letter from Committee Ranking

Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Oct. 27, 2021) (internal footnotes omitted).

- f. February 14, 2022, Letter to Dr. Francis Collins – The Committee sent a letter to Dr. Collins concerning suppression of scientific debate that SARS-CoV-2 could have originated from a research related incident. A similar letter was sent to Dr. Fauci, but neither has responded to.
- g. February 24, 2022, Letter to Dr. Lawrence A. Tabak – “On February 24, 2022, we raised concerns with you that NIH failed to effectively enforce its policies and regulations over EcoHealth Alliance. Specifically, EcoHealth withheld attribution of data to another federal grant from NIH, raising the possibility it was double-billing two federal agencies for the same research. Additionally, EcoHealth Alliance’s inability to provide laboratory notebooks and electronic files called into question the safety of the research conducted on humanized mice. Additionally, the letter expressed that, in contravention of federal regulations regarding financial disclosures, EcoHealth Alliance may have hidden from NIH the identities of its private donors. Several questions were requested to be answered by March 24, 2022. To date, NIH has not sent a written response.” Exhibit “30”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (Feb. 24, 2022)
- h.

- i. April 25, 2022, Letter to Dr. Lawrence A. Tabak – “On April 25, 2022, we wrote to you raising concerns that EcoHealth Alliance was potentially omitting key information in research allegedly conducted at WIV in order to obtain a renewal of federal grant funding. Specifically, information related to mice deaths (the higher death rates with mice infected by chimeric viruses, a supposedly unexpected result) may have been withheld from peer reviewers during the grant renewal’s application. These nondisclosures may have prevented peer reviewers from examining the complete research findings, thereby preventing them from questioning the riskiness of the experiments conducted with federal grant funds. While NIH has provided some information in a bipartisan briefing, many questions remain unanswered. NIH has not provided a written response to this letter.” Exhibit “31”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (Apr. 25, 2022)
- j. July 21, 2022, Letter to Dr. Lawrence A. Tabak – The committee sent a letter to NIH regarding its recent failure to convene a Scientific Management Review Board. Exhibit “32”, Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (July 21, 2022).
- k.

- l. August 11, 2022, Letter to Dr. Lawrence A. Tabak - This letter dealt with issues not directly related to this matter.
- m. October 24, 2022, Letter to Dr. Lawrence A. Tabak – “Last month we sent you a letter raising concerns about how NIH could contemplate funding a new EcoHealth Alliance grant considering this organization’s past noncompliance with regulatory requirements and grant terms. As we noted, EcoHealth Alliance’s history of failing to substantiate scientific experiments with material records and its slipshod oversight of its sub awardee, the WIV, should have caused NIH to conclude that EcoHealth Alliance could not be a responsible steward of federal grant funding. We submitted several questions for you to answer by November 7, 2022, regarding the NIH’s decision to renew its funding of EcoHealth Alliance. To date, we have not received a written response from NIH to this letter.”

M. Defendant EcoHealth Continues to Pursue Risky GOF and Other Research

360. Despite the wreckage caused by the Defendants’ and their co-conspirators’ dangerous research, and even though Defendant EcoHealth has refused to cooperate with Congressional inquiries, Defendant EcoHealth continues to engage in risky research that could cause another pandemic.
361. Within weeks of terminating the funding for the Wuhan lab in August 2022, the NIH awarded a new grant to EcoHealth: “Analyzing the potential for future bat coronavirus emergence in Myanmar, Laos, and Vietnam.”²¹⁹ The project number is 1R01AI163118-

²¹⁹ <https://reporter.nih.gov/search/0jAp779zVkaN-DEsKnKa5A/project-details/10522470>

01A1, while the contact PI/project leader is Peter Daszak and the Awardee Organization is EcoHealth Alliance, Inc.²²⁰

362. In questioning how NIH could continue to fund Defendant EcoHealth's research in light of the events discussed herein, the Committee on Energy and Commerce highlighted Defendant EcoHealth's past transgressions, including failure to substantiate scientific experiments with material records and careless oversight of WIV. This "should have caused NIH to conclude that EcoHealth Alliance could not be a responsible steward of federal grant funding."²²¹

363. Defendants continue to double, triple, and quadruple down on risky, dangerous research that has the potential to cause another pandemic. As noted in the *Intercept*:

The aim of the new research is to identify areas of potential concern for future pandemic emergence in order to help public health authorities suppress an outbreak before it breaks containment. But the process of performing the research introduces the risk of sparking an outbreak that would not otherwise have occurred, a concern highlighted by The Intercept last year: "Virtually every part of the work of outbreak prediction can result in an accidental infection. Even with the best of intentions, scientists can serve as vectors for the viruses they hunt – and as a result, their work may put everyone else's lives on the line along with their own."²²²

364. In the words of Professor Richard Ebright, "[i]t is disturbing that additional funding continues to be awarded for the same high-risk research that may have caused the current pandemic, before there has been a national investigation of the origin of the current pandemic."²²³ In fact, congressional investigations to date have concluded it is "more

²²⁰ *Id.*

²²¹

²²² <https://theintercept.com/2022/10/04/ecohealth-alliance-lab-leak-nih-grant/> (accessed 11.17.22) (quoting <https://theintercept.com/2021/12/28/covid-pandemic-virus-hunters-ecohealth-alliance-peter-daszak-wuhan/> (last accessed 11.17.22)).

²²³ <https://theintercept.com/2022/10/04/ecohealth-alliance-lab-leak-nih-grant/> (accessed 11.17.22).

likely than not” that the Covid-19 pandemic resulted from a research incident.²²⁴ Indeed, the House Foreign Affairs Committee Report Minority Staff in August 2021 issued an addendum to their September 2020 *Final Report*, entitled *The Origins of COVID-19: An Investigation of the Wuhan Institute of Virology*. There, the committee concluded:

It is the opinion of the Committee Minority Staff, **based on the preponderance of available information**; the documented efforts to obfuscate, hide, and destroy evidence; and the lack of physical evidence to the contrary; that **SARS-CoV-2 was accidentally released from a Wuhan Institute of Virology laboratory**... Its release was due to poor lab safety standards and practices, exacerbated by dangerous gain-of-function research being conducted at inadequate biosafety levels, including BSL-2.”²²⁵

VI. INJURIES – PLAINTIFF-SPECIFIC ALLEGATIONS

Plaintiff McKinniss

365. Plaintiff Kathleen McKinniss’ Decedent, Rosemarie McKinniss was exposed to SARS-CoV-2 in a nursing home and died from said exposure on April 24, 2020.²²⁶ See Exhibit “8” to Compl.: McKinniss Death Certificate; See Exhibit “9” to Compl., Photo of McKinniss.
366. Decedent Rosemarie McKinniss’ death was directly and proximately caused by Defendants’ and their co-conspirators’ actions and omissions as alleged herein.
367. Decedent Rosemarie McKinniss was extremely fearful for her life and well-being upon contracting SARS-CoV-2 and was isolated from her family and friends in her final days after suffering through a quarantine that caused all of them extreme emotional distress,

²²⁴ See Exhibit “13”, e.g., Source: Senate Minority Interim Report October 2022 @ 23.

²²⁵ See Exhibit “13” Senate Minority Interim Report October 2022, *The Origins of COVID-19: An Investigation of the Wuhan Institute of Virology* at 62 (emphasis added).

²²⁶ See Exhibit “8” to Compl.: Rosemarie McKinniss Death Certificate, showing cause of death was Covid-19).

intense pain and physical suffering, all due to Defendants' and their co-conspirators' actions and omissions as alleged herein.

368. The death of Decedent Rosemarie McKinniss caused extreme emotional pain, physical harm, and economic loss to Plaintiff Kathleen McKinniss, a direct and proximate result of Defendants' and their co-conspirators' acts and omissions as alleged herein.

Plaintiff Rosado

369. Plaintiff Carin Rosado was a front-line, essential worker with the NYC Fire Department working as an EMT.
370. Plaintiff Rosado worked through the early stages of SARS-CoV-2 when its consequences were then unknown and being concealed by Defendants, and contracted SARS-CoV-2 and since then has been suffering neurological, financial and emotional injuries.
371. Plaintiff Rosado was injured by exposure to SARS-CoV-2, including suffering an illness that caused migraines, high fever, cough, and intense fear due to the unknown consequences of contracting SARS-CoV-2, a novel virus.
372. Plaintiff Rosado further suffers from skin sensitivity, and loss of taste and smell due to exposure to SARS-CoV-2, affecting her ability to protect herself as a front-line worker because skin sensitivity and sense of smell are essential components of an EMT employee necessary to protect the EMT, and those in need and receiving emergency services.
373. On January 20, 2022, Plaintiff Rosado was fired by her employer for refusing a Covid-19 vaccination, thus suffering economic and property loss as a result of her loss of employment with the City of New York in the FDNY/EMT unit because of Defendants' **GOF SARS-CoV-2 virus creation.**

374. Plaintiff Rosado brings this action on her own behalf seeking compensation for her injuries directly and proximately caused by Defendants' wrongful conduct, causing her physical harm, emotional injuries, and economic loss.

Plaintiff Finn

375. Plaintiff Geraldine Finn's Decedent, James Finn, was admitted to Montefiore Nyack Hospital in Nyack New York, on March 25, 2021, and after receiving the standard COVID treatment protocol, and died on April 18, 2021.
376. Decedent James Finn's Death Certificate lists his death as Covid 19. See Exhibit "11", Finn Death Certificate. See Exhibits "11 & 12" to Compl., re: Finn Death Certificate and Photos.
377. Plaintiff Finn's husband James suffered from intense pain and fear prior to his death and was ventilated as a standard COVID treatment protocol suffering an agonizing death.
378. Plaintiff Finn was isolated and quarantined from his family during his final days causing all of them extreme emotional distress and anguish.
379. The death of James Finn caused emotional and physical harm, and economic loss to Plaintiff Geraldine Finn and to James Finn's heirs, a direct and proximate result of Defendants' and their co-conspirators' actions and omissions as alleged herein.

Plaintiff Caddoo

380. Plaintiff David Caddoo's mother, Decedent, Patricia Caddoo, was a resident of an assisted living facility in Lewisville, TX.
381. On December 5, 2020, Decedent Caddoo was sent to the emergency room at Medical City Hospital in Lewisville, TX where she tested positive for COVID.

382. Decedent Caddoo was intubated immediately in the ER and admitted to the ICU where she was not expected to survive the night.
383. On December 6, 2020, Decedent was extubated and sent back to her assisted living facility where she never regained consciousness and passed away on December 9, 2020. Exhibit “33” Death Certificate of Patricia Cadoo re: Covid 19.
384. Decedent Patricia Caddoo’s death was directly and proximately caused by Defendants’ and their co-conspirators’ actions and omissions as alleged herein.
385. Plaintiff Caddoo’s mother Patricia suffered from intense pain and fear prior to her death and received the standard COVID treatment protocol she received suffering an agonizing death.
386. Plaintiff Caddoo was isolated and quarantined from her family during her final days causing all of them extreme emotional distress and anguish.
387. The death of Patricia Caddoo caused emotional and physical harm, and economic loss to Plaintiff David Caddoo and to Patricia Caddoo’s heirs, a direct and proximate result of Defendants’ and their co-conspirators’ actions and omissions as alleged herein.

Plaintiff Smith

388. Plaintiff Melanie Smith’s Decedent, Robert Sendzischew, upon having difficulty breathing the morning of August 1, 2021, was taken by ambulance to South Nassau Mt. Sinai Hospital where he tested positive for COVID-19.
389. After receiving the standard COVID treatment protocol, he died on December 13, 2021. See Exhibit “34” Sendzischew Death Certificate, re: Covid 19.
390. Decedent Robert Sendzischew’s death was directly and proximately caused by Defendants’ and their co-conspirators’ actions and omissions as alleged herein.

391. Decedent Robert Sendzischew was extremely fearful for his life and well-being upon contracting SARS-CoV-2 and was isolated from his family and friends in his final days after suffering through a quarantine that caused all of them extreme emotional distress, intense pain and physical suffering, all due to Defendants' and their co-conspirators' actions and omissions as alleged herein.

392. The death of Decedent Robert Sendzischew caused extreme emotional pain, physical harm, and economic loss to Plaintiff Melanie Smith, a direct and proximate result of Defendants' Defendants' and their co-conspirators' acts and omissions as alleged herein.

Plaintiff Lewis

393. Plaintiff Kimberly Lewis' husband, Decedent, Robert Lewis, was admitted to Mercy Hospital in Buffalo, New York, on December 28, 2021, and after receiving the standard COVID treatment protocol, died on January 15, 2022. Exhibit "35" Lewis Death Certificate, re: Covid 19.

394. Plaintiff Lewis' husband Robert Lewis suffered from intense pain and fear prior to suffering an agonizing death.

395. Plaintiff Lewis was isolated and quarantined from his family during his final days causing all of them extreme emotional distress and anguish.

396. The death of Robert Lewis caused emotional and physical harm, and economic loss to Plaintiff Lewis and Robert Lewis' a direct and proximate result of Defendants' and their co-conspirators' actions and omissions as alleged herein.

Plaintiff Peter

397. Plaintiff Lisa Peter's mother, Decedent, Patricia Chislett, tested positive for COVID on November, 20, 2021 and was admitted to Sister's of Charity Hospital in Buffalo, New

York, on November 24, 2021 where she was ventilated on December 15, 2021 and died on December 18, 2021. Exhibit “36”, Death Certificate Chislett, re: Covid 19.

398. Plaintiff Peter’s mother Patricia suffered from intense pain and fear prior to her death, treated with the standard COVID treatment protocol and suffered an agonizing death.
399. Decedent Chislett was isolated and quarantined from her family during her final days causing all of them extreme emotional distress and anguish.
400. The death of Patricia Chislett caused emotional and physical harm, and economic loss to Plaintiff Lisa Peter and to Patricia Chislett’s heirs, a direct and proximate result of Defendants’ and their co-conspirators’ actions and omissions as alleged herein.

Plaintiff Jones

401. Plaintiff Roxanne Jones’ husband, Decedent, Dale Jones, was admitted to Mercy Hospital in Buffalo, New York, on July 30, 2022. He remained stable in the hospital until August 13, 2022 when he was put on a ventilator and moved to ICU, put on a ventilator . Decedent Dale Jones died in the hospital on September 2, 2021.
402. Plaintiff Jones’ husband Dale suffered from intense pain and fear prior to her death, treated with the standard COVID treatment protocol and suffered an agonizing death. Exhibit “37”, Jones’ Death Certificate, re: Covid 19.
403. Decedent Jones was isolated and quarantined from his family during his final days causing extreme emotional distress and anguish.
404. The death of Dale Jones caused emotional and physical harm, and economic loss to Plaintiff Roxanne Jones and to Dale Jones’ heirs, a direct and proximate result of Defendants’ and their co-conspirators’ actions and omissions as alleged herein.

VII. TOLLING OF THE STATUTE OF LIMITATIONS

A. Discovery Rule Tolling

405. Plaintiffs had no way of knowing about the Defendants' actions and omissions as alleged herein with respect to the SARS-CoV-2 virus.
406. Within the time period of any applicable statutes of limitation, Plaintiffs and all others similarly situated could not have discovered through the exercise of reasonable diligence that the Defendants were concealing the conduct complained of herein and exposing the general public to great risks of harm, illness, and death.
407. Plaintiffs did not discover, and did not know of, facts that would have caused a reasonable person to suspect that the Defendants did not report information within their knowledge to federal and state authorities, the medical community, and the general public; nor would a reasonable and diligent investigation have disclosed that the Defendants had concealed information about the creation and release of the ultra-hazardous SARS-CoV-2 virus, which was discovered by Plaintiffs only shortly before this action was filed. Nor, in any event, would such an investigation on the part of Plaintiffs have disclosed that the Defendants' actions and omissions led to a worldwide pandemic and unquantifiable human suffering and damages.
408. For these reasons, all applicable statutes of limitation have been tolled by operation of the discovery rule with respect to claims as to the SARS-CoV-2 virus.

B. Fraudulent Concealment Tolling

409. All applicable statutes of limitations have also been tolled by the Defendants' knowing and active fraudulent concealment and denial of the facts alleged herein throughout the time period relevant to this action.

410. Instead of disclosing the dangerous nature of the SARS-CoV-2 virus they created, Defendants intentionally obfuscated and sought to convince the world, including Plaintiffs, that the SARS-CoV-2 virus was a natural virus.

411. For these reasons, all applicable statutes of limitation have been tolled due to Defendants' fraudulent concealment related to the origins of the SARS-CoV-2 virus as well as to the existence of Plaintiffs' causes of action.

C. Estoppel

412. The Defendants were under a continuous duty to disclose to Plaintiffs the true character, abnormally dangerous and lethality of the SARS-CoV-2 virus that was released by them into the environment first reported on about December of 2019 in the media.

413. The Defendants knowingly, affirmatively, and actively concealed or recklessly disregarded the true nature, dangerousness, and lethality of the SARS-CoV-2 virus, putting Plaintiffs, at increased risk of harm.

414. Based on the foregoing, the Defendants are estopped from relying on any statutes of limitations in defense of this action.

VIII. CAUSES OF ACTION

FIRST CAUSE OF ACTION (Negligence)

415. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.

416. Defendants, individually and collectively, failed to use ordinary care while researching, developing, creating, and maintaining the SARS-CoV-2 virus at the WIV or elsewhere.

Duty

417. Defendants, individually and collectively, owed a duty to each Plaintiff and Decedent to act as a reasonably prudent person(s) would act under the circumstances when conducting dangerous research on viruses that have the potential to cause a pandemic.
418. Defendants, individually and collectively, and those working in furtherance of their enterprise and within the scope of their authority, owed a duty of care to Plaintiffs and Decedents to protect them from the risks of exposure to SARS-CoV-2, because Defendants were in the best position to protect against the risk of harm that resulted in damages to each Plaintiff and Decedent, as alleged herein.
419. Defendants, individually, collectively, and those working in furtherance of their enterprise and within the scope of their authority, owed Plaintiffs and Decedents a duty to maintain their research under an appropriate biosafety level while implementing proper protective measures so that there would be no leak of the ultra-hazardous SARS-CoV-2 from the WIV or elsewhere.
420. Defendants, individually, collectively, and those working in furtherance of their enterprise and within the scope of their authority, owed the Plaintiffs and Decedents a duty to perform an appropriate risk assessment of the laboratories where their research was conducted so that there would be no leak of the ultra-hazardous SARS-CoV-2 from WIV or elsewhere.
421. Defendants, individually, collectively and their co-conspirators owed a duty to Plaintiffs and Decedents to immediately warn them that a pathogen with potential to cause a pandemic had leaked from the WIV or elsewhere.
422. Defendants, individually, collectively and those working in furtherance of their enterprise and within the scope of their authority were in the best position to learn about the release

of SARS-CoV-2 and warn Plaintiffs, Decedents, and others similarly situated of the potential risks and consequences of exposure to this novel virus.

Breach

423. Defendants, individually and collectively, breached their duty of care to Plaintiffs and Decedents by conducting abnormally dangerous research on viruses, which led to the release of SARS-CoV-2 and damages to Plaintiffs and Decedents, as alleged herein.
424. Defendants, individually, collectively, and their co-conspirators further breached their duty to Plaintiffs and Decedents by engaging in dangerous **GOF** research despite knowledge of its dangers, including a moratorium on such research and acknowledgement of such dangers in the medical literature and elsewhere.
425. Defendants, individually, collectively, and their co-conspirators nonetheless continued to perform dangerous **GOF** research at the WIV and elsewhere, eventually causing the COVID-19 pandemic when SARS-CoV-2 was released on the global population, injuring and/or killing Plaintiffs and/or Decedents.
426. Defendants, individually, collectively and their co-conspirators further breached their duty to Plaintiffs and Decedents by conducting dangerous **GOF** research in inadequate and unsafe laboratories, including BSL-2 and BSL-4 labs.
427. Defendants, individually, collectively, and those working in furtherance of their enterprise and within the scope of their authority, breached their duty by failing to maintain their research under an appropriate biosafety level and/or use enhanced bio-safety containment processes, which upon information and belief led to the release of SARS-CoV-2 from the WIV or elsewhere.

428. Defendants failed to perform an appropriate risk assessment of their research laboratories to avoid a leak of the ultra-hazardous SARS-CoV-2 from WIV or elsewhere and disregarded multiple substantial warnings about safety breaches and lax biosecurity standards at the WIV, termed the “Wild West” as alleged herein.
429. Defendants breached their duty to Plaintiffs and Decedents by causing SARS-CoV-2 to be released due to their carelessness and failure to employ ordinary care.
430. Defendants, and those working in furtherance of their enterprise and within the scope of their authority, further breached their duty by failing to implement reasonable and proper protective measures to prevent a lab leak of SARS-CoV-2, as alleged herein, and by failing to protect Plaintiffs and Decedents from the risks of exposure to SARS-CoV-2, a product and creation of their abnormally dangerous research and experiments on viruses at the WIV and elsewhere.
431. Defendants breached their duty to Plaintiffs and Decedents by failing to immediately warn them about the release of SARS-CoV-2, including potential risks and consequences of exposure to the novel SARS-CoV-2. In furtherance of their enterprise and conspiracy, Defendants and their co-conspirators actively sought to downplay their role in a potential lab leak of SARS-CoV-2, in the process withholding critical information about the novel virus, its makeup, and its origin.
432. Defendants, individually and collectively, and their co-conspirators instead worked diligently to advance alternative theories concerning the origin of SARS-CoV-2, including that the virus originated in a wet market in Wuhan, or was released through frozen food imported to China.

433. Defendant Daszak and his co-conspirators' statements regarding the origins and release of the ultra-hazardous SARS-CoV-2 virus into the environment were knowingly false and misleading, designed by Defendants to mislead other medical researchers, immunologists, doctors, the medical community, and the public about their **GOF** research and as to Defendants' and their co-conspirators' role in the origins, creation and release of the ultra-hazardous SARS-CoV-2 virus into the environment.
434. Defendants' concerted actions took the form of an express or implied agreement not to warn and was achieved by providing substantial assistance or encouragement to one another to conceal their wrongful course of conduct.²²⁷
435. Defendants, individually and collectively, and their co-conspirators failed to disclose or to warn Plaintiffs of the known dangers associated with the exposure to Defendants' ultra-hazardous SARS-CoV-2 virus.

CAUSATION

436. Defendants', individually and collectively, and their co-conspirators' acts and omissions as alleged herein directly and proximately caused physical and emotional injury, economic loss, and/or death to Plaintiffs and/or Decedents in that Defendants' acts and omissions were a substantial factor(s) in bringing about said injuries and/or death.
437. But for Defendants', individually and collectively, and their co-conspirators' acts and omissions relating to the dangerous **GOF** research and subsequent release of the abnormally dangerous SARS-CoV-2, and the ensuing cover-up about its origins, Plaintiffs

²²⁷ Emails show scientists discussed masking their involvement in key journal letter on COVID origins. US Right to Know Feb 15, 2021, <https://usrtk.org/covid-19-origins/scientists-masked-involvement-in-lancet-letter-on-covid-origin/> accessed 11.17.2022 & Exhibit 3, Huff Declaration.

and Decedents would not have suffered injuries and/or death due to SARS-CoV-2 or could have mitigated such outcomes.

DAMAGES

438. As a result of Defendants', individually and collectively, and their co-conspirators' acts and omissions as alleged herein, Plaintiffs and Decedents were damaged by exposure to the SARS-CoV-2 virus, causing Plaintiffs and/or Decedents to suffer physical and emotional injury, economic loss, and/or death.
439. The limitations on liability set forth in CPLR § 1601 do not apply to this action by reason of one or more of the exceptions set forth in CPLR § 1602.
440. WHEREFORE, Plaintiffs demand judgment in their favor against all Defendants, individually, jointly, severally, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

SECOND CAUSE OF ACTION (Gross Negligence)

441. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
442. Defendants, individually and collectively, and their co-conspirators failed to use even slight care while researching, developing, creating, and maintaining the SARS-CoV-2 virus at the WIV or elsewhere.
443. Defendants', individually and collectively, and their co-conspirators' conduct as alleged herein was so careless that it shows a complete disregard for the rights and safety of others, including Plaintiffs and Decedents.

Duty

444. Defendants, individually and collectively, owed a duty to each Plaintiff and Decedent to act as a reasonably prudent person(s) would act under the circumstances when conducting abnormally dangerous research on viruses.
445. Defendants, individually and collectively, and those working in furtherance of their enterprise and within the scope of their authority, owed a duty of care to Plaintiffs and Decedents to protect them from the risks of exposure to SARS-CoV-2, because Defendants were in the best position to protect against the risk of harm that resulted in damages to each Plaintiff and Decedent, as alleged herein.
446. Defendants, and those working in furtherance of their business and within the scope of their authority, owed Plaintiffs and Decedents a duty to maintain their research under an appropriate biosafety level while implementing proper protective measures so that there would be no leak of the ultra-hazardous SARS-CoV-2 from the Wuhan Lab or elsewhere.
447. Defendants, and those working in furtherance of their enterprise and within the scope of their authority, owed the Plaintiffs and Decedents a duty to perform an appropriate risk assessment so that there would be no leak of the ultra-hazardous SARS-CoV-2 from WIV or elsewhere.
448. Defendants, individually and collectively, and their co-conspirators owed a duty to Plaintiffs and Decedents to immediately warn them that a pathogen with potential to cause a pandemic had leaked from the WIV or elsewhere.
449. Defendants and those working in furtherance of their enterprise and within the scope of their authority were in the best position to learn about the release of SARS-CoV-2 and

warn Plaintiffs, Decedents, and others similarly situated of the potential risks and consequences of exposure to this novel virus.

Breach

450. Defendants, individually and collectively, failed to use even slightest care in conducting abnormally dangerous research on viruses at inappropriate and unsafe facilities, which on information and belief, resulted in the release of SARS-CoV-2 and damages to Plaintiffs and Decedents, as alleged herein.
451. Defendants, individually and collectively, and their co-conspirators further breached their duty to Plaintiffs and Decedents by engaging in dangerous **GOF** research despite knowledge of its dangers, including a moratorium on such research and acknowledgement of such dangers in the medical literature and elsewhere.
452. Defendants, individually and collectively, and their co-conspirators nonetheless continued to perform dangerous **GOF** research at the WIV and elsewhere, eventually causing the COVID-19 pandemic when SARS-CoV-2 was released on the global population, injuring and/or killing Plaintiffs and/or Decedents.
453. Defendants and their co-conspirators further breached their duty to Plaintiffs and Decedents by conducting dangerous **GOF** research in inadequate and unsafe laboratories, including BSL-2 and BSL-4 labs.
454. Defendants, and those working in furtherance of their enterprise and within the scope of their authority, breached their duty by failing to maintain their research under an appropriate biosafety level and/or use enhanced bio-safety containment processes, which upon information and belief led to the release of SARS-CoV-2 from the WIV or elsewhere.

455. Defendants failed to perform an appropriate risk assessment of their research laboratories to avoid a leak of the ultra-hazardous SARS-CoV-2 from WIV or elsewhere and disregarded multiple substantial warnings about safety breaches and lax biosecurity standards at the WIV, termed the “Wild West” as alleged herein.
456. Defendants further breached their duty to Plaintiffs and Decedents by causing SARS-CoV-2 to be released due to their carelessness and failure to employ ordinary care.
457. Defendants, and those working in furtherance of their enterprise and within the scope of their authority, further breached their duty by failing to implement reasonable and proper protective measures to prevent a lab leak of SARS-CoV-2, as alleged herein, and by failing to protect Plaintiffs and Decedents from the risks of exposure to SARS-CoV-2, a product and creation of their abnormally dangerous research and experiments on viruses at the WIV and elsewhere.
458. Defendants, individually and collectively, and their co-conspirators further breached their duty to Plaintiffs and Decedents by failing to immediately warn them about the release of SARS-CoV-2, including potential risks and consequences of exposure to the novel SARS-CoV-2.
459. In furtherance of their enterprise and conspiracy, Defendants and their co-conspirators actively sought to downplay and conceal their role in a potential lab leak of SARS-CoV-2, by withholding critical information about the novel virus, its makeup, and its origin.
460. Defendants and their co-conspirators instead worked diligently to advance alternative theories concerning the origin of SARS-CoV-2, including that the virus originated in a wet market in Wuhan, or was released through frozen food imported to China that was knowingly false to them.

461. Defendants, individually and collectively, and those working in furtherance of their enterprise and within the scope of their authority, breached their duty by failing to protect Plaintiffs and Decedents from the risks of exposure to SARS-CoV-2, a product and creation of their abnormally dangerous research and experiments on viruses at the WIV and elsewhere.

Causation

462. Defendants, individually, and their co-conspirators' failure to use even slight care, as alleged herein, directly and proximately caused physical and emotional injury, economic loss, and/or death to Plaintiffs and/or Decedents.

463. Defendants, individually and collectively, and their co-conspirators' acts and omissions were a substantial factor(s) in bringing about Plaintiffs' alleged injuries and/or deaths.

464. But for Defendants', individually and collectively, and their co-conspirators' acts and omissions relating to the dangerous **GOF** research and subsequent release of the abnormally dangerous SARS-CoV-2, and the ensuing cover-up about its origins, Plaintiffs and Decedents would not have suffered injuries and/or death due to SARS-CoV-2 or could have mitigated such outcomes.

Damages

465. As a result of Defendants', individually and collectively, and their co-conspirators' reckless and/or careless disregard for the rights and safety of others, as alleged herein, Plaintiffs and Decedents were damaged by exposure to the SARS-CoV-2 virus, causing Plaintiffs and/or Decedents to suffer physical and emotional injury, economic loss, and/or death.

466. The limitations on liability set forth in CPLR § 1601 do not apply to this action by reason of one or more of the exceptions set forth in CPLR § 1602.
467. WHEREFORE, Plaintiffs demand judgment in their favor against all Defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

THIRD CAUSE OF ACTION
(Strict Liability)

468. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
469. Defendants, individually and collectively, and their co-conspirators engaged in uncommon, abnormally dangerous research on viruses that created a foreseeable and highly significant risk of physical harm to others, even if all actors had exercised reasonable care.
470. Defendants' and their co-conspirators' **GOF** research involving bat coronaviruses was and is abnormally dangerous.
471. Defendants and their co-conspirators knew and had reason to know of the abnormally risky nature of their **GOF** research at WIV, UNC, and elsewhere.
472. SARS-CoV-2 has been designated by the Department of Health and Human Services ("HHS") as a biological agent or toxin with "potential to pose a severe threat to public health and safety."²²⁸

²²⁸ CFR § 73.3(a) and (b).

473. Defendants and their co-conspirators were engaging in an abnormally dangerous activity subject to strict liability without regard to fault for any injury to person or property caused by that activity.
474. SARS-CoV-2 was known by Defendants to be dangerous to Plaintiffs' health at the time it was released into the environment, and Defendants knew or should have known SARS-CoV-2 was harmful and deleterious.
475. At all times relevant, and as alleged herein, Defendants and their co-conspirators knew, or should have known, about the serious biosecurity problems at the WIV and its ties to the Chinese military prior to subcontracting their **GOF** research under the guise of pandemic preparedness.
476. Defendants, individually, and their co-conspirators knew the NIH imposed a moratorium on **GOF** research in October 2014, to "be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function policy."
477. Defendants and their co-conspirators further had knowledge that many scientists had serious concerns about the risks of **GOF** research and worked to conceal the SARS-Cov-2 origins.²²⁹
478. The SARS-CoV-2 virus and related "spike protein" are ultra-hazardous and abnormally dangerous because they necessarily involve a risk of serious harm to humans, which could not have been eliminated by the exercise of utmost care and are not items of common usage.
479. Defendants, individually, and their co-conspirators at WIV and elsewhere, as part of their enterprise with Defendant EcoHealth, funded, designed, and created the abnormally

²²⁹ Burki, Talha: *Ban on gain-of-function studies ends*, *The Lancet, Infectious Diseases* (Vol. 18, Issue 2, P. 148-49, Feb. 1, 2018). [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(18\)30006-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30006-9/fulltext)

dangerous SARS-CoV-2 in an unsafe and inherently dangerous manner. As expected, SARS-CoV-2 caused serious bodily harm and/or death to Plaintiffs and/or Decedents.

480. Defendants outsourced their **GOF** research to the WIV without required safety protocols in place for the kind of ultra-hazardous research conducted there as alleged herein, demonstrating a willful and reckless disregard for the dangers associated with **GOF** genetic virus manipulation that, when later released into the environment, directly and proximately caused Plaintiffs' and Decedents' injuries and/or death.

481. Defendants', individually and collectively, and their co-conspirators' actions as alleged herein were a substantial factor in bringing about Plaintiffs' and Decedents' injuries and/or death.

482. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**FOURTH CAUSE OF ACTION
(Negligent Failure to Warn)**

483. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.

484. Defendants possessed superior knowledge concerning the true hazards of SARS-CoV-2, and with intent, concealed said knowledge from Plaintiffs and Decedents.

485. Defendants concealed their knowledge and role in causing the Covid-19 pandemic to avoid liability and the public shame that would cause irreparable harm to their reputation(s).

486. As researchers, manufacturers and funders of the ultra-hazardous, abnormally dangerous SARS-CoV-2, Defendants and their co-conspirators knew or should have known of its hazards and dangers.
487. Defendants negligently failed to provide adequate and proper warnings to Plaintiffs as to the dangers of the exposure to SARS-CoV-2.
488. Defendants and their co-conspirators possessed the superior medical data and scientific knowledge which clearly indicated that their virus was ultra-hazardous to the environment and public health, and, prompted by pecuniary motives and self-interest, failed to act upon said medical data and scientific knowledge, and failed to disclose the information to health officials and the public, including Plaintiffs and Decedents, thus leaving them physically vulnerable and uninformed as to the consequences of exposure to the ultra-hazardous SARS-CoV-2.
489. Defendants and their co-conspirators failed to disclose their role(s) in the origin of SARS-CoV-2, failed to disclose their knowledge of its lethality, transmissibility and virulence, and failed to provide for safety precautions to be observed by persons who would reasonably and foreseeably come into contact with SARS-CoV-2.
490. Defendants negligently failed to warn and to convey whatever knowledge of the dangers, health hazards, or safety precautions they had to those innocent persons exposed to their ultra-hazardous coronavirus SARS-CoV-2, including Plaintiffs and Decedents.
491. Defendants and their co-conspirators negligently failed to warn Plaintiffs and Decedents of the risks and dangers to their health as a result of exposure to SARS-CoV-2, which information Plaintiffs and Decedents could have used to make an adequate and informed

judgment as to how to avoid such exposure, or treat the virus if and when exposed, impeding effective countermeasures that could have prevented injuries and saved lives.

492. As a direct and proximate result of Defendants' and their co-conspirators' concealment and negligent failure to warn, as alleged herein, Plaintiffs and Decedents have suffered and endured great physical pain and mental anguish and suffered loss of enjoyment of their lives, and/or death.

493. Plaintiffs and Decedents did not contribute in any manner to their own injuries and/or deaths caused by Defendants' ultra-hazardous SARS-CoV-2 virus released into the environment.

494. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**FIFTH CAUSE OF ACTION
(Intentional Infliction of Emotional Distress)**

495. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.

Extreme and outrageous conduct

496. Defendants' and their co-conspirators' acts and omissions as alleged herein were extreme and outrageous.

497. Defendants and their co-conspirators were well aware of the risks and dangers involved with **GOF** research, including the potential of causing a worldwide pandemic.

498. Defendants and their co-conspirators nonetheless proceeded with such research, eventually causing the Covid-19 pandemic by creating and releasing a highly transmissible and deadly lab-made virus, SARS-CoV-2.

499. Defendants and their co-conspirators knowingly and willfully manufactured SARS-CoV-2, negligently failed to advise Plaintiffs, Decedents, and the general public of the serious health consequences associated with the lab-made SARS-CoV-2 virus, and worse, intentionally engaged in a scheme to conceal the true laboratory origins of SARS-CoV-2. Such acts and omissions were extreme and outrageous.

Intent to cause, or disregard of a substantial probability of causing, severe emotional distress.

500. Defendants blatantly disregarded the substantial probability that their actions and omissions would cause severe emotional distress to Plaintiffs and others similarly situated, by having to confront the reality of a dangerous, novel virus that causes debilitating symptoms ranging from loss of taste and smell to death.

A causal connection between the conduct and the injury

501. Defendants' dangerous **GOF** research directly and proximately caused Plaintiffs' and Decedents' physical and emotional injuries and/or deaths, as alleged herein.

502. But for Defendants' and their co-conspirators' abnormally dangerous and risky research in an inadequate laboratory setting, Plaintiffs and Decedents would not have been injured and/or killed.

Severe emotional distress

503. As a result of Defendants' and their co-conspirators' acts and omissions, Plaintiffs and/or Decedents suffered and/or continue to suffer severe emotional distress and mental anguish, knowing their injuries and/or deaths were caused by Defendants' and their co-conspirators'

negligent, reckless, and wanton acts and omissions, which were fully avoidable. Plaintiffs' and Decedents' physical and emotional injuries and/or deaths have caused and continue to cause Plaintiffs severe emotional distress due to their debilitating symptoms and fear of contracting SARS-CoV-2 in the future.

504. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**SIXTH CAUSE OF ACTION
(Negligent Infliction of Emotional Distress)**

505. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
506. Defendants owed a duty of care to Plaintiffs and Decedents, as alleged herein.
507. Defendants breached their duty of care by directly and unreasonably endangering Plaintiffs' and/or Decedents' physical safety, and/or directly causing Plaintiffs and/or Decedents to fear for their own safety.
508. Plaintiffs' and Decedents' injuries and/or death are a direct and proximate result of Defendants' abnormally dangerous activity, negligence and carelessness, and their demonstrated wanton and reckless disregard for Plaintiffs' safety and well-being, directly and unreasonably endangering Plaintiffs' and/or Decedents' physical safety, and/or directly causing Plaintiffs and/or Decedents to fear for their own safety.
509. At all times relevant herein, Defendants negligently inflicted emotional distress on each Plaintiff and/or Decedent by creating, releasing and exposing them to SARS-CoV-2,

directly and unreasonably endangering Plaintiffs' and/or Decedents' physical safety, and/or directly causing Plaintiffs and/or Decedents to fear for their own safety.

510. As a result of said conduct by Defendants and their co-conspirators, Plaintiffs and/or Decedents have sustained extreme emotional distress and mental anguish associated with their physical injuries as well as extreme emotional distress and mental anguish associated with the failure of Defendants to advise them of the serious health effects associated with exposure to SARS-CoV-2.

511. As a result of Defendants' and their co-conspirators' mishandling of SARS-CoV-2 as alleged herein, each Plaintiff and/or Decedent was exposed to a dangerous, ultra-hazardous lab-made virus, and as a direct and proximate result thereof have suffered the injuries alleged herein, unreasonably endangering Plaintiffs' and/or Decedents' physical safety, and/or directly causing Plaintiffs and/or Decedents to fear for their own safety.

512. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**SEVENTH CAUSE OF ACTION
(Assault and Battery)**

513. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.

514. Defendants intentionally and continuously committed battery to Plaintiffs' and Decedents' persons by releasing SARS-CoV-2 into Plaintiffs' and Decedents' work and living environments, exposing them to their **GOF** virus and experiment.

515. Defendants' assault and battery are a direct and proximate cause of injuries, damages, and/or death sustained by the Plaintiffs and/or Decedents.
516. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**EIGHTH CAUSE OF ACTION
(Medical Monitoring and Fear of Contracting Illness)**

517. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
518. As a direct and proximate result of Defendants' conduct as alleged herein, Plaintiffs have sustained personal injuries that are presently known, and which cause symptoms, pain, and suffering, and sequela.
519. As a direct and proximate result of Defendants' conduct as alleged herein, Plaintiffs have incurred and continue to incur the cost of medical treatment and monitoring requiring routine temperature tests, masking, PCR testing and other intrusive and distressing diagnostics.
520. As a direct and proximate result of Defendants' and their co-conspirators' conduct as alleged herein, Plaintiffs are at greater risk of suffering future injuries, symptoms, and pain and suffering from the latent and unknown effects of their exposure to SARS-CoV-2. As a direct and proximate result thereof, Plaintiffs will need continual medical treatment, testing and monitoring in the future.

521. As a result of the foregoing, Plaintiffs are entitled to recover the costs of past and future medical monitoring, testing and treatment from Defendants, as a separate claim for relief, or, alternatively, as additional damages under each of the other claims for relief above.
522. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**NINTH CAUSE OF ACTION
(Civil Conspiracy)**

523. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
524. Plaintiffs herein allege twelve (12) cognizable causes of action.

Agreement among the conspirators

525. Defendants and their co-conspirators agreed to conduct dangerous **GOF** research at WIV and elsewhere, despite knowledge of the dangers of **GOF** research, allegedly to prevent a pandemic.
526. Defendants and their co-conspirators agreed to perform dangerous **GOF** research at inadequately maintained laboratories, increasing the risk of a pandemic.
527. Defendants and their co-conspirators then worked to cover up the true origins of SARS-CoV-2 as alleged herein.
528. Defendants and their co-conspirators intentionally engaged in numerous overt acts in furtherance of their various agreements. For example, Defendant EcoHealth intentionally funneled money to WIV to conduct dangerous **GOF** research.

529. In addition, Defendants and their co-conspirators intentionally studied bat coronaviruses using **GOF** to make such viruses more transmissible and deadly, allegedly to prevent the next pandemic.
530. Additionally, Defendants Daszak, Cottingham, Baric, and Lipkin intentionally conspired among themselves and their co-conspirators to draft an article debunking the lab leak theory, instead pointing to a natural origin of SARS-CoV-2.
531. Defendants intentionally delayed and obfuscated instead of being forthcoming with Plaintiffs and the public, causing irreparable harm and damage in the interim period as alleged herein.
532. Defendants' and their co-conspirators' conspiracy caused physical and emotional harm, economic loss, and/or death to Plaintiffs and/or Decedents as alleged herein.
533. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**TENTH CAUSE OF ACTION
(Wrongful Death)**

534. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
535. Decedents are survived by family members entitled to recover damages from all Defendants for the wrongful death of their Decedents. These family members are among the Plaintiffs who are entitled to damages deemed as a fair and just compensation for their injuries resulting from the deaths of the Decedents.

536. The injuries and damages suffered by Plaintiffs McKinniss, Finn, Caddoo, Smith, Lewis, Peter, and Jones by virtue of the death of the Decedents, and the consequences resulting therefrom, were proximately caused by the intentional and reckless acts, omissions, and other tortious conduct of all Defendants as described herein.
537. As a direct and proximate result of the deaths of the Decedents, their heirs have been deprived of future aid, assistance, services, comfort, and financial support.
538. As a direct and proximate result of the Defendants' and their co-conspirators' negligent, dangerous, reckless, and deceptive acts and omissions as alleged herein, the heirs of the Decedents will forever grieve their deaths.
539. As a further result of Defendants' and their co-conspirators' negligent, dangerous, reckless and deceptive acts and omissions, Plaintiffs McKinniss, Rosado, Finn, Caddoo, Smith and Lewis, Peter, and Jones have been caused to expend various sums to administer the estates of Decedents and have incurred other expenses for which they are entitled to recover damages.
540. The statutes of limitations and statutes of repose (if any) for Wrongful Death are equitably tolled by virtue of Defendants' and their co-conspirators' continuing acts and omissions to cover up the origins of the SARS-CoV-2 virus, and their role with respect thereto, as alleged herein. Defendants must not be allowed to benefit from their fraudulent concealment of Plaintiffs' causes of action, as alleged herein.
541. WHEREFORE, Plaintiffs McKinniss, Finn, Caddoo, Smith, Lewis, Peter, and Jones demand judgment in their favor against all Defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent

Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**ELEVENTH CAUSE OF ACTION
(Survival)**

542. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.
543. Plaintiffs (except Rosado) bring this action for damages suffered by the Decedents and caused by Defendants' and their co-conspirators' actions and omissions.
544. As a result of the intentional and negligent acts of the Defendants and their co-conspirators as described above, the Decedents were placed in apprehension of harmful and offensive bodily contact (assault), suffered offensive and harmful bodily contact (battery), suffered extreme fear, anxiety, emotional and psychological distress (intentional/negligent infliction of emotional distress), and were mentally and physically harmed, trapped, and falsely imprisoned (false imprisonment) prior to their deaths.
545. As a result of the Defendants' and their co-conspirators' reckless and dangerous conduct, the Decedents suffered damages including pain and suffering, trauma, emotional distress, loss of life and life's pleasures, loss of earnings and earning capacity, loss of accretion to their estates, and other items of damages as fully set forth in the paragraphs above, which are incorporated herein by reference.
546. WHEREFORE, Plaintiffs demand judgment in their favor against all Defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

**TWELFTH CAUSE OF ACTION
BREACH OF WARRANTY**

547. 129. Plaintiffs repeat, reiterate and reallege each and every allegation contained in the foregoing paragraphs of the Verified Complaint with the same force and effect as if hereinafter set forth at length.
548. As part of their role as prime and subcontractors, and grant recipients of U.S. tax dollars, the Defendants, expressly and impliedly warranted that their virus research was safe, and fit for its intended purpose, i.e., pandemic preparedness.
549. There were implied/express warranties made by Defendants (as prime and subcontractors and grant recipients of U.S. tax dollars from NIH and NIAID), specifically, that the ultra-hazardous coronavirus SARS-Co V-2 research and creation was fit, and consistent with their particular, intended use, i.e., pandemic preparedness.
550. Defendants breached their implied\express warranties to the Plaintiffs by creating and releasing SARS-Co V-2 and concealing the fact that SARS-Co V-2 was a harmful, toxic lab-made virus that caused the severe and permanent personal injuries and death to Plaintiffs and/or Decedents while engaging in their ordinary course of conduct.
551. Defendants omitted reference to the *Gain of Function* elements of their coronavirus research being conducted with the Wuhan Lab in submissions for federal funding, breaching express and implied warranties.
552. Defendants also omitted reference to the CRISPR elements of their coronavirus research being conducted at the Wuhan Lab in submissions for federal funding.
553. Defendants further omitted reference to the serial passage elements of their coronavirus research being conducted at the Wuhan Lab in submissions for federal funding.
554. Defendants further omitted reference to capabilities of altering coronaviruses from their

submissions for federal funding to avoid detection of the risks to human safety associated with the research and to evade enhanced HHS oversight.

555. As a direct and proximate result of the breach of the implied/express warranties of good quality for fitness for the particular use, Plaintiffs were seriously injured and developed coronavirus related diseases and injuries and were caused to endure great pain and suffering and sequela.

556. As a result of Plaintiffs' and Decedents' continuing exposure to Defendants' ultrahazardous coronavirus SARS-Co V-2, each has suffered, and/or continues to suffer, emotional and physical injuries, economic loss, and/or death.

557. severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such

558. WHEREFORE, Plaintiffs demand judgment in their favor against all defendants, jointly, other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-Co V-2 or similar acts.

**THIRTEENTH CAUSE OF ACTION
(Punitive Damages)**

559. Plaintiffs repeat, reiterate and reallege each and every paragraph of the Verified Amended Complaint as if fully set forth herein.

560. The actions and omissions of all Defendants and their co-conspirators, acting in concert to carry out their unlawful objectives, were malicious, outrageous and in willful, wanton, and reckless disregard of the rights, safety, health and lives of all Plaintiffs and/or Decedents.

561. Defendants, acting individually and in concert, intended to carry out actions they knew would endanger the lives of the Plaintiffs and/or Decedents and all those similarly situated.
562. Defendants' and their co-conspirators' actions and omissions as alleged herein demonstrate a high degree of moral culpability and turpitude. Defendants' and their co-conspirators' conduct represents a high degree of immorality and shows such wanton dishonesty as to imply a criminal indifference to their civil obligations.
563. Defendants' and their co-conspirators' actions and omissions put Plaintiffs, Decedents at risk of contracting a novel and deadly pathogen, SARS-CoV-2. Defendants' and their co-conspirators' wanton and willful conduct must be punished to deter similar conduct, which is still continuing as alleged herein, and the attendant risks.
564. As a result of their intentional, malicious, outrageous, willful and wanton conduct, all Defendants are jointly and severally liable to all Plaintiffs for punitive damages in an amount to be determined at trial.
565. WHEREFORE, Plaintiffs demand judgment in their favor against all Defendants, jointly, severally, and/or individually, in an amount to be determined at trial, plus interest, costs, and such other monetary and equitable relief as this Honorable Court deems appropriate to prevent Defendants and others from ever again committing the dangerous acts related to the development and release of SARS-CoV-2 or similar acts.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs demand judgment against the Defendants on each of the above-referenced claims and causes of action and as follows:

1. Awarding compensatory damages in excess of the jurisdictional amount, including but not limited to pain, suffering, emotional distress, loss of enjoyment of life, and other non-economic damages in an amount to be determined at trial of this action;
2. Awarding compensatory damages to Plaintiffs for past and future damages, including, but not limited to, Plaintiffs' pain and suffering and for severe and permanent personal injuries sustained by Plaintiffs including health care costs and economic loss;
3. Awarding economic damages in the form of medical expenses, out of pocket expenses, lost earnings and other economic damages in an amount to be determined at trial of this action;
4. Awarding punitive damages to Plaintiffs in order to punish Defendants for their wanton, reckless, and malicious acts and omissions, and thereby discourage Defendants and others from acting in a similar way in the future;
5. Awarding special and consequential damages for conspiratorial conduct.
6. Pre-judgment interest;
7. Post-judgment interest;
8. Awarding Plaintiffs reasonable attorneys' fees;
9. Awarding Plaintiff the costs of these proceedings; and
10. Such other and further relief as this Court deems just and proper.

DEMAND FOR JURY TRIAL

Plaintiffs hereby demand trial by jury as to all issues.

DATED: 1 5 2023

Respectfully submitted,

s/Patricia Finn, Esq.

PATRICIA FINN ATTORNEY, P.C.

58 East Route 59, Suite 4

Nanuet, New York

845 398 0521

/s/ Thomas Renz

THOMAS RENZ

Pending Pro Hac Vice Admission

(Ohio Bar ID: 98645)

1907 W. State St. #162


Fremont, OH 43420

(419) 351-4248


renzlawllc@gmail.com

VERIFICATION OF AMENDED VERIFIED COMPLAINT


I, Kathleen McKinniss, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.


Kathleen McKinniss, Plaintiff

Sworn to before me this 29th day of December, 2022.



ASJA ROBERTA RIVERS FARMER
Notary Public, State of Ohio
My Commission Expires
June 29, 2026
COMMISSION: 2021-RE-832785



VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, Carin Rosado, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.


Carin Rosado, Plaintiff

Sworn to before me this 30 day of December, 2022.


ANNAMARIE O'CONNOR

ID # 2359182

NOTARY PUBLIC OF NEW JERSEY
MY COMMISSION EXPIRES APRIL 26, 2027


ANNAMARIE O'CONNOR
ID # 2359182

NOTARY PUBLIC OF NEW JERSEY
MY COMMISSION EXPIRES APRIL 26, 2027




VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, Geraldine Finn, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.



Geraldine Finn, Plaintiff

Sworn to before me this 30 day of December, 2022.



JUSTIN L. SWEET
Notary Public, State of New York
No. 01SW5056209

Qualified in Rockland County
Commission Expires March 4, April 23, 2026.



VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, David Caddoo, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.




David Caddoo, Plaintiff

Sworn to before me this 30 day of December, 2022.



VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, Melanie Smith, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.



Melanie Smith, Plaintiff

Sworn to before me this 29 day of December, 2022.

See Attached CA Notary Page

CALIFORNIA JURAT

GOVERNMENT CODE § 8202

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of Los Angeles

Subscribed and sworn to (or affirmed) before me on

this 29 day of December, 2022, by
Date Month Year(1) Melanie Ruth Smith(and (2) _____),
Name(s) of Signer(s)

proved to me on the basis of satisfactory evidence to be the person(s) who appeared before me.



Place Notary Seal and/or Stamp Above

Signature

Signature of Notary Public

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: Verification of Amended Verified Complaint

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____


VERIFICATION OF COMPLAINT

I, Kimberly Lewis, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.



Kimberly Lewis, Plaintiff

Sworn to before me this 29th day of December, 2022.


CHERIE M. UEBELHOER
Notary Public, State of New York
Qualified in Genesee County
My Commission Expires 03/05/2024

VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, Lisa Peter, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.



Lisa Peter, Plaintiff


Sworn to before me this 29 day of December, 2022.



DAWN A. PEARCE
NOTARY PUBLIC, STATE OF NEW YORK
QUALIFIED IN ERIE COUNTY
MY COMMISSION EXPIRES OCT. 12, 2025


VERIFICATION OF AMENDED VERIFIED COMPLAINT

I, Roxanne Jones, plaintiff, being duly sworn, deposes and says: I have read the annexed Complaint, and know the contents thereof; that the same is true to the knowledge of deponent except as to the matters therein stated to be alleged upon information and belief, and as to those matters he/she believes it to be true.



Roxanne Jones, Plaintiff

Sworn to before me this 30 day of December, 2022.



EMILY E PUTZER
NOTARY PUBLIC STATE OF NEW YORK
- ERIE COUNTY
LIC. #01PU6416597
COMM. EXP. 04/19/2025

EXHIBIT 1

EXHIBIT 1





EXHIBIT 2

EXHIBIT 2



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
National Institute of Allergy
and Infectious Diseases
Bethesda, Maryland 20892

October 21, 2014

Ms. Sherrie Settle
Director, Proposal Management
University of North Carolina at Chapel Hill
Office of Sponsored Research
Administrative Office Bldg, Suite 2200
104 Airport Drive #1350
Chapel Hill, NC 27599-1350

RE: 5U19 AI107810-02

Dear Ms. Settle:

NIAID has determined that the above referenced grant may include Gain of Function (GoF) research that is subject to the recently announced U.S. Government funding pause (<http://www.hhs.gov/s3/dualuse/Documents/gain-of-function.pdf>). Issued on October 17, 2014. The following specific aims appear to involve research covered under the pause:

Project 1: Role of Uncharacterized Genes In High Pathogenic Human Coronavirus Infection - Ralph S. Baric, PhD- Project Leader

- Specific Aim 2. Novel functions in virus replication in vitro.
- Specific Aim 3. Novel functions in virus pathogenesis in vivo.

Project 2: Determining the functions of novel genes for Influenza A and Ebola viruses (EBOV) - Yoshihiro Kawaoka, PhD- Project Leader

- Specific Aim 2. To determine the significance of uncharacterized IAV and EBOV genes in viral replication.
- Specific Aim 3. To determine the significance of uncharacterized IAV and EBOV genes in virus pathogenicity.

As your grant is currently funded, this pause is voluntary. Organizations conducting GoF research supported by the NIH have an opportunity to transition the applicable research to research that is not covered by the funding pause; halt the applicable GoF research until the outcome of the deliberative process is known; or continue to conduct the applicable GoF research until the end of the currently active budget period.

NIAID requests information on University of North Carolina at Chapel Hill's plans for the research outlined above within 90 days of the date of this letter.

- If you determine that the above research does NOT include GoF work subject to the funding pause, please provide a detailed explanation of the research being conducted and why it is not covered by the pause. NIAID will review this information and make the final determination.
- If the ongoing research includes GoF work subject to the funding pause and the grantee proposes to transition it to areas of research not covered by the pause, please provide the transition plan. It should identify the research to be transitioned, a detailed description of the new planned specific aims (in most cases this will require NIAID pre-approval), and a timeline for the proposed transition.
- If the grantee plans to voluntarily halt the research subject to the funding pause, please identify the research that will be halted and the proposed date by which the applicable research will be stopped. Please provide a confirmation that the research has been halted.
- If the ongoing research includes GoF work and the grantee plans on continuing the research until the end of the currently active budget period, please provide a detailed description of the GoF research to be conducted.

These plans are for the currently active budget period. Please be advised that while the funding pause is in effect, NIAID will not support GoF research identified in the pause after the end of the current grant budget period. Neither competing nor non-competing renewal applications will be funded to support applicable GoF research.

If you have any questions about this matter please do not hesitate to contact the NIAID program and/or grants management contact listed below.


Sincerely,



Chermay Mason

Grants Management Specialist

NIAID/NIH/DHHS



Vivien Dugan, Ph.D.

Program Officer

Division of Microbiology and Infectious Diseases

NIAID/NIH/DHHS

CC: Dr. Ralph Baric
Ms. Mary Kirker
Dr. Irene Glowinski

EXHIBIT 3

EXHIBIT 3



RENTZ LAW, LLC.

Declaration of Dr. Andrew G. Huff, PhD, M.S.

I attest that the following is a true and accurate representation of facts and my experiences:

Name: Andrew G. Huff, PhD, M.S.

Personal History/Background/Qualifications:

- From 2002 to 2008 I served in the U.S. Army in both the Minnesota National Guard and on active duty in the US Army as an infantryman.
- I was ordered to serve on active duty to support and fight in the Global War on Terrorism as part Operation Enduring Freedom as an infantryman in Central America, and I volunteered to serve in combat in Operation Iraqi Freedom, where I received numerous medals, awards, and accolades at the low ranks of Private First Class and Specialist.
- While performing combat operations in Iraq, I continued my undergraduate studies while it was my turn to sleep and prepared and competed in Non-Commissioned Officer Review Boards, where I performed the best among the candidates in all aspects of the review except fitness. I was also nominated by my commanding officer to attend Officer Candidate School at the end of my tour in Iraq, based on my performance, leadership ability, and success at executing officer level tasks, which were assigned to me.
- After returning home from Iraq, I completed a heavily research and quantitatively focused bachelor's degree in Psychology at the University of Minnesota, which is one of the top psychological research institutions in the world. I worked directly with many of the world's leading experts in personality, vocational, career interests, clinical, and counseling psychology research, and completed independent quantitative psychological research which was submitted for peer review publication.
- Simultaneously, to earning my Bachelor's degree, I was a program assistant and contracts technical representative (COTR) for the United States Department of Veterans Affairs, where I relocated and opened several new outpatient mental healthcare offices for the agency and managed numerous contracts and relationships with healthcare providers. My supervisor became severely ill, and I independently and successfully managed the organization and contract facilities across the upper Midwest and staff in his absence at the age of 26, which resulted in a financial bonus paid by the government.



RENTZ LAW, LLC.

- Next, I earned a master's degree in Security Technologies with a minor in Geographic Information Systems, finishing at the top of my class, from the College of Science and Engineering at the University of Minnesota. In the program, I learned to solve national security problems against different types of critical infrastructures using complex systems analysis, systems modeling, high performance computing, intelligence collection techniques and trade craft, international security, bioterrorism, behavioral threat analysis, cryptography, cyber security, vulnerability, and risk assessment among other things. Upon completion of my master's degree coursework and research thesis defense, in only fifteen months, my thesis committee strongly encouraged me to obtain a PhD and was informed that I should meet with one of my instructors which was a member of the faculty in the School of Public Health.
- After meeting with Dr. Jeff Bender from the School of Public Health and College of Veterinary Medicine at the University of Minnesota, I was offered full employment as a Research Fellow at a Department of Homeland Security Center of Excellence at the University of Minnesota, along with a full scholarship to obtain a Ph.D. related to the fields of bioterrorism, biowarfare, chemical warfare or terrorism, pandemics, and emerging infectious disease. This is the best possible offer a Ph.D. student can receive anywhere throughout academia and is rare.
- I earned a Ph.D. from the University of Minnesota's School of Public Health's Environmental Health Science program with a specialization in Emerging Infectious Diseases. My core focus of my education and research was pandemic preparedness response, bioterrorism, biowarfare, biosecurity, chemical attacks & exposures, and biosafety. I completed the program at a record pace (around 3 years) and all my novel research was published in peer reviewed and referred journals before I submitted my dissertation for review.
- While working as a Research Fellow at a Department of Homeland Security Center of Excellence, I frequently traveled to Washington, D.C. and around the country where I became an active member of US government committees and meetings related to pandemics, public health, and national security. I was introduced to many high-level managers within the US government working in these areas, and I frequently presented my research at US government meetings, to executives in the private sector at large multinational companies, and worked directly with industry and state governments to help improve their national security in areas where I have subject matter expertise.
- Upon completing my Ph.D., I was recruited by Sandia National Laboratories, where I served the U.S. Government as a Senior Member of the Technical Staff and held a Department of Energy 'Q' clearance (equivalent to the Department of Defense's Top-



RENTZ LAW, LLC.

Secret designation). At Sandia, I analyzed complex national security problems in my areas of expertise, served as a subject matter expert in public health systems and food systems, and participated in a broad spectrum of projects related to pandemic preparedness, mitigation, and response. Wishing to leave the classified work environment, and due to a funding shortfall in my area of passion (preventing intentional contamination of the food supply), I decided to seek work elsewhere in the fall of 2014 and I applied to EcoHealth Alliance in September of 2014.

- Shortly after applying to a position at EcoHealth Alliance, I interviewed with Dr. Peter Daszak on the telephone and then traveled to EcoHealth Alliance's office in New York City for a comprehensive on-site interview. After completing the interview, I was offered and accepted a position as a Senior Scientist in charge of the Data and Technology team. Upon beginning work at EcoHealth Alliance, I was asked to perform a series of duties which would be considered normal in any kind of scientific or academic organization.

Information Related to EcoHealth Alliance and the Development of SARS-COV2:

- In late 2014, I was asked to prepare a report for the Intelligence Advanced Research Projects Activity, Office of the Directorate of National Intelligence, (IARPA). I later learned upon promotion to Associate Vice President while attending weekly finance updates that EcoHealth Alliance did not receive any funding from this agency (IARPA), as far as I am aware. **Reference: IARPA Collaborator Report from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- In late 2014, I was asked to review (provide edits, comments, and feedback) on a research proposal that was in preparation to be submitted to the National Institutes of Health's (NIH) National Institute for Allergens and Infectious Diseases (NIAID) to conduct Gain of Function research and development with numerous partners including the Wuhan Institute of Virology, which was supported by Dr. Ralph Baric at the University of North Carolina (UNC). **Reference: File name "CoV as submitted" titles "Understanding the Risk of Bat Coronavirus Emergence" Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
 - I attest that I reviewed the proposal that was submitted to NIH which detailed the gain of function virology work that was being conducted to create the agent known as SARS-COV2, which causes the disease known as COVID-19.
 - I attest that the proposal clearly stated that the gain of function work on SARS-COV2 was already underway in China, prior to October 2014, at the Wuhan



RENZ LAW, LLC.

Institute of Virology (WIV), with the support of USAID in collaboration with EcoHealth Alliance and EcoHealth Alliance's partners and sponsors.

- I attest that I made Dr. Peter Daszak aware of the lack of a Biological Security Officer (BSO) and Institutional Biosafety Committee (IBC) at EcoHealth Alliance in reference to the Select Agent Form on in the "Understanding the risk of Bat Coronavirus Emergence" proposal in accordance NIH requirements.
- I witnessed firsthand presentations by Dr. Shi Zhengli (WIV) and Dr. Ralph Baric (UNC) at EcoHealth Alliance related to their Gain of Function work managed and supported by EcoHealth Alliance.
- I witnessed firsthand presentations by the executive team at EcoHealth Alliance related to the gain of function work conducted at EcoHealth Alliance.
- I attest that EcoHealth Alliance's developed SARS-COV2 and is responsible for the development of the agent SARS-COV2 during my employment at the organization.
- I attest that I informed the EcoHealth Alliance executive team that I believed there were biosafety and biosecurity risks in contract laboratories during an executive meeting. Specifically, I was concerned that EcoHealth Alliance did not have enough visibility or firsthand knowledge of what was happening at foreign laboratories contracted and managed by EcoHealth Alliance. During this meeting I discussed bio-risk management with the team due to these concerns. Dr. Daszak refused to mitigate the risks without any objection or discussion from the other executives. In my opinion, Daszak was dismissive of my concerns. He did not seem concerned about EcoHealth's lack of oversight which I felt was strange because it is typically the CEO's duty to protect the organization from organizational threats and risks. After raising my concern, I accepted Peter's position that our control measures were adequate. **Reference: See leaked cables that the US Consulate Cables to the State Department reported Laboratory Safety Concerns at the Wuhan Institute of Virology.**
- In this same short time-period, I was asked to review and contribute to an investment "pitch deck" (i.e., a PowerPoint presentation used in venture capital presentations) that was presented to an organization called In-Q-Tel. In the pitch deck, we proposed an extension of the USAID global disease surveillance work, SARS-COV2 gain of function and humanized mice research conducted by Drs. Baric and Zhengli, and my work from my department developing advanced biosurveillance technologies and platforms. This



RENZ LAW, LLC.

work was presented to In-Q-Tel (which can be verified by their own records). I do not know what the outcome of that meeting as it was not communicated to me by Dr. Daszak.

Reference: File name Peter Daszak In-Q-Tel October 2015 from Dr. Huff's documents retained from his employment at EcoHealth Alliance and the In-Q-Tel Quarterly report.

- On or around June 2015, I was promoted to Vice President. After being promoted to Vice President, I was exposed and participated in more aspects of the organization, as would be expected from an Executive Officer at any organization.
- I began attending weekly financial meetings where I learned that the organization was tight on cash, depended heavily on government contract salary overhead to remain solvent, and that the organization was not involved in traditional conservation work as classically defined. This was upsetting as this was one of the main reasons that I wanted to join the organization (being a conservationist and naturalist). **Reference: EcoHealth Alliance Marketing video from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- I also observed that EcoHealth Alliance was engaged in irregular financial transactions regarding U.S. Government grants. Specifically, I believe there was timecard fraud and observed what I appear to be double dipping on contracts, between government organizations and private donors (e.g., Skoll Foundation, Google Foundation, Bill & Melinda Gates Foundation, & Wellcome Trust), or both. **Reference: Compare stated objectives, work locations, and data collection across a range of projects from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- I later confronted Dr. Peter Daszak, Harvey Kasdan (CFO, deceased), Dr. Aleksei Chmura about the financial fraud when I was upset, arguing for pay raises in my department, company-wide salary increases, and for myself. Shortly thereafter (1-2 days), CFO Harvey Kasdan passed away from a heart attack. I am not insinuating foul play, but I believe the stress was too much for him in his physical condition. **Reference: Harvey Kasdan's Obituary.**
- I also observed, while attending board meetings and in communications directly with board members, that Dr. Peter Daszak had a pattern of over-simplifying and lying by omission to our stakeholders (including the board of directors). For example, while EcoHealth Alliance positioned itself as a conservation organization, no substantial conservation work, as traditionally defined, was occurring at the organization.



RENTZ LAW, LLC.

- The USAID Predict program was a global hunt for viruses predicated upon the promise of predicting and preventing pandemics. I believe that the data limitations and methods for collecting and analyzing that data make this goal impossible to achieve. I further believe that this program is more strongly aligned with collecting the biological samples to conduct gain of function viral work, or intelligence collection, than prediction and prevention of pandemics.
- Gain of function research is a highly contentious topic in my scientific area of expertise. Those who are for it make the argument that if you can identify a high-risk pathogen, and then engineer the pathogen in the laboratory to increase its transmissibility, infectivity, pathogenicity, or virulence, then you can develop medical countermeasures to prevent the spread of disease, if an outbreak of a naturally evolving agent were to occur. I believe this logic to be inherently flawed because it is naïve to think that humans can modify or engineer a naturally occurring pathogen that would evolve similar to the way infectious agents naturally evolve. Typically, Gain of Function research (via selection of rare traits or genetic manipulation or engineering of the agent) undergoes thousands of years of unnatural evolution (decided by humans not by nature) in a laboratory in a matter of days weeks or months. This is akin to predicting the future, with the likelihood of success decreasing in every timestep.
- After being promoted to Vice President, I commented on several concerns I had related to protecting the organization including biosafety, biosecurity, enterprise security, and risk management. None of the other executives voiced any opposition to Gain of Function research being conducted at EcoHealth Alliance, and Dr. Daszak was heavily supportive of the work. Drs. Johnathan Epstein and Kevin Olival were supportive of the work and were key contributors to the gain of function work in the SARS-COV2 proposal funded by USAID and NIH, and executed by EcoHealth Alliance, the WIV, and UNC. My opposition to Gain of Functions research stemmed from my Ph.D. studies taught by my Committee Chair, Dr. Michael T. Osterholm, who was also President Joe Biden's COVID advisor.
- In November 2015, a scientifically peer reviewed, and referenced article was published by collaborators from the Wuhan Institute of Virology, the University of North Carolina Chapel Hill (UNC), the Food and Drug Administration, Harvard Medical School, and the Bellinzona Institute of Microbiology. The peer reviewed article was titled "A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence" in the journal *Nature Medicine*. The authors initially omitted the funding source from the USAID - EPT - PREDICT program, which I was a co-investigator and country coordinator while employed by EcoHealth Alliance. The USAID - EPT - PREDICT funding cited in the article was used to develop a relationship between Drs. Ralph Baric



RENZ LAW, LLC.

(UNC) and Zhengli-Li Shi of the Wuhan Institute of Virology at EcoHealth Alliance, which was orchestrated by Dr. Peter Daszak. Additionally, the USAID- EPT - PREDICT funding used in this peer reviewed paper was used to collect biological samples from bats globally. Then, the collaborators analyzed the collected samples to extract SARS like-corona viruses, and select or engineer genetic features within the viruses, collected with USAID - EPT - PREDICT funding, to create hybrid chimeric viruses. Chimeric viruses are defined as combining the genetic material from two or more distinct viruses. **The process of developing SARS-COV2 was also described in detail in the proposal submitted to, and ultimately funded by, the National Institutes of Health (HHS NIH), The National Institute of Allergy and Infectious Diseases (NIAID), by EcoHealth Alliance with the WIV and UNC listed as collaborators.** It is my attestation, that the creation of these SARS-like chimeric viruses described in this article include SARS-COV2. Lastly, the engineered SARS-COV2 was then used to test SARS vaccines and monoclonal antibody therapeutics against the disease in mice. **Reference: Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., ... & Baric, R. S. (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nature medicine*, 21(12), 1508-1513.**

- Dr. Peter Daszak approached me in late 2015 and stated that somebody from the Central Intelligence Agency (CIA) approached him and stated that they were interested in the places we were working, the people we were working with, and the data we were collecting. Peter then proceeded to ask me for my advice, and specifically asked whether we should work with them. I was shocked that Peter asked me this and was excited for the opportunity. I stated to Peter that "It never hurts to talk to them. There could be money in it." Peter then later confirmed over the next 2 months, between our weekly meetings that the relationship with them was proceeding.
- In March 2016, a paper was published by Dr. Ralph Baric, an EcoHealth Alliance gain of function collaborator working at UNC, in PNAS titled "SARS-like WIV1-CoV Poised for Human Emergence." In the article, the authors of the paper describe in detail how they used, designed, and constructed full-length and chimeric viruses to determine if they would replicate in human airway cultures. This specific paper is relevant because it compares and documents the effectiveness of different variations of coronavirus spike proteins at infecting human cells specifically by binding to ACE2 receptor, which was a critical and necessary step to design and engineer the SARS-COV2 virus. While employed at EcoHealth Alliance, I met both Dr. Shi Zhengli and Dr. Ralph Baric, where they presented their work on the design and engineering of SARS-CoV2 (coronavirus



RENTZ LAW, LLC.

gain of function research), and the use of highly specialized humanized mice models, which were necessary to successfully build SARS-COV2. These facts are supported by numerous recorded presentations by Dr. Peter Daszak and Dr. Ralph Baric from 2015-2019. Some of which, I personally attended while employed at EcoHealth Alliance. Additionally, the specific gain of function work described in this paper was presented by Dr. Peter Daszak to In-Q-Tel, a DoD and CIA venture capital firm. In the slides presented to In-Q-Tel, which I personally helped create at EcoHealth, describe the use of USAID – EPT – PREDICT funding to collect coronavirus samples from bats globally, where they are then analyzed to identify their most dangerous features to humans, and recombined to make new coronaviruses like SARS-COV2. Then, these viruses are tested on humanized mice to validate lethality and transmissibility. EcoHealth Alliance then used Dr. Baric's work for testing experimental vaccines, treatments, and therapeutics against the newly engineered SARS-COV2 strain to determine which countermeasures would be the most effective at mitigating the disease in humanized mice. **Reference: Menachery, V. D., Yount Jr, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., ... & Baric, R. S. (2016). SARS-like WIV1-CoV poised for human emergence. *Proceedings of the National Academy of Sciences*, 113(11), 3048-3053.**

- In late September or early October of 2019, I was contacted by Dr. Amy Jenkins and she was attempting to recruit me to be a Program Manager for emerging infectious disease work at the Defense Advanced Research Projects Agency (DARPA). I first met Dr. Amy Jenkins as a Ph.D. student and paid Research Fellow at a Department of Homeland Security Center of Excellence at the University of Minnesota in 2014. The position at DARPA was presented to me as if it was mine if I wanted it and I was told that it would need Top Secret Security clearance with a polygraph. I felt that the recruitment effort was quite strange as I had not worked full-time and directly in the national security space since 2014 at Sandia National Laboratories and I had no clue how Dr. Jenkins obtained my new personal cell phone number. Coincidentally, this is when epidemiological evidence indicates that the first cases of COVID-19 likely emerged. The two events may not be related; however, it is my belief that people working within the US government potentially identified me as a risk to knowing firsthand that the SARS-COV2 disease emergence event was a consequence of the US government's sponsorship of the genetic engineering of SARS-COV2 domestically and abroad. If I would have accepted the position, then I suspect that DARPA would have disclosed restricted information to me which would have consequently prevented me from discussing any of this information publicly, like I have been and am doing now. The recruitment effort itself was highly suspect as it seemed as if DARPA was completely circumventing the US government recruitment process for one of the most prestigious scientific positions in the world.



RENZ LAW, LLC.

- I attest that I analyzed the funding of Dr. Kristian Andersen of the Scripps Research Institute from data obtained from NIH funding databases. Dr. Andersen's funding dramatically increased after changing his position on the characterization of the agent as being manmade, to naturally emerging, after a series of discussions with Dr. Anthony Fauci.

**Total Funding Awarded Per Month Before
Fauci Teleconference**

\$393,079.65

**Total Funding Awarded Per Month After Fauci
Teleconference**

\$800,139.15

**Total Funding Awarded Per Calendar Year
Before Fauci Teleconference**

\$ 1,042,628.25

**Total Funding Awarded Per Calendar Year
After Fauci Teleconference**

\$2,284,161.08

**Total Continuing Funding Before Fauci
Teleconference
\$7,141,011.83**

**Total Continuing Funding After Fauci
Teleconference
\$23,724,681.83**

Total Continuing Funding INCREASE After Fauci Teleconference

\$16,583,670.00

- Lastly, at no point in time has any restricted information, including classified information, been shared with me related to the domestic or foreign engineering of the biological agent SARS-COV2, the subsequent release of SARS-COV2, the attempted cover-up of by officials working for the United States government. I have never leaked any legally obtained classified information or violated the rules and laws related to my past security clearances. The information that I have shared from my time at EcoHealth Alliance is not restricted by any non-disclosure agreement, nor is it US government protected or restricted information, as EcoHealth Alliance is supposedly a non-profit



RENZ LAW, LLC.

corporation conducting scientific research to protect human and animal health. All the documents that I have shared were created by myself or other personnel by EcoHealth Alliance and were not subject to derivative classification by the US government, which is standard practice in academic institutions. My findings, opinions, and analysis were informed by my highly specialized education in the field of emerging infectious diseases from one of the top 5 graduate programs in the world, by my experience working in the field, and by analysis of publicly available open source and open access information. Simply, I know how and where to find accurate and relevant information related to pandemics, emerging diseases, biowarfare, and bioterrorism quickly and know how to properly frame this information from my knowledge of how the government works in the context of relevant policy frameworks.

- In context, this series of events when they took place, did not seem of any consequence nor did I ever think or believe that I would be in this terrible position. I have been severely harassed by what appears to be state-sponsored actors based on the level of sophistication, persistence, and duration, of the harassment and crimes committed against me. I understand that these facts are difficult for our country. I have viewed this as a non-partisan issue since coming forward as a Whistleblower, as my only goal is to prevent another manmade pandemic from occurring. COVID-19, the disease caused by SARS COV2, in my professional opinion, is the result of Gain of Function research that was mismanaged by EcoHealth Alliance and its contractors.

I declare (or certify, verify, or state) under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed On (Date): 13 September 2022

Signature: 
Andrew G. Huff, Ph.D., M.S.

EXHIBIT 4

EXHIBIT 4

To: Baric, Ralph S (rbaric@email.unc.edu)
Cc: Alison Andre (andre@ecohealthalliance.org)
From: Peter Daszak (daszak@ecohealthalliance.org)
Sent: Mon 1/13/2020 7:55:43 PM (UTC-05:00)
Subject: RE: Call with NIH tomorrow

OK - great. It sounds like we're on the same call!

And my thoughts exactly re. the highly variable SARS-like CoV. I've told journalists about it, but it's a complicated story for them to get across.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001

Tel.
Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

-----Original Message-----

From: Baric, Ralph S (mailto:rbaric@email.unc.edu)
Sent: Monday, January 13, 2020 6:50 PM
To: Peter Daszak
Subject: RE: Call with NIH tomorrow

Hi Peter, I have to participate on an NIH call tomorrow at 10. I believe it's a strategic meeting designed to help craft a NIH response plan to the WU-CoV. Hope things are going well. Looks like we found our highly variable SARS-like CoV! Ralph

-----Original Message-----

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Monday, January 13, 2020 6:43 PM
To: Baric, Ralph S <rbaric@email.unc.edu>; Sims, Amy C <sims0018@email.unc.edu>
Cc: Alison Andre <andre@ecohealthalliance.org>
Subject: Call with NIH tomorrow

Ralph - I'm having an informational call with our program officer re the Wuhan outbreak tomorrow at 10am - do you want to join and are you available?

EXHIBIT 5

EXHIBIT 5

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 03:29:42 +0000
To: Peter Daszak
Subject: RE: Thank you for your public comments re COVID-19's origins

Peter:

Many thanks for your kind note.
Best regards,
Tony

From: Peter Daszak [REDACTED]
Sent: Saturday, April 18, 2020 9:43 PM
To: Morens, David (NIH/NIAID) [E] [REDACTED]; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Cc: Stemmy, Erik (NIH/NIAID) [E] [REDACTED] >; Erbelding, Emily (NIH/NIAID) [E]
[REDACTED] (b) (6) >; Aleksei Chmura [REDACTED] (b) (6)
Subject: Thank you for your public comments re COVID-19's origins
Importance: High

Tony (cc'ing David so that you might pass this on to Tony once he has a spare second)

As the PI of the R01 grant publicly targeted by Fox News reporters at the Presidential press briefing last night, I just wanted to say a personal thankyou on behalf of our staff and collaborators, for publicly standing up and stating that the scientific evidence supports a natural origin for COVID-19 from a bat-to-human spillover, not a lab release from the Wuhan Institute of Virology.

It's been a very hard few months as these conspiracy theorists have gradually become politicized and hardened in their stance. Especially because the work we've been doing in collaboration with Chinese virologists has given us incredible insight into the risks that these viruses represent, so that we can directly help protect our nation from bat-origin coronaviruses. We're fighting to keep the communications open with our Chinese colleagues, so that we can better address future pandemics like COVID-19.

From my perspective, your comments are brave, and coming from your trusted voice, will help dispel the myths being spun around the virus' origins.

Once this pandemic's over I look forward thanking you in person and let you know how important your comments are to us all.

Cheers,

Peter

EXHIBIT 6

EXHIBIT 6



8/15/21

International Health Regulations (IHR)

Protecting People Every Day

With the signing of the revised International Health Regulations (IHR) in 2005, the international community agreed to improve the detection and reporting of potential public health emergencies worldwide. IHR (2005) better addresses today's global health security concerns and are a critical part of protecting global health. The regulations require that all countries have the ability to detect, assess, report and respond to public health events.

CDC is working with countries around the globe to help meet IHR (2005) goals. CDC's global programs address over 400 diseases, health threats, and conditions that are major causes of death, disease, and disability. Our global programs are run by world leaders in epidemiology, surveillance, informatics, laboratory systems, and other essential disciplines. Through partnerships with other countries' ministries of health, CDC is improving the quantity and quality of critical public health services.

Building a Foundation for Global Health Security

IHR (2005) also serves as a foundation for [CDC and the Global Health Security Agenda](#). The GHS Agenda is "an effort by nations, international organizations, and civil society to accelerate progress toward a world safe and secure from infectious disease threats; to promote global health security as an international priority; and to spur progress toward full implementation of the IHR."¹

The GHS Agenda provides 11 clear targets which will serve as a road map to help countries create systems that are able to prevent, detect and respond to health threats. The GHS Agenda recognizes the challenges countries are facing, laying out practical and concrete steps countries can take toward strengthening their health systems, as well as ways in which countries can support each other.

About IHR

IHR Basics

With trade and travel expanding on a global level, the opportunity for greater disease transmission also increases. The public health and economic impact due to infectious diseases can cause great harm to humans and severely damage a country's resources. IHR (2005) is coordinated by the World Health Organization (WHO) and aims to keep the world informed about public health risks and events. As an international treaty, the IHR (2005) is legally binding; all countries must report events of international public health importance. Countries reference IHR (2005) to determine how to prevent and control global health threats while keeping international travel and trade as open as possible.

IHR (2005) requires that all countries have the ability to do the following:

- **Detect:** Make sure surveillance systems and laboratories can detect potential threats
- **Assess:** Work together with other countries to make decisions in public health emergencies
- **Report:** Report specific diseases, plus any potential international public health emergencies, through participation in a network of National Focal Points
- **Respond:** Respond to public health events

IHR (2005) also includes specific measures countries can take at ports, airports and ground crossings to limit the spread of health risks to neighboring countries, and to prevent unwarranted travel and trade restrictions.²

U.S. government agencies have just 48 hours to assess the situation after learning about a public health emergency of international concern (PHEIC).

Find answers to more questions about how IHR (2005) has changed the way we handle outbreaks and other public health threats.

IHR: Made for Today's Health Threats

In today's interconnected society, it's more important than ever to make sure all countries are able to respond to and contain public health threats.

In 2003, severe acute respiratory syndrome (SARS) threatened global health, showing us how easily an outbreak can spread. Recently, the Ebola epidemic in West Africa and outbreaks of MERS-CoV have shown that we are only as safe as the most fragile state. All countries have a responsibility to one another to build healthcare systems that are strong and that work to identify and contain public health events before they spread.

While previous regulations required countries to report incidents of cholera, plague, and yellow fever, IHR (2005) is more flexible and future-oriented, requiring countries to consider the possible impact of all hazards, whether they occur naturally, accidentally, or intentionally.³ In spite of broader global agreement to the importance of IHR (2005), **only about 1/3 of the countries in the world currently have the ability to assess, detect, and respond to public health emergencies.**⁴ These gaps in global preparedness leave Americans and the rest of the world vulnerable.

And global health security is not just a health issue; a crisis such as SARS or Ebola can devastate economies and keep countries from developing. The World Bank Group estimates that Guinea, Liberia, and Sierra Leone together will lose at least \$1.6 billion in forgone economic growth in 2015 as a result of the Ebola epidemic.⁵ The impact of this kind of economic devastation reaches farther and wider than ever.⁶

Protecting People

One of the most important aspects of IHR (2005) is the requirement that countries detect and report events that may constitute a potential public health emergency of international concern (PHEIC).

Under IHR (2005), a PHEIC is declared by the World Health Organization if the situation meets 2 of 4 criteria:

- Is the public health impact of the event serious?
- Is the event unusual or unexpected?
- Is there a significant risk of international spread?
- Is there a significant risk of international travel or trade restrictions?⁷

Once a WHO member country identifies an event of concern, the country must assess the public health risks of the event within 48 hours. If the event is determined to be notifiable under the IHR, the country must report the information to WHO within 24 hours.

Some diseases always require reporting under the IHR, no matter when or where they occur, while others become notifiable when they represent an unusual risk or situation.

Always Notifiable:⁸

- Smallpox
- Poliomyelitis due to wild-type poliovirus
- Human influenza caused by a new subtype
- Severe acute respiratory syndrome (SARS)

Other Potentially Notifiable Events:⁹

- May include cholera, pneumonic plague, yellow fever, viral hemorrhagic fever, and West Nile fever, as well as any others that meet the criteria laid out by the IHR.
- Other biological, radiological, or chemical events that meet IHR criteria

Since IHR (2005) was put into place, four PHEICs have been declared by WHO:

- H1N1 influenza (2009)
- Polio (2014)
- Ebola (2014)
- Zika virus (2016)

When a PHEIC is declared, WHO helps coordinate an immediate response with the affected country and with other countries around the world.


Global IHR Participation

IHR represents an agreement between 196 countries, including all WHO Member States, to work together for global health security.¹⁰

In the U.S., CDC works with state and local reporting and response networks to receive information at the federal level and then respond to events of concern at the local and federal levels. The Department of Health and Human Services (DHHS) has assumed the lead role in carrying out the reporting requirements for IHR (2005). The Health and Human Services' Secretary's Operations Center (SOC) is the National Focal Point responsible for reporting events to WHO. CDC works with other federal agencies to support IHR (2005) implementation.

Monitoring and Evaluation Framework

How We Assess Health Security Capacity

Being adequately prepared to manage these infectious disease outbreaks is a challenge for many countries. IHR (2005) Monitoring and Evaluation Framework  (MEF) provides a roadmap for assessing a country's health security capacity, enabling them to identify areas for improvement.

IHR MEF is composed of four processes:

- States Parties Self-Assessment Annual Reporting (SPAR),
- Joint External Evaluations, (JEE),
- After Action Reviews (AAR), and
- Simulation Exercises (SimEx).

The SPAR is a mandatory process under IHR (2005); the JEE, AAR, and SimEx are voluntary. Together, these provide a comprehensive approach to assessing a country's health security capacity and to developing recommendations for how to address associated gaps.

Additionally, results of the JEE and other country-based assessments can be used to guide the development of **National Action Plans for Health Security**. The NAPHS aims to address gaps in a country's health security capacity through a system that aligns to the JEE's recommendations.

When used together, these processes can help governments improve their preparedness against infectious disease threats, gain domestic support for health security work, and direct partners to the areas where more support is needed. To support IHR MEF activities within countries, CDC serves as a major contributor to global public health efforts to prevent, detect, and respond to public health risks.

Joint External Evaluation

The Joint External Evaluation (JEE) is a voluntary and comprehensive process to evaluate country capacity across 19 technical areas, to address infectious disease risks through a coordinated response.

The JEE process brings together experts from around the world to help a country assess its strengths and weaknesses and identify recommendations to improve its health security capacity. Multisectoral collaboration, through processes like the JEE, is key to strengthening health systems—this means engaging not just health partners, but other government sectors, such as environmental, agricultural, defense, and finance.


Through the JEE, countries are able to:

- Identify the most critical gaps within their health systems
- Prioritize opportunities for enhanced preparedness and response
- Engage with current and prospective donors and partners to effectively target resources


CDC has collaborated with WHO on developing and refining the JEE process and tools since its inception in 2016. As of July 2019, 100 JEEs have been completed, representing over half of the UN member states that committed to achieving the goals of the IHR 2005. CDC has provided assistance in over 60% of the JEEs conducted throughout the world, and helps countries who have completed this process translate JEE findings and recommendations into action.

Joint External Evaluation Assessments (January 2016–July 2019)



After a JEE is completed, the external experts work with their country counterparts to produce a written report, which includes the scores and all-important priority actions. This report serves as a guide for the country on how to build health security capacity within each technical area. The associated priority actions can feed directly into a National Action Plan for Health Security (NAPHS) and other post-JEE planning processes. JEE results are also published [online](#)  so that partners can work with countries in a more coordinated fashion to address health security gaps.

JEE Health Capacity Evaluation Process



National Action Plan for Health Security

CDC supports countries as they develop and strengthen their National Action Plan for Health Security (NAPHS) following a Joint External Evaluation (JEE). Through an all-of-government approach, the NAPHS is developed collectively, with input from different government sectors, and support from international partners. Developing the NAPHS helps countries identify activities that align to the 19 JEE Technical Areas and prioritize them for implementation. The resulting plan details the activities necessary to address gaps within a country's health security capacity. These activities are then monitored to determine what is working, what needs to be changed, and what to focus on next to continue to build country capacity.

CDC works with partners to generate a NAPHS that is realistic and actionable by providing technical expertise across all stages of development. Specifically, CDC works with partners to facilitate:

- Communication, coordination, and collaboration
- Prioritization, resource mapping, and mobilization
- Implementation and monitoring

More Information

- [National Action Plan for Health Security \(NAPHS\)](#)
- [JEE Feature Story: A Project to Assess and Build Global Health Security](#)
- [Blog: Assessing health security in Côte d'Ivoire](#)

References

1. CDC. [CDC and the Global Health Security Agenda](#). Page accessed 7/5/19
2. WHO. [Strengthening health security by implementing the International Health Regulations \(2005\)](#) [\[PDF\]](#). Page accessed 7/5/19
3. Gostin, Lawrence, The International Health Regulations and beyond; The Lancet, [Vol. 4, Issue 10](#) [\[PDF\]](#), 606–607. Page accessed 7/5/19
4. WHO. [Strengthening health security by implementing the International Health Regulations \(2005\)](#) [\[PDF\]](#). Page accessed 7/5/19
5. World Bank. [The Economic Impact of the 2014 Ebola Epidemic](#) [\[PDF\]](#) [\[PDF\]](#). Page accessed 7/5/2019
6. Heymann, David L et al., [Global health security: the wider lessons from the west African Ebola virus disease epidemic](#) [\[PDF\]](#); The Lancet, Vol. 385, Issue 9980, 1884 – 1901. Page accessed 7/5/19
7. WHO. [IHR Procedures concerning public health emergencies of international concern \(PHEIC\)](#) [\[PDF\]](#). Page accessed 7/5/19
8. WHO. [Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations \(2005\)](#) [\[PDF\]](#) [\[PDF\]](#). Page accessed 7/5/19

Page last reviewed: August 19, 2019

EXHIBIT 7

EXHIBIT 7



National Institutes of Health
Bethesda, Maryland 20892

October 20, 2021

The Honorable James Comer
Ranking Member, Committee on Oversight and Reform
U.S. House of Representatives
Washington, D.C. 20515

Dear Representative Comer:

Thank you for your continued interest in the work of the National Institutes of Health (NIH). I am writing today to provide additional information and documents regarding NIH's grant to EcoHealth Alliance, Inc.

It is important to state at the outset that published genomic data demonstrate that the bat coronaviruses studied under the NIH grant to EcoHealth Alliance, Inc. and subaward to the Wuhan Institute of Virology (WIV) are not and could not have become SARS-CoV-2. Both the progress report and the analysis attached here again confirm that conclusion, as the sequences of the viruses are genetically very distant.

The fifth and final progress report for Grant R01AI110964, awarded to EcoHealth Alliance, Inc. is attached with redactions only for personally identifiable information. This progress report was submitted to NIH in August 2021 in response to NIH's compliance enforcement efforts. It includes data from a research project conducted during the 2018-19 grant period using bat coronavirus genome sequences already existing in nature.

The limited experiment described in the final progress report provided by EcoHealth Alliance was testing if spike proteins from naturally occurring bat coronaviruses circulating in China were capable of binding to the human ACE2 receptor in a mouse model. All other aspects of the mice, including the immune system, remained unchanged. In this limited experiment, laboratory mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus. As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do. Regardless, the viruses being studied under this grant were genetically very distant from SARS-CoV-2.

The research plan was reviewed by NIH in advance of funding, and NIH determined that it did not fit the definition of research involving enhanced pathogens of pandemic potential (ePPP) because these bat coronaviruses had not been shown to infect humans. As such, the research was not subject to departmental review under the HHS P3CO Framework. However, out of an abundance of caution and as an additional layer of oversight, language was included in the terms and conditions of the grant award to EcoHealth that outlined criteria for a secondary review, such as a requirement that the grantee report immediately a one log increase in growth. These

The Honorable James Comer
Page 2

measures would prompt a secondary review to determine whether the research aims should be re-evaluated or new biosafety measures should be enacted.

EcoHealth failed to report this finding right away, as was required by the terms of the grant. EcoHealth is being notified that they have five days from today to submit to NIH any and all unpublished data from the experiments and work conducted under this award. Additional compliance efforts continue.


The second document is a genetic analysis demonstrating that the naturally occurring bat coronaviruses used in experiments under the NIH grant from 2014-2018 are decades removed from SARS-CoV-2 evolutionarily. The analysis compares the sequence relationships between:

- SARS-CoV-1, the cause of the SARS outbreak in 2003;
- SARS-CoV-2, the cause of COVID-19 pandemic;
- WIV-1, a naturally occurring bat coronavirus used in experiments funded by the NIH;
- RaTG13, one of the closest bat coronavirus relatives to SARS-CoV-2 collected by the Wuhan Institute of Virology; and
- BANAL-52, one of several bat coronaviruses recently identified from bats living in caves in Laos.

While it might appear that the similarity of RaTG13 and BANAL-52 bat coronaviruses to SARS-CoV-2 is close because it overlaps by 96-97%, experts agree that even these viruses are far too divergent to have been the progenitor of SARS-CoV-2. For comparison, today's human genome is 96% similar to our closest ancestor, the chimpanzee. Humans and chimpanzees are thought to have diverged approximately 6 million years ago.

The analysis attached confirms that the bat coronaviruses studied under the EcoHealth Alliance grant could not have been the source of SARS-CoV-2 and the COVID-19 pandemic.

If you or your staff have questions, NIH would be pleased to brief you on these documents.



Lawrence A. Tabak, D.D.S., Ph.D.
Principal Deputy Director

EXHIBIT 8

EXHIBIT 8

NYSCEF DOC. NO. 90

Ohio Department of Health

RECEIVED NYSCEF: 02/05/2022

Primary Reg. Dist. No. 2506

VITAL STATISTICS

State File No. 2020041965

Registrar's No.

2500-2020004424

CERTIFICATE OF DEATH

DECEDENT	1. Decedent's Legal Name (First, Middle, Last, Suffix) (Include AKA's if any) ROSEMARIE MCKINNISS						2. Sex FEMALE	3. Date of Death (Mo/Day/Year) APRIL 24, 2020
	4. Social Security Number [REDACTED]		5a. Age (Years) 85	5b. Under 1 Year Months	5c. Under 1 day Hours Minutes	6. Date of Birth (Mo/Day/Year) MARCH 22, 1935	7. Birthplace (City and State or Foreign Country) COLUMBUS, OHIO	
	8a. Residence State OHIO		8b. County FRANKLIN			8c. City or Town WORTHINGTON		
	8d. Street Address and Zip Code 1030 HIGH STREET 43085						9. Ever in US Armed Forces? NO	
DISPOSITION	10. Marital Status at Time of Death WIDOWED (AND NOT REMARRIED)						11. Surviving Spouse's Name (If wife, give name prior to first marriage)	
	12. Decedent's Education HIGH SCHOOL GRADUATE OR GED				13. Decedent of Hispanic Origin NO		14. Decedent's Race WHITE	
	15. Father's Name CARL J MEHRLE				16. Mother's Name (prior to first marriage) HELEN KRAMMER			
	17a. Informant's Name KATHLEEN MCKINNISS				17b. Relationship to Decedent DAUGHTER		17c. Mailing Address (Street and Number, City, State, Zip Code) 160 WEST WILSON BRIDGE ROAD 631	
CERTIFIER	18a. Place of Death NURSING HOME/LONG TERM CARE FACILITY						18b. Facility Name (If not Institution, give street & number) THE LAURELS OF WORTHINGTON	
	18c. City or Town, State and Zip Code WORTHINGTON, OH 43085						18d. County of Death FRANKLIN	
	19. Funeral Service Licensee or Other Agent JOHN A TIBERI				20. License Number (of licensee) 008008		21. Name and Complete Address of Funeral Facility MAEDER-QUINT-TIBERI FUNERAL HOME INC	
	22. Method and Place of Disposition BURIAL - SAINT JOSEPH CEMETERY, LOCKBOURNE, OH						23. Local Registrar SANDRA TAYLOR	
CAUSE OF DEATH	24. Date Filed (Month/Day/Year) APRIL 28, 2020						25. Name and Complete Address of Funeral Facility 1068 S HIGH ST COLUMBUS, OH 43206	
	26a. Certifier (Check only one) <input checked="" type="checkbox"/> Certifying Physician: To the best of my knowledge, death occurred at the time, date, and place; and due to the cause(s) and manner stated. <input type="checkbox"/> Coroner or Medical Examiner: On the basis of examination and/or investigation, in my opinion, death occurred at the time, date, and place; and due to the cause(s) and manner stated.						26b. Time of Death 22:45	
	26c. Date Pronounced Dead (Month/Day/Year) APRIL 24, 2020						26d. Was Case Referred to Medical Examiner or Coroner? NO	
	26e. Certifier Name and Title DANIEL LAWRENCE MILLER MD						26f. License number 35.084230	
CAUSE OF DEATH	26g. Date Signed (Month/Day/Year) APRIL 28, 2020						27. Name and Address of Person who Completed Cause of Death DANIEL LAWRENCE MILLER, 3525 OLENTANGY RIVER RD, COLUMBUS, OH 43214	
	28. Part I. Enter the disease, injuries, or complications that caused the death. Do not enter the mode of dying, such as cardiac or respiratory arrest, shock, or heart failure. List only one cause on each line. Type or print in permanent blue or black ink.						Approximate Interval: Onset and Death	
	Immediate Cause (Final disease or condition resulting in death) a. PRESUMED COVID-19						DAYS	
	Sequentially list conditions, if any, leading to immediate cause. b. Due to (or as Consequence of) DEMENTIA						YEARS	
CAUSE OF DEATH	Enter Underlying Cause (Disease or injury that initiated events resulting in a death) c. Due to (or as Consequence of)							
	d. Due to (or as Consequence of)							
	Part II. Other significant conditions contributing to death but not resulting in the underlying cause given in Part I.						29a. Was An Autopsy Performed? NO	
	29b. Were Autopsy Findings Available Prior To Completion Of Cause of Death? NOT APPLICABLE						30. Did Tobacco Use Contribute to Death? NO	
CAUSE OF DEATH	31. If Female, Pregnancy Status NOT APPLICABLE.						32. Manner of Death NATURAL	
	33a. Date of Injury (Mo/Day/Year)		33b. Time of Injury		33c. Place of Injury (e.g., Decedent's home, construction site, restaurant, wooded area)		33d. Injury at Work?	
	33e. Location of Injury (Street and Number or Rural Route Number, City or Town, State)							
	33f. Describe How Injury Occurred:						33g. If Transportation Injury, Specify:	

HEA 2724 Rev. 08/18

EXHIBIT 9

EXHIBIT 9





EXHIBIT 10

EXHIBIT 10



Bureau of Human Resources

January 31, 2022

CARIN ROSADO
60 ROBIN ROAD
ROCKY POINT, NY 11778

Subject: LWOP & Non-Compliance with COVID-19 Vaccine Mandate

Dear Member,

As you are aware, the City has issued several orders concerning mandated vaccination against COVID-19. Executive Orders 75 and 76 mandated that, effective August 2, 2021, all New Hires be fully vaccinated against COVID-19 and subsequently, the Health Commissioner's Order dated October 21, 2021 mandated vaccination for all City employees.

Our records indicate that you have been on unpaid leave as a result of non-compliance with the Health Commissioner's Order dated October 21, 2021 and have not chosen to continue health benefits coverage through June 30, 2022 pursuant to a union agreement. Please note, the deadline has passed for requesting continued health benefits.

Compliance with this requirement is a condition of your continued employment with the City. If you do not provide proof of vaccination by February 11, 2022, your employment with the City will be terminated. You must submit proof of vaccination to HR via the **COVID Test Result and Vaccination Proof Upload application** on the FDNY Intranet homepage or via email to: HRVaxProof@fdny.nyc.gov.

NYC COVID-19 and Flu Vaccine Finder: [NYC COVID-19 and Flu Vaccine Finder](#)

If you believe that you received this letter in error, please contact: FDNYHuman.Resources@fdny.nyc.gov

Any inquiries or responses to this notice may be submitted via email to: FDNYHuman.Resources@fdny.nyc.gov.

Fire Department, City of New York
9 MetroTech Center, Brooklyn, NY 11201
nyc.gov/fdny | connect @fdny

EXHIBIT 11

EXHIBIT 11

NYSCEF DOC. NO. 4324

REGISTER NUMBER
167NEW YORK STATE
DEPARTMENT OF HEALTH

RECEIVED NYSCEF: 00/05/2022

CERTIFICATE OF DEATH

131-2021-00037564

STATE FILE NUMBER

1. NAME: FIRST James J. Finn		MIDDLE	LAST	2. SEX: MALE <input checked="" type="checkbox"/> 1 FEMALE <input type="checkbox"/> 2	3A. DATE OF DEATH: MONTH DAY YEAR 04 18 2021	3B. HOUR: 09:05 PM
4A. PLACE OF DEATH: (Check one) HOSPITAL DOA <input type="checkbox"/> ER <input type="checkbox"/> HOSPITAL OUTPATIENT <input type="checkbox"/> HOSPITAL INPATIENT <input checked="" type="checkbox"/> NURSING HOME <input type="checkbox"/> PRIVATE RESIDENCE <input type="checkbox"/> HOSPICE FACILITY <input type="checkbox"/> OTHER (Specify): <input type="checkbox"/>		4B. IF FACILITY, DATE ADMITTED: MONTH DAY YEAR 03 25 2021		4C. NAME OF FACILITY: (If not facility, give address) Montefiore Nyack Hospital		
4D. LOCALITY: (Check one and specify) CITY VILLAGE TOWN <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Nyack Village		4E. COUNTY OF DEATH: Rockland				
4F. MEDICAL RECORD NO.		4G. WAS DECEDENT TRANSFERRED FROM ANOTHER INSTITUTION? (If yes, specify institution name, city or town, county and state) NO <input type="checkbox"/> YES <input type="checkbox"/>				
5. DATE OF BIRTH: MONTH DAY YEAR 04 28 1931		6A. AGE IN YEARS: 89	6B. IF UNDER 1 YEAR ENTER: months days	6C. IF UNDER 1 DAY ENTER: hours minutes	7A. CITY AND STATE OF BIRTH: (If not USA, Country and Region/Province) New York, New York	
8. SERVED IN U.S. ARMED FORCES? (Specify years) NO <input type="checkbox"/> YES <input checked="" type="checkbox"/> 1		9. DECEDENT OF HISPANIC ORIGIN? Check the boxes that best describe whether the decedent is Spanish/Hispanic/Latino: A <input checked="" type="checkbox"/> No, not Spanish/Hispanic/Latino B <input type="checkbox"/> Yes, Mexican, Mexican American, Chicano C <input type="checkbox"/> Yes, Puerto Rican D <input type="checkbox"/> Yes, Cuban E <input type="checkbox"/> Yes, Other Spanish/Hispanic/Latino (Specify)		10. DECEDENT'S RACE: Check one or more races to indicate what the decedent considered himself or herself to be: A <input checked="" type="checkbox"/> White/Caucasian B <input type="checkbox"/> Black or African American C <input type="checkbox"/> Asian Indian D <input type="checkbox"/> Chinese E <input type="checkbox"/> Filipino F <input type="checkbox"/> Japanese G <input type="checkbox"/> Korean H <input type="checkbox"/> Vietnamese J <input type="checkbox"/> Native Hawaiian K <input type="checkbox"/> Guamanian or Chamorro M <input type="checkbox"/> Samoan N <input type="checkbox"/> American Indian or Alaska Native (specify) P <input type="checkbox"/> Other Asian (specify) R <input type="checkbox"/> Other Pacific Islander (specify) S <input type="checkbox"/> Other (specify)		
11. DECEDENT'S EDUCATION: Check the box that best describes the highest degree or level of school completed at the time of death. 1 <input type="checkbox"/> ≤ 8th grade 2 <input checked="" type="checkbox"/> 9th-12th grade; no diploma 3 <input type="checkbox"/> High school graduate or GED 4 <input type="checkbox"/> Some college credit, but no degree 5 <input type="checkbox"/> Associate's degree 6 <input type="checkbox"/> Bachelor's degree 7 <input type="checkbox"/> Master's degree 8 <input type="checkbox"/> Doctorate/Professional degree		12. SOCIAL SECURITY NUMBER: [REDACTED]		13. MARITAL STATUS: NEVER MARRIED <input type="checkbox"/> 1 MARRIED <input checked="" type="checkbox"/> 2 WIDOWED <input type="checkbox"/> 3 DIVORCED <input type="checkbox"/> 4 SEPARATED <input type="checkbox"/> 5		14. SURVIVING SPOUSE: Enter birth name of spouse if married or separated. Geraldine Schierloh
15A. USUAL OCCUPATION: (Do not enter retired) Police Officer		15B. KIND OF BUSINESS OR INDUSTRY: Law Enforcement		15C. NAME AND LOCALITY OF COMPANY OR FIRM: Bronx, NY		
16A. RESIDENCE: (State or Country if not USA) NY		16B. County or Region/Province if not USA: Rockland		16C. LOCALITY: (Check one and specify) CITY VILLAGE TOWN <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Clarkstown Town		16F. IF CITY OR VILLAGE, IS RESIDENCE WITHIN CITY OR VILLAGE LIMITS? <input type="checkbox"/> YES <input type="checkbox"/> NO IF NO, SPECIFY TOWN:
16D. STREET AND NUMBER OF RESIDENCE: 7 Brookhill Drive, West Nyack Hamlet		16E. ZIP CODE: 10994				
17. BIRTH NAME OF FATHER / PARENT: FIRST MI LAST Patrick Finn		18. BIRTH NAME OF MOTHER / PARENT: FIRST MI LAST Julia Morrison				
19A. NAME OF INFORMANT: Geraldine Finn		19B. MAILING ADDRESS: (include zip code) 7 Brookhill Drive, West Nyack Hamlet, NY 10994				
20A. 1 <input checked="" type="checkbox"/> BURIAL 2 <input type="checkbox"/> CREMATION 3 <input type="checkbox"/> REMOVAL 4 <input type="checkbox"/> HOLD 5 <input type="checkbox"/> DONATION MONTH DAY YEAR 04 28 2021		20B. PLACE OF BURIAL, CREMATION, REMOVAL OR OTHER DISPOSITION: St. Anthony's Cemetery				
20C. LOCATION: (City or town and state) Nanuet Hamlet, New York						
21A. NAME AND ADDRESS OF FUNERAL HOME: Joseph W Sorce Funeral Home Inc 728 W Nyack Rd, W Nyack, NY 10994		21B. REGISTRATION NUMBER: 00945				
22A. NAME OF FUNERAL DIRECTOR: Stacey E Damon		22B. SIGNATURE OF FUNERAL DIRECTOR: Stacey E Damon Electronically Signed				
23A. SIGNATURE OF REGISTRAR: Patricia Evans Electronically Signed		23B. DATE FILED: MONTH DAY YEAR 04 20 2021		24A. BURIAL OR REMOVAL PERMIT ISSUED BY: Patricia Evans		24B. DATE ISSUED: MONTH DAY YEAR 04 20 2021
ITEMS 25 THRU 33 COMPLETED BY CERTIFYING PHYSICIAN -- OR -- CORONER/CORONER'S PHYSICIAN OR MEDICAL EXAMINER						
25A. CERTIFICATION: To the best of my knowledge, death occurred at the time, date and place and due to the causes stated. Certifier's Name: Scott Jordan Silver, MD License No.: 259246 Signature: Scott Jordan Silver, MD Electronically Signed Month Day Year 04 18 2021						
25B. If coroner is not a physician, enter Coroner's Physician's name & title: License No.: Address: 160 N Midland Ave, Nyack Village, NY 10960						
25C. If certifier is not attending physician, enter Attending Physician's name & title: License No.: Address:						
26A. Attending physician attended deceased: FROM Month Day Year TO Month Day Year 03 25 2021 04 18 2021						
26B. Deceased last seen alive by attending physician: Month Day Year 04 18 2021						
26C. Pronounced Dead ON Month Day Year Time 04 18 2021 09:05 PM						
27. MANNER OF DEATH: NATURAL CAUSE <input checked="" type="checkbox"/> 1 ACCIDENT <input type="checkbox"/> 2 HOMICIDE <input type="checkbox"/> 3 SUICIDE <input type="checkbox"/> 4 UNDETERMINED CIRCUMSTANCES <input type="checkbox"/> 5 PENDING INVESTIGATION <input type="checkbox"/> 6						
28. WAS CASE REFERRED TO CORONER OR MEDICAL EXAMINER? 0 <input type="checkbox"/> NO 1 <input checked="" type="checkbox"/> YES						
29A. AUTOPSY? NO YES REFUSED <input type="checkbox"/> 0 <input type="checkbox"/> 1 <input type="checkbox"/> 2						
29B. IF YES, WERE FINDINGS USED TO DETERMINE CAUSE OF DEATH? 0 <input type="checkbox"/> NO 1 <input type="checkbox"/> YES						
CONFIDENTIAL SEE INSTRUCTION SHEET FOR COMPLETING CAUSE OF DEATH CONFIDENTIAL						
30. DEATH WAS CAUSED BY: (ENTER ONLY ONE CAUSE PER LINE FOR (A), (B), AND (C).) PART I. IMMEDIATE CAUSE: (A) cardio-pulmonary arrest DUE TO OR AS A CONSEQUENCE OF: (B) covid pneumonia DUE TO OR AS A CONSEQUENCE OF: (C) <<<<<<>>>>> APPROXIMATE INTERVAL BETWEEN ONSET AND DEATH min weeks <<<<<<>>>>>						
PART II. OTHER SIGNIFICANT CONDITIONS CONTRIBUTING TO DEATH BUT NOT RELATED TO CAUSE GIVEN IN PART I (A): atrial fibrillation, hypertension, non-hodgkin's lymphoma, waldenstrom's macroglobulinemia						
31A. IF INJURY, DATE: MONTH DAY YEAR 04 18 2021		31B. INJURY LOCALITY: (City or town and county and state)		31C. DESCRIBE HOW INJURY OCCURRED:		DID TOBACCO USE CONTRIBUTE TO DEATH? 0 <input type="checkbox"/> NO 1 <input type="checkbox"/> YES 2 <input type="checkbox"/> PROBABLY 3 <input checked="" type="checkbox"/> UNKNOWN
31F. IF TRANSPORTATION INJURY, SPECIFY: 1 <input type="checkbox"/> Driver/Operator 2 <input type="checkbox"/> Passenger 3 <input type="checkbox"/> Pedestrian 4 <input type="checkbox"/> OTHER (specify)		32. WAS DECEDENT HOSPITALIZED IN LAST 2 MONTHS? NO YES <input type="checkbox"/> 0 <input type="checkbox"/> 1		33A. IF FEMALE: 0 <input type="checkbox"/> Not pregnant within last year 1 <input type="checkbox"/> Pregnant at time of death 3 <input type="checkbox"/> Not pregnant, but pregnant 43 days to 1 year before death 2 <input type="checkbox"/> Not pregnant, but pregnant within 42 days of death 4 <input type="checkbox"/> Unknown if pregnant within past year		31E. INJURY AT WORK? NO YES <input type="checkbox"/> 0 <input type="checkbox"/> 1
33B. DATE OF DELIVERY: MONTH DAY YEAR						

EXHIBIT 12

EXHIBIT 12









EXHIBIT 13

EXHIBIT 13

An Analysis of the Origins of the COVID-19 Pandemic

Interim Report



Senate Committee on Health Education, Labor and Pensions

Minority Oversight Staff

October 2022

Table of Contents

Foreword	3
Introduction	4
<u>Section I:</u> Analysis of Natural Zoonotic Origins Hypothesis.....	5
a. Epidemiology of SARS-CoV-2 Outbreak Differs from Previous Natural Zoonotic Spillovers	7
b. Missing Evidence of a Natural Zoonotic Spillover.....	10
c. Problems with the Natural Zoonotic Hypothesis	11
<u>Section II:</u> Analysis of Research-Related Incident Hypothesis	13
a. Coronavirus Research in Wuhan and at the Wuhan Institute of Virology	13
b. WIV Research on SARS-related Coronaviruses with Pandemic Potential.....	15
c. WIV Biosafety and Biosecurity Patents and Procurements in 2019	16
d. WIV Biosafety and Biosecurity Events in 2019	17
<u>Section III:</u> China's Early COVID-19 Vaccine Development Versus the U.S. Operation Warp Speed	20
a. U.S. Operation Warp Speed.....	20
b. China's COVID-19 Vaccine Development Program.....	21
<u>Section IV:</u> Basis for Assessment that Research-Related Incident is More Likely Origin of SARS-CoV-2	23
a. Coronavirus Research at the Wuhan Institute of Virology	23
b. Evidence of Biosafety Failures at the WIV.....	24
c. Management and training concerns at the WIV.....	24
d. Anomalies in Epidemiology of SARS-COV-2 Outbreak	25
Conclusion	26

Foreword

Over one million Americans have died from COVID-19 and tens of millions have died from this virus worldwide. In addition to the tragic loss of life, over the past three years we have experienced the social, educational, and economic costs of a global pandemic.

Last summer, Chair Murray and I announced a bipartisan Health, Education, Labor and Pensions (HELP) Committee oversight effort into the origins of SARS-CoV-2, the virus that caused the COVID-19 pandemic as part of our effort to address pandemic preparedness and response programs, and we continue to work together on that project.

This is an interim report produced by HELP Committee Minority oversight staff. The objective was to review publicly available, open-source information to examine the two prevailing theories of origin of the SARS-CoV-2 virus: a natural zoonotic outbreak or a research-related incident. This Senate Health, Education, Labor, and Pensions (HELP) Committee Minority oversight staff report is the product of that review.

Over the last fifteen months, HELP Committee Minority oversight staff carefully reviewed several hundred publicly available scientific studies, interviewed several dozen subject matter experts, and analyzed previous reports and studies on the possible origins of the virus. I believe that this report provides a significant contribution to the existing body of evidence and helps establish parameters for how future analyses should be reviewed.

The lack of transparency and collaboration from government and public health officials in the People's Republic of China with respect to the origins of SARS-CoV-2 prevents reaching a more definitive conclusion.

With COVID-19 still in our midst, it is critical that we continue international efforts to uncover additional information regarding the origins of this deadly virus. I hope this report will guide the World Health Organization and other international institutions and researchers as they proceed with planned work to continue investigating the origins of this virus. Uncovering the answers to this critical question is imperative to our national and international ability to ensure that a pandemic of this size and scope does not happen again.

My ultimate goal with this report is to provide a clearer picture of what we know, so far, about the origins of SARS-CoV-2 so that we can continue to work together to be better prepared to respond to future public health threats. I believe this interim report does just that.



Richard Burr

United States Senator

Ranking Member, U.S. Senate Committee on Health, Education, Labor, and Pensions

Introduction

Three years after its emergence in Wuhan, exactly how SARS-CoV-2 first emerged as a respiratory pathogen capable of sustained human-to-human transmission remains the subject of active debate.¹ Experts have put forward two dominant theories on the origins of the virus.² The first theory is that SARS-CoV-2 is the result of a natural zoonotic spillover.³ The second theory is that the virus infected humans as a consequence of a research-related incident.⁴

Understanding the virus's origin is essential to understanding how this outbreak happened, why detection and reporting systems did not work as anticipated, and to better prepare for future health threats. This report has reviewed open source, publicly available information relevant to the origins of the virus to consolidate additional information that can be contributed to the body of work investigating the answer to this question.

Establishing a clear picture of the likely origin of the virus has proven challenging. Since January 3, 2020, government officials in the People's Republic of China (PRC) have prohibited sharing or publishing any information on SARS-CoV-2 without state review and approval.⁵ Restrictions on SARS-CoV-2 information remain in place today and, therefore, any information on SARS-CoV-2 and the COVID-19 pandemic published by government officials and scientists in China must be reviewed with these restrictions in mind.

As a result, establishing an approximate timeline for when SARS-CoV-2 first infected humans is difficult. Government officials and public health authorities in the PRC have claimed that there were no SARS-CoV-2 cases before early December 2019.⁶ However, available epidemiologic evidence strongly suggests that SARS-CoV-2 began infecting humans in Wuhan or the surrounding area between mid-October and early to mid-November 2019.⁷

While precedent of previous outbreaks of human infections from contact with animals favors the hypothesis that a natural zoonotic spillover is responsible for the origin of SARS-CoV-2, the emergence of SARS-CoV-2 that resulted in the COVID-19 pandemic was most likely the result of a research-related incident. This conclusion is not intended to be dispositive. The lack of transparency from government and public health officials in the PRC with respect to the origins of SARS-CoV-2 prevents reaching a more definitive conclusion. Should additional information be made publicly available, and subject to independent verification, it is possible that these conclusions would be subject to review and reconsideration.

Section I
Analysis of Natural Zoonotic Origins Hypothesis

Zoonotic spillovers, in which animal diseases cross the species barrier and infect humans, are a well-known, well-documented natural phenomena.⁸ By some estimations, natural zoonotic spillovers are responsible for 60 to 75 percent of emerging diseases in humans.⁹ Coronaviruses, to which SARS-CoV-2 belongs, are a large family of viruses that cause disease in a variety of domestic and farmed animals and have been responsible for previous outbreaks of new diseases in humans.¹⁰ All coronaviruses known to infect humans are the result of natural zoonotic spillover from animals into humans.¹¹

Two recent and prominent examples include Severe Acute Respiratory Syndrome (“SARS”) and Middle East Respiratory Syndrome (“MERS”), both of which are caused by a coronavirus (“SARS-CoV” and “MERS-CoV” respectively) leading to severe respiratory disease in humans.¹² Moreover, recent infectious disease pandemics, with the exception of the 1977 Russian Flu pandemic, are believed to have natural zoonotic origins.¹³





Figure 1: Example of a zoonotic spillover from bats. A: Direct spillover from bat to humans followed by human-to-human transmission. B: Spillover from a bat to an unknown intermediate host and then to humans, followed by human-to-human transmission.¹⁴

Natural zoonotic spillovers are a sequential process.¹⁵ In this process, an animal virus must evolve in order to become a human-adapted virus. First, a virus infects animals. Second, those infected animals come into contact with humans (known as the human-animal interface). Third, the virus is able to infect humans. Fourth, the virus is able to adapt to efficiently transmit between humans.¹⁶ Thus, a spillover event, in which disease is spread from animal to human, can result in one of two outcomes—either the pathogen, once transmitted from animals, is then transmitted from humans to humans, or the pathogen does not spread, resulting in a “dead-end” spillover. In many respects, once human-to-human transmission of SARS-CoV-2 was established, the onward human-to-human transmission of the virus would look similar regardless of whether it originated from a natural zoonotic spillover or a research-related incident.¹⁷

The natural zoonotic spillover hypothesis is a plausible explanation for how the COVID-19 pandemic started. There are a number of anomalies in the SARS-CoV-2 outbreak and the early COVID-19 pandemic compared to the emergence of past natural zoonotic spillovers, most notably the 2002-2004 SARS epidemic.



(GRAPHIC) K. FRANKLIN/SCIENCE; (DATA) DAVID ROBERTSON AND SPYROS LYTRAS/MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH; S. LYTRAS ET AL.,

GENOME BIOLOGY AND EVOLUTION, 14, 2 (2022)

Figure 2: Map showing location of known SARS-related viruses most closely related to SARS-CoV-2 with five most closely related SARS-related coronaviruses to SARS-CoV-2 within the red box.¹⁸

Based on the precedent of past natural zoonotic spillovers, if SARS-CoV-2 is the result of a zoonotic spillover, it likely needed to circulate in an intermediate host to increase the virus' chances of being able to infect and replicate in humans.¹⁹ Adaptation during circulation in an intermediate host is believed to have played a critical role in the emergence of SARS and MERS, as well as other bat viruses, such as hendra.²⁰ The identity of SARS-CoV-2's intermediate animal species remains unknown.²¹ If such an intermediate animal species exists, where these intermediate species came into contact with and first infected humans is also unknown.²² While it is likely that SARS-CoV-2 originated from a bat virus, most likely one found in horseshoe bats residing in Southern China or Southeast Asia, it remains unknown how SARS-CoV-2 traveled more than 1,000 miles from Southern China or Southeast Asia before emerging in Wuhan.²³ Almost three years after the COVID-19 pandemic began there is still no evidence of an animal

infected with SARS-CoV-2, or a closely related virus, before the first publicly reported human COVID-19 cases in Wuhan in December 2019.²⁴

a. Epidemiology of SARS-CoV-2 Outbreak Differs from Previous Natural Zoonotic Spillovers

Most recent natural zoonotic spillovers of respiratory viruses with pandemic potential have left behind evidence of where and how they occurred.²⁵ Failed inter-species transmissions, or “dead-end” spillovers, typically leave behind serological evidence in the form of antibodies in humans and animals that were exposed and infected but did not effectively transmit the virus to others.²⁶ Failed transmissions also typically leave behind genetic evidence at the animal-human interface.²⁷

Like interspecies transmission, human-to-human transmission also leave behind epidemiological evidence. The SARS epidemic saw at least five independent spillovers of the SARS virus into humans that then spread the virus to other humans, with other spillovers likely going unidentified and failing to cause sustained chains of transmission.²⁸ These spillovers occurred across multiple geographically distant live animal markets in Guangdong Province, China over a period of several months in 2002-2003.²⁹ Late-2003 to 2004 also saw isolated outbreaks of human SARS cases caused by additional independent spillovers of the virus.³⁰ Within six months of the start of the 2002-2004 SARS epidemic, intermediate host animal species candidates were identified, and numerous animals infected with SARS were found soon after the outbreak was identified.³¹ In addition, early SARS virus samples retrieved from infected humans contained genetic mutations that reflected its period of circulation and adaptation in palm civets, the intermediate species.³²

SARS-CoV-2's emergence also contrasts with outbreaks of human cases of Avian Influenza H7N9 in 2013. Like the 2002-2004 SARS outbreak, H7N9 started with multiple independent introductions of the virus into humans across multiple locations, even though the total number of human infections numbered less than 500.³³ Geographically disparate, independent spillovers imply that H7N9 Avian Influenza had circulated in bird populations for some time and across several provinces in China before the first known human infections. This is in contrast to the lack of geographically disparate cases of early COVID-19 cases in Hubei or China.³⁴

The occurrence of natural zoonotic spillovers is also determined in part by probability. The frequency with which humans are exposed to an intermediate animal species infected with a zoonotic viral agent “is likely to be an important determinant in disease emergence.”³⁵ This makes poorly regulated live animal markets in China and Southeast Asia effective conduits of zoonotic diseases.³⁶ The crowded conditions at these live animal markets mean that different members of multiple animal species that ordinarily would not come into contact are placed in close proximity to each other and large numbers of humans. These animals are often in poor health and shed viruses.³⁷




Figure 3: Comparison of Early Outbreaks of SARS-CoV and Avian Influenza H7N9.

Left: Map showing geographic distribution of SARS outbreak in Guangdong Province with dates of independent outbreaks of SARS from Nov. 2002 to Jan. 2003.³⁸

Right: Map of confirmed human cases of avian influenza A (H7N9) from Feb. 19, 2013 to April 29, 2013.³⁹




Figure 4: Map showing geo-temporal spread of COVID-19 in China from Dec. 31, 2019 to Feb. 11, 2020, starting only in Wuhan.⁴⁰

A number of epidemiologists and virologists – and, at first, the Chinese government – have asserted that the COVID-19 pandemic originated from a natural zoonotic transmission occurring at the Huanan Seafood Market.⁴¹ Government officials in China have subsequently also postulated the theory that SARS-CoV-2 arrived in China on the surface of imported frozen seafood or was brought into China by infected people or animals after being created by the U.S. military. Support for these alternative theories is limited to government-controlled publications in China and is not credible absent independent corroboration.⁴²

Two key facts bolster the natural zoonotic origin argument. First, approximately 33 percent of the earliest known human COVID-19 cases (with symptom onset dates in mid- to late-December 2019) were associated with the Huanan Seafood Market in Wuhan.⁴³ Second, a number of animal species susceptible to SARS-CoV-2 were sold alive and in poor animal welfare conditions at the market.⁴⁴

However, there is no published genetic evidence that SARS-CoV-2 was circulating in animals *prior* to the start of the COVID-19 pandemic.⁴⁵ Additionally, the genomes of early COVID-19 cases did not show genetic evidence, in the form of adaptive mutations that SARS-CoV-2 recently circulated in another animal species other than humans.⁴⁶ Moreover, the genetic similarity between the environmental samples and

human viral samples supports the likelihood that the virus found at the Huanan Seafood Market was shed by infected humans, rather than by infected animals.⁴⁷

There also do not appear to have been subsequent spillovers of the virus that generated sustained transmission in humans, or any other independent spillovers of SARS-CoV-2, from the intermediate host animal(s) to humans since the pandemic started.⁴⁸ It is also noteworthy that the earliest variants of SARS-CoV-2 were well-adapted for human-to-human transmission.⁴⁹




Figure 5: Spatial distribution of Weibo social media platform users who used COVID-19 assistance channel, a web application people searched when looking for flu-like symptoms, from Dec. 20, 2019 to Jan. 18, 2020, overlaid with location of Huanan Seafood Market and Wuhan Institute of Virology's campus in central Wuhan. (Adapted from: Peng, Z., Wang, R., Liu, L., & Wu, H. (2020). Exploring Urban Spatial Features of COVID-19 Transmission in Wuhan Based on Social Media Data. *ISPRS International Journal of Geo-Information*, 9(6), 402. MDPI AG. Retrieved from <http://dx.doi.org/10.3390/ijgi9060402>).

These facts represent a significant break from the precedent of other zoonotic spillovers involving respiratory viruses, such as MERS and SARS. Relevant past zoonotic spillovers are those involving respiratory viruses that, like SARS-CoV-2, spread primarily through aerosols. Relatively recent spillovers involving live animal markets in urban areas are also relevant. Isolated spillovers of viruses in rural areas involving a small number of human infections have less precedential value, as do viruses that transmit primarily through close physical contact or are vector-borne. Accordingly, the SARS epidemic, the emergence of MERS, and several outbreaks of avian-influenzas have greater precedential value than viruses

like monkeypox, Zika, human immunodeficiency virus (HIV), or Ebola, because the viruses and the circumstances of their emergence are more similar to that of SARS-CoV-2.

Early SARS-CoV-2 variants had little genetic diversity and were closely related to each other, differing by only two nucleotides out of approximately 29,900 nucleotides.⁵⁰ The fact that only two early variants of the virus have been identified indicates the virus had not been circulating widely or for a long period of time, and hence had little opportunity to mutate and cause new viral variants.⁵¹ This also suggests that SARS-CoV-2 spilled over into humans only once or twice over an approximately two week period, and that these one to two spillovers resulted in sustained human-to-human transmission.⁵² This successful spillover also only appears to have occurred in Wuhan or closely surrounding areas.⁵³

Understanding the epidemiology of the outbreak is difficult, as the earliest known COVID-19 cases are unlikely to be the first humans actually infected with SARS-CoV-2.⁵⁴ The earliest identified COVID-19 cases, reported by PRC government officials, have a symptom onset date of December 8, 2019.⁵⁵ A majority of epidemiological modeling indicates that SARS-CoV-2 spilled over into humans between mid-October and early to mid-November 2019.⁵⁶ These early Wuhan cases seeded the virus in Wuhan as SARS-CoV-2 spread from person to person after the initial spillover event(s).⁵⁷

The PRC has reported finding no retrospective evidence of COVID-19 cases in October or November 2019.⁵⁸ However, retrospective case searches by PRC public health authorities were limited to individuals requiring medical treatment.⁵⁹ As a result, the PRC's retrospective case search likely missed between 80 to 95 percent of all COVID-19 cases, which were asymptomatic or mildly symptomatic.⁶⁰ Undercounting of early COVID-19 cases is also likely due to China's restrictive case definitions which initially required not only severe COVID-19 symptoms, but a link to the Huanan Seafood Market.⁶¹ It is estimated that during the period from mid-January to early March 2020, China's case definitions did not account for approximately 200,000 COVID-19 cases.⁶²

b. Missing Evidence of a Natural Zoonotic Spillover

Environmental samples collected between January and March 2020 at the Huanan Seafood Market from countertops, fridges, gloves, and other surfaces tested positive for SARS-CoV-2.⁶³ According to presentations made to the World Health Organization (WHO) by PRC government officials and scientists in early 2020, none of the animals at the market when it was closed, in the market's supply chain, or in China's animal farming industry were infected with SARS-CoV-2.⁶⁴ That would be a significant variation from multiple precedents from previous natural zoonotic spillovers. For example, the discovery of infected palm civets during the SARS epidemic, and infected chickens and other farmed birds during multiple outbreaks of avian influenza, indicate a pattern where infected animals are expected to be present at the location of zoonotic spillovers and in the related supply chains.⁶⁵




Figure 6: Animal species found to be naturally infected with SARS-CoV-2. Arrows show route of transmission. Red box highlights mink as the only animal known to have transmitted SARS-CoV-2 back to humans.⁶⁶

Cases of human-to-animal transmission of SARS-CoV-2 have led to the identification of a number of mammal species susceptible to the virus that were sold at the Huanan Seafood Market, including mink, foxes, and raccoon dogs.⁶⁷ Of these, mink is the only industrially farmed animal identified to have transmitted SARS-CoV-2 from animals to humans with documented cases of farm workers being infected with mink-specific SARS-CoV-2 variants.^{68,69}

China is the world's largest producer of farmed mink, raccoon dogs, and foxes.⁷⁰ Animal welfare conditions on these farms are poor and present an ideal environment for the spread and zoonotic spillover of SARS-CoV-2.⁷¹ Scientists expect, because of SARS-CoV-2's ability to infect multiple species, that SARS-CoV-2 will likely become endemic in a number of wild animal populations, including mink, deer, and foxes.⁷² However, PRC officials still have not reported a single SARS-CoV-2 infection in its farmed or wild mink, raccoon dog, or fox populations.⁷³ PRC officials and scientists have also reported to the WHO that they have not found a single instance of an animal infected with SARS-CoV-2 prior to the COVID-19 pandemic.⁷⁴

c. Problems with the Natural Zoonotic Hypothesis

Based on precedent and genomics, the most likely scenario for a zoonotic origin of the COVID-19 pandemic is that SARS-CoV-2 crossed over the species barrier from an intermediate host to humans.⁷⁵ However, the available evidence is also consistent, perhaps more so, with a direct bat-to-human spillover. Both scenarios remain plausible and, in the absence of additional information, should be considered equally valid hypotheses.⁷⁶ However, nearly three years after the COVID-19 pandemic began, critical evidence that would prove that the emergence of SARS-CoV-2 and resulting COVID-19 pandemic was caused by a natural zoonotic spillover is missing.

As described in this report, the following facts and gaps in information are reasons why the natural zoonotic hypothesis is unlikely to explain the origins of SARS-CoV-2:

- The intermediate host species for SARS-CoV-2, if one exists, remains unidentified. By comparison, within six months of the first known human case of SARS, public health officials in China found SARS infections in palm civets and raccoon dogs in live animal markets in Guangdong Province.⁷⁷
- Unlike SARS, the genomes of early COVID-19 cases from the first months of the pandemic do not show genetic evidence of SARS-CoV-2 having circulated in another animal species other than humans. None of the animals tested from the Huanan Seafood Market's supply chain, or in China's animal farming industry were infected with SARS-CoV-2, according to presentations by PRC officials to the WHO.⁷⁸
- SARS-CoV-2's high binding affinity for human ACE2 receptors suggests that it is possible for it to directly infect humans without needing a period of adaptation in an intermediate host.⁷⁹ Direct spillover from a bat would explain the failure to find an intermediate host.⁸⁰ While direct bat-to-human spillover of coronaviruses has never been confirmed to cause a human outbreak, it is theoretically possible and there is circumstantial evidence suggesting it may occur under limited specific circumstances.⁸¹
- Based on the available evidence, Wuhan is the only location where SARS-CoV-2 spilled over into humans.⁸² After the unidentified source transmitted SARS-CoV-2 to humans, it stopped transmitting SARS-CoV-2.⁸³ This is at odds with the precedent of the 2002-2004 SARS epidemic where infected palm civets continued to transmit the virus to humans and to raccoon dogs.⁸⁴ If the COVID-19 pandemic is the result of a zoonotic spillover from an intermediate host of SARS-CoV-2, the virus would be expected to continue to circulate in the infected intermediate host population, creating the potential for additional independent spillovers into humans and other animals.⁸⁵
- The low genetic diversity of the earliest SARS-CoV-2 samples suggests that the COVID-19 pandemic is most likely the result of a single successful spillover of SARS-CoV-2.⁸⁶ Although the possibility of two spillover events cannot be ruled out, both the SARS epidemic and the 2013 avian influenza A (H7N9) outbreaks saw multiple independent spillovers of those viruses and exhibited much greater genetic diversity than early SARS-CoV-2 strains.

Based on this combination of factors, the available evidence appears to be inconsistent with both historic precedent and the scientific understanding of how natural zoonotic spillovers of respiratory viruses like SARS-CoV-2 occur. Ultimately, without increased transparency and publicly available and reproducible evidence that addresses these missing pieces of evidence, it is difficult to support the natural zoonotic origin hypothesis for the SARS-CoV-2 outbreak and COVID-19 pandemic.

Section II

Analysis of Research-Related Incident Hypothesis

Research-related incidents at labs in China, the United States, and elsewhere have happened and, in some instances, resulted in limited human-to-human transmission. For example, there have been at least six research related incidents involving the escape of SARS-CoV from high-containment laboratories in China (four), Taiwan (one), and Singapore (one).⁸⁷ The 1977 Influenza A (H1N1) pandemic is now widely accepted to have been the result of research-related incident, most likely a vaccine trial in the Soviet Union or China.⁸⁸ In June 2014, while investigating the unintentional exposure of one its researchers to potentially viable anthrax during an experiment in one of its biosafety level (BSL) 3 laboratories, the U.S. Centers for Disease Control and Prevention (CDC) discovered that a culture of non-pathogenic avian influenza was unintentionally cross-contaminated with the highly pathogenic H5N1 strain of influenza and shipped to a BSL3 U.S. Department of Agriculture laboratory.⁸⁹ There were no personnel exposures as a result of this event.

In short, human errors, mechanical failure, animal bites, animal escapes, inadequate training, insufficient funding, and pressure for results can lead to an escape of virulent pathogens, which could, in turn, infect animals and humans and lead to a release of a virus from a lab.

a. Coronavirus Research in Wuhan and at the Wuhan Institute of Virology

In the aftermath of the 2002-2004 SARS epidemic, Chinese authorities emphasized research on potential pandemic pathogens, including SARS-related coronaviruses, to develop vaccines and other medical countermeasures with the goal of attempting to predict and prevent the next coronavirus pandemic.⁹⁰ Wuhan is a global hub of coronavirus research. The Wuhan Institute of Virology is China's premier coronavirus research institute.⁹¹ Although the WIV's coronavirus research is best documented because of its collaborations with western scientists, multiple institutions in Wuhan study coronaviruses including: Wuhan University, Huazhong Agricultural University, Hubei Centers for Disease Control and Prevention, Hubei Animal Centers for Disease Control and Prevention, Wuhan Centers for Disease Control and Prevention, and the Wuhan Institute of Biological Products, a vaccine manufacturing subsidiary of state-owned Sinopharm.⁹² These institutes operate a number of biosafety level (BSL) 2, BSL3, and animal biosafety level (ABSL) 3 laboratories. Several of the BSL3 laboratories are relatively new, having been built only in the last five years. In all, laboratories are spread out across nine different campuses in Wuhan, with six hosting BSL3 or ABSL3 laboratories. The WIV is the only institute in Wuhan with a BSL4 laboratory.⁹³

WIV researchers and their collaborators undertook large scale virus collection expeditions to Southern China and Southeast Asia, where bats naturally harbor SARS-related viruses, on an annual basis from 2004 onwards.⁹⁴ During these expeditions, scientists collected bat blood, saliva, and urine samples.⁹⁵ The WIV collected more than 15,000 bat-related samples around the time the pandemic began.⁹⁶ Of these, the WIV had identified more than 220 SARS-related coronaviruses, at least 100 of which have not been made public.⁹⁷




Figure 7: Map of BSL2, 3, and 4 (including ABSL3) laboratories in Wuhan as of December 2019.⁹⁸

WIV researchers actively sampled bats in Southern China and mainland Southeast Asia where the SARS-related coronaviruses most similar to SARS-CoV-2 have been collected and identified.⁹⁹ Viruses collected from these regions are 90.7 to 96.8 percent similar overall to SARS-CoV-2.¹⁰⁰ These include RaTG13, which was collected by WIV researchers in Yunnan Province.¹⁰¹ RaTG13 is 96.3 percent genetically similar to SARS-CoV-2, and its existence was first made public only after the start of the COVID-19 pandemic, in February 2020.¹⁰²

Presentations given by WIV researchers in 2018 show personnel on field expeditions wearing inadequate levels of personal protective equipment while handling bats.¹⁰³ Some personnel are photographed wearing “thin surgical masks and rubber gloves as they work [to collect bat samples], while others are unmasked with bare hands.”¹⁰⁴ By contrast, a Wuhan Chinese Centers for Disease Control and Prevention (CCDC) scientist, who also regularly conducts bat sampling expeditions, said in a 2019 documentary that “[i]t is while discovering new viruses that we [researchers] are most at risk of infection.”¹⁰⁵ The CCDC scientist further stated, “[i]f our skin is exposed, it can easily come in contact with bat excrement and contaminated matter, which means this is quite risky.”¹⁰⁶

Following field collection, samples were transported to Wuhan where they were screened for the presence of coronaviruses.¹⁰⁷ The WIV has two campuses, one in central Wuhan, Xiaohongshan, which

houses BSL2 and 3 laboratories, and a second, newer campus in Wuhan's southern suburbs, Zhengdian, which houses its BSL4 laboratory in addition to a BSL3 and multiple BSL2 laboratories. Researchers at the WIV then conducted experiments on newly isolated and sequenced coronaviruses.¹⁰⁸ Particular attention was given to SARS-related coronaviruses that have the ability to bind to human ACE2 receptors.¹⁰⁹ These viruses were considered by researchers at the WIV to be potential pandemic pathogens and pose a high-risk for spillover into humans.¹¹⁰ Viruses were then sequenced and evaluated for their potential pandemic risk.¹¹¹

The WIV conducted genetic recombination experiments as part of its coronavirus research in both BSL2 and BSL3 laboratories.¹¹² The WIV also conducted transgenic humanized mice experiments to assess the pandemic potential of SARS-related viruses.¹¹³ They also tested the efficacy of vaccines in these mice and other animal species.¹¹⁴ These animal experiments generate highly-infectious aerosols that are "ubiquitous... and are difficult to detect."¹¹⁵ There were concerns about conducting this type of research in a BSL2 laboratory. As of May 2019, a Chinese CCDC biosafety expert expressed concern about China's lack of national BSL2 regulations, recommending that "[m]anipulation of highly pathogenic microorganisms should be performed in high level biosafety laboratories namely BSL3 or BSL4."¹¹⁶

This research process takes several years, leading to a multi-year gap between discovery of a virus and completing a paper ready for publication. For example, a virus genetically similar to SARS-CoV-2, the aforementioned RaTG13, was collected in 2013 and partially sequenced in 2016.¹¹⁷ The remaining segments of RaTG13 were sequenced in 2018 and the sequence of the virus was finally made public in February 2020.¹¹⁸ In another instance, one WIV graduate student took several years to publish data that resulted from field collection activities.¹¹⁹

b. WIV Research on SARS-related Coronaviruses with Pandemic Potential

By 2018, the WIV showed interest in finding SARS-related coronaviruses that used human ACE2 receptors to enter cells in order to determine whether SARS antibodies would effectively neutralize those viruses.¹²⁰ This research effort is described in a March 2018 grant proposal submitted to the Defense Advanced Research Projects Agency (DARPA) by a consortium of research entities, including the WIV, led by the U.S.-based non-governmental organization EcoHealth Alliance. The group proposed to collect and conduct genetic recombination experiments on SARS-related coronaviruses possessing specific traits making them "high-risk" for zoonotic spillover into animals and humans.¹²¹

Notably, the proposal describes the WIV's intent to search for SARS-related coronaviruses with potential to bind to human ACE2 receptors and that have naturally occurring furin cleavage sites in Yunnan Province, China.¹²² According to the proposal, if WIV researchers were unable to find a SARS-related virus with these traits during sampling expeditions, they then proposed to manipulate the ACE2 receptors of SARS-related coronaviruses to increase binding affinity to human lung tissue and to insert furin cleavage sites at the same location where one appears in SARS-CoV-2.¹²³ This proposal was not ultimately funded by DARPA.

Furin cleavage sites are known to enhance virulence and increase viral replication in avian influenza and Ebola viruses. The grant proposal is in line with research trends in the field of virology in China. In 2015, researchers at Huazhong Agricultural University in Wuhan inserted an artificial furin

cleavage site in Porcine Epidemic Diarrhea virus (an alpha coronavirus).¹²⁴ In 2019, researchers in China inserted a four amino acid furin cleavage site into Infectious Bronchitis coronavirus that affects poultry.¹²⁵ The WIV also received funding from PRC government agencies for research examining the spillover potential of SARS-related coronaviruses.¹²⁶

In an interview with *Science*, Shi Zhengli, a senior scientist at the WIV and SARS-related coronavirus expert, disclosed that her team infected civets and mice that expressed human ACE2 receptors with chimeric SARS-related coronaviruses.¹²⁷ The results of these experiments indicated that SARS-related bat coronaviruses could infect and cause severe illness in humanized mice.¹²⁸ The WIV was later terminated as a sub-grantee by the National Institutes of Health (NIH) for failing to produce its laboratory notes and other records relating to these other experiments.¹²⁹

c. WIV Biosafety and Biosecurity Patents and Procurements in 2019

Patents by WIV researchers published in 2018, 2019, and 2020, and procurements made by the WIV in 2019, indicate that the WIV struggled to maintain key biosafety capabilities at its high-containment BSL3 and BSL4 laboratories.¹³⁰ The following are examples of some of these patents and procurements:

- On April 24, 2019, WIV researchers submitted a patent for an auxiliary exhaust fan to maintain negative air pressure gradients in BSL3 and BSL4 high-containment laboratories.¹³¹ This auxiliary fan was designed to prevent loss of negative pressure in the event of fan control failures, mechanical failures during fumigation, or human error.¹³² These exhaust fans also addressed problems fumigating and disinfecting ventilation shafts and improving penetration of disinfectants into HEPA filters.¹³³
- On August 14, 2019, the WIV issued a procurement notice for a project involving its environmental air disinfection system at the WIV's campus in central Wuhan.^{134,135,136} The upgraded disinfection system used vaporized hydrogen peroxide to decontaminate laboratory surfaces.¹³⁷ A gaseous hydrogen peroxide disinfection system is an effective, less corrosive means to sterilize a laboratory than formaldehyde and other agents used by WIV researchers.¹³⁸
- On September 16, 2019, the WIV issued a procurement notice seeking consultation for a "central air conditioning renovation project" at the new Zhengdian campus.¹³⁹ According to the U.S. CDC:

[HVAC] system design separates potentially contaminated laboratory air from areas outside the laboratory by maintaining the BSL-3/ABSL-3 areas at negative pressure to adjacent areas, by preventing re-circulation of laboratory exhaust air to other areas of the building, and by employing special engineering controls that prevent the occurrence of laboratory airflow reversals to outside the containment boundary.¹⁴⁰

- On November 19, 2019, the WIV issued a sole source procurement request for an air incinerator at the original Xiaohongshan campus in central Wuhan.¹⁴¹ The contract for the procurement was to

be issued by December 5, 2019.¹⁴² Air incinerators, though expensive to install and operate, were the mainstay of high-containment air sterilization prior to HEPA filtration.^{143, 144, 145} The procurement stated that the incinerator was needed to sterilize exhaust gas from an autoclave, and that it would be added to the exhaust pipe after existing HEPA filters outside the autoclave to incinerate all the media discharged from within.¹⁴⁶

- On December 11, 2019, WIV researchers filed a patent for a sensor to detect when biocontainment transfer cabinet HEPA filters had failed or were not operating correctly.¹⁴⁷ Experiments with infected animals often require moving the animals from a BSL3/BSL4 laboratory to a holding facility ABSL3/ABSL4 or transferring them from an animal holding room to a specific procedure room.¹⁴⁸ These animals create a variety of potentially hazardous infectious aerosols from urine, feces, fur, and by respiration.¹⁴⁹ The patent states, “when an accident occurs in the transportation process, an effective monitoring device is not available for judging whether the equipment is normal or not.”¹⁵⁰
- On November 13, 2020, WIV researchers filed a patent for a disinfectant formulation that improved upon one used in the Institute’s high-containment laboratories.¹⁵¹ The patented formulation “[r]educ[e]s the corrosion effect to metal, especially stainless steel material.”¹⁵² As described in the patent, “[l]ong-term use [of the previous disinfectant] will lead to corrosion of metal components such as stainless steel, thereby reducing the protection of ... facilities and equipment...shorten[s] its service life and cause economic losses, but also lead to the escape of highly pathogenic microorganisms into the external environment of the laboratory, resulting in loss of life and property and serious social problems.”¹⁵³ The patent followed a March 2018 study that described WIV researchers using a disinfectant at a concentration more than three times higher than is recommended by the manufacturer.^{154,155} The licensed U.S. manufacturer of the disinfectant states that “the higher ... concentration, the more corrosive the solution will be.”¹⁵⁶

d. WIV Biosafety and Biosecurity Events in 2019

With the start of operations at the WIV’s new BSL4 laboratory in late-2017 to 2018, government officials pressured WIV researchers to “leapfrog development” by conducting cutting-edge infectious disease research that contributed to China’s national goals for biotechnology.¹⁵⁷ Throughout 2019, WIV experts published on challenging biosafety and biosecurity conditions faced by high-containment laboratories in China, including the WIV.

In May 2019, the Director of the WIV BSL4 laboratory warned that in high-containment laboratories in China:

Maintenance cost[s] [are] generally neglected; several high-level BSLs have insufficient operational funds for routine yet vital processes. Due to the limited resources, some BSL-3 laboratories run on extremely minimal operational costs or in some cases none at all...

Currently, most laboratories lack specialized biosafety managers and engineers. In such facilities, some of the skilled staff is composed by part-time researchers. **This makes it difficult to identify and mitigate potential safety hazards in facility and equipment operation early enough.** Nonetheless, biosafety awareness, professional knowledge, and operational skill training still need to be improved among laboratory personnel. (emphasis added)¹⁵⁸

In July 2019, China's National People's Congress drafted legislation, which later became law, to strengthen the management of laboratories involved in pathogen research and improve adherence to national standards and requirements for biosafety. It specifies that:

[L]ow-level pathogenic microorganism laboratories **shall not engage in pathogenic microorganism experiments that should be conducted in high-level pathogenic microorganism laboratories...**High-level pathogenic microorganism laboratories engaging in experimental activities of highly pathogenic or suspected highly pathogenic microorganisms shall be approved by the health or agriculture and rural authorities at or above the provincial level. For pathogenic microorganisms that have not been discovered or have been eliminated...relevant experimental activities shall not be carried out without approval. (emphasis added)¹⁵⁹

Efforts by the WIV to improve biosafety were hampered by what officials called the “stranglehold problem,” which meant a lack of access to advanced foreign biosafety technologies and materials.¹⁶⁰ Leadership at the WIV emphasized during a June 2019 meeting with WIV officials that addressing the “stranglehold problem” was critical to “pushing forward the construction and... development of science and technology for the nation.”¹⁶¹ The WIV's limited access to key foreign biosafety technologies forced the researchers to develop biosafety methods and construct equipment to remedy shortfalls.¹⁶²

In July 2019, WIV leadership led a series of internal meetings on problems of operations in management at the WIV. The deputy director of the BSL4 laboratory issued a report on biocontainment equipment shortages and the impact of meeting the research goals of the government.¹⁶³ The report cited major problems that existed in the BSL4 laboratory including “hardware and technological aspects of the laboratory facilities” and “the management of biosafety.”¹⁶⁴ The same report noted that the Director of the WIV urged the institute's senior personnel to “prioritize solving the urgent problems we are currently facing.”¹⁶⁵

On September 12, 2019 between the hours of 2:00 and 3:00 a.m. local time,¹⁶⁶ the WIV took down its online depository of data on viral sequences called the Wildlife-Borne Viral Pathogen Database.¹⁶⁷ The database was intermittently accessible from December 2019 to February 2020, before being permanently taken offline February 2020.¹⁶⁸ This database was previously accessible to the public, with the exception of a password protected section, which held unpublished sequence data accessible only to WIV personnel.¹⁶⁹ The WIV had a collection of more than 15,000 samples from bats, from which they had identified more

than 1,400 bat viruses, including an estimated 100 unpublished sequences of SARS-related coronaviruses – the genre of coronaviruses to which SARS-CoV-2 belongs.¹⁷⁰ More than three years after it was first disabled, public access to the database has not been restored.¹⁷¹

On November 12, 2019, the WIV's BSL4 laboratory team issued a report on the achievements of the BSL4 laboratory since it began operations in 2018.¹⁷² With respect to the "stranglehold problem", the report states that the WIV had overcome "the three no's" of "no equipment and technology standards, no design and construction teams, and no experience operating or maintaining" a high-containment laboratory.¹⁷³ The report continues to say that WIV personnel "brought into reality the 'three haves' of a complete system of standards, a superior team that operates and maintains [the lab], and valuable experience with construction."¹⁷⁴ This was achieved by "reinventing" imported equipment to make "the lab construction satisfy domestic and international standards" and making the French design of the BSL4 laboratory "conform to the requirements of Chinese construction."¹⁷⁵

The report also described a high-pressure work environment. "In the laboratory, they often need to work for four consecutive hours, even extending to six hours," the report revealed. "During this time, they cannot eat, drink, or relieve themselves. This is an extreme test of a person's will and physical endurance. This not only demands that research personnel possess proficient operational skills, but they must also possess the ability to respond to various unexpected situations."¹⁷⁶

The November 12, 2019 report suggested a biosafety problem had occurred at the WIV sometime before November 2019:

Owing to [the fact] that the subject of research at the P4 lab is highly pathogenic microorganisms, inside the laboratory, once you have opened the stored test tubes, it is just as if having opened Pandora's Box. These viruses come without a shadow and leave without a trace. Although [we have] various preventive and protective measures, it is nevertheless necessary for lab personnel to operate very cautiously to avoid operational errors that give rise to dangers. **Every time this has happened, the members of the Zhengdian Lab [BSL4] Party Branch have always run to the frontline, and they have taken real action to mobilize and motivate other research personnel.** (emphasis added)¹⁷⁷

On November 19, 2019, seven days after the BSL4 teams' report was issued, the WIV hosted a special training session run by a senior Chinese Academy of Sciences biosafety/biosecurity official who relayed "important oral and written instructions" from PRC leadership in Beijing to the WIV regarding the "complex and grave situation facing [bio]security work."¹⁷⁸ At the same training session, the Deputy Director of the Office of Safety and Security at the WIV "pointed to the severe consequences that could result from hidden safety dangers, and stressed that the rectification of hidden safety risks must be thorough, and management standards must be maintained."¹⁷⁹

Section III

China's Early COVID-19 Vaccine Development Versus the U.S. Operation Warp Speed

Once the scale of the COVID-19 pandemic became clear, governments around the world scrambled to accelerate development of a vaccine to prevent death and severe disease from infection. In order to start vaccine development, researchers required the complete sequence of the target virus.¹⁸⁰ The full genetic sequence of SARS-CoV-2 was first posted to a global virus database on January 11, 2020 by a professor in China who acted in violation of PRC government restrictions on sharing information about SARS-CoV-2. As a consequence of his action, his laboratory was shut down for “rectification.”¹⁸¹

After the SARS-CoV-2's sequence became available, vaccine developers inserted portions of the viral sequence into cells to produce the proteins that elicit an immune system response.¹⁸² The cells that produce the proteins are called “constructs” and have to be created before vaccine development can begin.¹⁸³ After the construct is complete, the next developmental steps are preclinical animal toxicity, safety and efficacy studies, human clinical safety and efficacy trials, and commercial scale vaccine production.¹⁸⁴ Typically, these steps are done sequentially.¹⁸⁵

During the COVID-19 pandemic, the urgent need for a vaccine resulted in these steps being done concurrently, which reduced the time spent on each step from years to a few months.¹⁸⁶ However, while pre-clinical studies and vaccine production can be done simultaneously, each step has its own timeline to completion that is difficult to compress. For example, animal studies are designed to last a specific length of time and cannot be curtailed without compromising the resulting data.¹⁸⁷ Similarly, the time it takes to grow the amount of vaccine needed for phase I trials is a limiting step, depending on the vaccine platform and scale of production.

a. U.S. Operation Warp Speed

The companies with candidate vaccines that would later be funded and supported by Operation Warp Speed in the United States all started vaccine development work on January 11, 2020 after the public release of the first SARS-CoV-2 sequence.¹⁸⁸ While mRNA vaccine candidates were able to design their vaccine construct in two days, because mRNA vaccines only need the coronavirus' genetic sequence to make a vaccine and no virus has to be cultivated in labs, traditional vaccine platforms take longer.¹⁸⁹

The fastest of the Operation Warp Speed vaccine candidates to enter phase I human clinical trials among the non-mRNA vaccines was AstraZenca-Oxford's vaccine, ChAdOx1.¹⁹⁰ The AstraZeneca-Oxford team leveraged an existing vaccine construct and extensive experience with it to advance their candidate into phase I human clinical trials in an unprecedented 103 days.¹⁹¹ Johnson & Johnson's vaccine candidate, Ad26, went from sequence to phase I clinical trials in 185 days.¹⁹² As with AstraZeneca-Oxford, Johnson & Johnson was able to modify an existing construct it had developed for Ebola, as well as extensive institutional experience in vaccine development.¹⁹³ Both Ad26 and ChAdOx1 were adenovirus vaccines, in which a weakened version of the virus that cannot replicate is used to stimulate an immune reaction.¹⁹⁴

Operation Warp Speed brought the first COVID-19 vaccines from sequence publication to regulatory approval in approximately eight months; “[o]ther medical miracles have been achieved, but few

with the speed and success of developing the Covid-19 vaccines.”¹⁹⁵ Operation Warp Speed accelerated development of COVID-19 vaccines by coordinating with the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention, providing technical assistance, breaking through supply chain and manufacturing bottlenecks with the Defense Production Act, and de-risking vaccine development through guaranteed purchase agreements.¹⁹⁶ Vaccine developers ran clinical trials concurrently and on an accelerated timeline. The lessons learned from Operation Warp Speed have been widely shared, studied, and publicized, so it can serve as a model for how to quickly mobilize the government and private sector in response to an emergency.¹⁹⁷

b. China’s COVID-19 Vaccine Development Program

China also initiated a COVID-19 vaccine development with at least four research teams involved.¹⁹⁸ China did not initially have a mRNA vaccine candidate.¹⁹⁹ Two of these research teams were from the People’s Liberation Army’s Academy of Military Medical Sciences (AMMS), with the others from the Chinese Academy of Sciences (CAS) and the Chinese Centers for Disease Control and Prevention (CCDC).²⁰⁰ The two AMMS teams reached notable early milestones in COVID-19 vaccine development. One AMMS team, led by Major General Chen Wei, using the same adenovirus vaccine platform as AstraZeneca-Oxford and Johnson & Johnson, went from sequence publication on January 11, 2020 to phase I human clinical trials on March 18, 2020, a span of only 67 days.²⁰¹




Figure 8: Comparison of Adenovirus Platform Timelines. Operation Warp Speed Vaccines: Johnson & Johnson’s Ad26 and AstraZeneca-Oxford’s ChADOx1 compared to Chen-AMMS’s SV8000

The second AMMS team, led by Brigadier General Yusen Zhou, was the first to patent a COVID-19 vaccine on February 24, 2020.²⁰² The Zhou AMMS team’s patent included data from a mouse experiment showing that the vaccine construct neutralized SARS-CoV-2 infections.²⁰³ Other researchers in China working with the same vaccine platform took between three to four months to develop their candidate

vaccine.²⁰⁴ The Zhou AMMS COVID-19 vaccine candidate does not appear to have advanced into phase I human clinical trials.²⁰⁵ The Chen AMMS COVID-19 vaccine is commercially produced by CanSino.²⁰⁶

Given Operation Warp Speed's success, it is unusual that the two AMMS COVID-19 vaccine development teams were able to reach early milestones in vaccine development even more quickly. The Chen AMMS team beat AstraZeneca-Oxford to phase I clinical trials by 38 days. The Zhou AMMS team built and validated the effectiveness of its COVID-19 candidate vaccine 44 days after the sequence of SARS-CoV-2 was released. The extremely accelerated vaccines development timelines achieved by the AMMS teams pose the following two outstanding questions:

- What additional steps, processes, or novel techniques did AMMS researchers take that advanced the development of their vaccine faster than the Operation Warp Speed timeline?
- If no additional steps were taken to speed up the development timeline, when did researchers in China have access to the genomic sequence? Was it before January 11, 2020? If so, how far in advance of January 11, 2020?

Section IV

Basis for Assessment that Research-Related Incident is More Likely Origin of SARS-CoV-2

Nearly three years after the COVID-19 pandemic began, substantial evidence demonstrating that the COVID-19 pandemic was the result of a research-related incident has emerged. A research-related incident is consistent with the early epidemiology showing rapid spread of the virus in Wuhan, with the earliest calls for assistance being located in the near the WIV's original campus in central Wuhan.²⁰⁷ It also explains the low genetic diversity of the earliest known SARS-CoV-2 human infections in Wuhan, because the likely index case, would be an infected researcher, is the likely primary source of the virus in Wuhan.²⁰⁸ A research-related incident also explains the failure to find an intermediate host as well as the failure to find any animal infections pre-dating human COVID-19 cases.²⁰⁹

Although the WIV's coronavirus research is best documented because of its collaborations with western scientists, multiple institutions in Wuhan study coronaviruses including: Wuhan University, Huazhong Agricultural University, Hubei Centers for Disease Control and Prevention, Hubei Animal Centers for Disease Control and Prevention, Wuhan Centers for Disease Control and Prevention, and the Wuhan Institute of Biological Products, a vaccine manufacturing subsidiary of state-owned Sinopharm.

a. Coronavirus Research at the Wuhan Institute of Virology

The WIV is an epicenter of advanced coronavirus research that was designed to predict and prevent future pandemics by collecting, characterizing, and experimenting on "high-risk" coronavirus with the potential to spill over into humans:

- In the aftermath of the 2002-2004 SARS epidemic, WIV researchers undertook annual virus collection expeditions to Southern China and Southeast Asia, where bats naturally harbor SARS-related viruses, from 2004 onward.²¹⁰
- WIV researchers actively sampled bats in Southern China and Southeast Asia where the SARS-related coronaviruses most similar to SARS-CoV-2 have been collected and identified.²¹¹
- The WIV had collected more than 15,000 samples from bats, from which they had identified more than 1,400 bat viruses, including an estimated 100 unpublished sequences of SARS-related coronaviruses – the genre of coronaviruses to which SARS-CoV-2 belongs.²¹² The database containing the sequences of viruses collected by the WIV, including unpublished SARS-related coronaviruses, was taken offline starting in September 2019.
- Following field collection, samples were transported to Wuhan, where they were screened for the presence of coronaviruses.²¹³ WIV researchers performed animal and human cell-related research using recombinant genetic techniques with the express goal of discovering human adapted SARS-like chimeric viruses. The WIV conducted these experiments in BSL2 and BSL3 laboratories.

- Senior coronavirus researcher Shi Zhengli disclosed that in 2018-2020, her team infected civets and humanized mice that expressed human ACE2 receptors with chimeric SARS-related coronaviruses.²¹⁴ The results of these experiments have never been published.
- The EcoHealth Alliance NIH grants and DARPA grant proposals, in partnership with the WIV, sought to collect and conduct genetic recombination experiments on SARS-related coronaviruses with specific traits that made those viruses a “high-risk” for zoonotic spillover into animals and humans.²¹⁵ SARS-CoV-2 shares many of the traits these researchers were interested in finding in SARS-related coronaviruses or interested in engineering such traits if they were not found naturally.

b. Evidence of Biosafety Failures at the WIV

WIV patents and procurements suggest that the WIV experienced persistent biosafety problems relevant to the containment of an aerosolized respiratory virus like SARS-CoV-2.

- April 24, 2019: Auxiliary exhaust patent
- August 14, 2019: Environmental air disinfection system procurement
- September 16, 2019: Central air conditioning
- November 19, 2019: Sole source procurement for air incinerator
- December 11, 2019: Biocontainment transfer cabinet HEPA filter failure patent
- November 13, 2020: Disinfectant formulation patent

c. Management and training concerns at the WIV

Academic articles, reports, and meetings from the WIV also suggest that the WIV experienced persistent biosafety problems relevant to the containment of an aerosolized respiratory virus like SARS-CoV-2:

- In May 2019, the Director of the WIV BSL4 laboratory warned that in high-containment laboratories in China maintenance costs were neglected and part-time researchers made it “**difficult to identify and mitigate potential safety hazards in facility and equipment operation early enough.**” (emphasis added)²¹⁶
- Leadership at the WIV emphasized during a June 2019 meeting with WIV officials that addressing the “stranglehold problem” was critical to “pushing forward the construction and... development of science and technology for the nation.”²¹⁷
- In July 2019, the deputy director of the BSL4 laboratory issued a report on shortages of biosafety equipment and its impact on meeting the research expectations of the government.²¹⁸

- In July 2019, China's National People's Congress began the process of drafting the law to strengthen the management of laboratories involved in pathogen research and improve adherence to national standards and requirements for biosafety.²¹⁹
- A November 12, 2019 report suggested a biosafety problem had occurred at the WIV sometime before November 2019.²²⁰
- On November 19, 2019, the WIV hosted a special training session by the senior Chinese Academy of Sciences biosafety/biosecurity official who relayed "important oral and written instructions" from PRC leadership to the WIV regarding the "complex and grave situation facing [bio]security work."²²¹ This one-day training session for senior leadership was followed on November 20-21, 2019 with two days of safety training for personnel from the WIV and other Wuhan area high-containment laboratories.

d. Anomalies in Epidemiology of SARS-COV-2 Outbreak

- SARS-CoV-2 spilled over into humans only in Wuhan.²²² This is a break with the precedent of SARS, MERS, and multiple outbreaks of avian influenza, all of which were much less transmissible than SARS-CoV-2 and infected fewer animals.
- The low genetic diversity of the earliest SARS-CoV-2 samples, coupled with one of the two early lineages being more closely related to bat coronaviruses, suggests that COVID-19 pandemic is most likely the result of one, or at most two, spillovers of SARS-CoV-2.²²³ SARS-CoV-2's low initial genetic diversity is also a break with the precedent of recent zoonotic spillovers of respiratory viruses.
- Critical corroborating evidence of a natural zoonotic spillover is missing. While the absence of evidence is not itself evidence, the lack of corroborating evidence of a zoonotic spillover or spillovers, three years into the pandemic, is highly problematic. If the COVID-19 pandemic is the result of the zoonotic spillover of SARS-CoV-2 in Wuhan from an intermediate host species, there should be evidence of SARS-CoV-2 circulating in animals before it spilled over into humans. Instead, there is no evidence that any animal was infected with SARS-CoV-2 prior to the first human cases.²²⁴

Conclusion

As noted by the WHO Scientific Advisory Group for the Origins of Novel Pathogens, the COVID-19 Lancet Commission, and the U.S. Office of the Director of National Intelligence 90-Day Assessment on the COVID-19 Origins, more information is needed to arrive at a more precise, if not a definitive, understanding of the origins of SARS-CoV-2 and how the COVID-19 pandemic began.²²⁵ Governments, leaders, public health officials, and scientists involved in addressing the COVID-19 pandemic and working to prevent future pandemics, must commit to greater transparency, engagement, and responsibility in their efforts.

Based on the analysis of the publicly available information, it appears reasonable to conclude that the COVID-19 pandemic was, more likely than not, the result of a research-related incident. New information, made publicly available and independently verifiable, could change this assessment. However, the hypothesis of a natural zoonotic origin no longer deserves the benefit of the doubt, or the presumption of accuracy. The following are critical outstanding questions that would need to be addressed to be able to more definitively conclude the origins of SARS-CoV-2:

- What is the intermediate host species for SARS-CoV-2? Where did it first infect humans?
- Where is SARS-CoV-2's viral reservoir?
- How did SARS-CoV-2 acquire its unique genetic features, such as its furin cleavage site?

Advocates of a zoonotic origin theory must provide clear and convincing evidence that a natural zoonotic spillover is the source of the pandemic, as was demonstrated for the 2002-2004 SARS outbreak. In other words, there needs to be verifiable evidence that a natural zoonotic spillover actually occurred, not simply that such a spillover could have occurred.

¹ Tan, C. C. S., Lam, S. D., Richard, D., Owen, C. J., Berchtold, D., Orengo, C., Nair, M. S., Kuchipudi, S. V., Kapur, V., van Dorp, L., & Balloux, F. (2022). Transmission of SARS-CoV-2 from humans to animals and potential host adaptation. *Nature Communications*, 13(1). <https://doi.org/10.1038/s41467-022-30698-6>.

² Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). (June 9, 2022). Preliminary Report. World Health Organization. <https://cdn.who.int/media/docs/default-source/scientific-advisory-group-on-the-origins-of-novel-pathogens/sago-report-09062022.pdf>.

³ *Id.*

⁴ *Id.*

⁵ China delayed releasing coronavirus info, frustrating WHO. (n.d.). AP NEWS. <https://apnews.com/article/united-nations-health-ap-top-news-virus-outbreak-public-health-3c061794970661042b18d5aeaad9fae>.

⁶ Cohen, Jon. (Aug. 18, 2022). Where did the pandemic start? Anywhere but here, argue papers by Chinese scientists echoing party line. *Science*. 2022: 377 (6608). <https://www.science.org/content/article/pandemic-start-anywhere-but-here-argue-papers-chinese-scientists-echoing-party-line>.

⁷ Pekar J, Worobey M, Moshiri N, Scheffler K, Wertheim JO., et. al. (Mar. 18, 2021). Timing the SARS-CoV-2 index case in Hubei province. *Science*. 2021;372(6540):412-417. doi:10.1126/science.abf8003.

⁸ Ellwanger JH, Chies JAB. (June 4, 2021). Zoonotic spillover: Understanding basic aspects for better prevention. *Genet Mol Biol*. 2021;44(1 Suppl 1). doi:10.1590/1678-4685-GMB-2020-0355.

⁹ *Id.*

¹⁰ *Id.*

¹¹ Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. (Mar. 15, 2020). Zoonotic origins of human coronaviruses. *Int J Biol Sci*. 2020;16(10):1686-1697. doi:10.7150/ijbs.45472.

¹² *Id.*

¹³ Rozo M, Gronvall GK. (Aug. 18, 2015). The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate. *mBio*. 2015;6(4):e01013-15. doi:10.1128/mBio.01013-15; Pike BL, Saylor KE, Fair JN, et al. (June 2010). The Origin and Prevention of Pandemics. *Clin Infect Dis*. 2010;50(12):1636-1640. doi:10.1086/652860.

¹⁴ Adapted from Segreto R, Deigin Y, McCairn K, Sousa A, Sirotkin D, Sirotkin K, Couey JJ, Jones A, Zhang D. (Mar. 25, 2021). Should we discount the laboratory origin of COVID-19? *Environ Chem Lett*. 2021;19(4):2743-2757. doi: 10.1007/s10311-021-01211-0.

¹⁵ Plowright RK, Parrish CR, McCallum H, et al. (May 2017). Pathways to Zoonotic Spillover. *Nature Reviews Microbiology*. 2017;15(8):502-510. doi:10.1038/nrmicro.2017.45/

¹⁶ *Id.*

¹⁷ Worobey M, Levy JJ, Malpica Serrano L, et al. (July 26, 2022). The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. *Science*. 2022;377(6609):951-959. doi:10.1126/science.abp8715.

¹⁸ Cohen, Jon. (April 22, 2022). Looking for Trouble. *Science*. 2022: 376 (6590). doi:10.1126/science.abq2305.

¹⁹ *Supra*, note 17.

²⁰ *Supra*, note 8.

²¹ Farag EA, Islam MM, Enan K, El-Hussein AM, Bansal D, Haroun M. SARS-CoV-2 at the human-animal interphase: A review. *Heliyon*. 2021;7(12):e08496. doi:10.1016/j.heliyon.2021.e08496

²² Wang Q, Chen H, Shi Y, et al. (Sept. 29, 2021). Tracing the origins of SARS-CoV-2: lessons learned from the past. *Cell Research*. 31, 1139-1141. <https://doi.org/10.1038/s41422-021-00575>

²³ Lytras S, Xia W, Hughes J, Jiang X, Robertson DL. (Aug. 17, 2021). The animal origin of SARS-CoV-2. *Science*. 373(6558):968-970. doi:10.1126/science.abh0117.

²⁴ *Supra*, note 2.

²⁵ Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. (Mar. 15, 2021). Zoonotic origins of human coronaviruses. *Int J Biol Sci*. 16(10):1686-1697. doi:10.7150/ijbs.45472.

- ²⁶ James M. Hughes, Mary E. Wilson, Brian L. Pike, Karen E. Saylor, Joseph N. Fair, Matthew LeBreton, Ubald Tamoufe, Cyrille F. Djoko, Anne W. Rimoin, Nathan D. Wolfe. (June 15, 2010). The Origin and Prevention of Pandemics. Clin Infect Dis. 2010. 50(12):1636-1640. doi:10.1086/652860/.
- ²⁷ *Id.*
- ²⁸ Wang, L.F., Eaton, B.T. (2007). Bats, Civets and the Emergence of SARS. In: Childs, J.E., Mackenzie, J.S., Richt, J.A. (eds) Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission. Current Topics in Microbiology and Immunology, vol 315. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70962-6_13.
- ²⁹ *Id.*
- ³⁰ Liang G, Chen Q, Xu J, et al. (Oct. 10, 2004). Laboratory Diagnosis of Four Recent Sporadic Cases of Community-Acquired SARS, Guangdong Province, China. Emerg Infect Dis. <https://doi.org/10.3201%2Feid1010.040445>.
- ³¹ *Supra*, note 28.
- ³² *Id.*
- ³³ Butler D. (April 24, 2013). Mapping the H7N9 Avian Flu Outbreaks. Nature. <https://doi.org/10.1038/nature.2013.12863>.
- ³⁴ Jernigan, Daniel, et. al. (May 10, 2013). Emergence of Avian Influenza A(H7N9) Virus Causing Severe Human Illness — China, February–April 2013. Morbidity and Mortality Weekly Report (MMWR). Retrieved October 26, 2022, from <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a6.htm#:~:text=April%2029%2C%202013>.
- ³⁵ *Supra*, note 26.
- ³⁶ *Supra*, note 16.
- ³⁷ *Supra*, note 8.
- ³⁸ Zhong N, Zheng B, Li Y, et al. (Oct. 25, 2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet. 362(9393):1353-1358. doi:10.1016/s0140-6736(03)14630-2).
- ³⁹ *Supra*, note 34.
- ⁴⁰ CDC Weekly, C. (2020). The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly. 2(8), 113–122. <https://doi.org/10.46234/ccdcw2020.032>.
- ⁴¹ *Supra*, note 6.
- ⁴² *Supra*, note 3.
- ⁴³ World Health Organization. (2021) “WHO-convened global study of origins of SARS-CoV-2: China Part”; <https://www.who.int/publications/i/item/who-convened-global-study-of-origins-of-sars-cov-2-china-part>.
- ⁴⁴ *Supra*, note 17.
- ⁴⁵ *Supra*, note 43.
- ⁴⁶ Zhan, Shing Hei & Deverman, Benjamin E. & Chan, Alina Yujia. (May 2, 2020). SARS-CoV-2 is well adapted for humans. What does this mean for re-emergence?. bioRxiv; doi: <https://doi.org/10.1101/2020.05.01.073262>.
- ⁴⁷ Gao, George & Liu, William & Liu, Peipei & Lei, Wenwen & Jia, Zhiyuan & He, Xiaozhou & Liu, Lin-Lin & Shi, Weifeng & Tan, Yun & Zou, Shumei & Zhao, Xiang & Wong, Gary & Wang, Ji & Wang, Feng & Wang, Gang & Qin, Kun & Gao, Rong-bao & Zhang, Jie & Li, Min & Wu, Guizhen. (Feb. 25, 2022). Surveillance of SARS-CoV-2 in the environment and animal samples of the Huanan Seafood Market. Research Square. <https://doi.org/10.21203/rs.3.rs-1370392/v1>.
- ⁴⁸ Pekar JE, Magee A, Parker E, et al. (Jul. 26, 2022). The Molecular Epidemiology of Multiple Zoonotic Origins of SARS-CoV-2. Science. 377(6609):960-966. <https://doi.org/10.1126/science.abp8337>.
- ⁴⁹ *Id.*
- ⁵⁰ *Supra*, note 43.
- ⁵¹ *Supra*, note 48.
- ⁵² *Id.*
- ⁵³ *Supra*, note 43.
- ⁵⁴ *Id.*

⁵⁵ *Id.*

⁵⁶ *Id.*

⁵⁷ Epidemiology Team. (Feb. 17, 2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC weekly. 2(8); (2020): 113-122.

doi: [10.46234/ccdcw2020.032](https://doi.org/10.46234/ccdcw2020.032)

⁵⁸ *Supra*, note 43.

⁵⁹ *Id.*

⁶⁰ Menachemi N, Dixon BE, Wools-Kaloustian KK, Yiannoutsos CT, Halverson PK. (May-Jun. 2021). How Many SARS-CoV-2-Infected People Require Hospitalization? Using Random Sample Testing to Better Inform Preparedness Efforts. J Public Health Manag Pract. 01;27(3):246-250. doi: 10.1097/PHH.0000000000001331. PMID: 33729203; see also Wang, Vivian (Feb. 27, 2020). Most Coronavirus Cases Are Mild. That's Good and Bad News. The New York Times. <https://www.nytimes.com/2020/02/27/world/asia/coronavirus-treatment-recovery.html>.

⁶¹ *Id.*

⁶² Tsang, Tim K., Peng Wu, Yun Lin, Eric HY Lau, Gabriel M. Leung, and Benjamin J. Cowling. (May 1, 2020). Effect of Changing Case Definitions for COVID-19 on the Epidemic Curve and Transmission Parameters in Mainland China: a Modelling Study. The Lancet Public Health. Vol.5, no. 5. [https://doi.org/10.1016/S2468-2667\(20\)30089-X](https://doi.org/10.1016/S2468-2667(20)30089-X).

⁶³ *Supra*, note 43.

⁶⁴ *Supra*, note 2.

⁶⁵ Li, K., Guan, Y., Wang, J. et al. (Jul. 8, 2004). Genesis of a Highly Pathogenic and Potentially Pandemic H5N1 Influenza Virus in Eastern Asia. Nature. 430: 209–213. <https://doi.org/10.1038/nature02746>.

⁶⁶ Figure adapted from Fenollar F, Mediannikov O, Maurin M, Devaux C, Colson P, Levasseur A, Fournier P-E and Raoult D (April 1, 2021) Mink, SARS-CoV-2, and the Human Animal Interface. Front. Microbiol. 12:663815 <https://doi.org/10.3389/fmicb.2021.663815>.

⁶⁷ *Supra*, note 43.

⁶⁸ *Supra*, note 66.

⁶⁹ Pomorska-Mól M, Włodarek J, Gogulski M, Rybska M. (Jul. 15, 2021). Review: SARS-CoV-2 infection in farmed minks - an overview of current knowledge on occurrence, disease and epidemiology. Animal. 15(7):100272. <https://doi.org/10.1016/j.animal.2021.100272>

⁷⁰ Lung, Yuan-Chin & Lin Sophie. (July 2019). China's Fur Trade and Its Position in the Global Fur Industry. Act Asia. <https://www.actasia.org/wp-content/uploads/2019/10/China-Fur-Report-7.5.pdf>.

⁷¹ Shah, S., & Comrie, T. (Jan. 19, 2022). Animals That Infect Humans Are Scary. It's Worse When We Infect Them Back. The New York Times. <https://www.nytimes.com/2022/01/19/magazine/spillback-animal-disease.html>

⁷² Phillips, N. (Feb. 16, 2021). The Coronavirus is Here to Stay — Here's What That Means. Nature, 590(7846), 382–384. <https://doi.org/10.1038/d41586-021-00396-2>.

⁷³ *Supra*, note 43.

⁷⁴ *Id.*

⁷⁵ *Supra*, note 17.

⁷⁶ *Supra*, note 43.

⁷⁷ Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., Butt, K. M., Wong, K. L., Chan, K. W., Lim, W., Shortridge, K. F., Yuen, K. Y., Peiris, J. S., & Poon, L. L. (2003). Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. Science. 302(5643), 276–278. <https://doi.org/10.1126/science.1087139>.

⁷⁸ *Supra*, note 43.

⁷⁹ *Id.*

⁸⁰ *Id.*

⁸¹ Wang, N., Li, S. Y., Yang, X. L., Huang, H. M., Zhang, Y. J., Guo, H., Luo, C. M., Miller, M., Zhu, G., Chmura, A. A., Hagan, E., Zhou, J. H., Zhang, Y. Z., Wang, L. F., Daszak, P., & Shi, Z. L. (2018). Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. Virologica Sinica, 33(1), 104–107. <https://doi.org/10.1007/s12250-018-0012-7>.

⁸² *Supra*, note 17.

⁸³ The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020, 2(8): 113-122. doi: 10.46234/ccdcw2020.032.

⁸⁴ *Supra*, note 28.

⁸⁵ *Id.*

⁸⁶ Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (Mar. 26, 2020). Origins of SARS-CoV-2. World Health Organization.

https://apps.who.int/iris/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Virus_origin-2020.1-eng.pdf

⁸⁷ Senior K. (Nov. 3, 2003). Recent Singapore SARS case a Laboratory Accident. The Lancet. Infectious Diseases. 3(11), 679. [https://doi.org/10.1016/S1473-3099\(03\)00815-6](https://doi.org/10.1016/S1473-3099(03)00815-6); *see also*: Walgate R. (Apr. 27, 2004). SARS Escaped Beijing lab Twice. Genome Biology. 4: spotlight-20040427-03. <https://doi.org/10.1186/gb-spotlight-20040427-0>; Taiwan: CIDRAP (December 17, 2003), Taiwanese SARS researcher infected. University of Minnesota. (Dec. 17, 2003). Taiwanese SARS Researcher Infected. CIDRAP. <https://www.cidrap.umn.edu/news-perspective/2003/12/taiwanese-sars-researcher-infected>.

⁸⁸ *Supra*, note 13.

⁸⁹ CDC Press Release. (January 1, 2016). U.S. Centers for Disease Control and Prevention.

<https://www.cdc.gov/media/releases/2014/p0711-lab-safety.html>.

⁹⁰ Wuhan Institute of Virology. (n.d.). History-Wuhan Institute of Virology. institute.wuhanvirology.org. Accessed October 10, 2022. http://institute.wuhanvirology.org/About_Us2016/History2016/index.htm.

⁹¹ BurNIH-00000483-495 (on file with staff).

⁹² Demaneuf, G. (May 29, 2022). BSL Laboratories in Wuhan and their roles in coronaviruses research. Medium. <https://gillesdemaneuf.medium.com/overview-of-biological-laboratories-in-wuhan-with-their-roles-in-coronavirus-research-bca6c1cd1f74>.

⁹³ *Id.*

⁹⁴ Qiu J. (June 1, 2020). How China's "Bat Woman" Hunted Down Viruses from SARS to the New Coronavirus. Scientific American. 322, 6, 24-32. doi:10.1038/scientificamerican0620-24.

⁹⁵ *Id.*, *see also*: Areddy JT. (Apr. 21, 2020). China Bat Expert Says Her Wuhan Lab Wasn't Source of New Coronavirus. Wall Street Journal. <https://www.wsj.com/articles/chinas-bats-expert-says-her-wuhan-lab-wasnt-source-of-new-coronavirus-11587463204>.

⁹⁶ *Id.*

⁹⁷ Editorial Board. We're still Missing the Origin Story of this Pandemic. China is Sitting on the Answers. The Post's View. Washington Post. <https://www.washingtonpost.com/opinions/2021/02/05/coronavirus-origins-mystery-china/>; *see also* Contributor, Anonymous & Bostickson, Billy & Demaneuf, Gilles. (2021). An Investigation into the WIV Databases that were Taken Offline. DOI: [10.13140/RG.2.2.28029.08160](https://doi.org/10.13140/RG.2.2.28029.08160)

⁹⁸ *Supra*, note 92

⁹⁹ BurNIH-00000483-495 (on file with staff).

¹⁰⁰ *Supra*, note 18.

¹⁰¹ Zhou, P., Yang, XL., Wang, XG. et al. (Feb. 3, 2020). A Pneumonia Outbreak Associated with a new Coronavirus of Probable Bat Origin. Nature. 579: 270–273. <https://doi.org/10.1038/s41586-020-2012-7> <https://www.nature.com/articles/s41586-020-2012-7>.

¹⁰² *Id.*

¹⁰³ Dou, Eva & Kuo, Lily. (Jun. 2, 2021). A Scientist Adventurer and China's "Bat Woman" are under Scrutiny as Coronavirus lab-leak Theory gets Another Look. Washington Post. https://www.washingtonpost.com/world/asia_pacific/coronavirus-bats-china-wuhan/2021/06/02/772ef984-beb2-11eb-922a-c40c9774bc48_story.html.

¹⁰⁴ *Id.*

¹⁰⁵ Woodward A. (Jun. 8, 2021). A 2019 Video Shows Scientists from the Wuhan CDC Collecting Samples in Bat caves — but the Agency hasn't Revealed any Findings. Business Insider. <https://www.businessinsider.com/chinese-scientists-bat-caves-video-2021-6>.

¹⁰⁶ *Supra*, note 91,

¹⁰⁷ Cohen J. Wuhan. (Jul. 31, 2020). Coronavirus Hunter Shi Zhengli Speaks out. Science. 369(6503):487-488. <https://doi.org/10.1126/science.369.6503.487>.

¹⁰⁸ *Supra*, note 91.

¹⁰⁹ *Id.*

¹¹⁰ *Id.*

¹¹¹ *Id.*

¹¹² *Id.*

¹¹³ *Id.*

¹¹⁴ *Supra*, note 107.

¹¹⁵ Li, N., Hu, L., Jin, A., & Li, J. (2019). Biosafety laboratory risk assessment. Journal of Biosafety and Biosecurity, 1(2), 90–92. <https://doi.org/10.1016/j.jobb.2019.01.011>.

¹¹⁶ Wu, G. (2019). Laboratory biosafety in China: Past, present, and future. Biosafety and Health. <https://doi.org/10.1016/j.bsheat.2019.10.003>

¹¹⁷ Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., & Zheng, X.-S. (2020). Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 588(7836), E6–E6. <https://doi.org/10.1038/s41586-020-2951-z>

¹¹⁸ *Id.*

¹¹⁹ BurrNIH-0000016-54. (on file with staff).

¹²⁰ EcoHealth Alliance Project DEFUSE Proposal (on file with staff).

¹²¹ *Id.*

¹²² *Id.*

¹²³ *Id.*

¹²⁴ Li W, Wicht F, van Kuppeveld FJM, He Q, Rottier PJM, Bosch B-J. (May 13, 2015). A Single Point Mutation Creating a Furin Cleavage Site in the Spike Protein Renders Porcine Epidemic Diarrhea Coronavirus Trypsin Independent for cell entry and fusion. Journal of Virology. 2015 89(15) 80778081. <https://doi.org/10.1128/jvi.00356-15>.

¹²⁵ Sun, X., Belser, J. A., Yang, H., Pulit-Penaloza, J. A., Pappas, C., Brock, N., Zeng, H., Creager, H. M., Stevens, J., & Maines, T. R. (2019). Identification of key hemagglutinin residues responsible for cleavage, acid stability, and virulence of fifth-wave highly pathogenic avian influenza A(H7N9) viruses. Virology, 535, 232–240. <https://doi.org/10.1016/j.virol.2019.07.012>.

¹²⁶ Table of PRC Government Grants (on file with staff).

¹²⁷ *Supra*, note 107.

¹²⁸ *Supra*, note 91.

¹²⁹ Amrit, B.L.S. (Oct. 26, 2022). COVID-19: US NIH Partially Terminates Grant to EcoHealth Alliance. The Wire Science. <https://science.thewire.in/the-sciences/us-national-institute-of-health-terminates-grant-to-nonprofit-that-worked-with-wuhan-institute/>

¹³⁰ WIV patents on file with staff.

¹³¹ Wuhan Institute of Virology (2019). Patent: Biological Safety Laboratory Exhaust System.(on file with staff).

¹³² *Id.*

¹³³ *Id.*

¹³⁴ Wuhan Institute of Virology. Announcement of winning the bid for the procurement project of the environmental air disinfection system and the scalable automated sample storage management system of the Wuhan Institute of Virology, Chinese Academy of Sciences. (14 Aug. 2019). China Government Procurement Network. (on file with staff).

¹³⁵ *Id.*

¹³⁶ House Foreign Affairs Committee Report Minority Staff. (August 2021). The Origins of Covid-19: An Investigation of the Wuhan Institute of Virology. <https://gop-foreignaffairs.house.gov/wp-content/uploads/2021/08/ORIGINS-OF-COVID-19-REPORT.pdf>

¹³⁷ *Supra*, note 134.

¹³⁸ Henneman JR, McQuade EA, Sullivan RR, Downard J, Thackrah A, Hislop M. (Mar. 15, 2022). Analysis of Range and Use of a Hybrid Hydrogen Peroxide System for Biosafety 3 and Animal Biosafety Level 3 Agriculture laboratory Decontamination. *Applied Biosafety*. 27:1. <https://doi.org/10.1089/apb.2021.0012>. *See also*: Zhang S, Wu, J, Zhang E, et al. (Feb. 20, 2019). Research and Development of Airtight Biosafety Containment Facility for Stainless Steel Structures 2019. *Journal of Biosafety and Biosecurity*. 1: 56-62. <https://doi.org/10.1016/j.jobbb.2019.01.010>. *See also*; Zhang H, Peng C, Liu B, Liu J, Zhiming Y, Shi, Z. (Mar. 1, 2018). Evaluation of MICRO-CHEM PLUS as a Disinfectant for Biosafety Level 4 Laboratory in China. *Applied Biosafety Journal of ABSA International*. 23(1): 32-38. <http://doi.org/10.1177/153567601875> *Id.*

¹³⁹ Jiali W. (September 16, 2019). Competitive Consultation on Central-air-Conditioning Renovation Project of Wuhan Institute of Virology, Chinese Academy Sciences China Government Procurement Network. (on file with staff).

¹⁴⁰ U.S. Department of Health and Human Services Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins (DSAT). (2014). BSL-3/ABSL-3 HVAC and Facility Verification. https://www.cdc.gov/cpr/ipp/docs/policy_import_bsl3_abs3_verification.pdf.

¹⁴¹ Wuhan Institute of Virology. (3 Dec. 2019). The Wuhan Institute of Virology of the Chinese Academy of Sciences Plans to use a Single-Source Procurement Method to Publicize the Procurement of Air Incineration Devices and Test Service Projects. China Government Procurement Network. (on file with staff).

¹⁴² *Id.*

¹⁴³ Hanel E, Phillips GB, Gremillion GG. (1962). Technical Manuscript 1. Laboratory Design for Study of Infectious Disease. Office of the Safety Director US Army Chemical Corps Research and Development Command. Defense Technical Information Command Document #: 269-530 (on file with staff).

¹⁴⁴ Barbeito MS, Taylor LA, Seiders RW. (Mar. 16, 1968). Microbiological Evaluation of a Large-Volume Air Incinerator. *Appl Microbiol*. 16(3):490-495. <https://doi.org/10.1128/am.16.3.490-495.1968>

¹⁴⁵ Kuehne RW. (Sept. 26, 1973). Biological Containment Facility for Studying Infectious Disease. *Appl Microbiol*. 26(3):239-243. <https://doi.org/10.1128/am.26.3.239-243.1973>.

¹⁴⁶ Wuhan Institute of Virology. (Dec. 3 2019). The Wuhan Institute of Virology of the Chinese Academy of Sciences plans to use a single-source procurement method to publicize the procurement of air incineration devices and test service projects. <https://archive.is/Jifqr#selection-229.0-229.197>.

¹⁴⁷ Gao D, Zhang Q, Han K, Qian Q, Wenbo A. (December 11, 2019). Integrated Biological Sensor CN 201922213832.2. Google Patent. (on file with staff).

¹⁴⁸ Guo M, Yong M, Liu J, Huang X, Li X. (March 2019). Biosafety and Data Quality Considerations for Animal Experiments with Highly Infectious Agents at ABSL-3 Facilities. *Journal of Biosafety and Biosecurity*. 1; 50-55. <https://doi.org/10.1016/j.jobbb.2018.12.011>.

¹⁴⁹ *Id.*

¹⁵⁰ *Supra*, note 147.

¹⁵¹ Jia W, Zhiming Y, Hao T, Jun L, Hao Q, Yi L, Lin W. Object surface disinfectant for high-grade biosafety laboratory and preparation method thereof. (on file with staff).

¹⁵² *Id.*

¹⁵³ *Id.*

¹⁵⁴ Zhang *supra*, note 137.

¹⁵⁵ National Chemical Laboratories. (May 2022). Safety Data Sheet.

https://www.nclonline.com/products/view/micro_chem_plus_#tab-safety.

¹⁵⁶ Email communication US Senate HELP Committee with Technical Representative National Chemical Laboratories May 11 2022 (on file with staff).

¹⁵⁷ Wuhan Institute of Virology. (09 July 2019). Communist Party Leaders Urge “Leapfrog Development” and Focus on “Stranglehold” Challenges: “Xiang Shuilun Examines the Wuhan Institute of Virology’s Work of Establishing a ‘Red Flag Party Branch’”. *See also*: Wuhan Institute of Virology. (July 9, 2019). WIV Leaders Discuss and Correct “Shortcomings” & “Foundational Problems”. *See also*: Wuhan Institute of Virology. (July 9,

2019). Wuhan Institute of Virology Organizes Centralized Study on the Educational Theme of ‘Staying True to our Original Aspiration, Keeping Firmly in Mind our Mission’. (on file with staff).

¹⁵⁸ Yuan Zhiming. (Sept. 2019). Current Status and Future Challenges of High-Level Biosafety Laboratories in China. *Journal of Biosafety and Biosecurity*. 1:2. <https://doi.org/10.1016/j.jobbb.2019.09.005>.

¹⁵⁹ Cao C. (2021 Jun 30). China's Evolving Biosafety/Biosecurity Legislations. *J Law Biosci*. 8(1):lsab020. doi: 10.1093/jlb/lsab020; *see also* Translate, C. L. (Oct. 18, 2020). Biosecurity Law of the P.R.C. China Law Translate. <https://www.chinalawtranslate.com/en/biosecurity-law/>

¹⁶⁰ Wuhan Institute of Virology. (June 11, 2019). Xiang Shuilun Examines the Wuhan Institute of Virology’s Work of Establishing a ‘Red Flag Party Branch’. (on file with staff).

¹⁶¹ *Supra*, note 157.

¹⁶² Wuhan Institute of Virology. (June 11, 2019). Xiang Shuilun Examines the Wuhan Institute of Virology’s Work of Establishing a ‘Red Flag Party Branch’. *See also*: Wuhan Institute of Virology. (July 9, 2019). Wuhan Institute of Virology Organizes Centralized Study on the Educational Theme of ‘Staying True to our Original Aspiration, Keeping Firmly in Mind our Mission’. (on file with staff).

¹⁶³ *Id.*

¹⁶⁴ *Id.*

¹⁶⁵ Wuhan Institute of Virology. (July 30 2019). Wuhan Institute of Virology Convenes Study by the Party Committee’s Plenary Central Group and Special Investigation and Study Meeting of the Educational Theme ‘Never Forgetting our Original Aspiration and Keeping Firmly in Mind our Mission’. (on file with staff).

¹⁶⁶ *Supra*, notes 97 & 136.

¹⁶⁷ *Id.*

¹⁶⁸ *Id.*

¹⁶⁹ *Id.*

¹⁷⁰ *Id.*

¹⁷¹ Staff attempts to access the WIV database as recently as October 18, 2022 were unsuccessful. The website is <http://batvirus.whiov.ac.cn/>

¹⁷² Wuhan Institute of Virology. (Nov. 12, 2019). Keep Firmly in Mind Your Responsibilities, Hold Fast to the Mission, Be a Pioneer for our Nation in the Realm of High-Level Biosafety – The Achievements of the Zhengdian Lab Party Branch of the Chinese Academy of Sciences Wuhan Institute of Virology. (on file with staff).

¹⁷³ *Id.*

¹⁷⁴ *Id.*

¹⁷⁵ *Id.*

¹⁷⁶ *Id.*

¹⁷⁷ *Id.*

¹⁷⁸ Wuhan Institute of Virology. (Nov. 21, 2019). Wuhan Institute of Virology Launches Training on Safety Work. (on file with staff).

¹⁷⁹ *Id.*

¹⁸⁰ National Human Genome Research Institute. (August 31, 2021.). COVID-19 mRNA Vaccine Production. Genome.gov. <https://www.genome.gov/about-genomics/fact-sheets/COVID-19-mRNA-Vaccine-Production>

¹⁸¹ Campbell, C. (Aug. 24, 2020). Exclusive: Chinese Scientist Who First Sequenced COVID-19 Genome Speaks About Controversies Surrounding His Work. *Time*. <https://time.com/5882918/zhang-yongzhen-interview-china-coronavirus-genome/>.

¹⁸² Krammer, F. (Sept. 23, 2020). SARS-CoV-2 Vaccines in Development. *Nature*. 586, 516–527. <https://doi.org/10.1038/s41586-020-2798-3>

¹⁸³ Cantrell, Jasper. (Mar. 16, 2020). How To: Recombinant Protein Construct Design Genetics And Genomics. Labroots. <https://www.labroots.com/trending/genetics-and-genomics/17061/to-recombinant-protein-construct-design>.

¹⁸⁴ United States Government Accountability Office. (2020). COVID-19 Federal Efforts Accelerate Vaccine and Therapeutic Development, but More Transparency Needed on Emergency Use Authorizations Report to Congressional Addressees. GAO-21-207. <https://www.gao.gov/assets/gao-21-207.pdf>.

¹⁸⁵ United States Government Accountability Office. (2021). OPERATION WARP SPEED Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges Report to Congressional Addressees. GAO-21-319. <https://www.gao.gov/assets/gao-21-319.pdf>.

¹⁸⁶ *Supra*, note 184.

¹⁸⁷ *Supra*, note 182.

¹⁸⁸ University of Oxford. (n.d.). About. Covid19vaccintrial.co.uk. <https://covid19vaccintrial.co.uk/about>.

¹⁸⁹ Bendix, S. N., Andrew Dunn, Aria. (Dec. 19, 2020). Moderna's Groundbreaking Coronavirus Vaccine was Designed in Just 2 Days. Business Insider. <https://www.businessinsider.com/moderna-designed-coronavirus-vaccine-in-2-days-2020-11>.

¹⁹⁰ *Supra*, note 185.

¹⁹¹ University of Oxford. (January 20, 2022). A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers. Clinicaltrials.gov. <https://clinicaltrials.gov/ct2/show/NCT04324606?term=phase+1%2C+ChAdOx1&cond=covid-19&draw=2&rank=1>.

¹⁹² Janssen Vaccines & Prevention B.V. (September 12, 2022). A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older. Clinicaltrials.gov. <https://clinicaltrials.gov/ct2/show/study/NCT04436276>.

¹⁹³ Zimmer C. (July 17, 2020). Inside Johnson & Johnson's Nonstop Hunt for a Coronavirus Vaccine. The New York Times. <https://www.nytimes.com/2020/07/17/health/coronavirus-vaccine-johnson-janssen.html>.

¹⁹⁴ *Supra*, note 185.

¹⁹⁵ Shulkin, D. (January 21, 2021). What Health Care Can Learn from Operation Warp Speed The "RAPID" Process Used in Operation Warp Speed Achieved Amazing Results at a Time of Great Need. NEJM Catalyst; New England Journal of Medicine. <https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0001>.

¹⁹⁶ Slaoui, M., & Hepburn, M. (2020). Developing Safe and Effective Covid Vaccines — Operation Warp Speed's Strategy and Approach. New England Journal of Medicine. <https://doi.org/10.1056/nejmp2027405>.

¹⁹⁷ *Supra*, note 195.

¹⁹⁸ Le, Nhung. (Feb. 9, 2022). Meet the Scientist at the Center of the Covid lab leak Controversy. MIT Technology Review. <https://www.technologyreview.com/2022/02/09/1044985/shi-zhengli-covid-lab-leak-wuhan/>.

¹⁹⁹ Stevenson, A. (February 18, 2022). These Vaccines Have Been Embraced by the World. Why Not in China? The New York Times. <https://www.nytimes.com/2022/02/18/business/china-coronavirus-vaccines.html>

²⁰⁰ An Y, Li S, Jin X, et al. (2022) A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerg Microbes Infect. 11(1):1058-1071.

<https://doi.org/10.1080/22221751.2022.2056524>

²⁰¹ Ball P. (Dec. 18, 2020). The Lightning-Fast Quest for COVID Vaccines - and What it Means for Other Diseases. Nature. 589(7840):16-18. doi: 10.1038/d41586-020-03626-1. PMID: 33340018.

²⁰² Zhou Y, Zhao G, Gu H; Sun S, He L, Li Y, Han G, Lang X, Liu J, Geng S, Sheng X. (Feb. 24, 2020). Preparation of COVID-19 Vaccine Comprising RBD Domain-Fc Fusion Protein for Prevention and Therapy of SARS-CoV-2 Virus Infection. State Intellectual Property Office of the People's Republic of China. CN111333704A. https://qxb-img-oss-cache.qixin.com/patents_pdf_new/b916b8b4b29175cb63ab43dabe6ae785.pdf.

²⁰³ *Id.*

²⁰⁴ Pan, X., Zhou, P., Fan, T., Wu, Y., Zhang, J., Shi, X., Shang, W., Fang, L., Jiang, X., Shi, J., Sun, Y., Zhao, S., Gong, R., Chen, Z., & Xiao, G. (2020). Immunoglobulin Fragment F(ab')₂ Against RBD Potently Neutralizes SARS-CoV-2 in Vitro. Antiviral Research. 182 104868. <https://doi.org/10.1016/j.antiviral.2020.104868>.

²⁰⁵ Sun S, He L, Zhao Z, et al. (Mar. 21, 2021). Recombinant Vaccine Containing an RBD-Fc Fusion Induced Protection against SARS-CoV-2 in Nonhuman Primates and Mice. Cell Mol Immunol. 18(4):1070-1073. <https://doi.org/10.1038/s41423-021-00658-z>.

²⁰⁶ Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, Ikram A, Lanan F, Lourdes Guerrero M, Muñoz Navarro SR, Sued O, Lioznov DA, Dzutseva V, Parveen G, Zhu F, Leppan L, Langley JM, Barreto L, Gou J, Zhu T. CanSino COVID-19 Global Efficacy Study Group. (Dec. 23, 2021). Final efficacy Analysis, Interim Safety Analysis, and Immunogenicity of a Single Dose of Recombinant Novel Coronavirus Vaccine (adenovirus type 5 vector) in Adults 18 years and Older: an International, Multicentre, Randomised, Double-blinded, Placebo-Controlled Phase 3 trial. Lancet. 2022399(10321):237-248.

²⁰⁷ *Supra*, note 43.

-
- ²⁰⁸ Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (Jul. 15, 2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature microbiology*, 5(11), 1403–1407. <https://doi.org/10.1038/s41564-020-0770-5>.
- ²⁰⁹ *Supra*, note 43.
- ²¹⁰ *Supra*, note 94.
- ²¹¹ BurNIH-00000483-495 (on file with staff).
- ²¹² *Supra*, note 97.
- ²¹³ Cohen J. (Jul. 31, 2020). Wuhan Coronavirus Hunter Shi Zhengli speaks out. *Science*. 369(6503), 487–488. <https://doi.org/10.1126/science.369.6503.487>.
- ²¹⁴ *Id.*
- ²¹⁵ *Id.*
- ²¹⁶ *Supra*, note 158.
- ²¹⁷ Wuhan Institute of Virology. (June 21, 2019). Wuhan Institute of Virology Convenes Promotion Meeting for Work on the Educational Theme of ‘Staying True to our Original Aspiration, Keeping Firmly in Mind our Mission’ and a Study Session of the Expanded Party Committee Central Group. (on file with staff).
- ²¹⁸ Wuhan Institute of Virology. (July 30, 2019). Wuhan Institute of Virology Convenes Study by the Party Committee’s Plenary Central Group and Special Investigation and Study Meeting of the Educational Theme ‘Never Forgetting our Original Aspiration and Keeping Firmly in Mind our Mission’. (on file with staff).
- ²¹⁹ *Supra*, note 159.
- ²²⁰ *Supra*, note 172.
- ²²¹ Wuhan Institute of Virology. (Nov. 21, 2019). Wuhan Institute of Virology Launches Training on Safety Work. (on file with staff).
- ²²² *Supra*, note 17.
- ²²³ *Supra*, note 86.
- ²²⁴ *Supra*, note 43.
- ²²⁵ *Supra*, note 2; *see also* Sachs, J. D., Karim, S. S. A., Akin, L., Allen, J., Brosbøl, K., Colombo, F., Barron, G. C., Espinosa, M. F., Gaspar, V., Gaviña, A., Haines, A., Hotez, P. J., Koundouri, P., Bascuñán, F. L., Lee, J.-K., Pate, M. A., Ramos, G., Reddy, K. S., Serageldin, I., & Thwaites, J. (2022). The Lancet Commission on lessons for the future from the COVID-19 pandemic. *The Lancet*, 0(0). [https://doi.org/10.1016/S0140-6736\(22\)01585-9](https://doi.org/10.1016/S0140-6736(22)01585-9). *See also*: Office of the Director of National Intelligence. (2021). Updated Assessment on COVID-19 Origins. <https://www.dni.gov/files/ODNI/documents/assessments/Declassified-Assessment-on-COVID-19-Origins.pdf>.

EXHIBIT 14

EXHIBIT 14



RENTZ LAW, LLC.

September 12, 2022

Donald Trump, Senator Ron Johnson, Senator Rand Paul, Rep. Jim Jordan, and others were right. As early as late April or early May of 2020 former President Trump spoke of the creation of SARS-COV2 in a lab in Wuhan, China. Since that time both the investigation and the cover-up have continued but the evidence provided herein clearly demonstrate that SARS-COV2 was indeed created in a lab in Wuhan China by EcoHealth Alliance and with funding from Anthony Fauci's NIH/NIAID.

Evidence included herein demonstrate the following key points (amongst others):

1. SARS-COV2 was created in the lab in Wuhan, China;
2. Anthony Fauci funded the creation of SARS-COV2 and lied to Congress about funding Gain-of-Function work;
3. The US Intelligence Community was aware of and appeared to have been involved with the funding of said Gain-of-Function work;
4. A number of well-connected public and private partners were involved in the Gain-of-Function work that resulted in the creation and release of SARS-COV2;
5. Anthony Fauci and others coordinated to cover-up the funding of the Gain-of-Function work that resulted in SARS-COV2.

Given the recent high-profile criminal enforcement actions taken by Congress and the DoJ, we expect immediate investigations will see bi-partisan support in light of this newly compiled information. Renz Law and Make Americans Free Again (MAFA) will provide any and all support possible in such investigations and prosecutions. Further, with the additional high-profile revelations that certain segments of the government have promoted censoring this information, presumably as part of this same cover-up, we will voluntarily support any good-faith efforts by the media to correct the record.

As has been the case since early in the pandemic, Renz Law and MAFA will continue to seek truth and justice in this matter for all that have been impacted by the worst man-made pandemic in human history.

Sincerely,

Thomas Renz

Renz Law, LLC



RENZ LAW, LLC.

Answering Crucial Questions About Sars-CoV-2

Thomas Renz, attorney at law

Pamela A. Popper, Make Americans Free Again

Executive Summary

In early 2020, billions of people were told by governments and health agencies all over the world that a “novel virus” had caused severe illness in several individuals in Wuhan, China. Shortly after this announcement, people were told that the lethality rate for this virus, SARS-CoV-2, could be ten times higher than typical flu. The entire world started organizing to prevent the healthcare system from being overwhelmed with seriously ill patients, and to prevent as many deaths as possible. Government and health officials issued orders requiring businesses, schools, and houses of worship to close. People were told not to leave their homes except to purchase food and essential items and for emergency healthcare. Masks were required in all public indoor and outdoor places. Parks and beaches and trails were closed. Special events worldwide were cancelled for almost two years. Life as we know it came to a screeching halt and has not yet returned to normal.

In spite of these draconian measures, the World Health Organization reports that as of September 9, 2022, there have been over 600 million cases of SARS-CoV-2 and over 6.4 million deaths reported worldwide.¹

Damage due to SARS-CoV-2 is not limited to illness and death from the virus itself. Hundreds of thousands of businesses were bankrupted and families lost their livelihoods. The unemployment rate skyrocketed. The incidence of depression, anxiety, and other psychological disorders increased dramatically. Unprecedented harm was inflicted on children; school closures, masks, and relentless fear resulted in developmental delays and academic failure for millions of kids of all ages.

The response to this disaster must be to prevent this from happening again. The only way to protect the world from another devastating debacle like this is to get to the bottom of its origin. Almost three years after the first SARS-CoV-2 patients were reported in Wuhan, China, most Americans still do not know the truth about the origin of SARS-CoV-2. There are many as-yet unanswered questions:

- Where did SARS-CoV-2 come from? Lab? Animal?
- If SARS-CoV-2 was developed in a lab, which one(s)?
- Who was involved in the development of SARS-CoV-2?

¹ WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/> accessed 9.9.2022



RENZ LAW, LLC.

- Who paid for it?
- And why has this information not been made public?

This document is designed to answer these questions, with the best evidence available at this time. Arriving at a conclusion required the analysis of large amounts of research, some of which is quite complex. We have done our best to summarize complex data in relatively easy-to-understand terms.

The story of SARS-CoV-2 involves many government officials and agencies; academic research centers and research centers; and funding sources. We will discuss many of them here, but have determined that only a few bare most of the responsibility for SARS-CoV-2, and this document focuses on these individuals and organizations:

- Peter Daszak and his organization EcoHealth Alliance,
- Anthony Fauci, head of The National Institute of Allergy and Infectious Diseases,
- Shi Zhengli, Chinese virologist who headed the Center for Emerging Infectious Diseases at the Wuhan Institute of Virology,
- Ralph Baric, Professor in the Department of Epidemiology and the Department of Microbiology and Immunology at the University of North Carolina, Chapel Hill.

We believe that in the coming weeks and months, partly in response to making this document public, more evidence will become available. We do not expect new disclosures to change any conclusions herein; but rather that more people coming forward will strengthen our findings.

As for how to organize our findings, we decided to relate the information as sequentially as possible, and to provide background information where appropriate. This document, is, essentially, the “story of SARS-CoV-2.”



RENZ LAW, LLC.

Table of Acronyms

BLAST	Basic Local Alignment Search Tool
BSL	Bio-Safety Level
CCP	Chinese Communist Party
CDC	Centers for Disease Control
DARPA	U.S. Defense Advanced Research Projects Agency
DHHS	Department of Health and Human Services
EUA	Emergency Use Authorization
FCS	Furin Cleavage Site
FOIA	Freedom of Information Act
GoF	Gain of Function
NCBI	National Center for Biotechnology Information
NIAH	National Institute of Aging
NIAID	National Institute of Allergy and Infectious Diseases
NIH	National Institutes of Health
PRC	People's Republic of China
UNCH	University of North Carolina, Chapel Hill
USAID	U.S. Agency for International Development
USG	US Government
WHO	World Health Organization
WIV	Wuhan Institute of Virology



RENTZ LAW, LLC.

Table of Contents

About Andrew G. Huff	page 6
What is Gain-of-Function Research?	page 8
What is a Chimeric Virus?	page 10
The Wuhan Institute of Virology	page 11
Dr. Shi's Research at WIV	page 13
The Government and Scientific Community Knew GoF Was a Problem	page 15
Government/Health Officials Knew That Labs in China Were Not Secure	page 16
EcoHealth Alliance and Peter Daszak	page 17
Could SARS-CoV-2 Have Come From an Animal?	page 21
Addressing the Myth That SARS-CoV-2 Originated at the Seafood Market	page 22
Conclusion: The Creation of SARS-CoV-2 Was Funded by NIH, NIAID, and EcoHealth Alliance and Took Place in a Lab	page 28
The Cover-Up	page 31
From the Declaration by Andrew G. Huff	page 42
Other Individuals, Research Institutes and Organization of Interest	page 43
Declaration of Dr. Andrew G. Huff, PhD, M.S.	page 48



RENZ LAW, LLC.

About Andrew G. Huff PhD.

Andrew G. Huff worked at EcoHealth Alliance for a period of time and was a first-hand witness to the design and engineering of SARS-CoV-2. Dr. Huff has provided considerable valuable information to Renz Law concerning the origin of SARS-CoV-2 and the misbehavior that took place during the planning and execution of research supported by or conducted by EcoHealth Alliance. Information from his first-hand account, which is supported by a deposition under penalty of perjury, is included in this document.

Dr. Huff served in the U.S. Army, was involved in the Global War on Terrorism in Central America, and was engaged served in combat operations in Iraq.

After returning home from Iraq, Dr. Huff completed a bachelor's degree in psychology at the University of Minnesota, one of the top psychology research institutions in the world. He worked for the U.S. Department of Veterans Affairs, both relocating and building new outpatient mental healthcare offices.

Dr. Huff then earned a master's degree in Security Technologies with a Geographic Information Systems minor, also from the University of Minnesota. He was offered a full scholarship and earned a Ph.D. in the fields of bioterrorism, biowarfare, chemical warfare, pandemics, and emerging infectious disease. His research was published in peer-reviewed journals before he submitted his dissertation for review.

Dr. Huff then worked as a Research Fellow at the Department of Homeland Security Center of Excellence. During his tenure there, he presented research at high-level government meetings and to executives in the private sector.

While employed with Sandia National Laboratories, Dr. Huff was given Department of Energy "Q" clearance, which is equivalent to a Department of Defense "Top Secret" Clearance with a Special Access Programs designation. He analyzed national security problems, served as a subject matter expert in public health and food protection, and worked on projects related to pandemic preparedness, mitigation, and response.

When he decided to leave public sector work, he applied for a position at EcoHealth Alliance in September 2014. Dr. Peter Daszak offered, and Dr. Huff accepted, a position as Senior Scientist



RENZ LAW, LLC.

in charge of the Data and Technology team. During his time at EcoHealth, Dr. Huff was prepared reports for U.S. intelligence agencies, and reviewed proposals for funding gain of function research to the National Institute for Allergies and Infectious Diseases as routine scientific tasks. He eventually was promoted to Vice President after demonstrating that he could raise funds from wealthy donors and government project sponsors; design and successfully execute sophisticated research and development projects; and build high-functioning cohesive teams rapidly.

Dr. Huff has personal knowledge and documents related to the origin of COVID-19 and has shared both with Renz Law. His personal declaration is included in this document as evidence to support many assertions we make.



RENZ LAW, LLC.

What is Gain-of Function Research?

For purposes of this discussion, gain-of-function research involves manipulating viruses in a laboratory setting to investigate their potential to infect humans.

Here is a description of how gain-of-function research was conducted on a virus to make it transmissible to humans and to potentially make it more deadly to humans (in other words, the creation of SARS-CoV-2):

- First, the genome of an existing virus is mapped.
- In one approach, a virus is passaged in host animals (for example from mouse-to-mouse or ferret-to-ferret) repeatedly until a virus with different properties emerges. The virus may not have the capability of infecting a targeted animal species at the beginning of the project but gains this capability to infect the target animal through serial transmission.
- Another approach involves directly engineering changes in the genome of the virus. In the case of SARS-CoV-2, a genetically engineered spike protein created in the lab, was inserted into the genetic sequence of a virus. The high affinity of this spike protein to the ACE2 receptor in the body increased the infectivity of what became SARS-CoV-2.
- The new virus was then tested on humanized mice (biologically modified with a human receptor that enabled the new SARS-CoV-2 to enter their cells) and on human lung cells in the lab.
- Researchers succeeded in infecting human epithelial cell preparations and making the living mice sick with SARS-CoV-2. They knew they had created a virus that could infect humans.
- They then made the absurd claim that this process can happen in nature, which is why more funding should be allocated to conduct more of this type of research.

This type of research is controversial due to the risk of accidental release of a mutated virus that results from these experiments. While hundreds of researchers have spoken out against it, Dr. Anthony Fauci (head of the National Institute of Allergy and Infectious Diseases or NIAID) has historically defended this type of research. In an editorial in the *Washington Post* on December 30 2011, Fauci wrote: "[D]etermining the molecular Achilles' heel of these viruses can allow scientists to identify novel antiviral drug targets that could be used to prevent infection in those at risk or to better treat those who become infected. Decades of experience tells us that disseminating information gained through biomedical research to legitimate scientists and health



RENTZ LAW, LLC.

officials provides a critical foundation for generating appropriate countermeasures and, ultimately, protecting the public health."²

Despite Fauci's enthusiasm for it, the National Institutes of Health issued a moratorium on funding for gain-of-function research in 2014. Researchers involved in this type of work were urged to discontinue their activities until risks and benefits could be more clearly defined.³ The October 17, 2014, document that announced the moratorium included these statements expressing concern about this type of research:

"Gain-of-function studies, or research that improves the ability of a pathogen to cause disease, help define the fundamental nature of human-pathogen interactions, thereby enabling assessment of the pandemic potential of emerging infectious agents, informing public health and preparedness efforts, and furthering medical countermeasure development. Gain-of-function studies may entail biosafety and biosecurity risks; therefore, the risks and benefits of gain-of function research must be evaluated, both in the context of recent U.S. biosafety incidents and to keep pace with new technological developments, in order to determine which types of studies should go forward and under what conditions."

"In light of recent concerns regarding biosafety and biosecurity, effective immediately, the U.S. Government (USG) will pause new USG funding for gain-of-function research on influenza, MERS or SARS viruses, as defined below. This research funding pause will be effective until a robust and broad deliberative process is completed that results in the adoption of a new USG gain-of-function research policy 1. Restrictions on new funding will apply as follows:"

"New USG funding will not be released for gain-of-function research projects that may be reasonably anticipated to confer attributes to influenza, MERS, or SARS viruses such that the virus would have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route. The research funding pause would not apply to characterization or testing of naturally occurring influenza, MERS, and SARS viruses, unless the tests are reasonably anticipated to increase transmissibility and/or pathogenicity."

² Anthony S. Fauci, Gary J. Nabel and Francis S. Collins. A flu virus risk worth taking. *Washington Post* December 30 2011 https://www.washingtonpost.com/opinions/a-flu-virus-risk-worth-taking/2011/12/30/gIQAM9sNRP_story.html accessed 9.10.2022

³ Akst J. "Moratorium on Gain-of-Function Research." *The Scientist* October 21 2014



RENTZ LAW, LLC.

“In parallel, we will encourage the currently-funded USG and non-USG funded research community to join in adopting a voluntary pause on research that meets the stated definition.”⁴

It is important to note that the moratorium applied to NEW rather than existing funding. Research funded in part by The National Institute of Allergy and Infectious Diseases through EcoHealth which we have termed “The SARS-CoV-2 Creation Project” was already underway at the time the moratorium was declared. Ralph Baric, who was conducting gain of function research conducted at the University of North Carolina Chapel Hill and in partnership with researchers from the Wuhan Institute of Virology petitioned the NIH biosecurity board for an exemption from the pause. It was subsequently granted.

What is a Chimeric Virus?

A chimera, or chimeric virus, is a virus that contains genetic material from two or more distinct viruses. Chimeric viruses have been considered as potential bioweapons due to the increased lethality that can result from combining two pathogens in a lab.^{5 6 7}

⁴ U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS and SARS Viruses.

<https://www.phe.gov/s3/dualuse/documents/gain-of-function.pdf> accessed 9.10.2022

⁵ Collett Marc. "Impact of Synthetic Genomics on the Threat of Bioterrorism with Viral Agents". *Working Papers for Synthetic Genomics: Risks and Benefits for Science and Society* 2006:83–103.

⁶ Smithson A. "A Bio Nightmare." *Bulletin of the Atomic Scientists* 1999 Jul:

<https://journals.sagepub.com/doi/full/10.2968/055004019> accessed 9.9.2022

⁷ Ainscough MJ. *Next Generation Bioweapons: Genetic Engineering and BW*. US Airforce Counterproliferation Center Future Warfare Series No. 14

<https://media.defense.gov/2019/Apr/11/2002115480/-1/-1/0/14NEXTGENBIOWEAPONS.PDF> accessed 9.9.2022



RENTZ LAW, LLC.

The Wuhan Institute of Virology (WIV)

The Wuhan Institute of Virology (WIV) was originally founded in 1956 as the Wuhan Microbiology Laboratory. The Institute has operated under the jurisdiction of the Chinese Academy of Sciences since 1978. The Institute's labs range from Biosafety Level II (BSL-2) to Biosafety Level IV (BSL-4). BSL-4 labs are used for research with dangerous agents and substances.

The WIV BSL-4 LAB, which is of interest in the COVID-19 debacle, was developed by the People's Republic of China (PRC) in partnership with France following the 2003 SARS pandemic. Almost immediately after the project was undertaken, French officials expressed discomfort because it was suspected that the PRC had an ongoing biological warfare program, and the BSL-4 lab might be used for the purpose of developing biological weapons. To mitigate this concern, the parties agreed that all PRC/French research projects would be conducted under the supervision of French researchers on site at the lab. This did not, however, resolve the issue.

Disagreements between the parties continued. The French obtained information that led them to think that the PRC intended to build several BSL-4 labs. There were ongoing disputes over construction. After the Wuhan BSL-4 lab opened, the French became alarmed when the PRC requested biohazard suits that offered protection beyond what would have been necessary based on the research that should have been going on in the lab.

Of concern to everyone is the influence the Chinese Communist Party (CCP) had and continues to have on the Institute. High-level CCP officials serve on committees that decide the projects that will be undertaken in the lab and are also appointed to management positions.

Accidents at the lab have been another concern. For example, during a one-month period in 2004, the PRC reported nine new cases of SARS related to an accident during research using both live and inactivated samples of SARS-CoV.⁸

⁸ The Origins of the COVID-19 Global Pandemic, Including the Roles of the Chinese Communist Party and the World Health Organization. House Foreign Affairs Committee Minority Staff Interim Report. June 12, 2020 <https://gop-foreignaffairs.house.gov/wp-content/uploads/2020/08/Interim-Minority-Report-on-the-Origins-of-the-COVID-19-Global-Pandemic-Including-the-Roles-of-the-CCP-and-WHO-8.17.20.pdf> accessed 9.10.2022



RENTZ LAW, LLC.

The Institute is headed by Dr. Shi Zheng-Li, who is known as China's "Bat Woman" because she has spent a significant portion of her career collecting and studying bat viruses, ostensibly to facilitate the development of effective vaccines.⁹ Her colleagues include scientists and physicians who have close ties to both the political and military leadership of the PRC. An example is Guo Deyin, who has conducted research on AIDS and hepatitis vaccines, as well as genetic recombination methods.

⁹ Jane Qiu "How China's 'Bat Woman' Hunted Down Viruses from SARS to the New Coronavirus." *Scientific American* June 1 2020 <https://www.scientificamerican.com/article/how-chinas-bat-woman-hunted-down-viruses-from-sars-to-the-new-coronavirus1/> accessed 9.10.2022



RENTZ LAW, LLC.

Dr. Shi's Research at WIV

In a 2010 paper, Shi and her colleagues reported the results of their research on angiotensin-converting enzyme II (ACE2) protein, which is a known SARS-CoV receptor. The group looked at ACE2 molecules from seven bat species and tested the interaction of the ACE2 receptor with the human SARS-CoV spike protein. They used HIV-based pseudo type and live SARS-CoV infection assays. Spike proteins are structures that allow coronaviruses to bind to the receptor sites on human cells.

The researchers found that the ACE2s of two bat species – *Myotis daubentonii* and *Rhinolophus sinicus* were susceptible to SARS-CoV and might be candidates as the natural host of the SARS-CoV progenitor viruses.¹⁰

Shi was also a member of the Chinese research team that was involved in the controversial gain-of-function research financed by the National Institute of Allergy and Infectious Diseases (headed by Anthony Fauci), The National Institute of Aging of the US National Institutes of Health, and EcoHealth Alliance (headed by Peter Daszak), and conducted in partnership with a research team (led by Ralph Baric) at the University of North Carolina Chapel Hill. In a paper published in 2015 in *Nature Medicine*, the group characterized a chimeric virus with the spike protein SHC014 that was able to use multiple genes of the SARS receptor human angiotensin-converting enzyme II (ACE2) and “replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-Cov.” In other words, this virus could infect humans and quickly replicate. The article specifically stated, “...we synthetically re-derived an infectious full-length SHC014 recombinant virus and demonstrate robust viral replication both *in vitro* and *in vivo*.”

Furthermore, the team also reported replication of the chimeric virus in the lungs of mice. Most important, therapies typically used to treat SARS patients were found to be ineffective for treating the chimeric virus and vaccines did not prevent “infection with CoVs using the novel spike protein.”¹¹

¹⁰ Hou Y, Peng C, Yu M et al. “Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry.” *Arch Virol* 2010 Oct;155(10):1563-1569

¹¹ Menachery VD, Yount BL, Debbink K et al. “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.” *Nat Med* 2015 Nov;21:1508-1513



RENZ LAW, LLC.

Shi also conducted research on a virus called “WIV1” with clones of spike proteins and then tested the creation in humanized mice. The viruses quickly replicated, and the mice showed signs of severe pathogenesis. A peer-reviewed article reporting the results of this research listed Peter Daszak as an author.¹² What made this work especially risky was that WIV1 was already known to be potentially dangerous to humans. Baric had made this clear in an article titled “SARS-Like WIV1-CoV Poised for Human Emergence.”¹³

The bottom line: Researchers at the Wuhan lab, in partnership with U.S. scientists and funded by the government (directly through the NIAH and NIAID and indirectly via grants to EcoHealth Alliance) were conducting research on bat viruses, admitted that they were successful on at least one occasion in developing one that could infect humans, and this virus seemed to be resistant to treatment and prevention with vaccines.

¹² Zeng LP, Gao YT, Ge XY et al. “Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response.” *J Virol* 2016 Jun;90(14):6573-6582

¹³ Menachery VD, Yount BL, Sims AC et al. “SARS-like W1V10CoV poised for human emergence.” *PNAS* 2016 Mar;113(11):3048-3053



RENTZ LAW, LLC.

The Government and the Scientific Community Already Knew That Gain of Function Research was a Problem

In 2012, Dutch scientist Ron Fouchier conducted gain-of-function experiments designed to make a highly lethal avian influenza virus, H5N1, more transmissible. After several attempts, the team was successful. Live ferrets were used and H5N1 acquired mutations resulting from serial passage in ferrets. The result: H5N1 was transmissible between mammals without requiring recombination in an intermediate host. And it was created in a lab.¹⁴

Government officials were alarmed, which led to the 2014 moratorium. Then-President Obama mandated that gain-of-function research involving influenza, SARS, and MERS be paused until a new regulatory framework could be developed. Ralph Baric, who was at the time conducting gain-of-function research in partnership with Shi Zhengli (from the Wuhan Institute), petitioned the NIH biosecurity board for an exemption from the pause. It was subsequently granted.

Meanwhile Shi's lab was unencumbered by any restrictions and gain-of-function research continued at the Wuhan Institute. She and her colleagues researched how spike proteins in both natural and chimeric SARS-like viruses bind to the ACE2 receptors in the cells of humans, bats, and animals.¹⁵

¹⁴ Herfst S, Schrauwen EJA, Linster M et al. "Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets." *Science* 2012 Jun;336(6088):1534-1541

¹⁵ Ren W, Qu X, Wendong L et al. "Difference in Receptor Usage between Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-Like Coronavirus of Bat Origin." *J Virol* 2008 Feb;82(4):1899-1907



RENZ LAW, LLC.

Government and Health Officials Were Also Aware That Labs in China Were Not Secure

In 2004, the World Health Organization voiced concerns about lab security, particularly Chinese labs. According to the WHO, a SARS outbreak in 2003 infected nine people, one of whom died. This was the third outbreak of SARS that had been traced to a lab, and the WHO indicated that a better containment policy might be necessary, as well as a reduction in the number of labs that handled SARS viruses.¹⁶

The Wuhan Lab was the first in China to achieve the highest level of international bio research containment (BSL-4), but it was well-known that security was lax. Two years before the SARS-CoV-2 debacle, U.S. Embassy officials visited the Wuhan Institute several times and sent two “Sensitive but unclassified” cables to Washington stating that safety in the lab was inadequate. One of them warned about the lab’s experiments on bat viruses and the potential for human transmission and the risk of a SARS pandemic.¹⁷

¹⁶ Parry J. “Breaches of safety regulations are probable cause of recent SARS outbreak, WHO says.” *BMJ* 2004 May;328(7450):1222

¹⁷ Josh Rogin. Opinion: State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses. *Washington Post* April 14 2020
<https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/> accessed 9.10.2022



RENZ LAW, LLC.

EcoHealth Alliance and Peter Daszak

EcoHealth Alliance, formerly Wildlife Trust, is a nonprofit organization that at one time focused on wildlife conservation and matters like habitat loss, pollution, and environmental issues. In 2010, the organization rebranded itself to focus on “global health,” and the “relationships between ecosystems and animal and human health.”¹⁸

EcoHealth Alliance currently lists many partners on its website. These include¹⁹:

- The Centers for Disease Control
- The National Institutes of Health
- UC Davis California
- University of Pittsburgh Public Health
- Columbia University
- Princeton University
- Johns Hopkins Bloomberg School of Public Health
- Johnson and Johnson

Many of these organizations have been very involved with and some have profited from the SARS-CoV-2 debacle. For example, Johnson and Johnson is the maker of one of the COVID-19 vaccines approved under the Emergency Use Authorization, and sales have totaled billions of dollars.²⁰

During a several-year period of time starting in 2008, EcoHealth Alliance received funding from two U.S. government sources specifically related to Gain of Function Research:

The U.S. Agency for International Development (USAID) through a 5-year program called PREDICT.

¹⁸ Entering its Fifth Decade, Wildlife Trust Re-Brands as EcoHealth Alliance. September 21 2020 <https://www.ecohealthalliance.org/2010/09/entering-its-fifth-decade-wildlife-trust-re-brands-as-ecohealth-alliance>

¹⁹ <https://www.ecohealthalliance.org/partners>

²⁰ Spencer Kimball. J&J expects more than \$3 billion in COVID vaccine sales this year in mixed quarterly report. *CNBC* Jan 25 2022



RENTZ LAW, LLC.

National Institutes of Health and National Institute of Allergy and Infectious Diseases gave grants related to “Understanding the Risk of Bat Coronavirus Emergence.”²¹

Here are just a few of the grant awards:

2008 NIH/NIAID Project number 1R01AI079231-01²²
Risk of Viral Emergence from Bats
\$534,989

2009 NIH/NIAID Project number 5R01AI079231-02²³
Risk of Viral Emergence From Bats
\$535,156

2010 NIH/NIAID Project number 5R01AI0799231-03²⁴
Risk of Viral Emergence From Bats
\$480,423

2011 NIH/NIAID Project number 5R01AI0179231-04²⁵
Risk of Viral Emergence From Bats
\$510,005

2012 NIH/NIAID Project Number 5R01AI0179231-05²⁶
Risk of Viral Emergence From Bats
\$518,980

For the period 2002 through 2021, EcoHealth Alliance received a total of \$16,874,314 in grant money from NIH/NIAID.²⁷ Millions of dollars were allocated for researching bat viruses but

²¹ https://www.usaspending.gov/award/ASST_NON_R01AI110964_7529

²² https://reporter.nih.gov/search/CzU6U_tz2EG7c2LWkYMjLA/project-details/7509184

²³ https://reporter.nih.gov/search/CzU6U_tz2EG7c2LWkYMjLA/project-details/7688507 accessed 9.11.2022

²⁴ https://reporter.nih.gov/search/CzU6U_tz2EG7c2LWkYMjLA/project-details/7934526 accessed 9.11.2022

²⁵ https://reporter.nih.gov/search/CzU6U_tz2EG7c2LWkYMjLA/project-details/8142143 accessed 9.11.2022

²⁶ <https://reporter.nih.gov/search/DSSafL8TgkmP49MquyvTDQ/project-details/8313666> accessed 9.11.2022

²⁷ <https://reporter.nih.gov/search/Ho2wtHWeYeyi7P9MQUkUtQ/projects> accessed 9.11.2022



RENTZ LAW, LLC.

NIH also provided several hundred thousand dollars for research on the Nipah virus,²⁸ which has a 40-70% lethality rate, according to the WHO.²⁹

Some of this money received by EcoHealth – about six hundred thousand dollars – was given as a subgrant to the Wuhan Institute of Virology, in spite of the fact that security issues in Chinese labs and specifically at the Wuhan Institute were well-known.

Several hundred pages of emails obtained as a result of a lawsuit filed by the White Coat Waste Project reveal significant information about Daszak and his partners. In an email to NIAID, Daszak lists several “Senior/Key Personnel” involved in his projects including Ralph Baric at the University of North Carolina Chapel Hill, and Shi Zhengli along with several other scientists at the Wuhan Institute of Virology.³⁰

These emails also discuss collecting viruses from bats in several countries including Laos.³¹ Why is this significant? The emails show that it was decided to send samples to the Wuhan Institute of Virology.

Viruses isolated from the bats from Laos were genetically very close to SARS-CoV-2; the only thing missing was the furin cleavage site. But it defies logic that a bat virus that is almost identical to SARS-CoV-2 could have been transported to the Wuhan lab, where gain of function research was taking place, that the outbreak of SARS-CoV-2 took place in Wuhan, and that this could all be a coincidence.^{32 33 34} This is particularly unlikely in view of a grant proposal submitted by EcoHealth to another U.S. government agency that specifically referred to the “furin cleavage sites.”

In 2018, Daszak, at EcoHealth Alliance, in partnership with Shi, Baric, and Linfa Wang director of the Programme in Emerging Infectious Diseases at Duke-N.U.S. Medical School), submitted a \$14.2-million grant proposal to the U.S. Defense Advanced Research Projects Agency

²⁸ <https://reporter.nih.gov/search/DSSafL8TgkmP49MquyvTDQ/project-details/8326099>

²⁹ <https://www.who.int/news-room/fact-sheets/detail/nipah-virus>

³⁰ Gain of Function Communications Between EcoHealth Alliance and NIAID p 21-22

³¹ Gain of Function Communications Between EcoHealth Alliance and NIAID. P 61

³² White Coat Waste Project. From Laos to Wuhan: ECW FOIA Investigation Sheds Light on Pandemic's Origins. December 7 2021 <https://blog.whitecoatwaste.org/2021/12/07/from-laos-to-wuhan-ecw-foia-investigation-sheds-light-on-pandemics-origins/> accessed 9.10.2022

³³ Matt Riley. The COVID lab leak theory just got even stronger. *The Spectator* November 20 2021

³⁴ Wuhan scientists were studying Laos bat viral samples before COVID-Report. *Business Standard* November 22 2021 https://www.business-standard.com/article/current-affairs/wuhan-scientists-were-studying-laos-bat-viral-samples-before-covid-report-121112201019_1.html accessed 9.10.2022



RENZ LAW, LLC.

(DARPA).³⁵ This proposal was ultimately turned down. But the proposal included plans to insert “human-specific” furin cleavage sites into SARS-like coronaviruses, and then to test the altered viruses in human respiratory cells and humanized mice. The furin cleavage site is particularly important since it is the most distinguishing feature of SARS-CoV-2. It allows the virus to bind more efficiently and release genetic material into human cells. It is one of the reasons that SARS-CoV-2 transmits so easily from human to human and can be so harmful.

According to Richard Ebright, molecular biologist at Rutgers University, “The relevance of this is that SARS-CoV-2...is the only virus in its entire genus of SARS-related coronaviruses that contains a fully functional cleavage site at the S1, S2 junction. And here is a proposal from the beginning of 2018, proposing explicitly to engineer that sequence at that position in chimeric lab-generated coronaviruses.”³⁶

³⁵ <https://www.documentcloud.org/documents/21066966-defuse-proposal> accessed 9.10.2022

³⁶ Sharon Lerner, Maia Hibbet. Leaked Grant Proposal Details High Risk Coronavirus Research. *The Intercept* Sept 23, 2021 <https://theintercept.com/2021/09/23/coronavirus-research-grant-darpa/> accessed 9.10.2022



RENTZ LAW, LLC.

Could SARS-CoV-2 Have Come From an Animal?

It is possible, but not probable. SARS was found to have been transmitted from bats to civets and then to humans in November 2002.³⁷ It took about four months to make this determination.³⁸ MERS emerged in Saudi Arabia in 2012 spread from bats to camels to people.³⁹ It took about nine months to make this determination.⁴⁰ But almost three years after the first patients were identified, no animal has been identified as the source of SARS-CoV-2. At this time, such a discovery is not likely to occur. Authors of a World Health Organization report wrote in an August letter to *Nature*, "The window is rapidly closing on the biological feasibility of conducting the critical trace-back of people and animals inside and outside China." Daszak was a co-author of this letter.⁴¹

³⁷ Wang LF, Eaton BT. "Bats, civets and the emergence of SARS." *Curr Top Micro Immunol* 2007;315:325-344

³⁸ Guan Y, Zheng BJ, He YQ et al. "Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China." *Science* 2003 Oct;302(5643):276-278

³⁹ Han HJ, Yu H, Yu XJ. "Evidence for zoonotic origins of Middle East Respiratory syndrome coronavirus." *J Gen Virol* 2016 Feb;97(2):274-7280

⁴⁰ Omrani AS, Al-Tawfiq JA, Memish ZA. "Middle east respiratory syndrome coronavirus (MERS-CoV): animal to human interaction." *Pathog Glob Health* 2015 Dec;109(8):354-362

⁴¹ Koopmans M, Dszak P, Dedkov VG et al. "Origins of the SARS-CoV-2: window is closing for key scientific studies." *Nature* 2021 Aug <https://www.nature.com/articles/d41586-021-02263-6?proof=t%29Nature> accessed 9.10.2022



RENTZ LAW, LLC.

Addressing the Myth That SARS-CoV-2 Originated at the Huanan Seafood Market

The first official announcement from the Chinese government concerning SARS-CoV-2 was issued on December 30, 2019, when the Wuhan Municipal Health Commission reported that “cases of pneumonia of unknown cause” were linked to the Huanan Seafood Market, which sold live wild animals in addition to seafood, including hedgehogs, badgers, snakes, and turtledoves. It was also stated there was no evidence of “obvious human to human transmission and no infection among medical personnel.”⁴²

Timeline for the Deception

On January 1, 2020, the Huanan Seafood Market was closed for cleaning. Vendors reported that workers had started spraying disinfectant on December 30, 2019.⁴³

Scientists from China’s National Institute for Viral Disease Control and Prevention collected 515 samples from the Huanan Seafood Market for analysis, also on January 1, 2020 and returned to collect 70 more samples from vendors after the market re-opened.

At the same time, an official at the Hubei Provincial Health Commission ordered gene sequencing companies and labs to stop testing and to destroy all patient samples.⁴⁴

⁴² Zhang Jingshu and Wang Ruiwen Editor: Li Jie. Wuhan Central Hospital claims that SARS rumors spread through the internet, there is no doubt that the patient may be diagnosed. *Beijing News* 12.31.2019 <http://www.bjnews.com.cn/news/2019/12/31/668421.html> accessed 9.10.2022

⁴³ Seafood market closed after outbreak of ‘unidentified’ pneumonia. *Global Times* Jan 1 2020 <https://www.globaltimes.cn/content/1175369.shtml> accessed 9.10.2022

⁴⁴ The Origins of the COVID-19 Global Pandemic, Including the Roles of the Chinese Communist Party and the World Health Organization. House Foreign Affairs Committee Minority Staff Interim Report. June 12. 2020 <https://gop-foreignaffairs.house.gov/wp-content/uploads/2020/08/Interim-Minority-Report-on-the-Origins-of-the-COVID-19-Global-Pandemic-Including-the-Roles-of-the-CCP-and-WHO-8.17.20.pdf> accessed 9.10.2022



RENZ LAW, LLC.

On January 2, 2020 an analysis of samples from patients at Wuhan's Jinyintan Hospital by researchers at Wuhan Institute of Virology identified the novel coronavirus.⁴⁵

On January 3, 2020 the Wuhan Municipal Commission reported that 44 patients had been identified with symptoms consistent with "pneumonia of unknown origin" some of whom worked at the Huanan Seafood Wholesale Market and 11 of whom were severely ill.⁴⁶

On January 5 2020

A WHO statement was posted that included the following:

"The reported link to a wholesale fish and live animal market could indicate an exposure link to animals. The symptoms reported among the patients are common to several respiratory diseases, and pneumonia is common in the winter season; however, the occurrence of 44 cases of pneumonia requiring hospitalization clustered in space and time should be handled prudently."⁴⁷

According to the authorities, some patients were operating dealers or vendors in the Huanan Seafood market. Based on the preliminary information from the Chinese investigation team, no evidence of significant human-to-human transmission and no health care worker infections have been reported.⁴⁸

The WHO also posted this statement:

The reported link to a wholesale fish and live animal market could indicate an exposure link to animals. The symptoms reported among the patients are common to several respiratory diseases, and pneumonia is common in the winter season; however, the occurrence of 44 cases of pneumonia requiring hospitalization clustered in space and time should be handled prudently.⁴⁹

⁴⁵ Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 Feb 2020 <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> accessed 9.10.2022

⁴⁶ Lu H, Stratton CW, Tang YW. "Outbreak of Pneumonia of Unknown Etiology in Wuhan China: The mystery and the miracle." *J Med Viro* 2020 Apr;92(4):401-402

⁴⁷ IBID

⁴⁸ World Health Organization. Pneumonia of unknown cause – China. World Health Organization <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/> accessed 9.10.2022

⁴⁹ IBID



RENZ LAW, LLC.

In other words, the WHO was repeating the Chinese claim that the virus originated in the seafood market and gave the impression that there was no reason for concern.

January 12, 2020

WHO issued this statement: "China shared the genetic sequence of the novel coronavirus on 12 January, which will be of great importance for other countries to use in developing specific diagnostic tests." WHO also stated, "The evidence is highly suggestive that the outbreak is associated with exposures in one seafood market in Wuhan. The market was closed on 1 January 2020. At this stage, there is no infection among healthcare workers, and no clear evidence of human-to-human transmission."⁵⁰

January 14, 2020

WHO tweets, "Preliminary investigations conducted by the Chinese authorities have found no clear evidence of human-to-human transmission of the novel #coronavirus (2019-nCov) identified in #Wuhan, #China."⁵¹

January 26, 2020

The Institute of Virology and Chinese CDC announced that the novel coronavirus was present in 33 of the 585 environmental samples collected from the Wuhan Huanan Seafood Wholesale Market earlier in the month. Of these 33 samples, all but two were collected from an area of the market where wildlife vendors were located. Xinhua News Service says the results indicate "the virus stems from wild animals on sale at the market."⁵²

Almost immediately, however, published research showed that the market could not have been the source of the outbreak. The co-authors of an article published in the *Lancet*, including experts from Wuhan's leading infectious disease hospital, reported that among the first 41 patients identified in Wuhan, the first patient to show symptoms, on December 1, 2019, had no exposure to the market. Two of the next three patients to show symptoms, all on December 10, also had no exposure to the market. "No epidemiological link was found between the first patient and later cases," the researchers wrote. And, in fact, there were 13 patients with no link to the market.⁵³

⁵⁰ Novel Coronavirus—China. World Health Organization. January 12, 2020

<https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON233> accessed 9.10.2022

⁵¹ <https://twitter.com/WHO/status/1217043229427761152> accessed 9.10.2022

⁵² China Detects Large Quantity of Novel Coronavirus at Wuhan Seafood Market. *XinhuaNet* January 27, 2020 http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm accessed 9.10.2022

⁵³ Huang C, Wang Y, Li X et al. "Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China." *Lancet*, 2020 Feb;395(10223):P497-506



RENTZ LAW, LLC.

“That’s a big number, 13, with no link,” stated Daniel Lucey, an infectious disease specialist at Georgetown University, who went on to say that the *Lancet* paper raised questions about the overall accuracy of the data the CCP was providing to the world.

According to Lucey, the Wuhan Municipal Health Commission was the “official source” of public information and on January 11, 2020, reported that there were only 41 confirmed patients, that there was no evidence of human-to-human transmission, and that most cases were related to the market. Because the Wuhan Municipal Health Commission noted that diagnostic tests had confirmed these 41 cases by January 10, 2020, and officials presumably knew the case histories of each patient, Lucey said “China must have realized the epidemic did not originate in that Wuhan Huanan seafood market.”⁵⁴

An article published in the *Lancet* on January 30, 2020 reported that of 99 patients diagnosed with COVID-19 between Jan 1 and Jan 20, 2020, forty-nine had been exposed to the Huanan Seafood Market, and 50 had not.⁵⁵ And an article in the *New England Journal of Medicine* reported that of 425 confirmed cases, the majority (55%) with onset before January 1, 2020 were linked to seafood market, although this was true for only 8.6% of subsequent cases.⁵⁶ The theory that the seafood market was the source of the outbreak and that the virus was not transmissible between humans was falling apart.

It is important to note that the First National Health Commission arrived in Wuhan December 31, 2019, and determined that in order to diagnose SARS-CoV-2, three criteria needed to be met: **a history of exposure to the seafood market**, fever, and the full genome from respiratory or serum specimens identical to SARS-CoV-2 sequences.⁵⁷

The timeline above, however, indicates that the Chinese knew that one third had no contact with the seafood market when these criteria were established. So why were these criteria established? To mislead the world about the origin of the virus? The criteria were not changed until January 18, 2020, but on January 26, 2020, Chinese authorities were still claiming that the virus originated at the seafood market.

⁵⁴ Jon Cohen. Wuhan seafood market may not be source of novel virus spreading globally. *Science* Jan 26 2020 <https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> accessed 9.10.2022

⁵⁵ Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.” *Lancet* 2020 Feb;395(10223):P507-513

⁵⁶ Li Q, Med M, Guan X et al. “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.” *NEJM* 2020 Mar;382:1199-1207

⁵⁷ Han Y, Yang H. “The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective.” *J Med Virol* 2020 Mar;92:639-644



RENTZ LAW, LLC.

So where *did* this virus originate?

A sample of bronchoalveolar fluid from a single patient hospitalized on December 26, 2019, identified a new RNA virus strain most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses previously found in bats in China. The researchers noted that although SARS-like viruses have been identified widely in bats in China, viruses identical to SARS-CoV had not yet been documented. They noted that the Wuhan coronavirus was most closely related to bat coronaviruses and showed 100% amino acid similarity to bat SL-CoVZC45 in the nsp7 and E proteins.⁵⁸ The problem is that there were no bats at the seafood market, which means that the virus could not have originated there.

In a paper published in the *Lancet*, researchers wrote, “Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, in eastern China.”⁵⁹ The researchers were referring to a 2018 paper which reported the results of an analysis of 334 bats collected between 2015 and 2017 from Zhoushan City in Zhejiang province China. Coronaviruses were detected in 26.65% of these bats, and the viruses had 81% shared nucleotide identity with human/civet SARS-CoVs.⁶⁰ This sounds complicated, and it is, but what this means is that the Wuhan virus was very similar to bat viruses. Yet there were no bats at the seafood market. Also remember that “the bat lady” – Shi - had been studying bat viruses at the WIV for an exceptionally long time.

Again, the CCP was not forthcoming. The Shanghai lab where researchers published the first genome sequence of the coronavirus that caused COVID-19 was shut down by the Shanghai Health Commission for “rectification” on January 12, 2020, five days after Professor Yong-Zhen Zhang’s team published the genome sequence and made it available to the public. The team had reported that the virus resembled a group of viruses previously found in bats. This lab was a Level 3 biosafety facility and had just passed its annual inspection on January 5, 2020.⁶¹

⁵⁸ Wu F, Zhao S, Yu B et al. “A new coronavirus associated with human respiratory disease in China.” *Nature* 2020 Feb;579:265-269

⁵⁹ Lu R, Zhao X, Li J et al. “Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.” *Lancet* 2020 Feb;395:565-574

⁶⁰ Hu D, Zhu C, Ai L et al. “Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats.” *Emerg Microbes Infect* 2018 Sep;7:154

⁶¹ Zhuang Pinghui “Chinese laboratory that first shared coronavirus genome with world ordered to close for ‘rectification’, hindering its Covid-19 research.” *South China Morning Post* Feb 28 2020 <https://www.scmp.com/news/china/society/article/3052966/chinese-laboratory-first-shared-coronavirus-genome-world-ordered> accessed 9.10.2022



RENTZ LAW, LLC.

Indian researchers also studied the virus and found four insertions in the spike protein that are unique to SARS-CoV-2 and not present in other coronaviruses. The amino acid residues in all four insertions were found to be similar to amino acid residues in the structural proteins of HIV-1. The researchers noted that there are only 3 viruses that contain these sequences – HIV-1, the bat coronaviruses discovered by Shi, and the New Wuhan virus (COVID-19). They also noted that it was highly unlikely that this could have occurred naturally.⁶²

This article was later withdrawn. The Indian researchers wrote that they intended to revise it in response to comments received from the research community.⁶³ Almost a year later, Ashutosh Kumar Pandey, one of the researchers, told a reporter that the article was inconvenient for those who wanted to promote the natural origin theory. He stated that the paper was withdrawn due to pressure from “people with vested interests.”

Pandey also said that the original paper represented a small portion of the studies that he and his group had conducted. When they tried to include their entire findings in a new article, the revised manuscript was blocked by journal publishers. When asked how it was possible for scientific papers to be blocked to comply with a particular agenda, he replied, “Science is the new medieval church, those who are popes of it censor at their will.”⁶⁴

Notes from a lecture delivered by Shi shortly before the outbreak began disappeared from the Institute website.

The CCP’s order to labs to destroy samples, and its refusal to share information and samples to the world community has not helped to instill confidence in the integrity of Chinese officials and their representations concerning the virus.

Bottom Line: What we now call SARS-CoV-2 is almost identical to viruses obtained from bats in Laos and shares important characteristics with chimeric viruses created via gain-of-function research. There is almost no evidence to support the idea that this virus was transmitted directly from bats or other animals to humans, or that the original patients were infected at the wet market.

⁶² Pradhan P, Pandey AK, Mishra A et al. “Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag.” *BioRxiv* <https://doi.org/10.1101/2020.01.30.927871>

⁶³ IBID

⁶⁴ COVID-19 lab leak theory: Indian scientists had flagged ‘unnatural insertions’ in its genome, were forced to withdraw study. *OpIndia* June 4 2021 <https://www.opindia.com/2021/06/indian-scientists-had-found-unique-insertions-in-covid-19-virus-genome/> accessed 9.10.2022



RENTZ LAW, LLC.

Conclusion: The Creation of SARS CoV-2 Was Funded by NIH, NIAID, and EcoHealth Alliance and Took Place in a Lab

A comparison between a virus created in a lab, and described in a paper published in *Nature Medicine* reveals startling similarities to SARS-CoV-2.⁶⁵

- Younger mice were relatively unaffected.
- The virus was deadly to older mice or mice with compromised immune systems.
- Showed strong tendency to attack lung tissue, invade human bronchial epithelial cells.
- Caused weight loss in mice, a common side effect of SARS-CoV-2 in humans.
- Resistant to standard treatment.
- Researchers were unable to develop an effective vaccine.
- When a vaccine made of “inactivated whole SARS-CoV” was given to older animals they became sicker when re-exposed to SARS-CoV.
- Older animals vaccinated and then exposed: “augmented immune pathology was also observed, indicating the possibility of the animals being harmed because of the vaccination.”
- Exaggerated immune response after vaccination and re-exposure.

According to the article, this work was funded by EcoHealth Alliance, The National Institute of Allergy and Infectious Diseases (NIAID), and The National Institutes of Health. The authors of the paper included Zhengli-Li Shi (from the Wuhan Institute), Ralph Baric (UNCH) and Peter Daszak (EcoHealth Alliance).

Another clue as to the origin of SARS-CoV-2 comes from an interview with Daszak conducted by virologist Vincent Racaniello on December 19, 2019, just three weeks before the Wuhan Municipal Health Commission reported the first cases of what turned out to be COVID-19:

⁶⁵ Menachery VD, Yount BL, Debbink K et al. “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.” *Nat Med* 2015 Nov;21:1508-1513



RENTZ LAW, LLC.

At the 28:10 mark of the podcast interview, Daszak states that researchers found that SARS likely originated from bats and then set out to find more SARS-related coronaviruses, eventually finding over one hundred of them.

Daszak reported that some coronaviruses can "get into human cells in the lab," and others can cause SARS disease in "humanized mouse models."

He warned that such coronaviruses are "untreatable with therapeutic monoclonals [antibodies] and you can't vaccinate against them with a vaccine."

Daszak claimed that his team's goal was trying to find the next "spillover event" that could cause the next pandemic.

At the 29:54-mark Daszak is asked what can be done to deal with coronaviruses given that there are no therapeutics or vaccines for them, Daszak discusses that the goal of his GoF (gain-of-function) research was to develop a universal vaccine that could be used for many different types of coronaviruses.

Referring specifically to bat coronaviruses, Daszak said, "You can manipulate them in the lab pretty easily." He then mentioned the most unique characteristic of SARS-CoV-2 (which had not yet been named at the time of this podcast), the spike protein, stating "Spike protein drives a lot of what happens with the coronavirus, zoonotic risk." He also talked about inserting the spike protein "into a backbone of another virus" and then doing "some work in the lab."

Daszak acknowledged collaboration with Baric: "and we work with Ralph Baric at UNC [University of North Carolina] to do this."

Daszak also admitted the creation of chimeras in order to investigate vaccines: "Now, the logical progression for vaccines is, if you are going to develop a vaccine for SARS, people are going to use pandemic SARS, but let's try to insert these other related diseases and get a better vaccine."⁶⁶

Evidence also shows that SARS-CoV-2 is likely not only manmade but may have been developed in collaboration with other entities.

⁶⁶ Keoni Everington. WHO inspector caught on camera revealing coronavirus manipulation in Wuhan before pandemic. *Taiwan News* Jan 18 2021 <https://www.taiwannews.com.tw/en/news/4104828> accessed 9.10.2022



RENTZ LAW, LLC.

BLAST is an acronym for Basic Local Alignment Search Tool. It's a computer algorithm available for use at the National Center for Biotechnology Information (NCBI) website. The algorithm allows scientists to quickly query a DNA sequence to find matches or regions of similarity between protein sequences. Scientists worldwide deposit their sequences when they make new discoveries.

A distinguishing feature of SARS-CoV-2 is the furin cleavage site and the 12- nucleotide insertion in the spike protein, particularly its two consecutive CGG codons. Researchers conducted a BLAST search and found a 100% reverse match in a proprietary U.S. patent filed on February 4, 2016 (US patent 9,587,003).⁶⁷ According to the researchers, statistical analysis shows that the probability of this sequence randomly being present in a 30,000-nucleotide viral genome is 3.21×10^{-11} (less than one in one billion). The owner of the patent is Moderna, which makes COVID-19 vaccines using mRNA technology.⁶⁸

While nothing is impossible, a SARS virus mutating in nature and jumping species that contains a furin cleavage site that does not exist in nature but does exist in a Moderna patent – not at all likely. The authors write, “The presence in SARS-CoV-2 of a 19-nucleotide sequence encoding an FCS at amino acid 681 of its spike protein with 100% identity to the reverse complement of a proprietary MSH3 mRNA sequence is highly unusual. Potential explanations for this correlation should be further investigated.”⁶⁹

⁶⁷ Bancel S, Chakraborty T, De Fougerolles A, Elbashir SM, John M, Roy A, et al. *Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides*. Cambridge, MA: United States Patent. (2016). <https://pubchem.ncbi.nlm.nih.gov/patent/US-9587003-B2> accessed 9.10.2022

⁶⁸ Ambati BK, Varshney A, Lundstrom K et al. “MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site.” *Frontiers Virol* 2022 Feb; <https://doi.org/10.3389/fviro.2022.834808> accessed 9.10.2022

⁶⁹ IBID



RENZ LAW, LLC.

The Cover-Up

Peter Daszak, Anthony Fauci, and many others have invested considerable effort in trying to convince the public and the scientific community that the lab origin theory is false.

In February 2020, Daszak organized scientists to write an open letter published in the *Lancet* that included these statements: “The rapid, open, and transparent sharing of data on this outbreak is now being threatened by rumours and misinformation around its origins. We stand together to strongly condemn conspiracy theories suggesting that COVID-19 does not have a natural origin.”⁷⁰

Daszak was one of the authors. But prior to signing on, he expressed concern about distancing himself to hide his participation in gain-of-function research. In an email obtained through a Freedom of Information Act request, Daszak wrote to collaborator Ralph Baric: “I spoke with Linfa [Wang] last night about the statement we sent round. He thinks, and I agree with him, that you, me, and him should not sign this statement, so it has some distance from us and therefore doesn’t work in a counterproductive way. We’ll then put it out in a way that doesn’t link it back to our collaboration so we maximize an independent voice.”⁷¹

Baric agreed, writing back, “I also think this is a good decision. Otherwise it looks self-serving and we lose impact.”⁷²

⁷⁰ Calisher C, Carroll D, Colwell R et al. “Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19.” *The Lancet* 2020 Mar;395(10226):E42-E43

⁷¹ Emails show scientists discussed masking their involvement in key journal letter on COVID origins. US Right to Know Feb 15 2021 <https://usrtk.org/biohazards-blog/scientists-masked-involvement-in-lancet-letter-on-covid-origin/> accessed 9.10.2022

⁷² IBID



RENZ LAW, LLC.

The letter included this statement: “We declare no competing interests.”⁷³ Daszak also told the *Washington Post* that he had no conflicts of interest concerning his work with Shi Zhengli at the Wuhan Institute of Virology.⁷⁴

Daszak further tried to cover his tracks when he agreed to be part of a team sent to China by the World Health Organization in February 2021 to investigate the origin of SARS-CoV-2. Not surprisingly, the team reported that it was “extremely unlikely” that the virus has been released from a lab.⁷⁵ Team members were asked to sign a declaration of interest and according to the report, “All declared interests were assessed and found not to interfere with the independence and transparency of the work.”⁷⁶ It is difficult to believe that Dasak could have disclosed his connection to the Wuhan Institute and gain-of-function research and met the criteria for “independence and transparency.”

Daszak also hid his conflicts of interest concerning his research and his ties to the Wuhan Institute of Virology from Jeffrey Sachs, chair of the *Lancet* COVID-19 Commission. Daszak had been asked by Sachs to head a Task Force to look into the origins of COVID-19. According to Sachs, “It is clear that the NIH co-funded research at the Wuhan Institute of Virology that deserves scrutiny under the hypothesis of a laboratory-related release of the virus.”⁷⁷ Sachs ended the task force’s work after more information became public that questioned the veracity of statements made by Daszak.⁷⁸

Daszak’s collaborators are equally evasive. According to David Morens, Daszak’s work benefits humanity and we should all be grateful.”⁷⁹ But Morens is with the National Institute

⁷³ Calisher C, Carroll D, Colwell R et al. “Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19.” *The Lancet* 2020 Mar;395(10226):E42-E43

⁷⁴ Josh Rogin. Opinion: the coronavirus shows he risks of scientific collaboration with China. *Washington Post* Apr 23 2020 https://www.washingtonpost.com/opinions/global-opinions/the-coronavirus-crisis-shows-the-risks-of-scientific-collaboration-with-china/2020/04/23/4ccd5850-85a8-11ea-878a-86477a724bdb_story.html accessed 9.10.2022

⁷⁵ WHO-convened Global Study of the Origins of SARS-CoV-2: China Part. [file:///C:/Users/Pam/Downloads/Final-joint-report_origins-studies-6-April-201%20\(2\).pdf](file:///C:/Users/Pam/Downloads/Final-joint-report_origins-studies-6-April-201%20(2).pdf) accessed 9.10.2022

⁷⁶ IBID p 12

⁷⁷ Jeffrey Sachs. Finding the Origins of the COVID-19 and Preventing Future Pandemics. <https://www.jeffsachs.org/newspaper-articles/cp24mtcpswgty5st4pm29mwh6dt2d> accessed 9.10.2022

⁷⁸ COVID-19: *Lancet* investigation into origin of pandemic shuts down over bias risk. *BMJ* 2021;375:n2414

⁷⁹ Jon Cohen. Prophet in Purgatory. *Science* November 17 2021



RENZ LAW, LLC.

of Allergy and Infectious Diseases, which provides grant money to Daszak, and he co-authors articles defending the idea that SARS-CoV-2 came from nature.⁸⁰

Yet more evidence of a cover-up is described in email exchanges between Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, other NIH personnel and outside researchers.

On January 31, 2020, Fauci received an email from Greg Folkers of the National Institutes of Health.⁸¹ The email included no text, but an article published in *Science* was attached.⁸² This article reported that scientists were sharing and reviewing a growing number of genetic sequences of the virus obtained from infected patients. These had been posted in the Global Initiative on Sharing All Influenza Data database.⁸³ The author reported that there was some doubt as to whether the virus originated in the wet market, which was the story promoted by U.S. and Chinese authorities at the time. The author also reported that many scientists had been expressing concerns for many years about experiments conducted at the Wuhan Institute and cited the gain-of-function research fully described in the above-mentioned article in *Nature Medicine* in 2015.⁸⁴ This article included a disclosure that the research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), the division of the NIH headed by Fauci, along with the NIH and EcoHealth.

Within minutes, Fauci forwarded the *Science* article to Jeremy Farrar, the head of Wellcome Trust, a UK non-profit, and Kristian Andersen with Scripps Research Institute.⁸⁵ He later sent the article to Robert Kadlec at the Health and Human Services Office of the Assistant Secretary for Preparedness and Response.⁸⁶

⁸⁰ Morens D, Daszak P, Markel H, Taubenberger JK. "Pandemic COVID-19 Joins History's Pandemic Legion." *mBio* 2020 May;11(3):e00812-20

⁸¹ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3229 accessed 9.10.2022

⁸² Jon Cohen. Mining coronavirus genomes for clues to the outbreak's origins. *Science* Jan 31 2020
⁸³ <https://gisaid.org/database-features/flusurver-mutations-app/> accessed 9.10.2022

⁸⁴ Menachery VD, Yount BL, Debbink K et al. "A SARS-like cluster of circulating bat coronaviruses shows great potential for human emergence." *Nature Medicine* 2015 Nov;21:1508-1513

⁸⁵ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3187 accessed 9.10.2022

⁸⁶ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3222 accessed 9.10.2022



RENTZ LAW, LLC.

On the same day, Kristian Anderson wrote in an email to Fauci: “The unusual features of the virus make up a really small part of the genome (<0.1%) so one has to look really closely at all the sequences to see that some of the features (potentially) look engineered.”⁸⁷

The next day on February 1 2020, Fauci sent an email to Hugh Auchincloss, deputy director of NIAID.⁸⁸ The subject line was IMPORTANT (in all caps) and read: “It is essential that we speak this AM. Keep your cell phone on...Read this paper as well as the email that I will forward to you now. You will have tasks today that must be done.”

Attached to the second email was a document titled “Baric, Shi et al – Nature Medicine – SARS Gain of Function.pdf.” This is particularly important since Fauci denied under oath in front of a Senate hearing that Ralph Baric was conducting gain-of-function research at the University of North Carolina. Within a few seconds, Fauci forwarded the article from *Science*⁸⁹ to Auchincloss as well.⁹⁰ He then forwarded the *Nature Medicine* article to Lawrence Tabak at the National Institutes of Health with “IMPORTANT” in the memo.⁹¹

It seems that Fauci was concerned and was alerting his colleagues that disclosure of this information might be a problem. The others seemed equally concerned. Farrar sent an email at 10:34AM announcing that he had scheduled a conference call and wrote that his expectation was that “information and discussion is shared in total confidence and not to be shared until agreement on next steps.”⁹²

Auchincloss then wrote to Fauci, “The paper you sent me says the experiments were performed before the gain of function pause but have since been reviewed and approved by NIH. Not sure what that means since Emily is sure that no Coronavirus work has gone through the P3 framework. She will try to determine if we have any distant ties to this work abroad.”⁹³ Fauci replied, “OK. Stay tuned.”⁹⁴

⁸⁷ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p 3187 accessed 9.10.2022

⁸⁸ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p 3221 accessed 9.10.2022

⁸⁹ Jon Cohen. Mining coronavirus genomes for clues to the outbreak’s origins. *Science* Jan 31 2020

⁹⁰ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p 3215 accessed 9.10.2022

⁹¹ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3210 accessed 9.10.2022

⁹² <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3197 accessed 9.10.2022

⁹³ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3206 accessed 9.10.2022

⁹⁴ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3206 accessed 9.10.2022



RENTZ LAW, LLC.

During the conference call, Farrar sent an email to four of the people on the call, including Fauci, that read, "Can I suggest we shut down the call and then redial in? Just for 5-10 minutes?"⁹⁵

There are several follow-up emails between the parties but the most important are those that discuss the need to talk to World Health Organization Director-General Tedros. An email of particular interest is from Farrar to Fauci and NIH Director Collins, which was shared with others: "Tedros and Bernhard have apparently gone into conclave ... they need to decide today in my view. If they do prevaricate, I would appreciate a call with you later tonight or tomorrow to think how we might take forward [sic]."⁹⁶ In this email, Farrar expressed concern about an article published by ZeroHedge which discussed the potential lab release as the origin of the virus.⁹⁷ Subsequently ZeroHedge was banned from Twitter.

On February 3 2021, Tedros delivered a Report of the Director-General, 146th Meeting of the Executive Board, during which he emphasized the importance of controlling the spread of misinformation and announced that WHO was working with Google "to make sure people searching for information about coronavirus see WHO information at the top of their search results. Social media platforms including Twitter, Facebook, Tencent and Tiktok have also taken steps to limit the spread of misinformation."⁹⁸ The proper term to describe this might be "censorship."

In March 2020, a statement of support for the idea that SARS-CoV-2 was transmitted from an animal to a human was published in the *Lancet*.⁹⁹ It was signed by many people including Peter Daszak, President of EcoHealth Alliance and Christian Drosten. Then things start to get very interesting.

EcoHealth Alliance is the organization that received money from NIAID and distributed it to Ralph Baric at the University of North Carolina Chapel Hill, and Shi Zhengli, a virologist

⁹⁵ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p 3172 accessed 9.10.2022

⁹⁶ ⁹⁶ <https://assets.documentcloud.org/documents/20793561/leopold-nih-foia-anthony-fauci-emails.pdf> p3125 accessed 9.10.2022

⁹⁷ Tyler Durden. Coronavirus Contains "HIV Insertions", Stoking Fears Over Artificially Created Bioweapon. *ZeroHedge* Feb 1 2020

⁹⁸ Report of the Director-General, 146th Meeting of the Executive Board. <https://www.who.int/director-general/speeches/detail/report-of-the-director-general-146th-meeting-of-the-executive-board> accessed 9.10.2022

⁹⁹ Calisher C, Carroll D, Colwell R et al. "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19." *Lancet* 2020 Mar;395(10226):E42-E43



RENTZ LAW, LLC.

referred to as the “bat lady” at the Wuhan Institute of Virology. The money was earmarked for gain-of-function research. Emails obtained by U.S. Right to Know show that the “statement of solidarity” that appeared in the *Lancet* was actually drafted by Peter Daszak.¹⁰⁰

Apparently, Ralph Baric was shown drafts of Daszak’s letter but was informed by Daszak that he did not need to sign the statement. Baric agreed, stating that doing so would appear to be self-serving. Daszak wrote that other key people would be looking at the letter and that it would be “...put out in a way that doesn’t link it back to our collaboration so we maximize an independent voice.”¹⁰¹ Daszak also wrote, “Please note that this statement will not have EcoHealth Alliance logo on it and will not be identifiable as coming from any one organization or person, the idea is to have this as a community supporting our colleagues.”¹⁰² This shows deliberate intent to hide the relationships between the parties. Indeed, five of the signers of this “solidarity statement” were directly affiliated with EcoHealth Alliance¹⁰³ and two were partners of EcoHealth.¹⁰⁴

Christian Drosten is another signer of the solidary statement. He also has an interesting background. Drosten and his colleagues had published an article in *Eurosurveillance* on Jan 23, 2020, in which they claimed to have developed a RT-PCR test for SARS-CoV-2.¹⁰⁵ There were several problems with this paper, including the fact that that this group did not have SARS-CoV-2 viral material at the time that the article was published. The researchers acknowledged this, writing: “We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available.”¹⁰⁶ Instead, the group relied on theoretical sequences which were provided by a lab in China. Despite this, the test was immediately endorsed by World Health Organization Director General Tedros Adhanom. A large group of scientists has called for this paper to be retracted for many reasons, including undisclosed conflicts of interest for some of the authors and lack of peer review.¹⁰⁷

¹⁰⁰ https://usrtk.org/wp-content/uploads/2020/11/Biohazard_FOIA_Maryland_Emails_11.6.20.pdf accessed 9.10.2022

¹⁰¹ https://usrtk.org/wp-content/uploads/2021/02/Baric_Daszak_email.pdf p 273 accessed 9.10.2022

¹⁰² https://usrtk.org/wp-content/uploads/2021/02/Baric_Daszak_email.pdf p 274 accessed 9.10.2022

¹⁰³ Sainath Suryanarayanan. EcoHealth Alliance orchestrated key scientists statement on “natural origin” of SARS-CoV-2. *USRTK* Nov 18 2020 <https://usrtk.org/biohazards-blog/ecohealth-alliance-orchestrated-key-scientists-statement-on-natural-origin-of-sars-cov-2/> accessed 9.10.2022

¹⁰⁴ <https://www.ecohealthalliance.org/partners>

¹⁰⁵ Corman VM, Landt O, Kaiser M et al. “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.” *Euro Surveill* 2020 Jan;25(3):2000045

¹⁰⁶ IBID

¹⁰⁷ Borger P, Malhotra BR, Yeaton M et al. “External peer review of the RTPCR test t detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false positive results.” Corman-Drosten Review Report. November 27 2020 <https://cormandrostenreview.com/report/> accessed 9.10.2022



RENTZ LAW, LLC.

The bottom line: both Daszak and Drosten had significant motivation to keep the actual origin of the virus, their knowledge about it, and other details a secret; as did Fauci and other employees of the NIH and NIAID.

Kristian Andersen, who had, in late January, written to Fauci expressing his concerns that SARS-CoV-2 included sequences that appeared to be manmade, led a group that published an article in *Nature* on March 17, 2020, in support of the theory that the virus was transmitted from animals to humans.¹⁰⁸ After this, Andersen received a generous grant from the National Institutes of Health. At this time, we have no way of knowing if this was a form of quid pro quo, but it can at least be said that this does not pass the “smell test.”

Dr. Anthony Fauci continued to insist that gain-of-function research was not responsible for the creation of SARS-CoV-2 and stated under oath when testifying in front of a Senate Committee that neither his agency nor the National Institute of Health funded gain-of-function research. In response to questions from Senator Rand Paul he said, “With all due respect, you are entirely, completely incorrect.” He added that the NIH “...has not and does not now fund gain-of-function research in the Wuhan Institute of Virology.”¹⁰⁹

But The National Institutes of Health admitted that it funded gain-of-function research on bat coronaviruses at the Wuhan Institute in China. In a letter to Rep James Comer (R-KY), NIH Deputy Director Lawrence Tabak stated that the NIH had given a grant to EcoHealth Alliance Inc which then awarded a subgrant to the Wuhan Institute of Virology, and that EcoHealth had failed to submit reports as required under the terms of the grant. In this letter, Tabak stated that EcoHealth’s “limited experiment” looked at whether spike proteins from naturally occurring bat viruses circulating in China were capable of binding to the ACE2 receptor in a mouse model. Tabak stated that mice infected with the modified virus became sicker than those who were infected with the unmodified virus. Tabak also wrote, “As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do.”¹¹⁰

A letter dated Oct 27, 2021, from Congressional leaders to Frances Collins, (former) Director of the National Institutes of Health, concerned inadequate oversight of grants made from NIH to

¹⁰⁸ Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. “The proximal origin of SARS-CoV-2.” *Nature Medicine* 2020 Mar;26:450-452

¹⁰⁹ Jack Brewster. Fauci and Sen Rand Paul Spar Over Wuhan Lab Research and COVID-19 Origin. *Forbes* May 11 2021 <https://www.forbes.com/sites/jackbrewster/2021/05/11/fauci-and-sen-rand-paul-spar-over-wuhan-lab-research-and-covid-19-origin/?sh=5169857e1df9> accessed 9.10.2022

¹¹⁰ Emily Crane. NIH admits US funded gain-of-function in Wuhan – despite Fauci’s denials. *New York Post* Oct 21 2021 <https://nypost.com/2021/10/21/nih-admits-us-funded-gain-of-function-in-wuhan-despite-faucis-repeated-denials/> accessed 9.10.2022



RENTZ LAW, LLC.

EcoHealth Alliance. Some of these concerns arose from a bipartisan “in camera” review of documents conducted at the Department of Health and Human Services (DHHS). The documents were examined in chambers because the NIH refused to make the documents public.

Here are excerpts from this letter to Dr. Collins:

NIH terminated an EcoHealth Alliance grant in April 2020, reinstated the grant and then suspended the grant in July 2020 due to EcoHealth’s inadequate oversight of research at the Wuhan Institute of Virology.

EcoHealth Alliance refused to provide information to the NIH related to its subaward to the Wuhan Institute of Virology.

NIH failed to report EcoHealth’s noncompliance and grant suspension into the www.SAM.gov database that alerts other U.S. Government agencies to risky grant recipients.

Both Daszak and officials at the National Institute of Allergy and Infectious Disease appeared to have known that EcoHealth’s research was crossing the line in consideration of the moratorium on gain-of-function research. In a 2016 project report concerning to the NIH concerning his research, EcoHealth described its plans to carry out experiments involving humanized mice using two chimeric bat coronaviruses.¹¹¹

Subsequently NIH wrote to EcoHealth, stating that the research studies appeared “to involve research covered under the pause.”

Daszak replied on behalf of EcoHealth Alliance, and asserted that the organization’s research did not involve gain of function:

“These 2 chimeric bat-like CoVs were constructed on Sept. 24, 2015. They use the backbone of a group 2b SARS-like bat CoV WIV1 and the spike proteins of two newly discovered bat SL-CoVs (Rs7327 and RsSHC014). The construction of these chimeric viruses aims to understand the receptor usage and infectivity of bat SL-CoVs that may be progenitors of SARS-CoV. We have not yet tested the pathogenicity of these viruses in animals.”

¹¹¹ Understanding the Risk of Bat Coronavirus Emergency. Project Number 5R01AI110964-04 https://reporter.nih.gov/search/H_f9L5dZYESM-o4gIMrLig/project-details/9320765



RENTZ LAW, LLC.

Daszak offered no explanation concerning how RsSHC014 differed from the RsSCHO14 spike protein that was reported to be of great concern in 2015.¹¹²

Instead, Daszak stated that this work would not be considered GoF because "...the pause specifically targeted experiments that related to the pathogenicity or transmissibility of SARS-CoV, MERS CoV and any influenza virus. Our molecular clone is WIV1, which is a group 2b SARS-like bat coronavirus that has never been demonstrated to infect humans or cause human disease." But this was not true.

Gain of function research funded by the National Institute of Allergy and Infectious Diseases and the National Institute of Aging of the NIH concluded: "...viruses using the WIV1-CoV spike protein are capable of infecting HAE cultures directly without further spike adaptation. Whereas in vivo data indicate attenuation relative to SARS-CoV, the augmented replication in the presence of human *ACE2* in vivo suggests that the virus has significant pathogenic potential..."¹¹³

"...studies that build reagents based on viruses from animal sources cannot exclude the possibility of increased virulence or altered immunogenicity that promote escape from current countermeasures. As such, the potential of a threat, real or perceived, may cause similar exploratory studies to be limited out of an "abundance of caution."¹¹⁴

"...the WIV1-CoV cluster has been identified as a threat for future emergence in human populations due to robust replication in primary human airway epithelial cell cultures."¹¹⁵

In other words, WIV1 was known to be potentially dangerous to humans.

Daszak proposed that Daszak/EcoHealth and its collaborators would immediately stop their research and inform their NIAID program officer if the chimeras showed evidence of virus growth greater than 1 log (or 10 times) the growth rate of the original viruses and/or grow more efficiently in human lung cells.

¹¹² Menachery VD, Yount BL, Sims AC et al. "SARS-like WIV1-CoV poised for human emergence." *PNAS* 2016 Mar;113(11):3048-3053

¹¹³ Menachery VD, Yount BL, Sims AC et al. "SARS-like WIV1-CoV poised for human emergence." *PNAS* 2016 Mar;113(11):3048-3053

¹¹⁴ IBID

¹¹⁵ IBID



RENTZ LAW, LLC.

Ignoring obvious warning signs, NIAID agreed with EcoHealth's self-assessment and agreed to let EcoHealth police its own activities. A NIH July 7, 2016, response letter to EcoHealth included these statements:

NIAID is in agreement that the work proposed under Aim 3 to generate MERS-like or SARS-like chimeric coronaviruses (CoVs) is not subject to the GoF research funding pause. This determination is based on the following: (1) the chimeras will contain only S glycoprotein genes from phylogenetically distant bat CoVs; and (2) recently published work demonstrating that similar chimeric viruses exhibited reduced pathogenicity. Therefore, it is not reasonably anticipated that these chimeric viruses will have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route.

As a result, the NIAID added the following award condition, per the grant documents (NOTE: this is the specific language proposed by Daszak to NIAID):

NIAID acknowledges that if any of the MERS-like or SARS-like chimeras generated under this grant show **evidence of enhanced virus growth greater than 1 log over the parental backbone strain**, Dr. Daszak will immediately stop all experiments w/ these viruses and provide the NIAID Program Officer and Grants Management Specialist, and Wuhan Institute of Virology Institutional biosafety Committee, with the relevant data and information related to these unanticipated outcomes. (Emphasis added).¹¹⁶

Daszak and EcoHealth did not do what they promised. Sometime during the period June 2017-May 31, 2018, the experiments involving chimeric viruses and humanized mice were carried out. EcoHealth and the Wuhan Institute of Virology infected humanized mice with the WIV1 parental virus and three chimeric viruses containing SHC014S, WUV16S and Rs4231S. The SHC014S virus grew at 10,000 times greater than the parent virus. Mice lost 20% of the body weight in six days.

At day two and four, "Viral loads in lung tissues of mice challenged with all three chimeras reached $>10^6$ genome copies per/g, significantly higher than related WIV1 infection (Fig. 6b). This demonstrates that pathogenicity of SARS-related coronaviruses in humanized mice differs

¹¹⁶ <https://republicans-energycommerce.house.gov/wp-content/uploads/2021/11/2021.10.27-Letter-to-NIH.pdf>



RENZ LAW, LLC.

with divergent S proteins, confirming the value of this model in assessing novel SARS related coronavirus pathogenicity.” (Emphasis added).¹¹⁷

Despite running two years behind in submitting required reports to NIH, and the failure of EcoHealth to stop the experiments and report to NIAID as promised, NIH approved the renewal of EcoHealth’s grant on June 18, 2018. In its November 5, 2018, progress report to NIH for the period of June 1, 2014, through May 31 2019, EcoHealth reported that the strains of viruses it was using could represent a significant threat to public health because they could escape existing vaccine and therapeutic treatments.¹¹⁸

The Congressional letter raises many important issues that need to be investigated and ends with a long list of demands from the NIH concerning the agency’s grants to, and management and oversight of EcoHealth Alliance.

¹¹⁷ IBID

¹¹⁸ IBID



RENTZ LAW, LLC.

From the Declaration by Andrew Huff Ph.D., Former Employee of EcoHealth Alliance

After being promoted to Vice President of EcoHealth Alliance, Dr. Huff had access to information about the organization's finances. He learned that EcoHealth was heavily dependent on government contracts to remain solvent and that cash flow was often tight. He also observed first-hand that EcoHealth engaged in minor fraud by overbilling time on contracts and double-dipping on some contracts between government agencies and provide donors.

Dr. Huff was routinely involved in meetings and informal discussions during which gain-of-function research was discussed.

During direct participation in the USAID PREDICT program, Dr. Huff saw first-hand that EcoHealth failed to pay adequate attention to biosafety, biosecurity, and risk management. The organization did not perform proper oversight of foreign laboratories at which research funded by EcoHealth took place. Dr. Huff expressed his concerns regularly and they were routinely dismissed by Daszak and other EcoHealth staff.

Dr. Huff met Dr. Shi Zhengli and Dr. Ralph Baric and attended presentations at which they discussed their work on the design and engineering of SARS-CoV-2 and the use of humanized mice in their experiments.

Dr. Huff was involved in the creation of a slide deck presented to In-Q-Tel which included the use of USAID PREDICT funding to collect coronavirus samples from bats all over the world, to analyze these viruses to identify their most dangerous features to humans, and then create chimeras to test on humanized mice.



RENZ LAW, LLC.

Other Individuals, Research Institutions, and Organizations of Interest

The Rockefeller Foundation has given several grants to EcoHealth Alliance for the purpose of forming a network called One Health Alliance in South Asia (OHASA) for the purpose of investigating emerging infectious diseases, including bat viruses that have the potential to spread to humans.^{119 120}

In 2010, the Rockefeller Foundation published a report in partnership with the Global Business Network titled “Scenarios for the Future of Technology and International Development.”¹²¹ The collaboration used “scenario planning” to look at possible responses to hypothetical situations, including a pandemic. A scenario titled “LOCK STEP” describes a world of tighter top-down government control and more authoritarian leadership with innovation and growing citizen pushback after a pandemic is declared. The events described in this report are eerily like what started taking place in 2020.

In September 2020, The Rockefeller Foundation published a “Message Handbook” for “COVID-19 Testing and Tracing.” The Handbook was designed to teach health professionals and others how “...to motivate the public to participate in testing and tracing.” The Handbook provides messages developed through research, expert interviews, and testing that have been shown to lower resistance to regular testing and contact tracing. Readers are encouraged to reinforce “new norms” that include “ongoing, repetitive actions.” These include:

“Doctors, nurses, and health care workers are putting their lives at risk to care for people who need it. They need our help. Contact tracing stops more people from getting sick, so hospitals don’t get crowded, doctors and nurses can stay safe, and every patient gets the attention they need.”

¹¹⁹ The Rockefeller Initiative. Disease Surveillance Networks. <https://www.rockefellerfoundation.org/wp-content/uploads/Disease-Surveillance-Networks-Initiative.pdf>

¹²⁰ Epstein JH, Quan PL, Briese T et al. “Identification of GBV-D, a Novel GB-like Flavivirus From Old World Frugivorous Bats (*Pteropus giganteus*) in Bangladesh.” *PLoS* 2010 Jul <https://doi.org/10.1371/journal.ppat.1000972>

¹²¹ Technology’s Power to Transform the Lives of the Poor Revealed in New Study by the Rockefeller Foundation and Monitor’s Global Business Network.” https://www.tmcnet.com/usubmit/2010/06/21/4859175.htm#google_vignette accessed 9.10.2022



RENTZ LAW, LLC.

“If you test positive, there is a short window of time to pinpoint who else might have the virus before they could lose their health and their jobs. If you identify who you were in contact with, you can stop the virus in its tracks.”¹²²

In August 2022, <https://www.rockefellerfoundation.org/news/mercury-project-to-boost-covid-19-vaccination-rates-and-counter-public-health-mis-and-disinformation-in-17-countries-worldwide/>

UC Davis One Health Institute leads the PREDICT Project, with partners including EcoHealth Alliance, Metabiota, and the Smithsonian Institute. The purpose of this project is to “...enable global surveillance for pathogens that can spillover from animal hosts to people...” and “...discover viruses of pandemic potential.”¹²³

In a series of emails between members of the PREDICT research team obtained by US Right To Know:

EcoHealth Alliance made requests via the predict-outbreak@ucdavis.edu email system for travel approval for Dr. Peng Zhou and Dr. Shi Zhengli to travel to the U.S. Both were listed as “PREDICT China Country Coordinators,” both were listed as working at the Wuhan Institute of Virology, and both were traveling to the U.S. to meet with the PREDICT global team at EcoHealth Alliance for “China project updates.”¹²⁴

Metabiota also made several similar requests for foreign researchers to visit the U.S.

Emails also discuss subgrants through EcoHealth to other countries including China; and funds to Metabiota with subawards to other countries.

Many emails pertain to the Global Virome Project, which involves Nathan Wolfe at Metabiota and endeavors to “...identify virtually every viral pathogen on the planet.”

Some emails refer to PREDICT work in Laos, which is one of the sources of bat viruses which were sent to The Wuhan Institute, one of which has a genetic sequence almost identical to SARS-CoV-2 (discussed in this manuscript above).

One journal article included in the document with the emails describes a PREDICT project that involved isolation of an Ebola virus from bats in Sierra Leone.

¹²² Rockefeller Foundation. Message Handbook: COVID-19 Testing and Tracing. September 2020

¹²³ <https://whc.vetmed.ucdavis.edu/predict-project> accessed 9.10.2022

¹²⁴ <https://usrtk.org/wp-content/uploads/2021/10/UC-Davis-Jonna-Mazet-batch-1.pdf> accessed 9.10.2022



RENTZ LAW, LLC.

Many names in the email exchanges are redacted.¹²⁵

METABIOTA is an EcoHealth Alliance and UC Davis partner and received investment from the CIA and DoD investment firm In-Q-Tel¹²⁶ and numerous contracts and/or grants from the US government. Metabiota was funded in part by Rosemont Seneca, partially owned by Hunter Biden. An In-Q-Tel quarterly report titled "Mission Possible: Quenching Epidemics" lists Metabiota and EcoHealth Alliance as partners.¹²⁷

Metabiota was also part of a consortium that included EcoHealth Alliance, University of California Davis and others. This group was formed as part of the second phase of USAID PREDICT program to investigate coronaviruses, influenza viruses, and filoviruses such as Ebola.¹²⁸ EcoHealth's Fiscal Year Annual report 2014 report confirms this arrangement.¹²⁹

University of North Carolina Chapel Hill, Ralph Baric

Here are just a few of the projects involving Ralph Baric and conducted at or in partnership with UNCH:

Baric, in partnership with Chinese researchers, isolated and studied coronaviruses from bats with HKU spike protein. Funded by National Institutes of Health Grant R01AI89728 and R21AI109094

Yang Y, Du L, Liu C et al. "Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus." *PNAS* 2014;Aug;111(34):12516-12521

Baric and Shi Zhengli collaborated to study the virus surface spikes of MERS-CoV and a related bat coronavirus HKU4. Although HKU4 could not mediate viral entry into human cells, two mutations allowed it to do so.

Yang Y, Liu C, Du L et al. "Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus." *J Virol* 2015 Sep;89(17):9119-9123

Funded by NIH Grants R01AI089728 and R01AI110700

¹²⁵ <https://usrtk.org/wp-content/uploads/2021/10/UC-Davis-Jonna-Mazet-batch-1.pdf> accessed 9.10.2022

¹²⁶ John T. Reinert. In-Q-Tel: The Central intelligence Agency as Venture Capitalist. <https://scholarlycommons.law.northwestern.edu/njilb/vol33/iss3/4/> accessed 9.10.2022

¹²⁷ IQT Quarterly. Mission Possible: Quenching Epidemics. Winter 2016;7(3)

¹²⁸ USAID Announced Second Phase of Predict Project with Global Partners. November 21 2014. <https://www.ecohealthalliance.org/2014/11/usa-id-announces-second-phase-of-predict-project-with-global-partners> accessed 9.10.2022

¹²⁹ EcoHealth Alliance Fiscal Year 2014 Annual Report. <https://www.ecohealthalliance.org/wp-content/uploads/2016/01/EcoHealth-Alliance-FY14-Annual-Report.pdf> accessed 9.10.2022



RENZ LAW, LLC.

Baric and Shi Zhengli were both part of the research team which generated a chimeric SARS-CoV virus that could infect humans. Symptoms in infected humanized mice were similar to symptoms of SARS-C-V-2

Menachery VD, Yount BL, Debbink K et al. "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence." *Nat Med* 2015 Nov;21:1508-1513

Funded by grants from NIH and NIAID: U19AI109761 (R.S.B.), U19AI107810 (R.S.B.), AI085524 (W.A.M.), F32AI102561 (V.D.M.) and K99AG049092 (V.D.M.), USAID-EPT-PREDICT funding from EcoHealth Alliance

Columbia University

The Department of Ecology, Evolution and Environmental and Environmental Biology lists three individuals with EcoHealth Alliance, including Peter Daszak, as faculty members.¹³⁰

Columbia University Mailman School of Public Health announced a partnership with several organizations, including EcoHealth, to launch and operate New York City's first Pandemic Response Institute. The website states that this "...builds on Columbia's robust involvement in the NYC COVID-19 response and grants it a significant role in preparing New York City for future public health emergencies."¹³¹ EcoHealth's website lists Columbia University as a partner.¹³²

Yunnan Institute of Endemic Disease Control and Prevention

Received funding from The National Institute of Allergy and Infectious Disease (Grant #R01AI110964). Peter Daszak and EcoHealth served as consultants.

Li H, Daszak F, Chmura A, Zhang Y, Terry P, Fielder M. "Knowledge, Attitude and Practice Regarding Zoonotic Risk in Wildlife Trade, Southern China." *EcoHealth* 2021 Mar;18(2):95-106

Guandong Provincial Center for Disease Control and Prevention

Daszak authored papers with researchers from this institution concerning pathogens with pandemic potential. Funding was provided by "...generous support of the American people through the United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT program (Cooperative Agreement No. AID-OAA-A-14-00102)."

Monagin C, Paccha B, Liang N et al. "Serologic and behavioral risk survey of workers with wildlife contact in China." *PLoS One* 2018 Apr;13(4):e0194647

Wellcome Trust

¹³⁰ https://e3b.columbia.edu/faculty_location/eha-eco-health-alliance/ accessed 9.10.2022

¹³¹ <https://neighbors.columbia.edu/news/columbia-university-mailman-school-public-health-lead-new-york-citys-pandemic-response> accessed 9.10.2022

¹³² <https://www.ecohealthalliance.org/partners> accessed 9.10.2022



RENZ LAW, LLC.

Has a data sharing agreement with many organizations in public health emergencies. These include EcoHealth Alliance, The Chinese Academy of Sciences, and ¹³³The Chinese Centre for Disease Control and Prevention.

Google

Google.org has been funding studies conducted by EcoHealth Alliance since 2010. Here are some of the studies that include Daszak and/or EcoHealth Alliance Vice President Jonathon Epstein as authors and list Google as a funder:

Epstein JH, Quan PL, Briesse T et al. "Identification of GBV-D, a Novel GB-like Flavivirus from Old World Frugivorous Bats (*Pteropus giganteus*) in Bangladesh." *PLoS Pathog* 2010 Jul;6(7):e1000972

Pernet O, Schneider BS, Beaty SM et al. "Evidence for henipavirus spillover into human populations in Africa." *Nature Comm* 2014 Sep;5:5342

Lee MH, Rostal MK, Hughes T et al. "Macacine Herpesvirus 1 in Long-Tailed Macaques, Malaysia, 2009-2011." *Emerg Infect Dis* 2015 Jul;21(7):1107-1113

The Wuhan Institute of Virology
The University of North Carolina at Chapel Hill
For reasons stated earlier in this paper

¹³³ <https://wellcome.org/press-release/statement-data-sharing-public-health-emergencies> accessed 9.10.2022



RENTZ LAW, LLC.

Declaration of Dr. Andrew G. Huff, PhD, M.S.

I attest that the following is a true and accurate representation of facts and my experiences:

Name: Andrew G. Huff, PhD, M.S.

Personal History/Background/Qualifications:

- From 2002 to 2008 I served in the U.S. Army in both the Minnesota National Guard and on active duty in the US Army as an infantryman.
- I was ordered to serve on active duty to support and fight in the Global War on Terrorism as part Operation Enduring Freedom as an infantryman in Central America, and I volunteered to serve in combat in Operation Iraqi Freedom, where I received numerous medals, awards, and accolades at the low ranks of Private First Class and Specialist.
- While performing combat operations in Iraq, I continued my undergraduate studies while it was my turn to sleep and prepared and competed in Non-Commissioned Officer Review Boards, where I performed the best among the candidates in all aspects of the review except fitness. I was also nominated by my commanding officer to attend Officer Candidate School at the end of my tour in Iraq, based on my performance, leadership ability, and success at executing officer level tasks, which were assigned to me.
- After returning home from Iraq, I completed a heavily research and quantitatively focused bachelor's degree in Psychology at the University of Minnesota, which is one of the top psychological research institutions in the world. I worked directly with many of the world's leading experts in personality, vocational, career interests, clinical, and counseling psychology research, and completed independent quantitative psychological research which was submitted for peer review publication.
- Simultaneously, to earning my Bachelor's degree, I was a program assistant and contracts technical representative (COTR) for the United States Department of Veterans Affairs, where I relocated and opened several new outpatient mental healthcare offices for the agency and managed numerous contracts and relationships with healthcare providers. My supervisor became severely ill, and I independently and successfully managed the organization and contract facilities across the upper Midwest and staff in his absence at the age of 26, which resulted in a financial bonus paid by the government.



RENTZ LAW, LLC.

- Next, I earned a master's degree in Security Technologies with a minor in Geographic Information Systems, finishing at the top of my class, from the College of Science and Engineering at the University of Minnesota. In the program, I learned to solve national security problems against different types of critical infrastructures using complex systems analysis, systems modeling, high performance computing, intelligence collection techniques and trade craft, international security, bioterrorism, behavioral threat analysis, cryptography, cyber security, vulnerability, and risk assessment among other things. Upon completion of my master's degree coursework and research thesis defense, in only fifteen months, my thesis committee strongly encouraged me to obtain a PhD and was informed that I should meet with one of my instructors which was a member of the faculty in the School of Public Health.
- After meeting with Dr. Jeff Bender from the School of Public Health and College of Veterinary Medicine at the University of Minnesota, I was offered full employment as a Research Fellow at a Department of Homeland Security Center of Excellence at the University of Minnesota, along with a full scholarship to obtain a Ph.D. related to the fields of bioterrorism, biowarfare, chemical warfare or terrorism, pandemics, and emerging infectious disease. This is the best possible offer a Ph.D. student can receive anywhere throughout academia and is rare.
- I earned a Ph.D. from the University of Minnesota's School of Public Health's Environmental Health Science program with a specialization in Emerging Infectious Diseases. My core focus of my education and research was pandemic preparedness response, bioterrorism, biowarfare, biosecurity, chemical attacks & exposures, and biosafety. I completed the program at a record pace (around 3 years) and all my novel research was published in peer reviewed and referred journals before I submitted my dissertation for review.
- While working as a Research Fellow at a Department of Homeland Security Center of Excellence, I frequently traveled to Washington, D.C. and around the country where I became an active member of US government committees and meetings related to pandemics, public health, and national security. I was introduced to many high-level managers within the US government working in these areas, and I frequently presented my research at US government meetings, to executives in the private sector at large multinational companies, and worked directly with industry and state governments to help improve their national security in areas where I have subject matter expertise.
- Upon completing my Ph.D., I was recruited by Sandia National Laboratories, where I served the U.S. Government as a Senior Member of the Technical Staff and held a Department of Energy 'Q' clearance (equivalent to the Department of Defense's Top-



RENTZ LAW, LLC.

Secret designation). At Sandia, I analyzed complex national security problems in my areas of expertise, served as a subject matter expert in public health systems and food systems, and participated in a broad spectrum of projects related to pandemic preparedness, mitigation, and response. Wishing to leave the classified work environment, and due to a funding shortfall in my area of passion (preventing intentional contamination of the food supply), I decided to seek work elsewhere in the fall of 2014 and I applied to EcoHealth Alliance in September of 2014.

- Shortly after applying to a position at EcoHealth Alliance, I interviewed with Dr. Peter Daszak on the telephone and then traveled to EcoHealth Alliance's office in New York City for a comprehensive on-site interview. After completing the interview, I was offered and accepted a position as a Senior Scientist in charge of the Data and Technology team. Upon beginning work at EcoHealth Alliance, I was asked to perform a series of duties which would be considered normal in any kind of scientific or academic organization.

Information Related to EcoHealth Alliance and the Development of SARS-COV2:

- In late 2014, I was asked to prepare a report for the Intelligence Advanced Research Projects Activity, Office of the Directorate of National Intelligence, (IARPA). I later learned upon promotion to Associate Vice President while attending weekly finance updates that EcoHealth Alliance did not receive any funding from this agency (IARPA), as far as I am aware. **Reference: IARPA Collaborator Report from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- In late 2014, I was asked to review (provide edits, comments, and feedback) on a research proposal that was in preparation to be submitted to the National Institutes of Health's (NIH) National Institute for Allergens and Infectious Diseases (NIAID) to conduct Gain of Function research and development with numerous partners including the Wuhan Institute of Virology, which was supported by Dr. Ralph Baric at the University of North Carolina (UNC). **Reference: File name "CoV as submitted" titles "Understanding the Risk of Bat Coronavirus Emergence" Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
 - I attest that I reviewed the proposal that was submitted to NIH which detailed the gain of function virology work that was being conducted to create the agent known as SARS-COV2, which causes the disease known as COVID-19.
 - I attest that the proposal clearly stated that the gain of function work on SARS-COV2 was already underway in China, prior to October 2014, at the Wuhan



RENZ LAW, LLC.

Institute of Virology (WIV), with the support of USAID in collaboration with EcoHealth Alliance and EcoHealth Alliance's partners and sponsors.

- I attest that I made Dr. Peter Daszak aware of the lack of a Biological Security Officer (BSO) and Institutional Biosafety Committee (IBC) at EcoHealth Alliance in reference to the Select Agent Form on in the "Understanding the risk of Bat Coronavirus Emergence" proposal in accordance NIH requirements.
- I witnessed firsthand presentations by Dr. Shi Zhengli (WIV) and Dr. Ralph Baric (UNC) at EcoHealth Alliance related to their Gain of Function work managed and supported by EcoHealth Alliance.
- I witnessed firsthand presentations by the executive team at EcoHealth Alliance related to the gain of function work conducted at EcoHealth Alliance.
- I attest that EcoHealth Alliance's developed SARS-COV2 and is responsible for the development of the agent SARS-COV2 during my employment at the organization.
- I attest that I informed the EcoHealth Alliance executive team that I believed there were biosafety and biosecurity risks in contract laboratories during an executive meeting. Specifically, I was concerned that EcoHealth Alliance did not have enough visibility or firsthand knowledge of what was happening at foreign laboratories contracted and managed by EcoHealth Alliance. During this meeting I discussed bio-risk management with the team due to these concerns. Dr. Daszak refused to mitigate the risks without any objection or discussion from the other executives. In my opinion, Daszak was dismissive of my concerns. He did not seem concerned about EcoHealth's lack of oversight which I felt was strange because it is typically the CEO's duty to protect the organization from organizational threats and risks. After raising my concern, I accepted Peter's position that our control measures were adequate. **Reference: See leaked cables that the US Consulate Cables to the State Department reported Laboratory Safety Concerns at the Wuhan Institute of Virology.**
- In this same short time-period, I was asked to review and contribute to an investment "pitch deck" (i.e., a PowerPoint presentation used in venture capital presentations) that was presented to an organization called In-Q-Tel. In the pitch deck, we proposed an extension of the USAID global disease surveillance work, SARS-COV2 gain of function and humanized mice research conducted by Drs. Baric and Zhengli, and my work from my department developing advanced biosurveillance technologies and platforms. This



RENZ LAW, LLC.

work was presented to In-Q-Tel (which can be verified by their own records). I do not know what the outcome of that meeting as it was not communicated to me by Dr. Daszak.

Reference: File name Peter Daszak In-Q-Tel October 2015 from Dr. Huff's documents retained from his employment at EcoHealth Alliance and the In-Q-Tel Quarterly report.

- On or around June 2015, I was promoted to Vice President. After being promoted to Vice President, I was exposed and participated in more aspects of the organization, as would be expected from an Executive Officer at any organization.
- I began attending weekly financial meetings where I learned that the organization was tight on cash, depended heavily on government contract salary overhead to remain solvent, and that the organization was not involved in traditional conservation work as classically defined. This was upsetting as this was one of the main reasons that I wanted to join the organization (being a conservationist and naturalist). **Reference: EcoHealth Alliance Marketing video from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- I also observed that EcoHealth Alliance was engaged in irregular financial transactions regarding U.S. Government grants. Specifically, I believe there was timecard fraud and observed what I appear to be double dipping on contracts, between government organizations and private donors (e.g., Skoll Foundation, Google Foundation, Bill & Melinda Gates Foundation, & Wellcome Trust), or both. **Reference: Compare stated objectives, work locations, and data collection across a range of projects from Dr. Huff's documents retained from his employment at EcoHealth Alliance.**
- I later confronted Dr. Peter Daszak, Harvey Kasdan (CFO, deceased), Dr. Aleksei Chmura about the financial fraud when I was upset, arguing for pay raises in my department, company-wide salary increases, and for myself. Shortly thereafter (1-2 days), CFO Harvey Kasdan passed away from a heart attack. I am not insinuating foul play, but I believe the stress was too much for him in his physical condition. **Reference: Harvey Kasdan's Obituary.**
- I also observed, while attending board meetings and in communications directly with board members, that Dr. Peter Daszak had a pattern of over-simplifying and lying by omission to our stakeholders (including the board of directors). For example, while EcoHealth Alliance positioned itself as a conservation organization, no substantial conservation work, as traditionally defined, was occurring at the organization.



RENTZ LAW, LLC.

- The USAID Predict program was a global hunt for viruses predicated upon the promise of predicting and preventing pandemics. I believe that the data limitations and methods for collecting and analyzing that data make this goal impossible to achieve. I further believe that this program is more strongly aligned with collecting the biological samples to conduct gain of function viral work, or intelligence collection, than prediction and prevention of pandemics.
- Gain of function research is a highly contentious topic in my scientific area of expertise. Those who are for it make the argument that if you can identify a high-risk pathogen, and then engineer the pathogen in the laboratory to increase its transmissibility, infectivity, pathogenicity, or virulence, then you can develop medical countermeasures to prevent the spread of disease, if an outbreak of a naturally evolving agent were to occur. I believe this logic to be inherently flawed because it is naïve to think that humans can modify or engineer a naturally occurring pathogen that would evolve similar to the way infectious agents naturally evolve. Typically, Gain of Function research (via selection of rare traits or genetic manipulation or engineering of the agent) undergoes thousands of years of unnatural evolution (decided by humans not by nature) in a laboratory in a matter of days weeks or months. This is akin to predicting the future, with the likelihood of success decreasing in every timestep.
- After being promoted to Vice President, I commented on several concerns I had related to protecting the organization including biosafety, biosecurity, enterprise security, and risk management. None of the other executives voiced any opposition to Gain of Function research being conducted at EcoHealth Alliance, and Dr. Daszak was heavily supportive of the work. Drs. Johnathan Epstein and Kevin Olival were supportive of the work and were key contributors to the gain of function work in the SARS-COV2 proposal funded by USAID and NIH, and executed by EcoHealth Alliance, the WIV, and UNC. My opposition to Gain of Functions research stemmed from my Ph.D. studies taught by my Committee Chair, Dr. Michael T. Osterholm, who was also President Joe Biden's COVID advisor.
- In November 2015, a scientifically peer reviewed, and referenced article was published by collaborators from the Wuhan Institute of Virology, the University of North Carolina Chapel Hill (UNC), the Food and Drug Administration, Harvard Medical School, and the Bellinzona Institute of Microbiology. The peer reviewed article was titled "A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence" in the journal *Nature Medicine*. The authors initially omitted the funding source from the USAID - EPT - PREDICT program, which I was a co-investigator and country coordinator while employed by EcoHealth Alliance. The USAID - EPT - PREDICT funding cited in the article was used to develop a relationship between Drs. Ralph Baric



RENTZ LAW, LLC.

(UNC) and Zhengli-Li Shi of the Wuhan Institute of Virology at EcoHealth Alliance, which was orchestrated by Dr. Peter Daszak. Additionally, the USAID- EPT - PREDICT funding used in this peer reviewed paper was used to collect biological samples from bats globally. Then, the collaborators analyzed the collected samples to extract SARS like-corona viruses, and select or engineer genetic features within the viruses, collected with USAID - EPT - PREDICT funding, to create hybrid chimeric viruses. Chimeric viruses are defined as combining the genetic material from two or more distinct viruses. **The process of developing SARS-COV2 was also described in detail in the proposal submitted to, and ultimately funded by, the National Institutes of Health (HHS NIH), The National Institute of Allergy and Infectious Diseases (NIAID), by EcoHealth Alliance with the WIV and UNC listed as collaborators.** It is my attestation, that the creation of these SARS-like chimeric viruses described in this article include SARS-COV2. Lastly, the engineered SARS-COV2 was then used to test SARS vaccines and monoclonal antibody therapeutics against the disease in mice. **Reference: Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., ... & Baric, R. S. (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nature medicine*, 21(12), 1508-1513.**

- Dr. Peter Daszak approached me in late 2015 and stated that somebody from the Central Intelligence Agency (CIA) approached him and stated that they were interested in the places we were working, the people we were working with, and the data we were collecting. Peter then proceeded to ask me for my advice, and specifically asked whether we should work with them. I was shocked that Peter asked me this and was excited for the opportunity. I stated to Peter that "It never hurts to talk to them. There could be money in it." Peter then later confirmed over the next 2 months, between our weekly meetings that the relationship with them was proceeding.
- In March 2016, a paper was published by Dr. Ralph Baric, an EcoHealth Alliance gain of function collaborator working at UNC, in PNAS titled "SARS-like WIV1-CoV Poised for Human Emergence." In the article, the authors of the paper describe in detail how they used, designed, and constructed full-length and chimeric viruses to determine if they would replicate in human airway cultures. This specific paper is relevant because it compares and documents the effectiveness of different variations of coronavirus spike proteins at infecting human cells specifically by binding to ACE2 receptor, which was a critical and necessary step to design and engineer the SARS-COV2 virus. While employed at EcoHealth Alliance, I met both Dr. Shi Zhengli and Dr. Ralph Baric, where they presented their work on the design and engineering of SARS-CoV2 (coronavirus



RENZ LAW, LLC.

gain of function research), and the use of highly specialized humanized mice models, which were necessary to successfully build SARS-COV2. These facts are supported by numerous recorded presentations by Dr. Peter Daszak and Dr. Ralph Baric from 2015-2019. Some of which, I personally attended while employed at EcoHealth Alliance. Additionally, the specific gain of function work described in this paper was presented by Dr. Peter Daszak to In-Q-Tel, a DoD and CIA venture capital firm. In the slides presented to In-Q-Tel, which I personally helped create at EcoHealth, describe the use of USAID – EPT – PREDICT funding to collect coronavirus samples from bats globally, where they are then analyzed to identify their most dangerous features to humans, and recombined to make new coronaviruses like SARS-COV2. Then, these viruses are tested on humanized mice to validate lethality and transmissibility. EcoHealth Alliance then used Dr. Baric's work for testing experimental vaccines, treatments, and therapeutics against the newly engineered SARS-COV2 strain to determine which countermeasures would be the most effective at mitigating the disease in humanized mice. **Reference: Menachery, V. D., Yount Jr, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., ... & Baric, R. S. (2016). SARS-like WIV1-CoV poised for human emergence. *Proceedings of the National Academy of Sciences*, 113(11), 3048-3053.**

- In late September or early October of 2019, I was contacted by Dr. Amy Jenkins and she was attempting to recruit me to be a Program Manager for emerging infectious disease work at the Defense Advanced Research Projects Agency (DARPA). I first met Dr. Amy Jenkins as a Ph.D. student and paid Research Fellow at a Department of Homeland Security Center of Excellence at the University of Minnesota in 2014. The position at DARPA was presented to me as if it was mine if I wanted it and I was told that it would need Top Secret Security clearance with a polygraph. I felt that the recruitment effort was quite strange as I had not worked full-time and directly in the national security space since 2014 at Sandia National Laboratories and I had no clue how Dr. Jenkins obtained my new personal cell phone number. Coincidentally, this is when epidemiological evidence indicates that the first cases of COVID-19 likely emerged. The two events may not be related; however, it is my belief that people working within the US government potentially identified me as a risk to knowing firsthand that the SARS-COV2 disease emergence event was a consequence of the US government's sponsorship of the genetic engineering of SARS-COV2 domestically and abroad. If I would have accepted the position, then I suspect that DARPA would have disclosed restricted information to me which would have consequently prevented me from discussing any of this information publicly, like I have been and am doing now. The recruitment effort itself was highly suspect as it seemed as if DARPA was completely circumventing the US government recruitment process for one of the most prestigious scientific positions in the world.



RENTZ LAW, LLC.

- I attest that I analyzed the funding of Dr. Kristian Andersen of the Scripps Research Institute from data obtained from NIH funding databases. Dr. Andersen's funding dramatically increased after changing his position on the characterization of the agent as being manmade, to naturally emerging, after a series of discussions with Dr. Anthony Fauci.

**Total Funding Awarded Per Month Before
Fauci Teleconference**

\$393,079.65

**Total Funding Awarded Per Month After Fauci
Teleconference**

\$800,139.15

**Total Funding Awarded Per Calendar Year
Before Fauci Teleconference**

\$ 1,042,628.25

**Total Funding Awarded Per Calendar Year
After Fauci Teleconference**

\$2,284,161.08

**Total Continuing Funding Before Fauci
Teleconference**
\$7,141,011.83

**Total Continuing Funding After Fauci
Teleconference**
\$23,724,681.83

Total Continuing Funding INCREASE After Fauci Teleconference

\$16,583,670.00

- Lastly, at no point in time has any restricted information, including classified information, been shared with me related to the domestic or foreign engineering of the biological agent SARS-COV2, the subsequent release of SARS-COV2, the attempted cover-up of by officials working for the United States government. I have never leaked any legally obtained classified information or violated the rules and laws related to my past security clearances. The information that I have shared from my time at EcoHealth Alliance is not restricted by any non-disclosure agreement, nor is it US government protected or restricted information, as EcoHealth Alliance is supposedly a non-profit



RENZ LAW, LLC.

corporation conducting scientific research to protect human and animal health. All the documents that I have shared were created by myself or other personnel by EcoHealth Alliance and were not subject to derivative classification by the US government, which is standard practice in academic institutions. My findings, opinions, and analysis were informed by my highly specialized education in the field of emerging infectious diseases from one of the top 5 graduate programs in the world, by my experience working in the field, and by analysis of publicly available open source and open access information. Simply, I know how and where to find accurate and relevant information related to pandemics, emerging diseases, biowarfare, and bioterrorism quickly and know how to properly frame this information from my knowledge of how the government works in the context of relevant policy frameworks.

- In context, this series of events when they took place, did not seem of any consequence nor did I ever think or believe that I would be in this terrible position. I have been severely harassed by what appears to be state-sponsored actors based on the level of sophistication, persistence, and duration, of the harassment and crimes committed against me. I understand that these facts are difficult for our country. I have viewed this as a non-partisan issue since coming forward as a Whistleblower, as my only goal is to prevent another manmade pandemic from occurring. COVID-19, the disease caused by SARS COV2, in my professional opinion, is the result of Gain of Function research that was mismanaged by EcoHealth Alliance and its contractors.

I declare (or certify, verify, or state) under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed On (Date): 13 September 2022


Signature: 
Andrew G. Huff, Ph.D., M.S.

EXHIBIT 15

EXHIBIT 15

FILED: ROCKLAND COUNTY CLERK 02/04/2023 12:55 PM INDEX NO. 034252/2022
Peter Daszak <daszak@ecohealthalliance.org>; Baric, Toni C <antoINETTE_baric@med.unc.edu>
NYSCEF: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura [chmura@ecohealthalliance.org] RECEIVED NYSCEF: 02/04/2023
From: Baric, Ralph S [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=BB0D9CC80C184735A4E862C3BDD8A15D-RALPH S BAR]
Sent: Thur 2/6/2020 4:01:22 PM (UTC-05:00)
Subject: RE: No need for you to sign the "Statement" Ralph!!

I also think this is a good decision. Otherwise it looks self-serving and we lose impact. ralph

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Thursday, February 6, 2020 3:16 PM
To: Baric, Ralph S <rbaric@email.unc.edu>; Baric, Toni C <antoINETTE_baric@med.unc.edu>
Cc: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura <chmura@ecohealthalliance.org>
Subject: No need for you to sign the "Statement" Ralph!!
Importance: High

I spoke with Linfa last night about the statement we sent round. He thinks, and I agree with him, that you, me and him should not sign this statement, so it has some distance from us and therefore doesn't work in a counterproductive way.

Jim Hughes, Linda Saif, Hume Field, and I believe Rita Colwell will sign it, then I'll send it round some other key people tonight. We'll then put it out in a way that doesn't link it back to our collaboration so we maximize an independent voice.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel.
Website: www.ecohealthalliance.org
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

EXHIBIT 16

EXHIBIT 16



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
National Institute of Allergy
and Infectious Diseases
Bethesda, Maryland 20892

23 July 2021

Drs. Aleksei Chmura and Peter Daszak
EcoHealth Alliance, Inc.
460 W 34th St
Suite 1701
New York, NY 10001

Re: R01AI110964, U01AI151797, U01AI153420

Dear Drs. Chmura and Daszak:

Thank you for your correspondence of April 11, 2021 and April 23, 2021 regarding R01AI110964. We are in the process of conducting detailed analyses of your answers to our questions and well as of the documents you sent, and we have the following additional requests:

1. Records

For us to continue our analyses, we will need to receive and review WIV's records validating expenditures specific to R01AI110964 as well as any and all monitoring, safety, and financial reports specific to R01AI110964 that WIV submitted to you. As a reminder, subawardees are required to have a financial management system that includes records that identify adequately the source and application of funds for federally-funded activities. These records must contain information pertaining to Federal awards, authorizations, obligations, unobligated balances, assets, expenditures, income and interest and be supported by source documentation. 45 C.F.R. §§ 75.101 and 75.302.

As a term and condition of award, NIH "must have the right of access to any documents, papers, or other records of the non-Federal entity which are pertinent to the Federal award, in order to make audits, examinations, excerpts, and transcripts" (45 C.F.R. 75.364). This right of access applies not only to awardee records, but also to subawardee records. Awardees indicate their acceptance of an NIH award and its associated terms and conditions as they draw down the NIH grant funds to support the scientific project (see NIHGPS [Section 5](#)).



EcoHealth Alliance, Inc., Page 2
23 July 2021

We will also need to see subaward agreements, subawardee audit reports, subawardee safety monitoring documents, subawardee progress reports submitted to you, and subawardee financial and accounting records for two other NIH EcoHealth Alliance grants. Specifically, please send us all responsive documents for:

- U01AI151797 (Daszak): subawardees Chulalongkorn Hospital, Chulalongkorn University, Duke-National Singapore University, and University of North Carolina at Chapel Hill
- U01AI153420 (Epstein): subawardees International Center for Diarrhoeal Disease Research of Bangladesh, Institute of Epidemiology Disease Control and Research of Bangladesh.

We remind you that the Notice of Award for U01AI151797 already contains the following specific award conditions that must still be satisfied by 30 days from establishment.

Subaward Agreement Requirements: The ECOHEALTH ALLIANCE, INC. must provide NIAID with copies of all (existing and newly established) subaward agreements established under this award, including descriptions of the biosafety monitoring plans, within 30 days of establishment.

Federal Funding Accountability and Transparency Subaward Reporting System (FSRS) Requirements: This award is subject to the Transparency Act subaward reporting requirement of 2 CFR Part 170, which must be reported through the Federal Funding Accountability and Transparency Subaward Reporting System (FSRS). The ECOHEALTH ALLIANCE, INC. must provide NIAID with proof of documentation of timely entries of subaward information into the FSRS within 30 days of submitting to FSRS.

2. Reports

We are also writing to notify you that a review of our records for R01AI110964 indicates that EcoHealth Alliance, Inc. is out of compliance with requirements to submit the following reports that are outlined in the NIHGPS: the Federal Financial Report (FFR, see [8.4.1.2.3](#) Modified Financial Reporting Requirements) and the Interim Research Performance Progress Report (I-RPPR, see NIHGPS [8.4.1.4](#) Final Research Performance Progress Report).

R01AI110964 was issued under the Streamlined Noncompeting Award Process (SNAP). For awards under SNAP, an FFR must be submitted within 120 days after the end of the competitive segment and must report on the cumulative support awarded for the entire segment.

Additionally, NIH requires that organizations submit an Interim-RPPR while their Type 2 application is under consideration. In the event that the Type 2 is funded, NIH treats the Interim-RPPR as the annual performance report for the final year of the previous competitive segment.

EcoHealth Alliance, Inc., Page 3
23 July 2021

The FFR and I-RPPR for R01AI110964 were due within 120 days after the end of the project period. In this case, the competitive segment ended on May 31, 2019, and reports were due September 30, 2019. To date, NIH has still not received these reports. Compliance with [Section 8, Administrative Requirements](#) within the NIH Grants Policy Statement (NIHGPS) is a standard term and condition of award that applies to all NIH recipients.

A recipient's failure to comply with the terms and conditions of award, may cause NIH to take one or more actions on the award, depending on the severity and duration of the non-compliance. Additionally, a history of non-compliance related to R01AI110964, including reporting non-compliance, may impact other projects where EcoHealth serves as the primary grant recipient. When a recipient has a history of failure to comply with the general or specific terms and conditions of a previous Federal award, NIH may impose specific award conditions on other awards of the recipient, including withholding authority to proceed to the next phase of a project until receipt of evidence of acceptable performance (see NIHGPS [Section 8.5](#), Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support).

In closing, please be advised that EcoHealth Alliance, Inc. must satisfy the existing specific award condition for U01AI151797 by 30 days from establishment and must provide the remaining documents and reports requested herein for all three grants (R01AI110964, U01AI151797, U01AI153420) no later than August 27, 2021.

Please let me know if you have any questions concerning the information in this letter.

Sincerely,

Lauer, Michael (NIH/
OD) [E]

Digitally signed by Lauer,
Michael (NIH/OD) [E]
Date: 2021.07.23 17:24:01 -04'00'

Michael S Lauer, MD
NIH Deputy Director for Extramural Research
(b) (6)

cc: Ms. Emily Linde
Dr. Erik Stemmy

EXHIBIT 17

EXHIBIT 17



National Institutes of Health
Bethesda, Maryland 20892

August 19, 2022

The Honorable James Comer
Ranking Member, Committee on Oversight and Reform
U.S. House of Representatives
Washington, DC 20515

Dear Representative Comer:

Thank you for your interest in the work of the National Institutes of Health (NIH). I write to you today in a continuing effort to be responsive to your inquiries about NIH oversight of awards to EcoHealth Alliance (EHA).

As you know, the National Institute of Allergy and Infectious Diseases (NIAID) awarded EHA grant R01AI110964 ("R01 award") after the application received a meritorious score through the peer review process. This grant included three sub-awards, including one to the Wuhan Institute of Virology (WIV) and had a performance period starting on June 1, 2014. The renewal application for this grant underwent peer review, and the Notice of Award was issued on July 24, 2019. The research approved under this grant sought to understand how bat coronaviruses evolve naturally in the environment to become transmissible to the human population. This type of research is a critical component of pandemic preparedness. Identifying pathogens that have the potential to cause disease in humans allows the research community to prepare for how to respond if these pathogens do enter the human population.

NIH's Office of Extramural Research (OER) suspended EHA grant R01AI110964 on July 8, 2020, due to grant administrative non-compliance concerns. Over time, NIH reviewed EHA's compliance with requirements under the R01 award and requested information and documentation from EHA to enable NIH to conduct its review.

NIH also reviewed EHA's compliance with requirements under two other NIH awards to EHA, the Research Project Cooperative Agreements ("U awards"). See Table 1 for a list of all current NIH awards to EHA.

Table 1: Current NIH Awards to EHA

Award Number	Grant Title	Performance Period
R01AI110964	Understanding the Risk of Bat Coronavirus Emergence	July 1, 2014-May 31, 2019; Renewal: June 1, 2019-May 31, 2024*

The Honorable James Comer
Page 2

U01AI151797	Understanding Risk of Zoonotic Virus Emergence in Emerging Infectious Disease Hotspots of Southeast Asia	June 17, 2020-May 31, 2025**
U01AI153420	Study of Nipah Virus (NiV) Dynamics and Genetics in Bat Reservoirs and of Human Exposure to NiV Across Bangladesh to Understand Patterns of Human Outbreaks	September 15, 2020-June 30, 2025**

*This grant was suspended on July 8, 2020 and has remained suspended.

**Specific award conditions imposed on January 6, 2022 but was never suspended.

As NIH notified you on January 6, 2022, NIH sent a letter to EHA that day conveying the outcome of its detailed administrative review of compliance under the U awards. NIH identified a number of compliance issues, including inadequate oversight in monitoring the activities of its subawardees, failure to report subawards to the General Services Administration's Federal Subaward Reporting System, and errors in indirect rate charges. In cases of non-compliance, NIH's approach is generally to provide a grantee the opportunity to come into compliance in an effort to preserve the research, when possible. This approach is consistent with HHS grant regulations, which provide that in cases of non-compliance, a funding agency can impose specific award conditions; and if the agency determines that the non-compliance cannot be remedied by specific award conditions, then the agency may take more severe actions, such as terminating an award in whole or in part.

Our January 6, 2022 letter announced immediate imposition of specific award conditions on the U awards to allow NIH to monitor these awards more closely. The U awards were never suspended. In addition, the letter outlined areas where EHA needed to improve its administrative policies and practices. NIH requested EHA submit a Corrective Action Plan (CAP) to address these issues.

EHA provided a proposed CAP to NIH on February 4, 2022. The CAP outlined steps EHA would take to address the non-compliance NIH identified under the two U awards. Between February and April 2022, NIH approved EHA's CAP and EHA implemented the CAP. Pursuant to the CAP, EHA revised the U subaward agreements to include details on EHA's procedures for access to subawardees' records and financial statements, data-sharing and management of awards, and a correction of the Facilities and Administrative cost rate. EHA also provided NIH with new and updated EHA policies that describe how, for all EHA projects, EHA will comply with reporting requirements and other deficiencies identified by NIH.

I write today to update you on EHA's implementation of the CAP under the U awards, the conclusion of NIH's review of compliance under the R01 award, and the next steps NIH will take with EHA. At this time, EHA has successfully implemented the NIH-approved CAP for its active U awards, which includes rewriting subaward agreements, and improving monitoring and reporting conflicts of interest by its subawardees. Accordingly, NIH has determined that EHA was able to resolve the problems identified with those awards. For the R01 award, NIH identified the same issues that were present with the U awards (including inadequate oversight in monitoring the activities of its subawardees, failure to report subawards to the General Services Administration's Federal Subaward Reporting System, and errors in indirect rate charges), as

The Honorable James Comer

Page 3

well as reporting delinquencies, such as the late submission of the fifth year progress report. NIH has determined that these problems can be remedied by imposing specific award conditions, because EHA demonstrated that it could resolve these same problems under the U awards with the successful implementation of a CAP.

However, NIH also identified one non-compliance under the R01 award that cannot be remedied with specific award conditions. NIH has requested on two occasions that EHA provide NIH the laboratory notebooks and original electronic files from the research conducted at WIV. To date, WIV has not provided these records. Under 45 CFR 75.371, "If a non-federal entity fails to comply with federal statutes, regulations, or the terms and conditions of a federal award, the HHS awarding agency or pass-through entity may impose additional conditions, as described in § 75.207. If the HHS awarding agency or pass-through entity determines that non-compliance cannot be remedied by imposing additional conditions, the HHS awarding agency or pass-through entity may take one or more [enforcement] actions, as appropriate in the circumstances[.]" 45 CFR 75.371. Such actions may include partly terminating the federal award. Id. at 75.371(c).

Today, NIH has informed EHA that since WIV is unable to fulfill its duties for the subaward under grant R01AI110964, the WIV subaward is terminated for failure to meet award terms and conditions requiring provision of records to NIH upon request.

In light of the cooperation from EHA and the subsequent substantial improvements in administrative processes that EHA demonstrated with the two U awards, NIAID will begin to engage with EHA to renegotiate the specific aims and objectives of the R01 grant without the involvement of WIV. If an agreement is made, the revised grant will be reviewed again in its entirety to ensure all applicable policy and guideline requirements are met including the HHS Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (P3CO) and other relevant policies and guidelines. A revised Notice of Award will be issued, subject to specific award conditions and any additional precautions that may be appropriate for inclusion, and the suspension on the grant will be lifted. If revisions to the grant's aims and objectives cannot be revised to stay within the original peer reviewed, scientific scope of the project, NIH reserves the right to request a bilateral termination of the remainder of the award.

As specific award conditions, NIH will maintain a higher level of oversight over all EHA awards for a minimum of three years, including a doubling of the frequency for the required scientific progress and financial reports, and a requirement that EHA submit additional documents illustrating their subaward monitoring activity. In addition, EHA will be required to conduct onsite inspections of all of its subawardees every six months to confirm that all terms of subaward agreements are being fully and appropriately executed. EHA will also be required to submit updated subaward agreements under the revised R01 award that address the deficiencies identified by NIH.

NIH takes its oversight of grants very seriously and always considers what further measures can be taken to strengthen routine oversight of grants at NIH. In light of this compliance case, NIH has taken additional steps. NIH has incorporated additional automated systems of controls for


The Honorable James Comer

Page 4

the timely receipt of progress reports to ensure that the most recent information is received and accepted by program officers. NIH has implemented program scripts in the NIH grants system (eRA) that send additional reminders to grant recipients and NIH staff of delinquencies if progress reports are either delayed or not fully reviewed and accepted. Should this happen, the system establishes a "red bar" to funding of the next non-competing renewal, which would prevent the award from being processed until the "red bar" is resolved. NIH believes that these new measures will further strengthen our oversight of grantees while continuing the life-saving work done by NIH grantees.

NIH is committed to ensuring responsible stewardship and accurate reporting of the use of federal funds. In a continued effort to be transparent, NIH has attached to this letter the communications between NIH and EHA regarding the implementation of the CAP. I hope this information is helpful to you.

Sincerely,



Michael S. Lauer, M.D.

Deputy Director for Extramural Research
National Institutes of Health

Enclosures:

First letter from NIH to EHA on January 6, 2022

Second letter from NIH to EHA on January 6, 2022

CAP proposed by EHA (in 2 parts)

NIH response to EHA's CAP

Follow-up CAP documents submitted by EHA (in 5 parts)

Letter from NIH to EHA on August 19, 2022

EXHIBIT 18

EXHIBIT 18

Baric, Toni C[antoinette_baric@med.unc.edu]; Lowenthal, Micah[mlowenth@nas.edu]
NYSCEF jweduc@UTMB.EDU[jweduc@UTMB.EDU]; Dave Franz
LaTasha[LMorgan@nas.edu]; Baric, Toni C[antoinette_baric@med.unc.edu]; Lowenthal, Micah[mlowenth@nas.edu]
RECEIVED NYSCEF: 02/04/2023
From: Rusek, Benjamin[BRusek@nas.edu]
Sent: Thur 11/2/2017 3:22:49 PM (UTC-04:00)
Subject: NAS GNL invitation to participate in a meeting of U.S. and Chinese experts, Jan 16-18 2018
Wuhan Meeting Summary May 2017.pdf
NAS GNL Galveston meeting ltr of invite Baric.docx

Greetings Dr. Baric,

The U.S. National Academy of Sciences (NAS) and the Galveston National Laboratory (GNL) University of Texas Medical Branch are pleased to invite you to participate in a meeting of U.S. and Chinese experts working to counter infectious disease and improve global health. The meeting is being convened by the NAS and GNL and will take place January 16-18, 2018, in Galveston, Texas, USA. Please see the attached invitation letter (and the May 2017 Wuhan meeting summary mentioned in the letter) for additional information.

Kind regards,

Ben

Benjamin J. Rusek
Senior Program Officer
Policy and Global Affairs Division
The U.S. National Academy of Sciences
Phone:
Cell:
Fax:
Skype:

NYNYSCEF Benjamin Rusek (BRusek@nas.edu)[BRusek@nas.edu]
From: LeDuc, James W.[jwleduc@UTMB.EDU]
Sent: Sat 11/11/2017 11:23:31 AM (UTC-05:00)
Subject: Re: NAS mtg in Galveston

RECEIVED NYSCEF: 02/04/2023

Wonderful! Thanks so much. We look forward to welcoming you to Galveston and the GNL.
 Jim

Sent from my iPhone

On Nov 10, 2017, at 7:05 PM, Baric, Ralph S <rbaric@email.unc.edu> wrote:

Hi Jim and James, I do plan to attend. Greatly appreciate the invitation. Sorry for the delay in responding. ralph

From: LeDuc, James W. [mailto:jwleduc@UTMB.EDU]
Sent: Friday, November 10, 2017 5:02 PM
To: Baric, Ralph S <rbaric@email.unc.edu>
Cc: Benjamin Rusek (BRusek@nas.edu) <BRusek@nas.edu>
Subject: NAS mtg in Galveston
Importance: High

Hi Ralph,

I think that Ben has extended an invitation to you on behalf of the US National Academy of Sciences to join us at the GNL in Galveston for a meeting with participants from the Chinese Academies of Sciences, 16-18 Jan 2018. This will be similar to the meeting held in Beijing a couple of years ago in which you participated. I know that one of the Chinese leaders in coronavirus research is planning on attending and we hope that you will be able to come and offer a brief talk in this area as well. Please let us know at your earliest convenience if you can make it.

I look forward to welcoming you to Galveston!

Best regards,

Jim

James W. Le Duc, Ph.D.
 Director
 Galveston National Laboratory
 University of Texas Medical Branch
 Galveston, TX 77555-0610
 (t)
 (f)
 (m)

EXHIBIT 19

EXHIBIT 19

NYSCEF DOC. NO. 93
FRANK FALLONE, JR., NEW JERSEY
CHAIRMANRECEIVED NYSCEF: 02/04/2023
CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

June 10, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins:

As the committee of jurisdiction over public health, the Energy and Commerce Committee has authorizing responsibilities over the U.S. National Institutes of Health (NIH). We strongly support a comprehensive investigation into the origins of the COVID-19 pandemic, including the possibility of an accidental laboratory leak.

The Chinese Communist government has not yet allowed Chinese scientists to cooperate with an investigation into COVID-19 origins, and has admitted to destroying samples and records pertinent to such an investigation.¹ Thus, it is imperative we assemble all data and information in U.S. possession about bat coronavirus research experiments and lab safety protocols from all sources outside of China, particularly from EcoHealth Alliance (EHA). EHA is an NIH grantee who has been involved in bat coronavirus research in China and has issued grant subawards to the Wuhan Institute of Virology (WIV). It is also essential to collect information about the WIV, the laboratory that was conducting bat coronavirus experiments located in Wuhan, China, the epicenter of the COVID-19 outbreak. As a federal cognizant grant-making agency that funded bat coronavirus research at the WIV through EHA awards, NIH is in a unique position to publicly share detailed research reports in its possession. Importantly, NIH has full access to EHA records and EHA has refused to cooperate with our inquiry. Therefore, it is critical for NIH to cooperate with our objective fact-finding investigation as we continue to collect data about U.S. funded bat coronavirus research.

¹ Josh Chin, *China Told Labs to Destroy Coronavirus Samples to Reduce Safety Risks*, The Wall Street Journal (May 16, 2020) available at <https://www.wsj.com/articles/china-told-labs-to-destroy-coronavirus-samples-to-reduce-biosafety-risks-11589684291/>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 2

Since the Republican committee leaders March 18, 2021 letter to NIH, our investigation has found a number of additional issues that raise very serious concerns about the adequacy of NIH's oversight of grantees. The following newly found issues appear troubling and given the significance of these concerns, we expect the NIH to respond fully and substantively. Minority committee staff is continuing to work with your staff to schedule an NIH briefing. The NIH should be prepared to address these issues at the briefing, in addition to all of the questions from the March 18, 2021 letter that presently remain unanswered.

1. NIH's Award of \$2 million to EHA Despite Grant Suspension

On May 25, 2021, a spokesperson for EHA told Fox Business that its NIH funding is frozen and NIH did not give them guidance on when funds will be unfrozen.² EHA's representation about their NIH funding was not forthcoming. NIH terminated grant R01AI110964 to EHA entitled, "Understanding the Risk of Bat Coronavirus Emergence" in April 2020.³ NIH eventually converted the grant termination to a suspension on July 8, 2020, pending EHA's responses to seven requests from NIH related to WIV's actions. NIH could unfreeze the funding if EHA cooperates with NIH's requests, but apparently EHA has not yet done so. Despite EHA's obstruction of NIH requests, NIH gave new financial awards to EHA in June 2020 and August 2020, totaling \$2,127,602.⁴ By NIH authorizing new funding to EHA, an NIH-suspended grantee, the NIH undercut its July 8, 2020 suspension and has incentivized its grantees to defy NIH oversight with impunity.

2. NIH's Inadequate Oversight of EHA's Other Support

You testified during a May 25, 2021 Congressional hearing that NIH was, "...of course not aware of other sources of funds or other activities they might have undertaken outside of what our approved grant allowed," when asked about NIH grant recipient EHA, and the WIV, an EHA subaward recipient.⁵ Pursuant to the NIH Grants Policy, EHA was required to report all "other support," in-kind contributions such as laboratory space, equipment and supplies, and facilities and other resources for all individuals designated as the Principal Investigator (PI) personnel.⁶ Per the NIH grants policy, the grant Principal Investigator Dr. Peter Daszak and EHA were required to report its other research funding sources and activities to NIH.⁷ Without

² Fox News, *Biden State Department quietly ended team's work probing COVID origin*, State Department (May 25, 2021) available at <https://www.foxnews.com/politics/biden-state-department-shut-down-team-covid-origin-investigation>.

³ National Institutes of Health, *Understanding the Risk of Bat Coronavirus Emergence*, REPORTER (last accessed June 2, 2021) available at https://reporter.nih.gov/search/plodLH_U1kyZgyOhClrN2w/project-details/9320765#similar-Projects/.

⁴ USASpending.gov, *Cooperative agreement numbers U01AI151797 and U01AI153420*, EcoHealth Alliance available at

⁵ House Committee on Appropriations, *FY 2022 Budget Request for the National Institutes of Health*, Hearings (May 25, 2021) available at <https://appropriations.house.gov/events/hearings/fy-2022-budget-request-for-the-national-institutes-of-health>.

⁶ National Institutes of Health, *Other Support, Grants & Funding* (last accessed June 1, 2021) available at <https://grants.nih.gov/grants/forms/othersupport.htm>.

⁷ *Id.*

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 3

further details or documentation, your testimony bolsters the notion that NIH oversight is largely ignorant of other awards to the grantee.

3. NIH's Inadequate Oversight of EHA's Delinquent Financial Reports

As the prime recipient of NIH grant R01AI110964, EHA gave a total \$598,500 in five subaward transactions to the WIV from 2015 to 2019 for the WIV to, "conduct high-quality testing, sequencing, and analyses of field samples; maintenance of cold-chains from field to lab; ensuring quality control of sample storage and testing; collaborating on scientific publications and programmatic reporting."⁸ EHA also gave a total of \$201,217.10 in two subaward transactions to the Wuhan University School of Public Health (WUSPH) to "conduct targeted site-analyses, human behavioral surveillance including qualitative and quantitative surveys; analyses of data; collaborating on scientific publications and programmatic reporting," from 2016 through 2017.⁹

EHA is required to report its subawards to GSA's FFATA Subaward Reporting System (FSRS) by the end of the month following the month when the subaward was made.¹⁰ For example, when EHA issued a \$133,000 subaward to the WIV on May 29, 2015, EHA was required to report that subaward to FSRS by June 30, 2015.¹¹ USASpending is the U.S. government's open federal spending data source and when the grant number R01AI110964 data is downloaded, details reveal that EHA did not report subawards for that grant until 2020, even though EHA made subawards starting in 2015.¹² EHA reported all seven subaward transactions for R01AI110964 on July 13, 2020, five days following NIH's July 8, 2020 letter to EHA instructing EHA to ensure EHA reported all subaward data to FSRS.¹³ Before the year 2020, only one other EHA subaward grant is reported in USASpending.gov, in which three subaward transactions for NIH grant number R56TW009502 are recorded in 2014.¹⁴ EHA's apparent non-compliance of required financial reporting raises concerns about the adequacy of NIH oversight of NIH grants.

4. NIH's Possible Funding of EHA for Duplicative Research in China

EHA received federal funding as both a prime and sub-recipient not only from NIH, but also from the U.S. Agency for International Development (USAID) for its bat coronavirus research. The project descriptions and research articles are so similar that a distinction between the NIH bat coronavirus research objectives and achievements for the awards to EHA are almost interchangeable with EHA's USAID-funded bat coronavirus research objectives and

⁸ *Id.*

⁹ *Id.*

¹⁰ USASpending.gov, *Data Sources*, About (last accessed June 1, 2021), available at <https://www.usaspending.gov/about>.

¹¹ *Id.*

¹² USASpending.gov, *Advanced Search: Recipient – EcoHealth Alliance* (June 1, 2021) available at USASpending.gov/.

¹³ *Id.*

¹⁴ *Id.* See NIH grant number R56TW009502.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 4

achievements.¹⁵ The NIH grant progress reports will reveal details about the bat coronavirus research that can be compared to the reports from USAID-funded research. In its research funded by the USAID, EHA partnered with the WIV and with East China Normal University.¹⁶ We are very concerned that the NIH and USAID may have funded duplicate projects and that EHA partnered with additional unreported entities in China for NIH-funded research.

5. NIH's Inadequate Reconciliation of EHA's Grant Subawards

As far back as 2005, Peter Daszak of EHA has authored over 20 bat coronavirus and other zoonotic pathogen research articles with Dr. Zhengli Shi of the WIV, plus other researchers, about experiments funded by NIH.¹⁷ Their collaborative research has resulted in a 2005 publication entitled "Bats Are Natural Reservoirs of SARS-Like Coronaviruses," funded by NIH.¹⁸ In 2013, they published "Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor," funded by NIH and USAID.¹⁹ Their numerous publications acknowledge NIH as a research sponsor yet the only EHA support to the WIV in USASpending.gov was reported by EHA on July 13, 2020 (see concern number three above).²⁰ Vanity Fair reported that Dr. Shi "herself listed U.S. government grant support of more than \$1.2 million on her curriculum vitae: \$665,000 from the NIH between 2014 and 2019; and \$559,500 over the same period from USAID."²¹ EHA's late and potentially incomplete reporting of the WIV as its sub-award recipient raises questions about EHA's compliance with required financial reporting and also raises concerns about NIH's oversight of grant awards to EHA.

6. NIH's Inadequate Oversight of EHA's Place of Performance Reporting

The Federal Funding Accountability and Transparency Act of 2006 (FFATA) requires that federal award reporting must include the primary location of where the work will be performed, (including the city, state, congressional district, and country).²² For EHA's NIH awards, China is not listed as the place of performance in USASpending.gov and instead, EHA's

¹⁵ USASpending.gov, *Advanced Search: Recipient – EcoHealth Alliance* (June 1, 2021) available at USASpending.gov/.

¹⁶ USAID PREDICT-1 CONSORTIUM, *Reducing Pandemic Risk, Promoting Global Health*, Final Report (Dec. 2014) available at <https://ohi.sf.ucdavis.edu/sites/g/files/dgvnsk5251/files/files/page/predict-final-report-lo.pdf>.

¹⁷ NIH Reporter, *Anthropogenic change & emerging zoonotic paramyxoviruses*, Project Number 5R01TW005869-04 (Budget Start Date June 1, 2005) available at

<https://reporter.nih.gov/search/WMYBIQPE20aG4fAZLFj0lw/project-details/6923645#details>, NIH National Library of Medicine, *Advanced Search for 'Shi, Daszak'*, National Center for Biotechnology Information (June 2, 2021) available at https://pubmed.ncbi.nlm.nih.gov/?term=Daszak%2C+Shi&sort=date&sort_order=asc&size=200.

¹⁸ NIH National Library of Medicine, *Bats Are Natural Reservoirs of SARS-Like Coronaviruses*, PubMed (Sept. 5, 2005) available at <https://pubmed.ncbi.nlm.nih.gov/16195424/>.

¹⁹ Ge, XY., et al., *Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor*, *Nature* 503, 535–538 (May 16, 2013) available at <https://doi.org/10.1038/nature12711>.

²⁰ *Id.*

²¹ Katherine Eban, *The Lab-Leak Theory – Inside the Fight to Uncover COVID-19 Origins*, Vanity Fair (June 3, 2021) available at <https://www.vanityfair.com/news/2021/06/the-lab-leak-theory-inside-the-fight-to-uncover-covid-19s-origins>.

²² PL 109-282, Sept. 26, 2006 available at <https://www.govinfo.gov/content/pkg/PLAW-109publ282/pdf/PLAW-109publ282.pdf>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 5

primary place of performance is identified as New York.²³ The NIH grant documents, and the financial and progress reports we have requested will contain travel budgets and research details that will confirm the location(s) where EHA actually performed its research. Published research articles about NIH-funded experiments describe EHA's bat coronavirus research and surveillance activities often partnered with the WIV in China. We are very concerned about the discrepancy in EHA's primary place of performance as being New York in USASpending.gov when research articles, publications, and media interviews suggest EHA's primary place of performance is not domestic.²⁴

7. NIH's Lack of Visibility into EHA's Grant Subawards

USASpending.gov limits visible data to prime and subaward recipients, and does not disclose funds that are further disbursed subaward recipients.²⁵ EHA is a subaward recipient of NIH grant funds from the Arizona State University and the Trustees of Columbia University in New York City.²⁶ As a subaward recipient, EHA does not publicly report when it further distributes subaward funds to other organizations such as the WIV or other recipients in China.²⁷ NIH questions to EHA in the July 8, 2020 grant suspension letter suggest that NIH lacks information and visibility on sub-grant awards that are either issued or received by EHA.²⁸

8. NIH's Inadequate Oversight of EHA's Grant Fund Accounting

In our April 18, 2021 letter to EHA, we raised the issue that EHA reported a \$319,570 cash award grant and a \$126,792 cash award grant disbursed by wire to China for the purpose of "[u]nderstanding the risk of bat coronavirus emergence" on its IRS Form 990, calendar year 2016.²⁹ EHA reported giving \$321,700 for coronavirus and emerging diseases to China on its IRS Form 990, calendar year 2015.³⁰ EHA IRS Form 990's for other years do not include that purpose or identify the WIV as an organization to which funds were paid. With EHA organized as a 501 (c)(3) non-profit organization, its IRS Form 990's are public documents able to be reviewed by NIH. As a non-federal entity that expends more \$750,000 or more in federal funds in one year, EHA is required to submit a Single Audit report, previously known as the OMB Circular A-133 audit. The purpose of a Single Audit report is to provide assurance to the Federal Government that a non-federal entity has adequate internal controls in place, and is generally in

²³ *Id.*

²⁴ Nidhi Subbaraman, 'Heinous!': Coronavirus researcher shut down for Wuhan-lab link slams new funding restrictions, *Nature* (Aug. 21, 2020), available at <https://www.nature.com/articles/d41586-020-02473-4>.

²⁵ USASpending.gov, *Advanced Search: Recipient - EcoHealth Alliance* (June 1, 2021) available at [USASpending.gov/](https://www.usaspending.gov/).

²⁶ *Id.*

²⁷ *Id.*

²⁸ Internal Revenue Service, EHA 990 final, Schedule F, Parts I and II (May 3, 2017) available at https://apps.irs.gov/pub/epostcard/cor/311726494_201606_990_2017090514700974.pdf.

²⁹ U.S. Energy and Commerce Republicans, *Letter to EcoHealth Alliance*, The COVID-19 Origins Investigation (Apr. 16, 2021) available at <https://republicans-energycommerce.house.gov/the-covid-19-origins-investigation/>.

³⁰ Internal Revenue Service, EHA 990 final 2015, Schedule F, Parts I and II (May 3, 2017) available at https://apps.irs.gov/pub/epostcard/cor/311726494_201606_990_2017090514700974.pdf.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 6

compliance with program requirements.³¹ In EHA's Single Audit reports for years 2016 to 2020, no payments are evident for EHA funds paid to the WIV.³²

9. NIH's Inadequate Oversight of Its Funded Researchers in China

The WIV named NIH and EHA on its website as WIV international partner as of and prior to the date of our March 18, 2021 letter to NIH.³³ By March 22, 2021, the WIV had removed NIH as a partner from its website.³⁴ The NIH has characterized its relationship Chinese scientists as respectable scientific partners.³⁵ However, within three days following our letter to NIH which inquired about NIH grants to the WIV, the WIV quickly concealed its long-standing relationship with NIH by deleting evidence of its NIH partnership from its website. This action does not seem consistent with NIH's claim that the WIV and its scientists were a respectable scientific partner. It has been reported that some Chinese scientists working with EHA are current or former members of the People's Liberation Army of China.³⁶ It has also been reported that the Chinese military were conducting research at the WIV.³⁷ We are concerned that NIH-funded coronavirus research in China may not have undergone proper biodefense risk analysis.

10. NIH's Lack of Cooperation with Congressional Oversight Inquiry

NIH is supposed to be a transparent institution and the grant documents we requested should be a matter of public record.³⁸ Contrary to your public statement implying that we asked for "pretty sensitive materials, not quite classified, but getting close to that," the grant documents we requested are releasable to the public per NIH's own policy and should have already been provided to us.³⁹

As you are aware, the NIH grant documents and progress reports we requested will include details pertinent to our COVID-19 origins investigation, including information about: all research participants and collaborating organizations; location(s) of work performed; instruments, equipment and monies provided to grant sub-recipients; financial accounting

³¹ U.S. Department of Health and Human Services, *Single Audit* (Apr. 25, 2016) available at <https://www.hhs.gov/about/agencies/asfr/data-act-program-management-office/single-audit/index.html>.

³² Federal Audit Clearinghouse, *EcoHealth Alliance, Inc and Wildlife Preservation Trust Int. Single Audit Reports 2017-2021* (June 7, 2021) available at <https://facdissem.census.gov/SearchResults.aspx>.

³³ Internet Archive Wayback Machine, *Wuhan Institute of Virology, CAS, Partnerships* (Mar. 18, 2021) available at https://web.archive.org/web/20210318052528/http://english.whiov.cas.cn/International_Cooperation2016/Partnerships/.

³⁴ Internet Archive Wayback Machine, *Wuhan Institute of Virology, CAS, Partnerships* (Mar. 22, 2021) available at https://web.archive.org/web/20210322053537/http://english.whiov.cas.cn/International_Cooperation2016/Partnerships/.

³⁵ House Committee on Appropriations, *FY 2022 Budget Request for the National Institutes of Health*, Hearings (May 25, 2021) available at <https://appropriations.house.gov/events/hearings/fy-2022-budget-request-for-the-national-institutes-of-health>.

³⁶ Alexis, Shi Zhengli: Weaponizing Coronaviruses, with Pentagon Funding, at a Chinese Military Lab, <https://enviroshop.com/shi-zhengli-weaponizing-coronaviruses-with-pentagon-funding-at-a-chinese-military-lab/>.

³⁷ *Id.*

³⁸ National Institutes of Health, *NIH Grants Policy Statement*, Policy and Compliance (June 1, 2021) available at <https://grants.nih.gov/policy/nihgps/index.htm>.

³⁹ *Id.*

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 7

reports; research techniques and accomplishments; research products such as: technologies, patent applications, data or databases, physical collections, and models; significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents; and budgetary information and project outcomes.⁴⁰

As the federal grant awarding agency, NIH must have the right of access to any of EHA's documents or other records which are pertinent to NIH federal awards.⁴¹ The NIH grants policy states that the Freedom of Information Act (FOIA) and U.S. Department of Health and Human Services regulations require NIH to release certain grant documents and records requested by members of the public, regardless of the intended use of the information.⁴² Per NIH policy, NIH will generally release funded applications and progress reports pursuant to a FOIA request.⁴³ NIH considers most grant-related information in the application or post-award phases as being public information (emphasis added).⁴⁴

In support of this inquiry and the public interest in the origins of the COVID-19 pandemic, please provide written responses to the following by June 24, 2021:

1. We again renew our request for NIH's immediate compliance with our oversight inquiry for production of the grant documents and progress reports forthwith that we first requested on March 18, 2021.
2. What is NIH's policy for awarding funds to organizations when the organization has NIH grant funds in suspended status and are not cooperating NIH requests? If the NIH permits new award funding under these circumstances, please provide the policy, and explain how such funding does not undercut NIH's ability to oversee grantees and does not incentivize grantees to defy NIH's requests for information.
3. Please explain all oversight steps NIH has taken to ensure EHA's full compliance with federal financial subaward reporting requirements for all NIH grants. Please explain if EHA reported to NIH any subaward recipients other than the WIV or the WUSPH for NIH grant R01AI110964. Please provide all financial records of all NIH funds given to Dr. Zhengli Shi of the WIV.
4. For all NIH awards in which EHA was a subrecipient, please provide a financial accounting of EHA's subawards to the WIV or other organizations in China.

⁴⁰ Hugh Hewitt, *Dr. Francis Collis On The U.S. Funding of the Wuhan Lab and Congressional Oversight*, The Hugh Hewitt Show (June 2, 2021) available at <https://hughhewitt.com/dr-francis-collins-on-the-u-s-funding-of-the-wuhan-lab-and-congressional-oversight/>, National Institutes of Health, *Research Performance Progress Report, Grants & Funding* (May 4, 2021) available at <https://grants.nih.gov/grants/rppr/index.htm>.

⁴¹ *Id.*

⁴² National Institutes of Health, *NIH Grants Policy Statement*, Policy and Compliance (June 1, 2021) available at <https://grants.nih.gov/policy/nihgps/index.htm>.

⁴³ *Id.*

⁴⁴ *Id.*

Director Francis Collins, M.D., Ph.D.


June 10, 2021

Page 8

5. How does NIH ensure it does not award unapproved duplicate grants for same or similar research already funded by other agencies, to EHA or other NIH grant recipients? For all NIH awards to EHA, please provide accounting information for EHA subawards to recipients in China.
6. Please explain how NIH has reviewed EHA annual Single Audit reports to ensure how EHA has met program and reporting requirements.
7. How does NIH audit the financial reports submitted to the IRS by its 501(c)(3) non-profit organization grant award recipients to ensure NIH awards are accurately reported? How does NIH ensure its grantees do not act as a pass-through or money laundering provider to send U.S. research funding to China?
8. Please explain NIH's policy for ensuring its awardees accurately report the actual place of research performance. For all NIH-funded research, please provide all China site locations where EHA's work was performed.
9. Please explain if EHA reported its other funding or in-kind support, including awards from federal agency, to NIH. Please explain if EHA reported any support from organizations in China.
10. Did NIH perform a biodefense risk analysis for coronavirus research conducted at the WIV as research with potential for dual use of research concern, pandemic pathogen or bioweapon development, as outlined in the HHS *Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens*?⁴⁵ Please describe NIH's coordination procedures with the U.S. Intelligence Community that are completed before NIH funds research projects in foreign countries with existing biodefense programs.

Please make arrangements to schedule the briefing for Committee staff by June 24, 2021. If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff. Thank you for your attention to this request.

Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Fred Upton
Republican Leader
Subcommittee on Energy

⁴⁵ U.S. Department of Health and Human Services, *Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens*, Science Safety Security (Dec. 2017) available at <https://www.phe.gov/s3/dualuse/Pages/p3co.aspx>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021


Page 9



Bob Latta
Republican Leader
Subcommittee on Communications and
Technology



Brett Guthrie
Republican Leader
Subcommittee on Health



David McKinley
Republican Leader
Subcommittee on Environment and
Climate Change



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and
Investigations



Gus Bilirakis
Republican Leader
Subcommittee on Consumer Protection and
Commerce



Michael C. Burgess, M.D.
Member of Congress



Steve Scalise
Member of Congress



Adam Kinzinger
Member of Congress

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 10




Bill Johnson
Member of Congress



Billy Long
Member of Congress




Larry Bucshon, M.D.
Member of Congress




Markwayne Mullin
Member of Congress




Richard Hudson
Member of Congress



Tim Walberg
Member of Congress



Earl L. "Buddy" Carter
Member of Congress



Jeff Duncan
Member of Congress



Gary Palmer
Member of Congress



Neal P. Dunn, M.D.
Member of Congress

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 11



John Curtis
Member of Congress




Debbie Lesko
Member of Congress



Greg Pence
Member of Congress



Dan Crenshaw
Member of Congress



John Joyce, M.D.
Member of Congress



Kelly Armstrong
Member of Congress

EXHIBIT 20

EXHIBIT 20

FRANK PALLONE, JR., NEW JERSEY

CATHY McMORRIS RODGERS, WASHINGTON

CHAIRMAN

RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927

November 30, 2022

Lawrence A. Tabak, D.D.S., Ph.D.
Senior Official Performing the Duties of the Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dr. Tabak:

We write to urge the National Institutes of Health (NIH) to respond to our longstanding requests to provide us information related to the origins of the COVID-19 pandemic, including matters related to National Institute of Allergy and Infectious Diseases' (NIAID) grant to EcoHealth Alliance and subgrant to the Wuhan Institute of Virology (WIV), and other subjects. Some of these requests have been outstanding for more than a year. NIH's persistent lack of transparency with members of its authorizing committee of jurisdiction is troubling. According to its mission statement, a goal of the National Institutes of Health (NIH) is "to exemplify [...] the highest level of scientific integrity and public accountability."¹ However, given the overall lack of adequate responsiveness to our oversight letters, the NIH is falling short of the goal set forth in its mission statement.

Between March 18, 2021 through October 31, 2022, we sent a total of twelve letters requesting information from NIH that have gone largely unanswered related to the origins of COVID-19 and NIH's grant to EcoHealth Alliance, and three other topics.² As a convenient reminder, we courteously summarize each of those letters below:

¹ National Institutes of Health, Mission and Goals, What We Do (accessed July 14, 2021) available at <https://www.nih.gov/about-nih/what-we-do/mission-goals>.

² Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (March 18, 2021); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith et al to Francis Collins, M.D., Ph.D., Director, NIH (June 10, 2021); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (July 21, 2021); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (August 24, 2021); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy

Letter to Dr. Tabak

Page 2 of 6

March 18, 2021, Letter to Dr. Francis Collins:

On March 18, 2021, we sent an eleven-page letter, based on what was known at that time, requesting information related to where SARS CoV-2 originated and how NIH grant dollars at the WIV were used.³ We asked NIH to provide responses by April 19, 2021.⁴ Notably, on April 28, 2021, at a hearing before this Committee's Subcommittee on Health, Dr. Francis Collins testified NIH was working diligently to reply to the letter: "And we are working on answers to your letter with 29 questions and 40 footnotes and 11 pages. It is taking us *a little longer than a few days* (emphasis added)."⁵ While documents released in response to Freedom of Information Act requests suggest that NIH had prepared a draft written response, NIH never sent us a written response to our questions.

We acknowledge that you provided a briefing to bipartisan committee staff on June 28, 2021, for one hour in response to some of the questions. However, only the first 20 questions were covered. The other questions remain unanswered. As of today's date, November 30, 2022, *622 days later*, NIH has not provided a written response to the questions in the March 18, 2021, letter.

June 10, 2021, Letter to Dr. Francis Collins:

On June 10, 2021, we wrote to strongly express support for a "comprehensive investigation into the origins of the COVID-19 pandemic, including the possibility of an accidental laboratory leak."⁶ We identified several concerns related to the financial management and oversight of the NIH grant to EcoHealth Alliance and its subaward recipient, the WIV.⁷ We

McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (October 27, 2021); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (February 14, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (February 24, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (April 25, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (July 21, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (August 11, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (October 24, 2022); Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (October 31, 2022).

³ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (March 18, 2021).

⁴ *Id.*

⁵ *Hearing on the 'the Long Haul: Forging a Path Through the Lingering Effects of Covid-19'*, before the Subcomm. On Health, H. Energy & Commerce Comm. (Apr. 28, 2021), <https://energycommerce.house.gov/committee-activity/hearings/hearing-on-the-long-haul-forging-a-path-through-the-lingering-effects-of>

⁶ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith et al to Francis Collins, M.D., Ph.D., Director, NIH (June 10, 2021).

⁷ *Id.*

Letter to Dr. Tabak

Page 3 of 6

asked for written responses to our questions be submitted by June 24, 2021. To date, NIH has not provided a written response.

July 21, 2021, Letter to Dr. Francis Collins:

On July 21, 2021, we sent another letter reiterating our request for information to our March 2021 letter, which NIH failed to provide substantive written responses to.⁸ In addition, the letter requested information, by July 28, 2021, about NIH-supported gain-of-function research involving “humanized mice” as well as briefings from NIAID officials related to a grant award to EcoHealth Alliance, and an NIAID’s official visit to WIV.⁹ NIH has not provided a written response to the specific questions outlined in the July 2021 letter, although some information has emerged from subsequent NIH correspondence with EcoHealth Alliance.

August 24, 2021, Letter to Dr. Francis Collins:

We submitted an August 2021 letter again requesting information about NIAID’s coronavirus grant to EcoHealth Alliance.¹⁰ Specifically, the letter raised concerns about EcoHealth Alliance’s oversight of its subgrantee WIV’s experiments to ensure compliance with biosafety requirements.¹¹ The letter further repeated its request that NIAID officials be made available for staff-level briefings and that NIH provide a response by September 7, 2021. To date, NIH has not provided a written response.¹²

October 27, 2021, Letter to Dr. Francis Collins:

Based on documents the Department of Health and Human Services arranged for the Committee to review *in camera*, we highlighted in an October 27, 2021, letter our concerns about NIH’s oversight of EcoHealth Alliance’s research proposal that purported it was not conducting gain-of-function research.¹³ In addition, the letter raised concerns EcoHealth Alliance failed to comply with NIH’s grant terms yet continued to receive millions of dollars in grant funds.¹⁴ NIH was asked to reply to our questions by November 10, 2021, but to date, NIH has not submitted a written response to this letter.¹⁵

February 14, 2022, Letter to Dr. Francis Collins:

On February 14, 2022, we sent a letter about concerns that Dr. Collins, while Director of NIH, may have taken steps to actively suppress scientific discussion that COVID-19 could have

⁸ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (July 21, 2021).

⁹ *Id.*

¹⁰ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Aug. 24, 2021).

¹¹ *Id.*

¹² *Id.*

¹³ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Oct. 27, 2021)

¹⁴ *Id.*

¹⁵ *Id.*

Letter to Dr. Tabak

Page 4 of 6

originated from a research-related incident, not just from natural transmission.¹⁶ We asked Dr. Collins for written responses to a series of questions by February 28, 2022, which to date, he has avoided answering.¹⁷ A similar letter was also sent to Dr. Anthony Fauci, the Director of the NIAID. To date, neither NIH nor NIAID have submitted written responses to these letters.

February 24, 2022, Letter to Dr. Lawrence A. Tabak:

On February 24, 2022, we raised concerns with you that NIH failed to effectively enforce its policies and regulations over EcoHealth Alliance.¹⁸ Specifically, EcoHealth withheld attribution of data to another federal grant from NIH, raising the possibility it was double-billing two federal agencies for the same research. Additionally, EcoHealth Alliance's inability to provide laboratory notebooks and electronic files called into question the safety of the research conducted on humanized mice.¹⁹ Additionally, the letter expressed that, in contravention of federal regulations regarding financial disclosures, EcoHealth Alliance may have hidden from NIH the identities of its private donors. Several questions were requested to be answered by March 24, 2022. To date, NIH has not sent a written response.

April 25, 2022, Letter to Dr. Lawrence A. Tabak:

On April 25, 2022, we wrote to you raising concerns that EcoHealth Alliance was potentially omitting key information in research allegedly conducted at WIV in order to obtain a renewal of federal grant funding.²⁰ Specifically, information related to mice deaths (the higher death rates with mice infected by chimeric viruses, a supposedly unexpected result) may have been withheld from peer reviewers during the grant renewal's application.²¹ These nondisclosures may have prevented peer reviewers from examining the complete research findings, thereby preventing them from questioning the riskiness of the experiments conducted with federal grant funds.²² While NIH has provided some information in a bipartisan briefing, many questions remain unanswered. NIH has not provided a written response to this letter.

July 21, 2022, Letter to Dr. Lawrence A. Tabak:

Although required by the NIH Reform Act of 2006, NIH has failed to convene the Scientific Management Review Board (SMRB) since 2015.²³ We wrote asking why this Board, intended to make NIH more efficient and effective, inexplicably stopped convening seven years ago.²⁴ In addition, we questioned whether funding intended for the SMRB, \$488,901 per year,

¹⁶ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Francis Collins, M.D., Ph.D., Director, NIH (Feb. 14, 2022).

¹⁷ *Id.*

¹⁸ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (Feb. 24, 2022).

¹⁹ *Id.*

²⁰ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (Apr. 25, 2022).

²¹ *Id.*

²² *Id.*

²³ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH (July 21, 2022).

²⁴ *Id.*

Letter to Dr. Tabak

Page 5 of 6

was being diverted elsewhere for the past seven years, thereby totaling \$2.9 million.²⁵ To date, NIH has not provided a written response.

August 11, 2022, Letter to Dr. Lawrence A. Tabak:

As highlighted in our August 11, 2022, letter, we received inadequate responses in 2021 as to why NIH failed to remove an alleged sexual perpetrator disciplined in three states from co-chairing an NIH steering committee, even after receiving complaints from female scientists alleging the misconduct.²⁶ We reported that the high volume of harassment complaints lodged against NIH grantees and NIH-supported researchers and raised questions about the NIH's handling of such complaints.²⁷ We requested you provide written responses to our requests by September 12, 2022. To date, NIH has not provided a written response.

October 24, 2022, Letter to Dr. Lawrence A. Tabak:

Last month we sent you a letter raising concerns about how NIH could contemplate funding a new EcoHealth Alliance grant considering this organization's past noncompliance with regulatory requirements and grant terms.²⁸ As we noted, EcoHealth Alliance's history of failing to substantiate scientific experiments with material records and its slipshod oversight of its sub awardee, the WIV, should have caused NIH to conclude that EcoHealth Alliance could not be a responsible steward of federal grant funding.²⁹ We submitted several questions for you to answer by November 7, 2022, regarding the NIH's decision to renew its funding of EcoHealth Alliance.³⁰ To date, we have not received a written response from NIH to this letter.

October 31, 2022, Letter to Dr. Lawrence A. Tabak:

Last month we sent you a letter requesting information related to a NIAID intramural experiment that would enhance the more dangerous version of the monkeypox virus by making the disease about 1000 percent more lethal in mice.³¹ The more lethal monkeypox virus has about a 10 percent mortality rate in unvaccinated people whereas the less lethal monkeypox virus has a mortality rate of less than one percent.³² We requested a written response by November 14, 2022. To date, we have not received a response.

We urge you to provide written responses to our longstanding requests from these letters immediately, but no later than December 16, 2022.

²⁵ *Id.*

²⁶ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (Aug. 11, 2022).

²⁷ *Id.*

²⁸ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (Octo. 24, 2022).

²⁹ *Id.*

³⁰ *Id.*

³¹ Letter from Committee Ranking Members (Full and Subcommittees, respectively) Cathy McMorris Rodgers, Brett Guthrie, Morgan Griffith to Lawrence A. Tabak, D.D.S., PhD., Acting Director, NIH (Oct. 31, 2022).

³² Christina L. Hutson, et al., *Dosage Comparison of Congo Basin and West African Strains of Monkeypox Virus using a Prairie Dog Animal Model of Systemic Orthopoxvirus Disease*, 402 VIROLOGY 72-82 (2010), available at <https://www.sciencedirect.com/science/article/pii/S0042682210001650?via%3Dihub>

Letter to Dr. Tabak

Page 6 of 6

Furthermore, this letter serves as a formal request to preserve all existing and future records and materials in your agency's possession relating to the topics addressed in this letter. You should construe this preservation notice as an instruction to take all reasonable steps to prevent the destruction or alteration, whether intentionally or negligently, of all documents, communications, and other information, including electronic information and metadata, that are or may be responsive to this congressional inquiry. This instruction includes all electronic messages sent using official and personal accounts or devices, including records created using text messages, phone-based message applications, or encryption software.


Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Brett Guthrie
Republican Leader
Subcommittee on Health



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and
Investigations

CC: The Honorable Frank Pallone, Chairman

The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations

The Honorable Anna G. Eshoo, Chair, Subcommittee on Health

Dr. Anthony Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases

EXHIBIT 21

EXHIBIT 21

FILED: ROCKLAND COUNTY CLERK 02/04/2023 12:55 PM INDEX NO. 034252/2022
Peter Daszak <daszak@ecohealthalliance.org>; Baric, Toni C <antoINETE_baric@med.unc.edu>
NYSCEF: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura [chmura@ecohealthalliance.org] RECEIVED NYSCEF: 02/04/2023
From: Baric, Ralph S [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=BB0D9CC80C184735A4E862C3BDD8A15D-RALPH S BAR]
Sent: Thur 2/6/2020 4:01:22 PM (UTC-05:00)
Subject: RE: No need for you to sign the "Statement" Ralph!!

I also think this is a good decision. Otherwise it looks self-serving and we lose impact. ralph

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Thursday, February 6, 2020 3:16 PM
To: Baric, Ralph S <rbaric@email.unc.edu>; Baric, Toni C <antoINETE_baric@med.unc.edu>
Cc: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura <chmura@ecohealthalliance.org>
Subject: No need for you to sign the "Statement" Ralph!!
Importance: High

I spoke with Linfa last night about the statement we sent round. He thinks, and I agree with him, that you, me and him should not sign this statement, so it has some distance from us and therefore doesn't work in a counterproductive way.

Jim Hughes, Linda Saif, Hume Field, and I believe Rita Colwell will sign it, then I'll send it round some other key people tonight. We'll then put it out in a way that doesn't link it back to our collaboration so we maximize an independent voice.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel.
Website: www.ecohealthalliance.org
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

EXHIBIT 21

EXHIBIT 21

FILED: ROCKLAND COUNTY CLERK 02/04/2023 12:55 PM INDEX NO. 034252/2022
Peter Daszak <daszak@ecohealthalliance.org>; Baric, Toni C <antoINETTE_baric@med.unc.edu>
NYSCEF: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura [chmura@ecohealthalliance.org] RECEIVED NYSCEF: 02/04/2023
From: Baric, Ralph S [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=BB0D9CC80C184735A4E862C3BDD8A15D-RALPH S BAR]
Sent: Thur 2/6/2020 4:01:22 PM (UTC-05:00)
Subject: RE: No need for you to sign the "Statement" Ralph!!

I also think this is a good decision. Otherwise it looks self-serving and we lose impact. ralph

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Thursday, February 6, 2020 3:16 PM
To: Baric, Ralph S <rbaric@email.unc.edu>; Baric, Toni C <antoINETTE_baric@med.unc.edu>
Cc: Alison Andre <andre@ecohealthalliance.org>; Aleksei Chmura <chmura@ecohealthalliance.org>
Subject: No need for you to sign the "Statement" Ralph!!
Importance: High

I spoke with Linfa last night about the statement we sent round. He thinks, and I agree with him, that you, me and him should not sign this statement, so it has some distance from us and therefore doesn't work in a counterproductive way.

Jim Hughes, Linda Saif, Hume Field, and I believe Rita Colwell will sign it, then I'll send it round some other key people tonight. We'll then put it out in a way that doesn't link it back to our collaboration so we maximize an independent voice.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel.
Website: www.ecohealthalliance.org
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

EXHIBIT 23

EXHIBIT 23



National Institutes of Health
Bethesda, Maryland 20892

August 19, 2022

The Honorable James Comer
Ranking Member, Committee on Oversight and Reform
U.S. House of Representatives
Washington, DC 20515

Dear Representative Comer:

Thank you for your interest in the work of the National Institutes of Health (NIH). I write to you today in a continuing effort to be responsive to your inquiries about NIH oversight of awards to EcoHealth Alliance (EHA).

As you know, the National Institute of Allergy and Infectious Diseases (NIAID) awarded EHA grant R01AI110964 ("R01 award") after the application received a meritorious score through the peer review process. This grant included three sub-awards, including one to the Wuhan Institute of Virology (WIV) and had a performance period starting on June 1, 2014. The renewal application for this grant underwent peer review, and the Notice of Award was issued on July 24, 2019. The research approved under this grant sought to understand how bat coronaviruses evolve naturally in the environment to become transmissible to the human population. This type of research is a critical component of pandemic preparedness. Identifying pathogens that have the potential to cause disease in humans allows the research community to prepare for how to respond if these pathogens do enter the human population.

NIH's Office of Extramural Research (OER) suspended EHA grant R01AI110964 on July 8, 2020, due to grant administrative non-compliance concerns. Over time, NIH reviewed EHA's compliance with requirements under the R01 award and requested information and documentation from EHA to enable NIH to conduct its review.

NIH also reviewed EHA's compliance with requirements under two other NIH awards to EHA, the Research Project Cooperative Agreements ("U awards"). See Table 1 for a list of all current NIH awards to EHA.

Table 1: Current NIH Awards to EHA

Award Number	Grant Title	Performance Period
R01AI110964	Understanding the Risk of Bat Coronavirus Emergence	July 1, 2014-May 31, 2019; Renewal: June 1, 2019-May 31, 2024*

The Honorable James Comer
Page 2

U01AI151797	Understanding Risk of Zoonotic Virus Emergence in Emerging Infectious Disease Hotspots of Southeast Asia	June 17, 2020-May 31, 2025**
U01AI153420	Study of Nipah Virus (NiV) Dynamics and Genetics in Bat Reservoirs and of Human Exposure to NiV Across Bangladesh to Understand Patterns of Human Outbreaks	September 15, 2020-June 30, 2025**

*This grant was suspended on July 8, 2020 and has remained suspended.

**Specific award conditions imposed on January 6, 2022 but was never suspended.

As NIH notified you on January 6, 2022, NIH sent a letter to EHA that day conveying the outcome of its detailed administrative review of compliance under the U awards. NIH identified a number of compliance issues, including inadequate oversight in monitoring the activities of its subawardees, failure to report subawards to the General Services Administration's Federal Subaward Reporting System, and errors in indirect rate charges. In cases of non-compliance, NIH's approach is generally to provide a grantee the opportunity to come into compliance in an effort to preserve the research, when possible. This approach is consistent with HHS grant regulations, which provide that in cases of non-compliance, a funding agency can impose specific award conditions; and if the agency determines that the non-compliance cannot be remedied by specific award conditions, then the agency may take more severe actions, such as terminating an award in whole or in part.

Our January 6, 2022 letter announced immediate imposition of specific award conditions on the U awards to allow NIH to monitor these awards more closely. The U awards were never suspended. In addition, the letter outlined areas where EHA needed to improve its administrative policies and practices. NIH requested EHA submit a Corrective Action Plan (CAP) to address these issues.

EHA provided a proposed CAP to NIH on February 4, 2022. The CAP outlined steps EHA would take to address the non-compliance NIH identified under the two U awards. Between February and April 2022, NIH approved EHA's CAP and EHA implemented the CAP. Pursuant to the CAP, EHA revised the U subaward agreements to include details on EHA's procedures for access to subawardees' records and financial statements, data-sharing and management of awards, and a correction of the Facilities and Administrative cost rate. EHA also provided NIH with new and updated EHA policies that describe how, for all EHA projects, EHA will comply with reporting requirements and other deficiencies identified by NIH.

I write today to update you on EHA's implementation of the CAP under the U awards, the conclusion of NIH's review of compliance under the R01 award, and the next steps NIH will take with EHA. At this time, EHA has successfully implemented the NIH-approved CAP for its active U awards, which includes rewriting subaward agreements, and improving monitoring and reporting conflicts of interest by its subawardees. Accordingly, NIH has determined that EHA was able to resolve the problems identified with those awards. For the R01 award, NIH identified the same issues that were present with the U awards (including inadequate oversight in monitoring the activities of its subawardees, failure to report subawards to the General Services Administration's Federal Subaward Reporting System, and errors in indirect rate charges), as

The Honorable James Comer
Page 3

well as reporting delinquencies, such as the late submission of the fifth year progress report. NIH has determined that these problems can be remedied by imposing specific award conditions, because EHA demonstrated that it could resolve these same problems under the U awards with the successful implementation of a CAP.

However, NIH also identified one non-compliance under the R01 award that cannot be remedied with specific award conditions. NIH has requested on two occasions that EHA provide NIH the laboratory notebooks and original electronic files from the research conducted at WIV. To date, WIV has not provided these records. Under 45 CFR 75.371, "If a non-federal entity fails to comply with federal statutes, regulations, or the terms and conditions of a federal award, the HHS awarding agency or pass-through entity may impose additional conditions, as described in § 75.207. If the HHS awarding agency or pass-through entity determines that non-compliance cannot be remedied by imposing additional conditions, the HHS awarding agency or pass-through entity may take one or more [enforcement] actions, as appropriate in the circumstances[.]" 45 CFR 75.371. Such actions may include partly terminating the federal award. Id. at 75.371(c).

Today, NIH has informed EHA that since WIV is unable to fulfill its duties for the subaward under grant R01AI110964, the WIV subaward is terminated for failure to meet award terms and conditions requiring provision of records to NIH upon request.

In light of the cooperation from EHA and the subsequent substantial improvements in administrative processes that EHA demonstrated with the two U awards, NIAID will begin to engage with EHA to renegotiate the specific aims and objectives of the R01 grant without the involvement of WIV. If an agreement is made, the revised grant will be reviewed again in its entirety to ensure all applicable policy and guideline requirements are met including the HHS Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (P3CO) and other relevant policies and guidelines. A revised Notice of Award will be issued, subject to specific award conditions and any additional precautions that may be appropriate for inclusion, and the suspension on the grant will be lifted. If revisions to the grant's aims and objectives cannot be revised to stay within the original peer reviewed, scientific scope of the project, NIH reserves the right to request a bilateral termination of the remainder of the award.

As specific award conditions, NIH will maintain a higher level of oversight over all EHA awards for a minimum of three years, including a doubling of the frequency for the required scientific progress and financial reports, and a requirement that EHA submit additional documents illustrating their subaward monitoring activity. In addition, EHA will be required to conduct onsite inspections of all of its subawardees every six months to confirm that all terms of subaward agreements are being fully and appropriately executed. EHA will also be required to submit updated subaward agreements under the revised R01 award that address the deficiencies identified by NIH.

NIH takes its oversight of grants very seriously and always considers what further measures can be taken to strengthen routine oversight of grants at NIH. In light of this compliance case, NIH has taken additional steps. NIH has incorporated additional automated systems of controls for


The Honorable James Comer

Page 4

the timely receipt of progress reports to ensure that the most recent information is received and accepted by program officers. NIH has implemented program scripts in the NIH grants system (eRA) that send additional reminders to grant recipients and NIH staff of delinquencies if progress reports are either delayed or not fully reviewed and accepted. Should this happen, the system establishes a “red bar” to funding of the next non-competing renewal, which would prevent the award from being processed until the “red bar” is resolved. NIH believes that these new measures will further strengthen our oversight of grantees while continuing the life-saving work done by NIH grantees.

NIH is committed to ensuring responsible stewardship and accurate reporting of the use of federal funds. In a continued effort to be transparent, NIH has attached to this letter the communications between NIH and EHA regarding the implementation of the CAP. I hope this information is helpful to you.

Sincerely,



Michael S. Lauer, M.D.

Deputy Director for Extramural Research
National Institutes of Health

Enclosures:

First letter from NIH to EHA on January 6, 2022

Second letter from NIH to EHA on January 6, 2022

CAP proposed by EHA (in 2 parts)

NIH response to EHA's CAP

Follow-up CAP documents submitted by EHA (in 5 parts)

Letter from NIH to EHA on August 19, 2022

EXHIBIT 24

EXHIBIT 24

FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

March 18, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins,

We write to request information, assistance, and needed leadership from the National Institutes of Health (NIH) to advance an independent, scientific investigation into the origins of the COVID-19 pandemic.

The COVID-19 pandemic has been the worst public health crisis in the U.S. in about a hundred years. Over a year has passed since the deadly virus reached our shores and yet, the origin of the virus has yet to be determined. An independent, expert investigation of the origin of COVID-19 is of paramount importance to public health and biosecurity. As noted by Stanford Medical School Professor David Relman:

A more complete understanding of the origins of COVID-19 clearly serves the interests of every person in every country on this planet. It will limit further recriminations and diminish the likelihood of conflict; it will lead to more effective responses to this pandemic, as well as efforts to anticipate and prevent the next one. It will also advance our discussions about risky science. And it will do something else: Delineating COVID-19's origin story will help elucidate the nature of our very precarious coexistence within the biosphere.¹

Recently, the World Health Organization (WHO) attempted to investigate the origin of COVID-19. The WHO said that this investigative mission would be guided by the science, be

¹ David A. Relman, *Opinion: To stop the next pandemic, we need to unravel the origins of COVID-19*, PNAS (Nov. 2020), available at <https://www.pnas.org/content/117/47/29246>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 2

“open-minded,” and “not exclude[e] any hypothesis.”² Unfortunately, China did not provide complete access or independence for the critical WHO mission. On February 13, 2021, National Security Advisor Jake Sullivan issued the following statement:

We have deep concerns about the way in which the early findings of the COVID-19 investigation were communicated and questions about the process used to reach them. It is imperative that this report be independent, with expert findings free from intervention or alteration by the Chinese government. To better understand this pandemic and prepare for the next one, China must make available its data from the earliest days of the outbreak.³

Because of rising tensions between the U.S. and China, the WHO scrapped plans for an interim report.⁴ An international group of science experts, including specialists in virology, microbiology, and zoology, asked for a new review.⁵

The NIH, as a premier scientific institution, must lead in order to foster a transparent, independent, and science-based investigation into the origin of the COVID-19 pandemic. Such an effort must meet the WHO’s stated goals of an open-minded investigation that does not exclude any plausible hypothesis.⁶ In addition, the NIH is well-positioned to gather and provide information through oversight of its grants and other federal awards. Thus, the NIH is in a unique position to investigate the possibility that the pandemic stemmed from a laboratory accident or leak, especially regarding the Wuhan Institute of Virology (WIV).

NIH raised concerns over a possible link between WIV and the COVID-19 outbreak during its review of federal awards to EcoHealth Alliance, a global environmental health nonprofit organization dedicated to protecting wildlife and public health from the emergence of disease. Of the \$13.7 million in federal awards that NIH authorized for EcoHealth Alliance, 17

² Smriti Mallapaty, *Where did COVID come from? WHO investigation begins but faces challenges*, NATURE (Nov. 11, 2020), available at <https://www.nature.com/articles/d41586-020-03165-9>.

³ The White House, Statement of National Security Advisor Jake Sullivan (Feb. 13, 2021), available at <https://www.whitehouse.gov/briefing-room/statements-releases/2021/02/13/statement-by-national-security-advisor-jake-sullivan/>.

⁴ Betsy McKay, Drew Hinshaw and Jeremy Page, *WHO Investigators to Scrap Plans for Interim Report on Probe of Covid-19 Origins*, THE WALL STREET JOURNAL (Mar. 4, 2021), available at https://www.wsj.com/articles/who-investigators-to-scrap-interim-report-on-probe-of-covid-19-origins-11614865067?mod=latest_headlines

⁵ Jaime Metzl, et al, *Call for a Full and Unrestricted International Forensic Investigation into the Origins of COVID-19* (March 4, 2021), available at [https://s.wsj.net/public/resources/documents/COVID%20OPEN%20LETTER%20FINAL%20030421%20\(1\).pdf](https://s.wsj.net/public/resources/documents/COVID%20OPEN%20LETTER%20FINAL%20030421%20(1).pdf). The co-organizer of the letter and a WHO advisor on human genome editing, Jaime Metzl, PhD, said there is an eighty-five percent chance the pandemic started with an accidental leak from the WIV or Wuhan CDC laboratory, available at <https://jamiemetzl.com/origins-of-sars-cov-2/>. (“I have no definitive way of proving this thesis but the evidence is, in my view, extremely convincing. If forced to place odds on the confidence of my hypothesis, I would say there’s an 85% chance the pandemic started with an accidental leak from the Wuhan Institute of Virology or Wuhan CDC and a 15% chance it began in some other way (in fairness, here is an article making the case for a zoonotic jump “in the wild”). If China keeps preventing a full and unrestricted international forensic investigation into the origins of the pandemic, I believe it is fair to deny Beijing the benefit of the doubt.”)

⁶ Washington Post Editorial Board, *We’re still missing the origin story of this pandemic. China is sitting on the answers*, THE WASHINGTON POST (Feb. 5, 2021), available at <https://www.washingtonpost.com/opinions/2021/02/05/coronavirus-origins-mystery-china/?arc404=true>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 3

projects sponsored by the National Institute of Allergy and Infectious Disease (NIAID) have provided over \$7.9 million in federal awards for research of viral emergence from bats in Southeast Asia.⁷ EcoHealth Alliance passed some of its funding to the WIV, and in 2020, NIH made efforts to obtain information from EcoHealth Alliance about WIV related to concerns about the origins of COVID-19. In April 2020, NIH wrote to EcoHealth Alliance and Columbia University about an NIH-funded project entitled, “Understanding the Risk of Bat Coronavirus Emergency:”

It is our understanding that one of the sub-recipients of the grant funds is the Wuhan Institute of Virology (‘WIV’). It is our understanding that WIV studies the interaction between corona viruses and bats. The scientific community believes that the coronavirus causing COVID-19 jumped from bats to humans likely in Wuhan where the COVID-19 pandemic began. There are now allegations that the current crisis was precipitated by the release from WIV of the coronavirus responsible for COVID-19. Given these concerns, we are pursuing suspension of WIV from participation in Federal programs. It is in the public interest that NIH ensure that a sub-recipient has taken all appropriate precautions to prevent the release of pathogens that it is studying. This suspension of the sub-recipient does not affect the remainder of your grant assuming that no grant funds are provided to WIV following receipt of this email during the period of suspension.⁸

In January 2021, the U.S. Department of State issued a fact sheet about the activity at the WIV.⁹ Among other revelations, it reported the following:

- The U.S. government has reason to believe that several researchers inside the WIV became sick in autumn 2019, before the first identified case of the outbreak, with symptoms consistent with both COVID-19 and common seasonal illnesses. This raises questions about the credibility of WIV senior researcher Shi Zhengli’s public claim that there was “zero infection” among the WIV’s staff and students of SARS-CoV-2 or SARS-related viruses.¹⁰
- Starting in at least 2016, WIV researchers conducted experiments involving RaTG13, the bat coronavirus identified by the WIV in January 2020 as the closest sample to SARS-CoV-2 (96.2 percent similar).¹¹ There was no indication that this research was suspended at any time prior to the COVID-19 outbreak.
- The WIV has a published record of conducting “gain-of-function” research to engineer chimeric viruses.¹² But the WIV has not been transparent or consistent about its record of

⁷ NIH RePORTER, *Research Portfolio Online Reporting Tools* (queried Mar. 4, 2021), available at <https://reporter.nih.gov/search/qlYUeI9DIk2JfWUdCcWxcA/projects/charts>.

⁸ Mark Moore, *NIH investigating Wuhan lab at center of coronavirus pandemic*, NEW YORK POST (Apr. 28, 2020), available at <https://nypost.com/2020/04/28/nih-investigating-wuhan-lab-at-center-of-coronavirus-pandemic/>.

⁹ U.S. Department of State, *Fact Sheet: Activity at the Wuhan Institute of Virology*, Office of the Spokesperson (Jan. 15, 2021), available at <https://2017-2021.state.gov/fact-sheet-activity-at-the-wuhan-institute-of-virology/index.html>.

¹⁰ *Id.*

¹¹ *Id.*

¹² *Id.*

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 4

studying viruses similar to the COVID-19 virus, including “RaTG13,” which was sampled from a cave in Yunnan Province in 2013 after several miners died of SARS-like illness.¹³

- WHO investigators must have access to the records of the WIV’s work on bat and other coronaviruses before the COVID-19 outbreak. As part of a thorough inquiry, they must have a full accounting of why the WIV altered and then removed online records of its work with RaTG13 and other viruses.¹⁴
- Despite the WIV presenting itself as a civilian institution, the U.S. has determined that the WIV has collaborated on projects with China’s military.¹⁵ The WIV has engaged in classified research, including laboratory animal experiments, on behalf of the Chinese military since at least 2017.¹⁶
- The U.S. and other donors who funded or collaborated on civilian research at the WIV have a right and obligation to determine whether any of our research funding was diverted to secret Chinese military projects at the WIV.¹⁷

Notably, the State Department’s former lead investigator who oversaw the Task Force into the COVID-19 virus origin stated recently that he not only believes the virus escaped from the WIV, but that it may have been the result of research that the Chinese military, or People’s Liberation Army, was doing on a bioweapon.¹⁸

Accordingly, it is imperative to determine not only where SARS-CoV-2 originated, but also how and if NIH’s funding and research to projects at the WIV could have contributed to SARS CoV-2. To assist our requests and inquiry, please provide the following by April 19, 2021:

1. An assessment from a classified U.S. Defense Intelligence Agency (DIA) report included the possibility that the origins of SARS CoV-2 could have emerged accidentally from a laboratory in Wuhan, China due to unsafe laboratory practices.¹⁹ The DIA report cited U.S. government and Chinese researchers who found “about 33 percent of the original 41 identified cases did not have direct exposure” to the market.²⁰ That, along with what is known of the WIV’s work in past few years, raised reasonable suspicion that the

¹³ *Id.*

¹⁴ *Id.*

¹⁵ *Id.*

¹⁶ *Id.*

¹⁷ *Id.*

¹⁸ Jennifer Griffin, Former top State Dept. investigator says COVID-19 outbreak may have resulted from bioweapons research accident, Fox News (March 13, 2021), available at <https://www.foxnews.com/world/top-state-official-coronavirus-bioweapon-accident>

¹⁹ Fred Guterl, Naveed Jamali and Tom O’Connor, *The Controversial Experiments at Wuhan Lab Suspected of Starting the Coronavirus Pandemic*, NEWSWEEK (Apr. 27, 2020), available at <https://www.newsweek.com/controversial-wuhan-lab-experiments-that-may-have-started-coronavirus-pandemic-1500503>.

²⁰ *Id.*

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 5

pandemic may have been caused by a lab error, not a wet market.²¹ Further, a WHO inspector on the recent mission noted that “we know not all of those first 174 early COVID-19 cases visited the market, including the man diagnosed in December 2019 with the earliest onset date.”²² What information does the NIH have on the earliest COVID-19 cases?

2. According to an editorial on February 23, 2021, in *The Wall Street Journal* by former Secretary of State Mike Pompeo and Miles Yu, “[China’s] army of scientists claim to have discovered almost 2,000 new viruses in a little over a decade.”²³ How many of these discovered viruses does the NIH have information on and were any of these viruses discovered at the WIV?
3. According to *The Wall Street Journal* editorial mentioned in the previous question, some have alleged that the WIV’s virus-carrying animals were sold as pets and may even show up at local wet markets.²⁴ Is the NIH aware of these allegations? If so, please provide any information the NIH has related to these allegations.
4. Please provide all information that NIH has about laboratory accidents and/or biosafety practices at the WIV since January 1, 2015.
5. Please provide all information that NIH has from NIH staff, grantees, sub-grantees, contractors, or subcontractors about communications and events at the WIV from August 2019 to the present.
6. Please provide all information that NIH has from NIH staff, grantees, sub-grantees, contractors, or subcontractors about their communications with China-based NIH, Chinese National Science Foundation, CDC, and China CDC about events at the WIV from August 2019 to the present.

State Department Cables

²¹ *Id.*

²² Dominic Dwyer, I was the Australian doctor on the WHO’s COVID-19 mission to China. Here’s what we found about the origins of the coronavirus, *THE CONVERSATION* (Feb. 21, 2021), available at <https://www.theguardian.com/commentisfree/2021/feb/22/i-was-on-the-whos-covid-mission-to-china-heres-what-we-found>. See also Jeremy Page and Drew Hinshaw, *China Refuses to Give WHO Raw Data on Early Covid-19 Cases*, *THE WALL STREET JOURNAL* (Feb. 12, 2021), available at [https://www.wsj.com/articles/china-refuses-to-give-who-raw-data-on-early-covid-19-cases-11613150580#:~:text=BEIJING%E2%80%94Chinese%20authorities%20refused%20to,over%20the%20lack%20of%20detail](https://www.wsj.com/articles/china-refuses-to-give-who-raw-data-on-early-covid-19-cases-11613150580#:~:text=BEIJING%E2%80%94Chinese%20authorities%20refused%20to,over%20the%20lack%20of%20detail.). (“Chinese authorities refused to provide World Health Organization investigators with raw, personalized data on early Covid-19 cases that could help them determine how and when the coronavirus first began to spread in China, according to WHO investigators who described heated exchanges over the lack of detail. The Chinese authorities turned down requests to provide such data on 174 cases of Covid-19 that they have identified from the early phase of the outbreak in the Chinese city of Wuhan in December 2019. Investigators are part of a WHO team that this week completed a monthlong mission in China aimed at determining the origins of the pandemic.”)

²³ *Id.*

²⁴ Mike Pompeo and Miles Yu, *NIH Presses U.S. Nonprofit for Information on Wuhan Virology Lab*, *THE WALL STREET JOURNAL* (Feb. 23, 2021), available at <https://www.wsj.com/articles/chinas-reckless-labs-put-the-world-at-risk-11614102828>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 6

7. What information does NIH have about the WIV's responses to the 2018 U.S. Department of State cables (attached to this letter) regarding safety concerns?
8. The April 2018 cable from the U.S. Department of State stated that the WIV planned to invite University of Texas Medical Branch Galveston (UTMBG) researchers to do research in Wuhan's labs. Please provide any information NIH received that indicates whether the WIV invited UTMBG researchers, and whether UTMBG researchers conducted any research in Wuhan's labs.
 - a. If there was such research, please provide information and any documents related to this research.
9. Why was it pertinent to the NIH investigation that the "nonprofit [EcoHealth Alliance] must provide the "WIV's responses to the 2018 Department of State cables regarding safety concerns"?²⁵
 - a. Did EcoHealth Alliance provide this information? If so, how did NIH use the information to further its investigation?

EcoHealth Alliance, Columbia University Health Sciences

10. Was the 2019 NIH federal award to EcoHealth Alliance reviewed and approved by the HHS Potential Pandemic Pathogen Care and Oversight (P3CO) committee?²⁶
 - a. If so, please provide the documentation with the committee's decision.
 - b. Please also provide the names of the individuals who were members of the committee at the time.
11. Please provide all correspondence and communications between NIH and EcoHealth Alliance, since January 1, 2020, related to federal funding involving the WIV. The documentation should include, but not be limited to, correspondence between NIH and EcoHealth Alliance dated sometime in April 2020, on July 8, 2020, and sometime in August 2020.
12. In April 2020, NIH suspended a 2019 federal award to EcoHealth Alliance, in part, because NIH did not believe the work aligned with "program goals and agency priorities."²⁷ Please specify the work that was done by the EcoHealth Alliance that did

²⁵ Meredith Wadman, *NIH imposes 'outrageous' conditions on resuming coronavirus grant targeted by Trump*, SCIENCEMAG (Aug. 19, 2020), available at <https://www.sciencemag.org/news/2020/08/nih-imposes-outrageous-conditions-resuming-coronavirus-grant-targeted-trump>.

²⁶ National Institutes of Health, *Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Project* (Dec. 19, 2017), available at <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-071.html>.

²⁷ *Id.*

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 7

not align with the agency's program goals and priorities, and when that work was conducted.

- a. Was an evaluation of EcoHealth Alliance's work and whether it aligned with the agency's program goals and priorities conducted by the NIH before the award was issued? If yes, please provide any related documentation. If not, why not?
13. In April 2020 correspondence with EcoHealth Alliance, NIH wrote that it "received reports that the Wuhan Institute of Virology...has been conducting research at its facilities in China that pose serious bio-safety concerns."²⁸ What are the sources for those reports to NIH and what were the specific allegations reported?
14. Why did the NIH request that EcoHealth Alliance provide a sample of the pandemic coronavirus that the WIV used to determine its genetic sequence for SARS CoV-2?²⁹
- a. Why is this information important to NIH's investigation?
 - b. Has NIH obtained the sample and if so, what evaluations have been done, and for what purpose?
 - c. If NIH has not yet obtained the sample, what are the planned studies and evaluations NIH will conduct with the sample when it is obtained?
15. What is the nature of NIH's concerns about purported restrictions at the WIV including "diminished cell-phone traffic in October 2019, and the evidence that there may have been roadblocks surrounding the facility from October 14-19, 2019[.]" about the WIV lab or virus origin?³⁰
- a. What is the basis of information to NIH about the purported restrictions at the WIV?
 - b. What are the other purported restrictions at the WIV in October 2019?
16. After terminating EcoHealth Alliance's 2019 project entitled "Understanding the Risk of Bat Coronavirus Emergence," the NIH later offered to reinstate the EcoHealth Alliance funding in July 2020 if EcoHealth Alliance agreed to meet certain conditions.³¹

²⁸ Betsy McKay, *NIH Presses U.S. Nonprofit for Information on Wuhan Virology Lab*, THE WALL STREET JOURNAL (Aug. 19, 2020), available at <https://www.wsj.com/articles/nih-presses-u-s-nonprofit-for-information-on-wuhan-virology-lab-11597829400>.

²⁹ Meredith Wadman, *NIH imposes 'outrageous' conditions on resuming coronavirus grant targeted by Trump*, SCIENCEMAG (Aug. 19, 2020), available at <https://www.sciencemag.org/news/2020/08/nih-imposes-outrageous-conditions-resuming-coronavirus-grant-targeted-trump>.

³⁰ *Id.*

³¹ Betsy McKay, *NIH Presses U.S. Nonprofit for Information on Wuhan Virology Lab*, THE WALL STREET JOURNAL (Aug. 19, 2020), available at <https://www.wsj.com/articles/nih-presses-u-s-nonprofit-for-information-on-wuhan-virology-lab-11597829400>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 8

- a. Please provide all of the information presented to NIH from EcoHealth Alliance in response to NIH's conditions for reinstatement.
 - b. What actions did NIH take based upon the information received? How has the information been used in NIH's investigation?
 - c. One condition for the federal award reinstatement was for EcoHealth Alliance to arrange for an outside inspection of the WIV and its records, "with specific attention to addressing the question of whether WIV staff had SARS-CoV-2 in their possession prior to December 2019."³² Why is it pertinent to the NIH's investigation if staff at WIV had SARS-CoV-2 in their possession prior to December 2019? What is the potential significance if the staff did have the virus in their possession prior to December 2019?
 - d. What information does NIH have that was used for the basis of requesting that the EcoHealth Alliance "must 'explain the apparent disappearance' of a scientist who worked in the Wuhan lab," and on social media was rumored to be "patient zero" of the pandemic?³³
 - i. What is the potential significance about the whereabouts of this scientist and the photo being removed from the website?
17. Please provide all correspondence and communications between NIH and Columbia University related to federal funding involving the WIV, including email correspondence in April 2020 between Dr. Michael Lauer, Deputy Director of extramural research, and Naomi Schrag of Columbia University.
- a. In an April 2020 email, Dr. Lauer advised Naomi Schrag of Columbia University that it would be helpful for NIH "to know about all China-based participants in this work since the Type 1 grant started in 2014 - who they were and how much money they received."³⁴ Why did NIH request that Columbia University provide information about all of the China-based participants?
 - i. What is the pertinence of the timeframe starting in 2014 for the requested information?
 - ii. Did Columbia University provide the NIH with the requested information about all of the China-based participants from all grantees since 2014? If so, please provide the information. If not, why not?

Federal Funding Records

³² *Id.*

³³ *Id.*

³⁴ Meredith Wadman and Jon Cohen, *NIH's axing of bat coronavirus grant a 'horrible precedent' and might break rules, critics say*, SCIENCEMAG (Apr. 30, 2020), available at <https://www.sciencemag.org/news/2020/04/nih-s-axing-bat-coronavirus-grant-horrible-precedent-and-might-break-rules-critics-say>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 9

18. Please provide ledgers or any accounting for dispersion of all NIH federal funding awards that EcoHealth Alliance has sent to the WIV, including through contracts, grants, donations, cooperative agreements, staffing, or any other support or means. In addition, please provide the results and outcomes from the funding and support.³⁵
19. What is the total amount of NIH federal funding per year from 2017 through 2021 that has directly or indirectly supported the WIV scientists or research through grant recipients, including to EcoHealth Alliance; Wildlife Trust, Inc.; Columbia University Health Sciences; Trustees of Columbia University; University of North Carolina Chapel Hill; Vanderbilt University; University of Virginia; and Oregon Health and Science University?³⁶
20. According to a report in *The Washington Post* on April 14, 2020, the WIV issued a news release in English about the final visit from U.S. Embassy scientist diplomats in Beijing, which occurred on March 27, 2018.³⁷ Does the NIH have a copy of this news release? If so, please provide a copy.
21. For NIH award recipients that have provided support to the WIV since January 1, 2012, please provide annual reports, trip reports related to the WIV, documentation of any survey or field trips by the WIV, and interim data summaries from the WIV.
22. Please provide copies of all grantee annual reports, progress reports, projects, studies, and observations since 2014 where foreign sites for all Type 1 and Type 2 awards have been documented as involving the WIV.
23. Please provide copies of all grantee annual reports, progress reports, projects, studies, and observations since 2014 for NIH domestic grantee awards with a foreign component involving the WIV.
24. Please provide the name(s) of the NIH program manager(s) or officer(s) responsible for overseeing the grants to EcoHealth Alliance and time period(s) of responsibility.
25. Please provide the name(s) of the NIH Scientific Review Officers responsible for reviewing and approving any NIH financial awards to EcoHealth Alliance and any other funding recipients that supported the WIV.

³⁵ Betsy McKay, *NIH Presses U.S. Nonprofit for Information on Wuhan Virology Lab*, THE WALL STREET JOURNAL (Aug. 19, 2020), available at <https://www.wsj.com/articles/nih-presses-u-s-nonprofit-for-information-on-wuhan-virology-lab-11597829400>.

³⁶ National Institutes of Health, Research Portfolio online Reporting Tools, NIH RePorter available at <https://report.nih.gov/> (last accessed March 6, 2020).

³⁷ Josh Rogin, *Opinion: State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses*, THE WASHINGTON POST (Apr. 14, 2020), available at <https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/>.

Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 10

26. According to an editorial in *The Wall Street Journal*, the WIV housed tens of thousands of bat samples and laboratory animals in 2019.³⁸ Please provide any information the NIH has on the number of bat samples and animals at the WIV.
- a. Did any NIH scientists who are fluent in Mandarin review the Chinese scientific literature on the WIV research related to coronaviruses that is dated before February 1, 2020?
27. Does the NIH have the unpublished sequences of bat coronaviruses that were maintained in the WIV database before December 30, 2019, or before the database was removed from the internet?³⁹ Does NIH have the full sequences of the eight viruses sampled in the Yunnan province on an EcoHealth Alliance bat-virus sampling trip in 2015?
- a. Please provide NIH's analysis if the sequences have been analyzed.
- b. If NIH does not have the sequences, can NIH get this information from the EcoHealth Alliance or from other NIH-funded sources?
28. Please provide the original version of "Origin and cross-species transmission of bat coronaviruses in China" that was submitted to *Nature* by EcoHealth Alliance on October 6, 2019, published August 25, 2020, and funded in part by NIAID (award number R01AI110964).⁴⁰ If NIH does not have the October 6, 2019 report, can NIH obtain it from EcoHealth Alliance for this response? If so, please provide the report.
29. Have NIH, EcoHealth Alliance, or other NIH award recipient(s) been denied permission or access to results of any WIV research, which indirectly received financial support from NIH awards? If so, please provide the date(s), individuals involved, and circumstances of each denial.

We request that the NIH provide the requested documents and information in a coordinated response from all stakeholders and the appropriate divisions within NIH, including but not limited to subject matter experts from NIH's Division of Security and Emergency Response, the Office of Management Assessment, the Center for Scientific Review, the National Institute of Allergy and Infectious Diseases, and the Office of Extramural Research. After the requested information has been provided, we ask that the NIH provide a briefing to the Minority Committee staff to discuss the information that the NIH has related to the origins of SARS-CoV-2, including any potential links to the WIV. Finally, we request that you appoint an NIH working group representing an appropriate diversity of scientific disciplines to collect data and

³⁸ Mike Pompeo and Miles Yu, *NIH Presses U.S. Nonprofit for Information on Wuhan Virology Lab*, THE WALL STREET JOURNAL (Feb. 23, 2021), available at <https://www.wsj.com/articles/chinas-reckless-labs-put-the-world-at-risk-11614102828>.

³⁹ Washington Post Editorial Board, *We're still missing the origin story of this pandemic. China is sitting on the answers*, THE WASHINGTON POST (Feb. 5, 2021), available at <https://www.washingtonpost.com/opinions/2021/02/05/coronavirus-origins-mystery-china/?arc404=true>.

⁴⁰ Latinne, A., Hu, B., Olival, K.J. et al., *Origin and cross-species transmission of bat coronaviruses in China*, *Nature* (Aug. 25, 2020), available at <https://www.nature.com/articles/s41467-020-17687-3#Ack1>.


Letter to the Honorable Francis Collins, M.D., Ph.D.

Page 11

information related to COVID-19 origins (including the WIV), and that the NIH working group coordinate and consult with foreign scientific agencies involved in similar work.

Your assistance with this request is greatly appreciated. If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff.


Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Brett Guthrie
Republican Leader
Subcommittee on Health



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and Investigations

Attachment

Cc: The Honorable Frank Pallone, Chairman
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations
The Honorable Anna Eshoo, Chair, Subcommittee on Health

2018 Cables from Embassy Beijing and Consulate General Wuhan to State Department
Headquarters in Washington, D.C.

UNCLASSIFIED

UNCLASSIFIED

SBU



MRN: 18 BEIJING 138
Date/DTG: Jan 19, 2018 / 190739Z JAN 18
From: AMEMBASSY BEIJING
Action: WASHDC, SECSTATE ROUTINE
E.O.: 13526
TAGS: SHLH, ETRD, ECON, PGOV, CN
Captions: SENSITIVE
Reference: 17 WUHAN 48
Subject: China Opens First Bio Safety Level 4 Laboratory

1. (SBU) **Summary and Comment:** The Chinese Academy of Sciences (CAS) has recently established what is reportedly China's first Biosafety Level 4 (BSL-4) laboratory in Wuhan. This state-of-the-art facility is designed for prevention and control research on diseases that require the highest level of biosafety and biosecurity containment. Ultimately, scientists hope the lab will contribute to the development of new antiviral drugs and vaccines, but its current productivity is limited by a shortage of the highly trained technicians and investigators required to safely operate a BSL-4 laboratory and a lack of clarity in related Chinese government policies and guidelines. (b)(5)

(b)(5)

(b)(5)

End Summary and Comment.

China Investing in Infectious Disease Control

2. (U) Between November 2002 and July 2003, China faced an outbreak of Severe Acute Respiratory Syndrome (SARS), which, according to the World Health Organization, resulting in 8,098 cases and leading to 774 deaths reported in 37 countries. A majority of cases occurred in China, where the fatality rate was 9.6%. This incident convinced China to prioritize international cooperation for infectious disease control. An aspect of this prioritization was China's work with the Jean Merieux BSL-4 Laboratory in Lyon, France, to build China's first high containment laboratory at Wuhan's Institute of Virology (WIV), an institute under the auspices of the Chinese Academy of Sciences (CAS). Construction took 11 years and \$44 million USD, and construction on the facility was completed on January 31, 2015. Following

UNCLASSIFIED

Page 1 of 3

UNCLASSIFIED

two years of effort, which is not unusual for such facilities, the WIV lab was accredited in February 2017 by the China National Accreditation Service for Conformity Assessment. It occupies four floors and consists of over 32,000 square feet. WIV leadership now considers the lab operational and ready for research on class-four pathogens (P4), among which are the most virulent viruses that pose a high risk of aerosolized person-to-person transmission.

Unclear Guidelines on Virus Access and a Lack of Trained Talent Impede Research

3. (SBU) In addition to accreditation, the lab must also receive permission from the National Health and Family Planning Commission (NHFP) to initiate research on specific highly contagious pathogens. According to some WIV scientists, it is unclear how NHFP determines what viruses can or cannot be studied in the new laboratory. To date, WIV has obtained permission for research on three viruses: Ebola virus, Nipah virus, and Xinjiang hemorrhagic fever virus (a strain of Crimean Congo hemorrhagic fever found in China's Xinjiang Province). Despite this permission, however, the Chinese government has not allowed the WIV to import Ebola viruses for study in the BSL-4 lab. Therefore, WIV scientists are frustrated and have pointed out that they won't be able to conduct research project with Ebola viruses at the new BSL-4 lab despite of the permission.

(b)(6)

(b)(6)

Thus, while the BSL-4 lab is ostensibly fully accredited, its utilization is limited by lack of access to specific organisms and by opaque government review and approval processes. As long as this situation continues, Beijing's commitment to prioritizing infectious disease control - on the regional and international level, especially in relation to highly pathogenic viruses, remains in doubt.

(b)(6)

noted that the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory. University of Texas Medical Branch in Galveston (UTMB), which has one of several well-established BSL-4 labs in the United States (supported by the National Institute of Allergy and Infectious Diseases (NIAID of NIH)), has scientific collaborations with WIV, which may help alleviate this talent gap over time. Reportedly, researchers from GTMB are helping train technicians who work in the WIV BSL-4 lab. Despite this, (b)(6) they would welcome more help from U.S. and international organizations as they establish "gold standard" operating procedures and training courses for the first time in China. As China is building more BSL-4 labs, including one in Harbin Veterinary Research Institute subordinated to the Chinese Academy of Agricultural Sciences (CAAS) for veterinary research use (b)(6) the training for technicians and investigators working on dangerous pathogens will certainly be in demand.

Despite Limitations, WIV Researchers Produce SARS Discoveries

UNCLASSIFIED

Page 2 of 3

UNCLASSIFIED

6. (SBU) The ability of WIV scientists to undertake productive research despite limitations on the use of the new BSL-4 facility is demonstrated by a recent publication on the origins of SARS. Over a five-year study, (b)(6) (and their research team) widely sampled bats in Yunnan province with funding support from NIAID/NIH, USAID, and several Chinese funding agencies. The study results were published in PLoS Pathogens online on Nov. 30, 2017 (1), and it demonstrated that a SARS-like coronavirus isolated from horseshoe bats in a single cave contain all the building blocks of the pandemic SARS-coronavirus genome that caused the human outbreak. These results strongly suggest that the highly pathogenic SARS-coronavirus originated in this bat population. Most importantly, the researchers also showed that various SARS-like coronaviruses can interact with ACE2, the human receptor identified for SARS-coronavirus. This finding strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like disease. From a public health perspective, this makes the continued surveillance of SARS-like coronaviruses in bats and study of the animal-human interface critical to future emerging coronavirus outbreak prediction and prevention. (b)(5)

(b)(5) WIV scientists are allowed to study the SARS-like coronaviruses isolated from bats while they are precluded from studying human-disease causing SARS coronavirus in their new BSL-4 lab until permission for such work is granted by the NHFCP.

1. Hu B, Zeng L-P, Yang X-L, Ge X-Y, Zhang W, Li B, et al. (2017) Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 13(11): e1006698. <https://doi.org/10.1371/journal.ppat.1006698>

Signature: BRANSTAD

Drafted By:

Cleared By:

Approved By:

Released By:

Info:

CHINA POSTS COLLECTIVE ROUTINE

Dissemination Rule:

Archive Copy

UNCLASSIFIED

SBU

UNCLASSIFIED

Page 3 of 3

UNCLASSIFIED

UNCLASSIFIED

SBU



MRN: 18 WUHAN 38
Date/DTG: Apr 19, 2018 / 190551Z APR 18
From: AMCONSUL WUHAN
Action: WASHDC, SECSTATE ROUTINE
E.O.: 13526
TAGS: SHLH, PGOV, CN, PREL, TBIO, KGH, CDC, EAID, KHIV, IN, JP, TW, TSPL, PINS, SENV
Captions: SENSITIVE
Reference: A) 18 BEIJING 138
B) 17 BEIJING 2458
C) 11 MUMBAI 630
D) 17 TOKYO 716
E) 13 SEOUL 790
Subject: China Virus Institute Welcomes More U.S. Cooperation on Global Health Security

1. (SBU) **Summary with Comment:** China's Wuhan Institute of Virology, a global leader in virus research, is a key partner for the United States in protecting global health security. Its role as operator of the just-launched Biosafety Level 4 (or "P4") lab -- the first such lab in China -- opens up even more opportunities for expert exchange, especially in light of the lab's shortage of trained staff (Ref A). (b)(5)

(b)(5)

(b)(5)

End Summary with

Comment.

2. (U) Wuhan Institute of Virology researchers and staff gave an overview of the lab and current cooperation with the United States to visiting Environment, Science, Technology and Health Counsellor Rick Switzer and Consulate Wuhan Consul General Jamie Fouss in late March. In the last year, the institute has also hosted visits from the National Institutes of Health (NIH), National Science Foundation, and experts from the University of Texas Medical Branch in Galveston. The institute reports to the Chinese Academy of Sciences in Beijing.

P4 Lab is Open and Transparent, Officials Emphasize

3. (SBU) The Wuhan P4 lab, referring to labs with the highest level of safety precautions, became fully operational and began working with live viruses early this year. Institute officials said they believed it is the only operational P4 lab in Asia aside from a U.S. Centers for Disease

UNCLASSIFIED

Page 1 of 4

UNCLASSIFIED

Control (CDC)-supported facility in Pune, India (Ref C). China plans to stand up a second P4 lab in Harbin. Institute officials said Japan's biosafety labs are "old" and lack cutting-edge equipment, so they consider Japan's labs to be "P3 Plus" (Note: the Japanese government says it has one P4-level lab in the Tokyo suburbs, though its activities are limited, and Japan is building a new P4 lab in Nagasaki, see Ref D. Taiwan operates at least one P4 lab. South Korea was close to opening a P4 lab as of last year, see Ref E. End Note.) Wuhan's lab is located about 20 miles from the city center in Zhengdian district, and the institute plans to gradually consolidate its other training, classroom and lab facilities at that location.

4. (U) Officials described the lab as a "regional node" in the global biosafety system and said it would play an emergency response role in an epidemic or pandemic. The lab's English brochure highlighted a national security role, saying that it "is an effective measure to improve China's availability in safeguarding national bio-safety if [a] possible biological warfare or terrorist attack happens."

5. (SBU) Institute officials said there would be "limited availability" for international and domestic scientists who had gone through the necessary approval process to do research at the lab. They stressed that the lab aimed to be a "worldwide, open platform" for virology. They said they welcomed U.S. Centers for Disease Control (CDC) experts, noting that the Chinese Academy of Sciences was not strong on human disease expertise, having only focused on it in the last 15 years, after the SARS outbreak. A Wuhan-based French consulate official who works on science and technology cooperation with China also emphasized that the lab, which was initiated in 2004 as a France-China joint project, was meant to be "open and transparent" to the global scientific community. "The intent was to set up a lab to international standards, and open to international research," he said. French experts have provided guidance and biosafety training to the lab, which will continue, the French official said. Institute officials said that France provided the lab's design and much of its technology, but that it is entirely China-funded and has been completely China-run since a "handover" ceremony in 2016.

6. (U) In addition to French assistance, experts from the NIH-supported P4 lab at the University of Texas Medical Branch in Galveston have trained Wuhan lab technicians in lab management and maintenance, institute officials said. The Wuhan institute plans to invite scientists from the Galveston lab to do research in Wuhan's lab. One Wuhan Institute of Virology researcher trained for two years at the Galveston lab, and the institute also sent one scientist to U.S. CDC headquarters in Atlanta for six months' work on influenza.

NIH-Supported Research Revises SARS Origin Story

7. (U) NIH was a major funder, along with the Natural Science Foundation of China (NSFC), of SARS research by the Wuhan Institute of Virology's (b)(6) (b)(6)

(b)(6) (b)(6) This lends weight to the theory that SARS originated in bat populations before jumping first to civet cats (likely via bat feces) and then to humans. (b)(6)

(b)(6) (b)(6) (b)(6)

UNCLASSIFIED

Page 2 of 4

UNCLASSIFIED

(b)(6)

(b)(6) team has provided support in statistical modeling to assess the risk of more coronaviruses like SARS crossing over to human populations.

Ready to Help with the Global Virome Project

8. (U) Institute officials expressed strong interest in the Global Virome Project (GVP), and said Chinese funding for the project would likely come from Chinese Academy of Sciences funding already earmarked for One Belt, One Road-related initiatives. The GVP aims to launch this year as an international collaborative effort to identify within ten years virtually all of the planet's viruses that have pandemic or epidemic potential and the ability to jump to humans. "We hope China will be one of the leading countries to initiate the Global Virome Project," one Wuhan Institute of Virology official said. China attended a GVP unveiling meeting in January in Thailand and is waiting for more details on the initiative. The officials said that the Chinese government funds projects similar to GVP to investigate the background of viruses and bacteria. This essentially constituted China's own Virome Project, officials said, but they noted the program currently has no official name.

9. (SBU) The Wuhan Institute of Virology's (b)(6) is the (b)(6) (b)(6) which is designed to show "proof of concept" and be a forerunner to the Global Virome Project. (b)(6) with the EcoHealth Alliance (a New York City-based NGO that is working with the University of California, Davis to manage the (b)(6) recently planned to visit Wuhan to meet with (b)(6) (b)(6) noted that China has expressed interest in building the GVP database, which would put China in a leadership position. Other countries have confidence in China's ability to build such a database, but are skeptical on whether China could remain transparent as a "gatekeeper" for this information (b)(6) said (b)(6) expressed frustration with the slow progress so far in launching GVP, noting that the effort lacked funding sources, needed to hire a CEO, and would have to boost its profile at G7, G20 and other high-level international meetings.

U.S.-China Workshop Explores Research Partnerships

10. (U) The Institute also has ongoing collaboration with the U.S. National Science Foundation, including a just-concluded workshop in Shenzhen, involving about 40 scientists from the United States and China, on the topic of the "Ecology and Evolution of Infectious Diseases." Co-sponsored by the Natural Science Foundation of China (NSFC), (b)(6)

(b)(6) The workshop explored opportunities for U.S.-China research cooperation in areas like using "big data" to predict emerging infectious diseases, climate change's effect on vector-borne diseases, and pathogen transmission between wildlife, domestic animals and humans.

11. (SBU) Some workshop participants also expressed skepticism about the Global Virome Project's (GVP) approach, saying that gaining a predictive understanding of viruses with pandemic potential would require going beyond the GVP's strategy of sample collection, to take an "ecological" approach that considers the virome beyond vertebrate systems to identify

UNCLASSIFIED

Page 3 of 4

UNCLASSIFIED

mechanisms driving pathogen evolution. A follow-on workshop will be held in June at the University of Berkeley. NSF and NSFC hope to jointly announce a funding call for collaborative projects later this year.

Signature: FOUSS

Drafted By:

Cleared By:

(b)(5)

Approved By:

Released By:

Info:

CHINA POSTS COLLECTIVE ROUTINE

Dissemination Rule:

Archive Copy

UNCLASSIFIED

SBU

UNCLASSIFIED

Page 4 of 4

EXHIBIT 25

EXHIBIT 25

NYSCEF DOC. NO. 92
FRANK FALLONE, JR., NEW JERSEY
CHAIRMAN

RECEIVED NYSCEF: 02/04/2023
CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

June 10, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins:

As the committee of jurisdiction over public health, the Energy and Commerce Committee has authorizing responsibilities over the U.S. National Institutes of Health (NIH). We strongly support a comprehensive investigation into the origins of the COVID-19 pandemic, including the possibility of an accidental laboratory leak.

The Chinese Communist government has not yet allowed Chinese scientists to cooperate with an investigation into COVID-19 origins, and has admitted to destroying samples and records pertinent to such an investigation.¹ Thus, it is imperative we assemble all data and information in U.S. possession about bat coronavirus research experiments and lab safety protocols from all sources outside of China, particularly from EcoHealth Alliance (EHA). EHA is an NIH grantee who has been involved in bat coronavirus research in China and has issued grant subawards to the Wuhan Institute of Virology (WIV). It is also essential to collect information about the WIV, the laboratory that was conducting bat coronavirus experiments located in Wuhan, China, the epicenter of the COVID-19 outbreak. As a federal cognizant grant-making agency that funded bat coronavirus research at the WIV through EHA awards, NIH is in a unique position to publicly share detailed research reports in its possession. Importantly, NIH has full access to EHA records and EHA has refused to cooperate with our inquiry. Therefore, it is critical for NIH to cooperate with our objective fact-finding investigation as we continue to collect data about U.S. funded bat coronavirus research.

¹ Josh Chin, *China Told Labs to Destroy Coronavirus Samples to Reduce Safety Risks*, The Wall Street Journal (May 16, 2020) available at <https://www.wsj.com/articles/china-told-labs-to-destroy-coronavirus-samples-to-reduce-biosafety-risks-11589684291/>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 2

Since the Republican committee leaders March 18, 2021 letter to NIH, our investigation has found a number of additional issues that raise very serious concerns about the adequacy of NIH's oversight of grantees. The following newly found issues appear troubling and given the significance of these concerns, we expect the NIH to respond fully and substantively. Minority committee staff is continuing to work with your staff to schedule an NIH briefing. The NIH should be prepared to address these issues at the briefing, in addition to all of the questions from the March 18, 2021 letter that presently remain unanswered.

1. NIH's Award of \$2 million to EHA Despite Grant Suspension

On May 25, 2021, a spokesperson for EHA told Fox Business that its NIH funding is frozen and NIH did not give them guidance on when funds will be unfrozen.² EHA's representation about their NIH funding was not forthcoming. NIH terminated grant R01AI110964 to EHA entitled, "Understanding the Risk of Bat Coronavirus Emergence" in April 2020.³ NIH eventually converted the grant termination to a suspension on July 8, 2020, pending EHA's responses to seven requests from NIH related to WIV's actions. NIH could unfreeze the funding if EHA cooperates with NIH's requests, but apparently EHA has not yet done so. Despite EHA's obstruction of NIH requests, NIH gave new financial awards to EHA in June 2020 and August 2020, totaling \$2,127,602.⁴ By NIH authorizing new funding to EHA, an NIH-suspended grantee, the NIH undercut its July 8, 2020 suspension and has incentivized its grantees to defy NIH oversight with impunity.

2. NIH's Inadequate Oversight of EHA's Other Support

You testified during a May 25, 2021 Congressional hearing that NIH was, "...of course not aware of other sources of funds or other activities they might have undertaken outside of what our approved grant allowed," when asked about NIH grant recipient EHA, and the WIV, an EHA subaward recipient.⁵ Pursuant to the NIH Grants Policy, EHA was required to report all "other support," in-kind contributions such as laboratory space, equipment and supplies, and facilities and other resources for all individuals designated as the Principal Investigator (PI) personnel.⁶ Per the NIH grants policy, the grant Principal Investigator Dr. Peter Daszak and EHA were required to report its other research funding sources and activities to NIH.⁷ Without

² Fox News, *Biden State Department quietly ended team's work probing COVID origin*, State Department (May 25, 2021) available at <https://www.foxnews.com/politics/biden-state-department-shut-down-team-covid-origin-investigation>.

³ National Institutes of Health, *Understanding the Risk of Bat Coronavirus Emergence*, REPORTER (last accessed June 2, 2021) available at https://reporter.nih.gov/search/plodLH_U1kyZgyOhClrN2w/project-details/9320765#similar-Projects/.

⁴ USASpending.gov, *Cooperative agreement numbers U01AI151797 and U01AI153420*, EcoHealth Alliance available at

⁵ House Committee on Appropriations, *FY 2022 Budget Request for the National Institutes of Health*, Hearings (May 25, 2021) available at <https://appropriations.house.gov/events/hearings/fy-2022-budget-request-for-the-national-institutes-of-health>.

⁶ National Institutes of Health, *Other Support, Grants & Funding* (last accessed June 1, 2021) available at <https://grants.nih.gov/grants/forms/othersupport.htm>.

⁷ *Id.*

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 3

further details or documentation, your testimony bolsters the notion that NIH oversight is largely ignorant of other awards to the grantee.

3. NIH's Inadequate Oversight of EHA's Delinquent Financial Reports

As the prime recipient of NIH grant R01AI110964, EHA gave a total \$598,500 in five subaward transactions to the WIV from 2015 to 2019 for the WIV to, "conduct high-quality testing, sequencing, and analyses of field samples; maintenance of cold-chains from field to lab; ensuring quality control of sample storage and testing; collaborating on scientific publications and programmatic reporting."⁸ EHA also gave a total of \$201,217.10 in two subaward transactions to the Wuhan University School of Public Health (WUSPH) to "conduct targeted site-analyses, human behavioral surveillance including qualitative and quantitative surveys; analyses of data; collaborating on scientific publications and programmatic reporting," from 2016 through 2017.⁹

EHA is required to report its subawards to GSA's FFATA Subaward Reporting System (FSRS) by the end of the month following the month when the subaward was made.¹⁰ For example, when EHA issued a \$133,000 subaward to the WIV on May 29, 2015, EHA was required to report that subaward to FSRS by June 30, 2015.¹¹ USASpending is the U.S. government's open federal spending data source and when the grant number R01AI110964 data is downloaded, details reveal that EHA did not report subawards for that grant until 2020, even though EHA made subawards starting in 2015.¹² EHA reported all seven subaward transactions for R01AI110964 on July 13, 2020, five days following NIH's July 8, 2020 letter to EHA instructing EHA to ensure EHA reported all subaward data to FSRS.¹³ Before the year 2020, only one other EHA subaward grant is reported in USASpending.gov, in which three subaward transactions for NIH grant number R56TW009502 are recorded in 2014.¹⁴ EHA's apparent non-compliance of required financial reporting raises concerns about the adequacy of NIH oversight of NIH grants.

4. NIH's Possible Funding of EHA for Duplicative Research in China

EHA received federal funding as both a prime and sub-recipient not only from NIH, but also from the U.S. Agency for International Development (USAID) for its bat coronavirus research. The project descriptions and research articles are so similar that a distinction between the NIH bat coronavirus research objectives and achievements for the awards to EHA are almost interchangeable with EHA's USAID-funded bat coronavirus research objectives and

⁸ *Id.*

⁹ *Id.*

¹⁰ USASpending.gov, *Data Sources*, About (last accessed June 1, 2021), available at <https://www.usaspending.gov/about>.

¹¹ *Id.*

¹² USASpending.gov, *Advanced Search: Recipient – EcoHealth Alliance* (June 1, 2021) available at USASpending.gov/.

¹³ *Id.*

¹⁴ *Id.* See NIH grant number R56TW009502.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 4

achievements.¹⁵ The NIH grant progress reports will reveal details about the bat coronavirus research that can be compared to the reports from USAID-funded research. In its research funded by the USAID, EHA partnered with the WIV and with East China Normal University.¹⁶ We are very concerned that the NIH and USAID may have funded duplicate projects and that EHA partnered with additional unreported entities in China for NIH-funded research.

5. NIH's Inadequate Reconciliation of EHA's Grant Subawards

As far back as 2005, Peter Daszak of EHA has authored over 20 bat coronavirus and other zoonotic pathogen research articles with Dr. Zhengli Shi of the WIV, plus other researchers, about experiments funded by NIH.¹⁷ Their collaborative research has resulted in a 2005 publication entitled "Bats Are Natural Reservoirs of SARS-Like Coronaviruses," funded by NIH.¹⁸ In 2013, they published "Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor," funded by NIH and USAID.¹⁹ Their numerous publications acknowledge NIH as a research sponsor yet the only EHA support to the WIV in USASpending.gov was reported by EHA on July 13, 2020 (see concern number three above).²⁰ Vanity Fair reported that Dr. Shi "herself listed U.S. government grant support of more than \$1.2 million on her curriculum vitae: \$665,000 from the NIH between 2014 and 2019; and \$559,500 over the same period from USAID."²¹ EHA's late and potentially incomplete reporting of the WIV as its sub-award recipient raises questions about EHA's compliance with required financial reporting and also raises concerns about NIH's oversight of grant awards to EHA.

6. NIH's Inadequate Oversight of EHA's Place of Performance Reporting

The Federal Funding Accountability and Transparency Act of 2006 (FFATA) requires that federal award reporting must include the primary location of where the work will be performed, (including the city, state, congressional district, and country).²² For EHA's NIH awards, China is not listed as the place of performance in USASpending.gov and instead, EHA's

¹⁵ USASpending.gov, *Advanced Search: Recipient – EcoHealth Alliance* (June 1, 2021) available at USASpending.gov/.

¹⁶ USAID PREDICT-1 CONSORTIUM, *Reducing Pandemic Risk, Promoting Global Health*, Final Report (Dec. 2014) available at <https://ohi.sf.ucdavis.edu/sites/g/files/dgvnsk5251/files/files/page/predict-final-report-lo.pdf>.

¹⁷ NIH Reporter, *Anthropogenic change & emerging zoonotic paramyxoviruses*, Project Number 5R01TW005869-04 (Budget Start Date June 1, 2005) available at

<https://reporter.nih.gov/search/WMYBIQPE20aG4fAZLFj0lw/project-details/6923645#details>, NIH National Library of Medicine, *Advanced Search for 'Shi, Daszak'*, National Center for Biotechnology Information (June 2, 2021) available at https://pubmed.ncbi.nlm.nih.gov/?term=Daszak%2C+Shi&sort=date&sort_order=asc&size=200.

¹⁸ NIH National Library of Medicine, *Bats Are Natural Reservoirs of SARS-Like Coronaviruses*, PubMed (Sept. 5, 2005) available at <https://pubmed.ncbi.nlm.nih.gov/16195424/>.

¹⁹ Ge, XY., et al., *Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor*, *Nature* 503, 535–538 (May 16, 2013) available at <https://doi.org/10.1038/nature12711>.

²⁰ *Id.*

²¹ Katherine Eban, *The Lab-Leak Theory – Inside the Fight to Uncover COVID-19 Origins*, Vanity Fair (June 3, 2021) available at <https://www.vanityfair.com/news/2021/06/the-lab-leak-theory-inside-the-fight-to-uncover-covid-19s-origins>.

²² PL 109-282, Sept. 26, 2006 available at <https://www.govinfo.gov/content/pkg/PLAW-109publ282/pdf/PLAW-109publ282.pdf>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 5

primary place of performance is identified as New York.²³ The NIH grant documents, and the financial and progress reports we have requested will contain travel budgets and research details that will confirm the location(s) where EHA actually performed its research. Published research articles about NIH-funded experiments describe EHA's bat coronavirus research and surveillance activities often partnered with the WIV in China. We are very concerned about the discrepancy in EHA's primary place of performance as being New York in USASpending.gov when research articles, publications, and media interviews suggest EHA's primary place of performance is not domestic.²⁴

7. NIH's Lack of Visibility into EHA's Grant Subawards

USASpending.gov limits visible data to prime and subaward recipients, and does not disclose funds that are further disbursed subaward recipients.²⁵ EHA is a subaward recipient of NIH grant funds from the Arizona State University and the Trustees of Columbia University in New York City.²⁶ As a subaward recipient, EHA does not publicly report when it further distributes subaward funds to other organizations such as the WIV or other recipients in China.²⁷ NIH questions to EHA in the July 8, 2020 grant suspension letter suggest that NIH lacks information and visibility on sub-grant awards that are either issued or received by EHA.²⁸

8. NIH's Inadequate Oversight of EHA's Grant Fund Accounting

In our April 18, 2021 letter to EHA, we raised the issue that EHA reported a \$319,570 cash award grant and a \$126,792 cash award grant disbursed by wire to China for the purpose of "[u]nderstanding the risk of bat coronavirus emergence" on its IRS Form 990, calendar year 2016.²⁹ EHA reported giving \$321,700 for coronavirus and emerging diseases to China on its IRS Form 990, calendar year 2015.³⁰ EHA IRS Form 990's for other years do not include that purpose or identify the WIV as an organization to which funds were paid. With EHA organized as a 501 (c)(3) non-profit organization, its IRS Form 990's are public documents able to be reviewed by NIH. As a non-federal entity that expends more \$750,000 or more in federal funds in one year, EHA is required to submit a Single Audit report, previously known as the OMB Circular A-133 audit. The purpose of a Single Audit report is to provide assurance to the Federal Government that a non-federal entity has adequate internal controls in place, and is generally in

²³ *Id.*

²⁴ Nidhi Subbaraman, 'Heinous!': Coronavirus researcher shut down for Wuhan-lab link slams new funding restrictions, *Nature* (Aug. 21, 2020), available at <https://www.nature.com/articles/d41586-020-02473-4>.

²⁵ USASpending.gov, *Advanced Search: Recipient - EcoHealth Alliance* (June 1, 2021) available at [USASpending.gov/](https://www.usaspending.gov/).

²⁶ *Id.*

²⁷ *Id.*

²⁸ Internal Revenue Service, EHA 990 final, Schedule F, Parts I and II (May 3, 2017) available at https://apps.irs.gov/pub/epostcard/cor/311726494_201606_990_2017090514700974.pdf.

²⁹ U.S. Energy and Commerce Republicans, *Letter to EcoHealth Alliance*, The COVID-19 Origins Investigation (Apr. 16, 2021) available at <https://republicans-energycommerce.house.gov/the-covid-19-origins-investigation/>.

³⁰ Internal Revenue Service, EHA 990 final 2015, Schedule F, Parts I and II (May 3, 2017) available at https://apps.irs.gov/pub/epostcard/cor/311726494_201606_990_2017090514700974.pdf.

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 6

compliance with program requirements.³¹ In EHA's Single Audit reports for years 2016 to 2020, no payments are evident for EHA funds paid to the WIV.³²

9. NIH's Inadequate Oversight of Its Funded Researchers in China

The WIV named NIH and EHA on its website as WIV international partner as of and prior to the date of our March 18, 2021 letter to NIH.³³ By March 22, 2021, the WIV had removed NIH as a partner from its website.³⁴ The NIH has characterized its relationship Chinese scientists as respectable scientific partners.³⁵ However, within three days following our letter to NIH which inquired about NIH grants to the WIV, the WIV quickly concealed its long-standing relationship with NIH by deleting evidence of its NIH partnership from its website. This action does not seem consistent with NIH's claim that the WIV and its scientists were a respectable scientific partner. It has been reported that some Chinese scientists working with EHA are current or former members of the People's Liberation Army of China.³⁶ It has also been reported that the Chinese military were conducting research at the WIV.³⁷ We are concerned that NIH-funded coronavirus research in China may not have undergone proper biodefense risk analysis.

10. NIH's Lack of Cooperation with Congressional Oversight Inquiry

NIH is supposed to be a transparent institution and the grant documents we requested should be a matter of public record.³⁸ Contrary to your public statement implying that we asked for "pretty sensitive materials, not quite classified, but getting close to that," the grant documents we requested are releasable to the public per NIH's own policy and should have already been provided to us.³⁹

As you are aware, the NIH grant documents and progress reports we requested will include details pertinent to our COVID-19 origins investigation, including information about: all research participants and collaborating organizations; location(s) of work performed; instruments, equipment and monies provided to grant sub-recipients; financial accounting

³¹ U.S. Department of Health and Human Services, *Single Audit* (Apr. 25, 2016) available at <https://www.hhs.gov/about/agencies/asfr/data-act-program-management-office/single-audit/index.html>.

³² Federal Audit Clearinghouse, *EcoHealth Alliance, Inc and Wildlife Preservation Trust Int. Single Audit Reports 2017-2021* (June 7, 2021) available at <https://facdissem.census.gov/SearchResults.aspx>.

³³ Internet Archive Wayback Machine, *Wuhan Institute of Virology, CAS, Partnerships* (Mar. 18, 2021) available at https://web.archive.org/web/20210318052528/http://english.whiov.cas.cn/International_Cooperation2016/Partnerships/.

³⁴ Internet Archive Wayback Machine, *Wuhan Institute of Virology, CAS, Partnerships* (Mar. 22, 2021) available at https://web.archive.org/web/20210322053537/http://english.whiov.cas.cn/International_Cooperation2016/Partnerships/.

³⁵ House Committee on Appropriations, *FY 2022 Budget Request for the National Institutes of Health*, Hearings (May 25, 2021) available at <https://appropriations.house.gov/events/hearings/fy-2022-budget-request-for-the-national-institutes-of-health>.

³⁶ Alexis, Shi Zhengli: Weaponizing Coronaviruses, with Pentagon Funding, at a Chinese Military Lab, <https://enviroshop.com/shi-zhengli-weaponizing-coronaviruses-with-pentagon-funding-at-a-chinese-military-lab/>.

³⁷ *Id.*

³⁸ National Institutes of Health, *NIH Grants Policy Statement*, Policy and Compliance (June 1, 2021) available at <https://grants.nih.gov/policy/nihgps/index.htm>.

³⁹ *Id.*

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 7

reports; research techniques and accomplishments; research products such as: technologies, patent applications, data or databases, physical collections, and models; significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents; and budgetary information and project outcomes.⁴⁰

As the federal grant awarding agency, NIH must have the right of access to any of EHA's documents or other records which are pertinent to NIH federal awards.⁴¹ The NIH grants policy states that the Freedom of Information Act (FOIA) and U.S. Department of Health and Human Services regulations require NIH to release certain grant documents and records requested by members of the public, regardless of the intended use of the information.⁴² Per NIH policy, NIH will generally release funded applications and progress reports pursuant to a FOIA request.⁴³ NIH considers most grant-related information in the application or post-award phases as being public information (emphasis added).⁴⁴

In support of this inquiry and the public interest in the origins of the COVID-19 pandemic, please provide written responses to the following by June 24, 2021:

1. We again renew our request for NIH's immediate compliance with our oversight inquiry for production of the grant documents and progress reports forthwith that we first requested on March 18, 2021.
2. What is NIH's policy for awarding funds to organizations when the organization has NIH grant funds in suspended status and are not cooperating NIH requests? If the NIH permits new award funding under these circumstances, please provide the policy, and explain how such funding does not undercut NIH's ability to oversee grantees and does not incentivize grantees to defy NIH's requests for information.
3. Please explain all oversight steps NIH has taken to ensure EHA's full compliance with federal financial subaward reporting requirements for all NIH grants. Please explain if EHA reported to NIH any subaward recipients other than the WIV or the WUSPH for NIH grant R01AI110964. Please provide all financial records of all NIH funds given to Dr. Zhengli Shi of the WIV.
4. For all NIH awards in which EHA was a subrecipient, please provide a financial accounting of EHA's subawards to the WIV or other organizations in China.

⁴⁰ Hugh Hewitt, *Dr. Francis Collis On The U.S. Funding of the Wuhan Lab and Congressional Oversight*, The Hugh Hewitt Show (June 2, 2021) available at <https://hughhewitt.com/dr-francis-collins-on-the-u-s-funding-of-the-wuhan-lab-and-congressional-oversight/>, National Institutes of Health, *Research Performance Progress Report, Grants & Funding* (May 4, 2021) available at <https://grants.nih.gov/grants/rppr/index.htm>.

⁴¹ *Id.*

⁴² National Institutes of Health, *NIH Grants Policy Statement*, Policy and Compliance (June 1, 2021) available at <https://grants.nih.gov/policy/nihgps/index.htm>.

⁴³ *Id.*

⁴⁴ *Id.*

Director Francis Collins, M.D., Ph.D.


June 10, 2021

Page 8

5. How does NIH ensure it does not award unapproved duplicate grants for same or similar research already funded by other agencies, to EHA or other NIH grant recipients? For all NIH awards to EHA, please provide accounting information for EHA subawards to recipients in China.
6. Please explain how NIH has reviewed EHA annual Single Audit reports to ensure how EHA has met program and reporting requirements.
7. How does NIH audit the financial reports submitted to the IRS by its 501(c)(3) non-profit organization grant award recipients to ensure NIH awards are accurately reported? How does NIH ensure its grantees do not act as a pass-through or money laundering provider to send U.S. research funding to China?
8. Please explain NIH's policy for ensuring its awardees accurately report the actual place of research performance. For all NIH-funded research, please provide all China site locations where EHA's work was performed.
9. Please explain if EHA reported its other funding or in-kind support, including awards from federal agency, to NIH. Please explain if EHA reported any support from organizations in China.
10. Did NIH perform a biodefense risk analysis for coronavirus research conducted at the WIV as research with potential for dual use of research concern, pandemic pathogen or bioweapon development, as outlined in the HHS *Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens*?⁴⁵ Please describe NIH's coordination procedures with the U.S. Intelligence Community that are completed before NIH funds research projects in foreign countries with existing biodefense programs.

Please make arrangements to schedule the briefing for Committee staff by June 24, 2021. If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff. Thank you for your attention to this request.

Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Fred Upton
Republican Leader
Subcommittee on Energy

⁴⁵ U.S. Department of Health and Human Services, *Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens*, Science Safety Security (Dec. 2017) available at <https://www.phe.gov/s3/dualuse/Pages/p3co.aspx>.

Director Francis Collins, M.D., Ph.D.

June 10, 2021


Page 9



Bob Latta
Republican Leader
Subcommittee on Communications and
Technology



Brett Guthrie
Republican Leader
Subcommittee on Health



David McKinley
Republican Leader
Subcommittee on Environment and
Climate Change



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and
Investigations



Gus Bilirakis
Republican Leader
Subcommittee on Consumer Protection and
Commerce



Michael C. Burgess, M.D.
Member of Congress



Steve Scalise
Member of Congress



Adam Kinzinger
Member of Congress

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 10




Bill Johnson
Member of Congress



Billy Long
Member of Congress



Larry Bucshon, M.D.
Member of Congress




Markwayne Mullin
Member of Congress




Richard Hudson
Member of Congress



Tim Walberg
Member of Congress



Earl L. "Buddy" Carter
Member of Congress



Jeff Duncan
Member of Congress



Gary Palmer
Member of Congress



Neal P. Dunn, M.D.
Member of Congress

Director Francis Collins, M.D., Ph.D.

June 10, 2021

Page 11



John Curtis
Member of Congress




Debbie Lesko
Member of Congress



Greg Pence
Member of Congress



Dan Crenshaw
Member of Congress



John Joyce, M.D.
Member of Congress



Kelly Armstrong
Member of Congress

EXHIBIT 26

EXHIBIT 26

FRANK PALLONE, JR., NEW JERSEY
CHAIRMANCATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States**House of Representatives****COMMITTEE ON ENERGY AND COMMERCE**

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

July 21, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins,

According to its mission statement, a goal of the National Institutes of Health (NIH) is “to exemplify . . . the highest level of scientific integrity and public accountability.”¹ However, under your leadership, the NIH is falling short of that goal. On March 18, 2021, we sent NIH a detailed, eleven-page request for information about origins of the COVID-19 pandemic, which the public deserves to see. Three months later, the NIH has refused to cooperate with that request. The NIH has not provided a single document to us or made any document available to the public that responds directly to the paramount question of whether NIH funding played a role in risky research in China that could have started the pandemic.

We specifically requested documents related to National Institute of Allergy and Infectious Diseases (NIAID) grant R01AI110964, “Understanding the Risk of Bat Coronavirus Emergence” to EcoHealth Alliance that in part funded the Wuhan Institute of Virology (WIV) research into bat coronaviruses. The NIH has not provided the documents and did not provide written responses to any of the 29 questions in the March 18th letter. Instead, the NIH only provided a one-hour oral briefing to bipartisan committee staff with no documents to address any of the topics covered by the 29 questions in the March 18th letter. Additionally, no subject matter experts from the NIAID were included in the briefing, even though we specifically requested to hear from NIAID, which is the NIH institute responsible for issuing this grant. The only written response provided by the NIH was a two-page May 21, 2021, letter signed by NIH Principal Deputy Director Lawrence Tabak that did not address any of the questions in the March 18th letter, but instead stated:

¹ National Institutes of Health, *Mission and Goals*, What We Do (accessed July 14, 2021) available at <https://www.nih.gov/about-nih/what-we-do/mission-goals>.

Letter to The Honorable Francis Collins

Page 2

The application [from EcoHealth Alliance] was subjected to rigorous peer review and did not propose research to enhance any coronavirus to be more transmissible or virulent. The research proposed in the grant application sought to understand how bat coronaviruses evolve naturally in the environment to become transmissible to the human population. This included studying viral diversity in bat reservoirs, surveying people who work in live animal markets or other jobs with high exposure to wildlife for evidence of bat-coronavirus infection, and analyzing data to predict which newly discovered viruses pose the greatest threat to human health. To support its work, EcoHealth made sub-awards to the Wuhan Institute of Virology and other institutions based in East Asia where coronaviruses tend to emerge and are prevalent. NIH is not currently funding the Wuhan Institute of Virology.²

In addition, the NIH has denied supporting “gain-of-function” research at the WIV through this NIAID grant. For example, NIAID Director Dr. Anthony Fauci testified, “The NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology.”³ You also stated: “Let me be very clear, we never approved any grant that would have supported gain of function research on dangerous coronaviruses to see if they could be more transmissible or lethal for individuals in the human species.”⁴ Yet, the NIH has declined to produce the underlying grant documents and records to substantiate these assertions. Importantly, the NIH has not provided complete information about exactly what the NIH did support at the WIV.

Based on published reports over the last few months and the NIH’s June 28, 2021, briefing with bipartisan committee staff, we have reason to believe that the NIH may have funded humanized mice experiments at the WIV, and that such experiments may have had the potential to start the pandemic. This recent information seems contrary to NIH’s characterizations of the EcoHealth grant and WIV research at issue.

Further, recent documents obtained under the Freedom of Information Act (FOIA) reveal that an NIAID official visited the WIV in 2017, and that NIAID had familiarity with the WIV research on bat coronaviruses and that some of these viruses could be transmissible to humans.

² NIH did not identify by name the “other institutions based in East Asia where coronaviruses tend to emerge and are prevalent” in its letter. The only institution (singular) other than the WIV reported by EcoHealth Alliance as a sub-grant recipient for this grant is the Wuhan University, the same institution from which a researcher requested NIH to remove its submissions to the NIH Sequence Read Archive (SRA) database and NIH removed them. Dr. Jesse Bloom of the Fred Hutchinson Cancer Center recovered some of the removed sequence data and determined that the sequences related to the SARS CoV-2 early Chinese COVID-19 patients.

³ Lori Robertson, *The Wuhan Lab and the Gain-of-Function Disagreement*, FactCheck.org (July 1, 2021) available at <https://www.factcheck.org/2021/05/the-wuhan-lab-and-the-gain-of-function-disagreement/>. We note collaborative projects between Dr. Ralph Baric of the University of North Carolina at Chapel Hill and the WIV, have produced research articles that describe Gain-of-Function research experiments when the WIV was technically funded through a USAID cooperative agreement facilitated by a consortium that included EcoHealth Alliance.

⁴ Samuel Chamberlain, NIH head accuses Rand Paul of ‘misinformation’ about US ties to Wuhan lab New York Post (May 14, 2021) available at <https://nypost.com/2021/05/14/nih-head-accuses-rand-paul-of-misinformation-about-us-ties-to-wuhan-lab/>.

Letter to The Honorable Francis Collins

Page 3

NIAID indirectly continued to fund the WIV research despite concerns about biosafety practices at the WIV raised in 2018 State Department cables, which were based in part on the NIAID visit in 2017.

First, we note that the FY 2018 abstract for the EcoHealth Alliance NIAID “Understanding the Risk of Bat Coronavirus Emergence” grant renewal openly discussed experiments with humanized mice. The abstract for the project declared that aim number three of the research project was to: “3. Test predictions of CoV inter-species transmission. Predictive models of host range (i.e. emergence potential) will be tested experimentally using reverse genetics, pseudovirus and receptor binding assays, and virus infection experiments across a range of cell cultures from different species and **humanized mice**.” (emphasis added).⁵ As noted by science writer Nicholas Wade, in such experiments, “laboratory mice, a cheap and ethical stand-in for human subjects, are genetically engineered to carry the human version of a protein called ACE2 that studs the surface of cells that line the airways.”⁶

Second, a recent article in Vanity Fair reported that the WIV and its bat coronavirus research director, Dr. Shi Zhengli, were involved with experiments in humanized mice in recent years. The article stated that “Shi’s own comments to a science journal, and grant information available on a Chinese government database, suggest that in the past three years her team has tested two novel but undisclosed bat coronaviruses on humanized mice, to gauge their infectiousness.”⁷

Third, such experiments have pandemic potential. As the EcoHealth Alliance wrote in the FY 2019 abstract for this same NIH grant, “We will use S protein sequence data, infectious clone technology, in vitro and in vivo infection experiments and analysis of receptor binding to test the hypothesis that % divergence thresholds in S protein sequences predict spillover potential.”⁸ Mr. Wade further explained the implications of this research:

What this means, in non-technical language, is that Shi set out to create novel coronaviruses with the highest possible infectivity for human cells. Her plan was to take genes that coded for spike proteins possessing a variety of measured affinities for human cells, ranging from high to low. She would insert these spike genes one by one into the backbone of a number of viral genomes (“reverse genetics” and “infectious clone technology”), creating a series of chimeric viruses. These chimeric viruses would then be tested for their ability to attack human cell cultures (“in vitro”) and humanized mice (“in vivo”). And this information would help

⁵ Grantome NIH, Abstract for Understanding the Risk of Bat Coronavirus Emergence, EcoHealth Alliance Inc. FY 2018 available at <https://grantome.com/grant/NIH/R01-AI110964-05>.

⁶ Nicholas Wade, *The origin of COVID: Did people or nature open Pandora’s box at Wuhan?*, Bulletin of the Atomic Scientists, (May 5, 2021), available at <https://thebulletin.org/2021/05/the-origin-of-covid-did-people-or-nature-open-pandoras-box-at-wuhan/>.

⁷ Katherine Eban, *The Lab Leak Theory: Inside the Fight to Uncover COVID 19’s origins*, Vanity Fair (June 3, 2021), available at <https://www.vanityfair.com/news/2021/06/the-lab-leak-theory-inside-the-fight-to-uncover-covid-19s-origins>.

⁸ Grantome NIH, Abstract for Understanding the Risk of Bat Coronavirus Emergence, EcoHealth Alliance Inc. FY 2019 available at <https://grantome.com/grant/NIH/R01-AI110964-05>.

Letter to The Honorable Francis Collins

Page 4

predict the likelihood of “spillover,” the jump of a coronavirus from bats to people.

The methodical approach was designed to find the best combination of coronavirus backbone and spike protein for infecting human cells. The approach could have generated SARS2-like viruses, and indeed may have created the SARS2 virus itself with the right combination of virus backbone and spike protein.⁹

From his review of WIV research, Dr. Richard Ebright, a molecular biologist and biosafety expert at Rutgers University, stated, “It is clear that the Wuhan Institute of Virology was systematically constructing novel chimeric coronaviruses and was assessing their ability to infect human cells and human-ACE2-expressing mice.”¹⁰ He further stated, “It is also clear that, depending on the constant genomic contexts chosen for analysis, this work could have produced SARS-CoV-2 or a proximal progenitor of SARS-CoV-2.”¹¹

Even Dr. Peter Daszak, the President of EcoHealth Alliance, noted the humanized mice and the risks of this research in a December 2019 interview.¹² Around minute 28 of the interview, Dr. Daszak stated:

And we have now found, you know, after 6 or 7 years of doing this, over 100 new SARS-related coronaviruses, very close to SARS. Some of them get into human cells in the lab, some of them can cause SARS disease in humanized mice models and are untreatable with therapeutic monoclonals and you can’t vaccinate against them with a vaccine. So, these are a clear and present danger....¹³

Likewise, Dr. Steven Quay noted the unique characteristic of efficient human-to-human transmission of SARS-CoV-2 in his testimony before the June 29, 2021, House Republican Forum that the SARS CoV-2 virus was “highly adapted for infection of humans from the start, unlike prior natural zoonoses. And growth in humanized mice would allow this lab [adaptation],”¹⁴ like in a March 2020 published paper by Dr. Ralph Baric of University of North Carolina and Dr. Shi of the WIV.

Fourth, the NIH in the June 28, 2021, staff briefing acknowledged that the NIH-funded research at the WIV involved mice. One of the two NIH briefers, Dr. Tabak stated that the only animals that were used in this NIH-funded research at the WIV were mice. However, to date, the

⁹ Wade, note 5.

¹⁰ *Id.*

¹¹ *Id.*

¹² Vincent Racaniello, *TWiV 615: Peter Daszak of EcoHealth Alliance - YouTube*, This Week in Virology, (May 19, 2020), available at https://www.youtube.com/watch?app=desktop&v=IdYDL_RK--w.

¹³ *Id.*

¹⁴ Led By Science: The COVID-19 Origin Story: Forum Before Select Subcomm. on the Coronavirus Crisis, H. Comm. on Oversight & Reform, 117th Cong. (June 29, 2021) (statement by Dr. Steven Quay).

Letter to The Honorable Francis Collins

Page 5

NIH has not clarified to the Committee whether the mice used in the NIH-supported research were *humanized* mice.

Fifth, humanized mice have not been ruled out as an intermediate animal host. According to the World Health Organization joint study with China, more than 80,000 animal samples were tested with no positive results for either SARS CoV-2 antibodies or for the virus itself in an attempt to identify the intermediate animal host to support the zoonotic origins theory.¹⁵ There is no evidence that any of these samples included samples of humanized mice at the WIV.

Finally, on October 26, 2017, Dr. Ping Chen, the Director of the NIAID office in China located in the U.S. embassy in Beijing, wrote to several NIAID officials stating that earlier in the week she had visited the P4 lab at the WIV and that her contact who helped arrange the visit was Dr. Zhengli Shi, “who is a Chinese collaborator on a NIAID grant to EcoHealth for SARS like corona virus project.”¹⁶

Unfortunately, the rest of this email and the trip report were redacted. But, in an April 15, 2020, email sent to Gray Handley of the NIAID with the subject “FW: 2018 Cable” with the January 2018 State Department cable attached, Dr. Chen stated: “Rick forwarded the cable. I was listed as a drafter. About half of the content was taken from my summary.”¹⁷ The January 2018 State Department cable discussed the BSL-4 lab at the WIV, China investing in infectious disease control, unclear guidelines on virus access, the lack of trained talent impeding research, and despite limitations, WIV researchers produce SARS discoveries. For the last topic, the cable noted the WIV research finding “strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like disease.”¹⁸ These redacted documents provide a reason to believe that the NIH – or at least the NIAID – had a much higher level of engagement and familiarity with the EcoHealth Alliance grant and WIV bat coronavirus research than just reading press reports during April-July 2020 as NIH suggested at the June 28, 2021, briefing with bipartisan Committee staff.¹⁹

Over 600,000 Americans have died from COVID-19 and more than 4 million people worldwide. We need answers to some basic questions about the origin of the virus, and yet, the NIH continues to frustrate our efforts to get answers. The stakes are too high to operate on an

¹⁵ World Health Organization, *WHO-convened Global Study of the Origins of SARS-CoV-2* (March 30, 2021) available at <https://www.who.int/health-topics/coronavirus/origins-of-the-virus>.

¹⁶ Judicial Watch, *Judicial Watch: New Documents Show Wuhan Lab Asked NIH Official for Information on Disinfectants; Nine Fauci Agency Grants for EcoHealth Bat Coronavirus Research*, Press Releases (July 8, 2021) available at <https://www.judicialwatch.org/press-releases/wuhan-lab-fauci-grants/>.

¹⁷ *Id.*

¹⁸ Josh Rogin, *Opinion: State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses*, The Washington Post (April 14, 2020) available at <https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/>.

¹⁹ Based on the questions the NIH Office of Extramural Research asked EcoHealth Alliance, it is unclear that NIH maintained control, oversight or responsibility of EcoHealth Alliance as its grantee. For example, in an April 2020 email to EcoHealth Alliance, the NIH Deputy Director of Extramural Research, Dr. Michael Lauer, asked EcoHealth Alliance for information about this same grant, to include, “...it would be helpful for us to know about *all* China-based participants in this work since the Type 1 grant started in 2014 - who they were and how much money they received.”

Letter to The Honorable Francis Collins


Page 6

honor system. This not only undermines NIH's mission goals, but also Congress' and the public's trust in the NIH. It is time for the NIH to share all information and documents that it has related to NIAID grant R01AI110964 with the public and the scientific community.

Therefore, we request that the NIH provide all documents related to the October 2017 visit to the WIV, all documents related to NIAID grant R01AI110964, and the identities of the "other institutions" referenced in NIH's May letter by July 28, 2021. In addition, we request staff briefings immediately and no later than July 28, 2021, with the following officials from NIAID: Dr. Ping Chen and Dr. Erik Stemmy, the program officer for NIAID grant R01AI110964.

If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff.


Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Brett Guthrie
Republican Leader
Subcommittee on Health



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and Investigations

CC: The Honorable Frank Pallone, Chairman
The Honorable Anna Eshoo, Chair, Subcommittee on Health
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations

EXHIBIT 27

EXHIBIT 27

FRANK PALLONE, JR., NEW JERSEY
CHAIRMANCATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States**House of Representatives****COMMITTEE ON ENERGY AND COMMERCE**

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

August 24, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins,

We have significant concerns that the National Institutes of Health (NIH) has not been adequately meeting its oversight responsibilities over the National Institute of Allergy and Infectious Diseases (NIAID) grant R01AI110964, "Understanding the Risk of Bat Coronavirus Emergence." The grant was awarded to the non-profit organization, EcoHealth Alliance, that funneled NIH funds to the Wuhan Institute of Virology (WIV) to conduct research on bat coronaviruses. In our July 21, 2021, letter to you, we requested that the NIH provide staff briefings with Dr. Ping Chen and Dr. Erik Stemmy, NIAID officials involved with this grant and responsibility for oversight of the WIV. Unfortunately, the NIH has ignored this request.

In addition to potentially inadequately assessing the inherent risks of the WIV research supported by NIH's grant, we are also concerned that the NIH failed to oversee biosafety concerns at the WIV. The WIV is a complex of laboratories with various Biosafety Level (BSL) levels up to a BSL-4, the most secure biosafety level laboratory. However, under the R01AI110964 grant, the WIV researchers specifically reported performing coronavirus research in BSL-2 laboratories.¹ Yet, risky coronavirus research should have been conducted in a laboratory with higher safety measures.

The grant award R01AI110964 was subject to biosafety requirements as acknowledged by NIH in its the July 8, 2020, grant suspension letter to EcoHealth Alliance: "NIH grantees and subawardees must comply with the biosafety requirements set forth in the NIH Grants Policy

¹ Lei-Ping Zeng, Peter Daszak, Zheng-Li Shi, et al, *Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response*, ASM Journal of Virology (June 24, 2016) available at <https://journals.asm.org/doi/full/10.1128/JVI.03079-15>,

Letter to the Honorable Francis Collins

Page 2

Statement (*see* NIH GPS, § 4.1.24 ‘Public Health Security’) and the Notice of Award (*e.g.*, requiring that ‘Research funded under this grant must adhere to the [CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL)]’).

These requirements are especially relevant given the history of serious lab accidents in China.² In 1977, the H1N1 influenza virus escaped from a lab in China that caused a worldwide pandemic.³ Two lab escapes of the first SARS virus in China were reported in the spring of 2004.⁴ Most recently in November 2019, an outbreak of brucellosis occurred in two research centers in Lanzhou, China, infecting over 100 students and staff members.⁵ Chinese experts have also raised concerns about laboratory safety in their own country, lamenting that “lab trash can contain man-made viruses, bacteria or microbes” and that “some researchers discharge laboratory materials into the sewer after experiments without a specific biological disposal mechanism.”⁶

We would expect the NIH to know about this history of lab accidents, and to know that Chinese researchers were conducting bat coronavirus work in BSL-2 labs. For example, bat coronavirus expert Dr. Ralph Baric of the University of North Carolina observed that “Historically, the Chinese have done a lot of their bat coronavirus research under BSL-2 conditions. Obviously, the safety standards of BSL-2 are different than BSL-3, and lab-acquired infections occur much more frequently at BSL-2. There is also much less oversight at BSL-2.”⁷

There is evidence that WIV conducted other coronavirus propagation research in BSL-2 facilities. We would expect that the NIH would know this as well, since the evidence is in published literature and presumably in NIH grant progress reports. For example, in 2016, the WIV and EcoHealth Alliance published a study partially funded by the NIAID grant that noted the following:

The SL-CoV WIV1 strain (GenBank accession number KF367457) and other viruses were propagated as described previously (2). Sendai virus (SeV) strain Cantell (kindly provided by Hanzhong Wang) was propagated in 10-day-old embryonated chicken eggs at 37°C for 48 h (24). **All experiments using live virus was conducted under biosafety level 2 (BSL2) conditions.**⁸ (Emphasis added).

² Rossana Segreto and Yuri Deigin, The genetic structure of SARS-CoV-2 does not rule out a laboratory origin, Wiley Online Library (Nov. 17, 2020) available at <https://onlinelibrary.wiley.com/doi/full/10.1002/bies.202000240>.

³ *Id.*

⁴ *Id.*

⁵ *Id.*

⁶ Liu Caiyu and Leng Shumei, *Biosafety guideline issued to fix chronic management loopholes at virus labs*, Global Times (Feb. 16, 2020) available at <https://www.globaltimes.cn/content/1179747.shtml>.

⁷ Rowan Jacobsen, *We never created a supervirus* Ralph Baric explains gain-of-function research, MIT Tech Review (July 26, 2021) available at <https://www.technologyreview.com/2021/07/26/1030043/gain-of-function-research-coronavirus-ralph-baric-vaccines/>.

⁸ Lei-Ping Zeng, *et al*, *Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORF4, Involved in Modulation of the Host Immune Response*, Journal of Virology, (Jul. 15, 2016) available at <https://archive.ph/dQRT#selection-1225.0-1245.93>

Letter to the Honorable Francis Collins

Page 3

We would also expect that the NIH would recognize that the NIAID grant was supporting deficient and potentially dangerous biosafety practices. We note that Dr. Baric stated all his research studies on bat coronaviruses are conducted in BSL-3 plus conditions, and that he would not conduct the WIV's experiments in BSL-2 labs. Dr. Baric said: "There's definitely some risk associated with these and other SARS-like bat viruses that can enter human cells."⁹

Further, the "Biosafety in Microbiological and Biomedical Laboratories" (BMBL) manual, co-authored by the NIH explains:

Biosafety Level 3 is applicable to clinical, diagnostic, teaching, research, or production facilities where work is performed with indigenous or exotic agents **that may cause serious or potentially lethal disease through the inhalation route of exposure**. [Emphasis added] Laboratory personnel must receive specific training in handling pathogenic and potentially lethal agents, and must be supervised by scientists competent in handling infectious agents and associated procedures.¹⁰

For this reason, the Centers for Disease Control and Prevention required that live virus samples of SARS CoV2 could only be shipped to BSL-3 labs.¹¹

NIH has admitted awareness of biosafety concerns at the WIV. In its July 8, 2020, letter to EcoHealth Alliance, NIH acknowledged receiving reports of serious biosafety concerns at the WIV:

However, as you are aware, the NIH has received reports that the Wuhan Institute of Virology (WIV), a subrecipient of EcoHealth Alliance under R01AI110964, has been conducting research at its facilities in China that pose serious bio-safety concerns and, as a result, create health and welfare threats to the public in China and other countries, including the United States.

NIH expressed its concerns that EcoHealth Alliance and the WIV had not satisfied safety requirements as recipients of NIH grant funds. NIH further acknowledged in the July 8, 2020, letter: "We have concerns that WIV has not satisfied safety requirements under the award, and that EcoHealth Alliance has not satisfied its obligations to monitor the activities of its subrecipient to ensure compliance." Specifically, former U.S. Deputy Assistant Secretary of State, David Feith, stated that he had uncovered safety issues at the WIV: "There was work with very dangerous viruses carried out at Biosafety Level 2, which has been compared to the safety level roughly of a dentist's office."¹²

⁹ Rowan Jacobsen, *We never created a supervirus* Ralph Baric explains gain-of-function research, MIT Tech Review (July 26, 2021) available at <https://www.technologyreview.com/2021/07/26/1030043/gain-of-function-research-coronavirus-ralph-baric-vaccines/>.

¹⁰ Lei-Ping Zeng, *Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response*, (Jun 24, 2016) available at <https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.pdf>.

¹¹ Glenn Rockman, *To accelerate innovation, the CDC should ease limits on which labs can handle the coronavirus*, STAT (Apr. 14, 2020) available at <https://www.statnews.com/2020/04/14/allow-bsl-2-labs-handle-novel-coronavirus/>.

¹² CBS News, *GOP seeks records on possible U.S. funding of research at Chinese lab before pandemic* (July 22, 2021) available at <https://www.cbsnews.com/news/gop-pressing-for-records-on-possible-us-funding-research-chinese-lab-before-pandemic/>.

Letter to the Honorable Francis Collins

Page 4

Though the NIH wrote in its July 8, 2020, letter to EcoHealth Alliance that U.S. State Department cables in 2018 raised safety concerns about the WIV, the NIH failed to acknowledge how its own scientist stationed in Beijing, Dr. Ping Chen of NIAID, personally visited the WIV in 2017 and co-wrote one of the 2018 U.S. State Department warning cables. The information about NIH's awareness of the WIV safety concerns and its part in supplying that information to the U.S. State Department, only became publicly known from recently released NIH emails in response to Freedom of Information Act requests. Although a representative from the NIAID played a critical role in the 2018 State Department cables raising concerns about the WIV, there is no record of NIH taking any oversight action regarding the EcoHealth Alliance grant until after April 14, 2020, when these Department cables were publicly revealed in a Washington Post column.

There is no apparent justification for NIH officials to permit the NIAID grant to support BSL-3 research at the BSL-2 level. When propagating a coronavirus and the risks of the research are unknown, work must be done in a BSL-3 lab until it is verified and confirmed that propagating a virus does not raise a public health concern. Only after such confirmation can the research be moved to BSL-2. The NIH, in accordance with its own policies and BMBL, should have required EcoHealth Alliance to ensure that all SARS CoV research by its sub-grantee was done in a BSL-3 lab. Even if the research did not meet a technical definition of gain-of-function research, we have concerns that NIH failed to address the potential risks associated with virus propagation research in a BSL-2 lab with pathogens like SARS CoV that has of Dual Use of Research Concern (DURC) potential, a research category of which gain-of-function research is a subset. Further, NIH's belated oversight interest in this grant in 2020 has been completely ineffective, and NIH has shown no interest or capability in getting compliance from its grantee EcoHealth Alliance.

EcoHealth Alliance's grant remains suspended in-house with NIH, though the NIH through the Department of Health and Human Services has failed to report publicly the grant suspension on the www.SAM.gov database, which provides a reporting mechanism that can alert other U.S. Government agencies of risky non-compliant behavior of grant recipients. For over a year, EcoHealth Alliance has not complied with the terms of the NIH award. In the June 28, 2021, virtual meeting with Committee staff, NIH gave no indication of any interest in taking further action against EcoHealth Alliance for award noncompliance. In fact, when asked if they would further pursue information gathering from EcoHealth Alliance, NIH stated that all of EcoHealth's research had been published. In order for NIH to be convinced they should take action to obtain NIH-funded data from EcoHealth Alliance, NIH put the burden on the Minority committee staff to supply documented statements from EcoHealth Alliance indicating that EcoHealth Alliance represented that they are in possession of unpublished bat coronavirus sequences. Despite the Minority staff supplying such statements, there is still no indication from NIH that they will do anything on this front.

Letter to the Honorable Francis Collins

Page 5

As indicated by the NIH's July 8, 2020, letter suspending EcoHealth Alliance's grant, the NIH and the grantee are not absolved from ensuring sound biosafety practices regardless of the merits of the research. After first notifying EcoHealth Alliance in April 2020 that it must provide information to NIH to be in compliance with the terms of its grant for project number R01AI110964, NIAID separately awarded a \$3 million cooperative agreement in June 2020 to EcoHealth Alliance, followed by another cooperative agreement award to EcoHealth Alliance in September 2020 for \$1.15 million.¹³ After notifying EcoHealth Alliance that their funding would stop until they complied with NIH's requests for information, providing additional funding to EcoHealth Alliance in \$4.5 million in NIAID cooperative agreements thereby undercut NIH's ability to get EcoHealth Alliance to comply with NIH's requests for information on biosafety practices and other issues at the WIV. The new funding to EcoHealth Alliance suggests that the NIH is not serious about oversight of NIH grants and, more specifically, its compliance requests of EcoHealth Alliance in its July 8, 2020, letter.

NIH's conduct in this case raises serious doubts about NIH's competent stewardship of research funds. If the NIH continues down this path, the NIH risks losing substantial public support and risks undermining public health efforts that are based on trust in NIH.

We urge you to be transparent and produce all documents and information related to the NIAID grant and to provide in writing the NIH's complete understanding of the NIH-supported research conducted at the WIV by September 7, 2021. Please immediately make arrangements to schedule the staff briefings with Dr. Ping Chen and Dr. Erik Stemmy. Finally, in light of our concerns, please respond to the following:

1. In recent testimony before the Senate Committee on Health, Education, Labor and Pensions, Dr. Anthony Fauci, Director of NIAID, testified that the WIV research in question "was judged by qualified staff up and down the chain as not being gain of function."
 - a. Please provide names and positions of the staff involved. Please provide details on the scope of the review and the process for how the review was conducted. Please identify all documents used in the review and submit these documents.
 - b. Did the staff review the biosafety practices and BSL level of labs that were involved with the WIV research? If so, what were their findings?
 - c. Did the staff know how many novel coronaviruses were being studied at the WIV? If so, please provide the information.
 - d. Were staff aware of the WIV's standard operating procedures for working with a novel coronavirus? If so, please provide the information.

¹³ USA Spending.gov, *EcoHealthAlliance*, Advanced Recipient Search (Aug. 2, 2021) available at <https://www.usaspending.gov/search/?hash=b2b11ac84d498190e8e69a33c04cdd99>.


Letter to the Honorable Francis Collins

Page 6

- e. Were staff aware of how the WIV collected virus samples? If so, please provide the information.
 - f. Were staff aware of the standard operating procedures at the WIV for propagating or culturing viruses? If so, please provide the information.
 - g. Did the staff have information on the biosafety procedures at the WIV designed to prevent potential exposure events? If so, please provide the information.
 - h. Did the staff know what cell lines were used at the WIV? If so, please provide the information.
 - i. Did the staff know what safety measures were used at the WIV to prevent cross-contamination? If so, please provide the information.
 - j. Did the staff have information on the training records of the staff? If so, please provide the information.¹⁴
2. Since EcoHealth Alliance still has its NIAID grant suspended due to lack of cooperation with the NIH, why is NIAID continuing to fund EcoHealth Alliance through other cooperative agreements?
3. When did the NIH first recognize biosafety concerns at the WIV? What actions were taken?

If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff.

Sincerely,



Cathy McMorris Rodgers
Ranking Member
Committee on Energy and Commerce




Brett Guthrie
Ranking Member
Subcommittee on Health

¹⁴ Sub-questions (g), and (j) were suggested by Dr. Ralph Baric to MIT Tech Review, note 9.

Letter to the Honorable Francis Collins

Page 7

A handwritten signature in black ink, appearing to read "H. Morgan Griffith", is written over a horizontal line.

H. Morgan Griffith
Ranking Member
Subcommittee on Oversight and
Investigations

CC: The Honorable Frank Pallone, Chairman
The Honorable Anna Eshoo, Chair, Subcommittee on Health
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations

EXHIBIT 28

EXHIBIT 28

FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

October 27, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dr. Collins,

We write again asking the National Institutes of Health (NIH) to be transparent about its relationship with EcoHealth Alliance (EcoHealth) and to provide information and documents related to National Institute of Allergy and Infectious Diseases (NIAID) grant project number R01AI110964, "Understanding the Risk of Bat Coronavirus Emergence."¹ In 2014, NIH awarded this grant to EcoHealth, the non-profit organization that in turn funneled those funds to the Wuhan Institute of Virology (WIV)² and to additional research organizations to support risky research in China.

Since March 2021, we have led a comprehensive examination of how the COVID-19 pandemic started. Understanding the root cause of this pandemic will help us prevent future pandemics. We are examining in connection with this effort whether NIH oversight of risky research conducted by an NIH sub-grantee in China was adequate to prevent or render it implausible that a lab accident could have been involved in the origins of the pandemic. Based on a review of documents and other information recently made available, we have significant

¹This is our fourth letter to NIH seeking information related to oversight of NIAID's grant R01AI110964. Our prior letters dated March 18, 2021, July 21, 2021 and August 24, 2021 are available at <https://republicans-energycommerce.house.gov/the-covid-19-origins-investigation/>. At this time, NIH has yet to respond in writing to any of the questions in these letters, and only produced EcoHealth grant documents to us after HHS had released them to *The Intercept* in response to a Freedom of Information Act lawsuit.

² This funding was in addition to USAID funding to EcoHealth that was also funneled to the WIV during this timeframe. USA Spending.gov, *EcoHealth Alliance*, Advanced Recipient Search (Aug. 2, 2021), available at <https://www.usaspending.gov/search/?hash=b2b11ac84d498190e8e69a33c04cdd99>. An April 6, 2016 correction to the Nov. 20, 2015 research article acknowledged the USAID-EPT-PREDICT funding source from EcoHealth Alliance to Zhengli Shi. Menachery, V. *et al.*, *Correction: Corrigendum: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence*, *Nature Medicine* (Apr. 6, 2016), available at <https://www.nature.com/articles/nm0416-446d>.

Letter to the Honorable Francis Collins

Page 2

concerns about the adequacy of NIH oversight of EcoHealth and the related research activities at the WIV and other organizations in China.

In 2016, EcoHealth proposed a research project with the WIV using humanized mice to test several chimeric viruses to see if these experiments would show whether these viruses could infect human cells. EcoHealth portrayed the risks of these experiments as if they were not of concern, and the NIH accepted EcoHealth's assertions without a searching inquiry. However, the assessment of the risks by both EcoHealth and the NIH do not seem to square with the understanding of the research risks at that time. Although the engineered viruses at the WIV were far from SARS CoV-2 on the coronavirus family tree, this research reflected a high tolerance for risk.³ As noted by Stanford University microbiologist David Relman, "[The WIV] were essentially playing Russian roulette with the virus that the world's expert had labelled poised for human emergence. It's the willingness to manipulate them without due concern."⁴

Further, the one condition imposed by the NIH was the requirement that EcoHealth stop the humanized mice experiment and notify the NIH if the result was a virus with enhanced growth by more than ten times (or one log) compared to the parental backbone or strains found in nature. The purpose of this policy was to safeguard against experiments creating viruses that could replicate quickly and had the potential to overwhelm the immune systems of humans. We believe the EcoHealth grant documents indicated such a reportable result from the experiment, but there is no evidence of EcoHealth taking the required actions, or the NIH raising any questions after getting the results of the experiment from EcoHealth. If EcoHealth and NIH could not handle compliance and oversight of such a basic policy, it raises more concerns about the overall adequacy of the oversight of this research, which leaves the public vulnerable to a serious lab accident.

In addition to how NIH examined the research proposal, the funding of EcoHealth by NIH after the suspension of their grant raises serious concerns about NIH's management and oversight of grants. Following an initial grant termination in April 2020, NIH reinstated the grant and then suspended the grant in July 2020 because of EcoHealth's inadequate oversight of the WIV.⁵ When NIH asked EcoHealth to provide information related to its subaward to the WIV, EcoHealth refused to comply with most of the requests.⁶ Despite EcoHealth's unwillingness to cooperate, NIH paid an additional \$369,819 to EcoHealth on July 13, 2020, a mere five days after its grant was suspended. NIH's payment seems inconsistent with NIH's grant policy and possibly violates other federal laws and regulations.⁷

NIH also failed to report EcoHealth's noncompliance and grant suspension into the www.SAM.gov database that alerts other U.S. Government agencies to risky grant recipients. Remarkably, the NIH, U.S. Agency for International Development (USAID), and Department of Defense (DoD) have paid EcoHealth more than \$23.4 million in new and renewed assistance

³ Carolyn Korman, *The Mysterious Case of the COVID-19 Lab Leak Theory*, The New Yorker (October 12, 2021), available at <https://www.newyorker.com/science/elements/the-mysterious-case-of-the-covid-19-lab-leak-theory>.

⁴ *Id.*

⁵ Mark Moore, *NIH investigating Wuhan lab at center of coronavirus pandemic*, NEW YORK POST (Apr. 28, 2020), available at <https://nypost.com/2020/04/28/nih-investigating-wuhan-lab-at-center-of-coronavirus-pandemic/>.

⁶ *Id.* EcoHealth did report select subgrant funding data on July 13, 2020 into a public database. NIH had raised concerns that EcoHealth had not accounted for its funding of subgrantees.

⁷ USA Spending.gov, *EcoHealth Alliance*, Advanced Recipient Search (Oct. 13, 2021), available at https://www.usaspending.gov/award/ASST_NON_R01AII10964_7529.

Letter to the Honorable Francis Collins

Page 3

awards since April 2020, when NIH should have reported the administrative action it took against EcoHealth's grant. To date, NIH has refused to address any of these concerns.

We outline our concerns in more detail about NIH's oversight of the EcoHealth grant in the discussion that follows.

Grant Documents and Other Information Made Recently Available

On September 7, 2021, after the Department of Health and Human Services (HHS) produced documents related to the EcoHealth grant because of a Freedom of Information Act (FOIA) lawsuit, HHS shared essentially the same documents with us.⁸ On September 29, 2021, Principal Deputy Director Lawrence Tabak briefed bipartisan Committee staff about the EcoHealth grant documents. Unfortunately, HHS and NIH did not accommodate the staff request to include subject matter experts and witnesses with first-hand knowledge from NIAID in this briefing. HHS arranged an in-person bipartisan Committee staff *in camera* review of the printed copies of the four highly relevant letters between NIH and EcoHealth about EcoHealth's humanized mice research proposal. These documents raise significant concerns about NIH's management and oversight of the EcoHealth grant.⁹

HHS Oversight Policy of Gain-of-Function Research Was Weakened in Recent Years

On August 30, 2021, the *Washington Post* published an article, *A Science in the Shadows*, detailing how the HHS oversight process over risky research, often referred to as Gain-of-Function (GOF) research, was weakened in recent years from the policy established in 2012.¹⁰ For example, in December 2017, the review process known as the *HHS Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens Care and Oversight* (P3CO) was revised to remove any authority by the HHS P3CO review group to block GOF research proposals.¹¹ Instead, HHS redefined GOF research, which has given NIH leaders the sole discretion to approve GOF projects without referring them to the HHS PC3O review group.¹²

In a significant policy change, the 2017 policy also narrowed the criteria for review of GOF research to cover only altered pathogens "likely capable of wide and uncontrollable spread in human populations."¹³ The review policy that started in October 2014, required experiments to

⁸ Sharon Lerner and Mara Hvistendahl, *New Details Emerge About Coronavirus Research at Chinese Lab*, The Intercept (Sept. 6, 2021), available at <https://theintercept.com/2021/09/06/new-details-emerge-about-coronavirus-research-at-chinese-lab/>. The NIH document production appears identical to their production to *The Intercept*, except the documents NIH provided to us do not include FOIA exemption numbers in the redactions and instead include Bates numbered pages.

⁹ A bipartisan *in camera* private in-person inspection of the physical copies of four letters dated May 18, 2016, June 8, 2016, July 7, 2016, and July 5, 2018 controlled by NIH was conducted at HHS headquarters on Oct. 5, 2021, monitored by HHS staff.

¹⁰ David Willman and Madison Muller, *A Science in the Shadows*, The Washington Post (Aug. 26, 2021), available at <https://www.washingtonpost.com/nation/interactive/2021/a-science-in-the-shadows/>.

¹¹ *Id.*

¹² *Id.*

¹³ U.S. Department of Health and Human Services, *Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens*, Dual Use Research of Concern (Dec. 19, 2017), available at <https://www.phe.gov/s3/dualuse/Documents/P3CO.pdf>.

Letter to the Honorable Francis Collins

Page 4

be reviewed if they expected to generate flu and coronaviruses that would be “transmissible among **mammals**” and might accidentally cause human infections.¹⁴ (Emphasis added).

A GOF Experiment Warning by Dr. Ralph Baric and Others

In 2015, Dr. Ralph Baric of the University of North Carolina – Chapel Hill, Dr. Zheng-Li Shi of the WIV, and others published a study in *Nature*, titled *A SARS-Like Cluster Of Circulating Bat Coronaviruses Shows Potential For Human Emergence*.¹⁵ Dr. Baric and Dr. Shi have each collaborated previously with EcoHealth. Importantly, EcoHealth, through its funding from USAID, helped support Dr. Shi of the WIV in this particular study.¹⁶ Near the end of this publication, the authors issued a warning about a potential threat of certain viruses identified with the SHC014 reference number:

We consider viruses with the SHC014 spike a potential threat owing to their ability to replicate in primary human airway cultures, the best available model for human disease. In addition, the observed pathogenesis in mice indicates a capacity for SHC014-containing viruses to cause disease in mammalian models, without RBD adaptation.¹⁷

In the next paragraph, the authors explain the context of GOF research and how their expectation that the viruses they created would not increase pathogenicity turned out to be wrong after they conducted the experiments:

In addition to offering preparation against future emerging viruses, this approach must be considered in the context of the U.S. government–mandated pause on gain-of-function (GOF) studies. On the basis of previous models of emergence, the creation of chimeric viruses such as SHC014-MA15 was not expected to increase pathogenicity. Although SHC014-MA15 is attenuated relative to its parental mouse-adapted SARS-CoV, similar studies examining the pathogenicity of CoVs with the wild-type Urbani spike within the MA15 backbone showed no weight loss in mice and reduced viral replication. Thus, relative to the Urbani spike–MA15 CoV, SHC014-MA15 shows a gain in pathogenesis.¹⁸

The authors then explain that scientific review panels may determine that similar studies would be too risky, so any further research may be limited going forward:

¹⁴ The White House, *Doing Diligence to Assess the Risks and Benefits of Life Sciences Gain-of-Function Research*, Blog (Oct. 17, 2014), available at <https://obamawhitehouse.archives.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research>.

¹⁵ Menachery, V. et al, *A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence*, *Nature Medicine* (Nov.20, 2015), available at <https://www.nature.com/articles/nm.3985>.

¹⁶ An April 6, 2016 correction to the Nov. 20, 2015 research article acknowledged the USAID-EPT-PREDICT funding source from EcoHealth Alliance to Zhengli Shi. Menachery, V. et al, *Correction: Corrigendum: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence*, *Nature Medicine* (Apr. 6, 2016), available at <https://www.nature.com/articles/nm0416-446d>.

¹⁷ Menachery, V. et al, *A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence*, *Nature Medicine* (Nov.20, 2015), available at <https://www.nature.com/articles/nm.3985.pdf>.

¹⁸ *Id.*

Letter to the Honorable Francis Collins

Page 5

On the basis of these findings, scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue, as increased pathogenicity in mammalian models cannot be excluded. Coupled with restrictions on mouse-adapted strains and the development of monoclonal antibodies using escape mutants, research into CoV emergence and therapeutic efficacy may be severely limited moving forward.¹⁹

Finally, the authors advise that the purpose of their study – to prepare potentially for and mitigate future outbreaks – must be carefully weighed against dangers posed by the experiments creating more dangerous pathogens. Notably, the authors considered whether similar studies should be pursued:

Together, these data and restrictions represent a crossroads of GOF research concerns; the potential to prepare for and mitigate future outbreaks must be weighed against the risk of creating more dangerous pathogens. In developing policies moving forward, it is important to consider the value of the data generated by these studies and whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved.²⁰

Letters Reveal NIH and EcoHealth Discussed GOF Research Concerns

HHS allowed bipartisan Committee staff to see three letters from NIH to EcoHealth (May 18, 2016, July 7, 2016, and July 5, 2018) and one letter from EcoHealth to NIH (June 8, 2016) in an *in camera* review.²¹ To our knowledge, NIH has not publicly disclosed these letters, although some of the contents in these letters appear to have been used in NIH correspondence to U.S. Senators.²²

During the 2014 GOF moratorium in the United States, EcoHealth submitted its Year Two progress report dated May 13, 2016, to NIAID for grant R01AI110964. EcoHealth disclosed it would conduct experiments in humanized mice using two chimeric bat coronaviruses.²³ In response to the experiment descriptions in EcoHealth's research progress report, NIH wrote to EcoHealth on May 28, 2016,²⁴ to advise that NIAID determined the R01AI110964 grant research project may include GOF experiments subject to the 2014 GOF research pause.²⁵

¹⁹ *Id.*

²⁰ *Id.*

²¹ A bipartisan *in camera* private in-person inspection of the physical copies of four letters dated May 18, 2016, June 8, 2016, July 7, 2016, and July 5, 2018, was conducted at HHS headquarters on Oct. 5, 2021, monitored by HHS staff. Information presented as letter excerpts are produced from detailed staff notes because NIH refused to release copies of the letters to the Committee.

²² See July 28, 2021, letter from NIH Director Francis Collins to U.S. Senator Charles Grassley, *available at* https://www.grassley.senate.gov/imo/media/doc/national_institutes_of_health_to_grassley_-_covid_origins_grant_oversight.pdf.

²³ Sharon Lerner and Mara Hvistendahl, *New Details Emerge About Coronavirus Research at Chinese Lab*, The Intercept (Sept. 6, 2021), *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

²⁴ May 18, 2016, NIH letter to EcoHealth (per notes taken by Minority Committee staff Oct. 5, 2021 during bipartisan *in camera* review).

²⁵ On Oct. 17, 2014, the White House Office of Science and Technology Policy and the U.S. Department of Health and Human Services instituted a pause on funding research of Gain-of-Function (GOF) experiments involving influenza, SARS, and MERS viruses following multiple biosafety accidents at U.S. laboratories. The White House, *Doing Diligence to Assess the Risks and Benefits of Life Sciences Gain-of-Function Research*, Blog (Oct. 17, 2014), *available at* <https://obamawhitehouse.archives.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research>, and *available at* <http://www.phe.gov/s3/dualuse/Documents/gain-of-function.pdf>.

Letter to the Honorable Francis Collins

Page 6

Under the signature of Dr. Peter Daszak, its president, chief scientist, and grant principal investigator, EcoHealth replied to NIH on June 8, 2016, asserting their research was not GOF.²⁶

These 2 chimeric bat-like CoVs were constructed on Sept. 24, 2015. They use the backbone of a group 2b SARS-like bat CoV WIV1 and the spike proteins of two newly discovered bat SL-CoVs (Rs7327 and RsSHC014). The construction of these chimeric viruses aims to understand the receptor usage and infectivity of bat SL-CoVs that may be progenitors of SARS-CoV. We have not yet tested the pathogenicity of these viruses in animals.²⁷

There was no discussion of how the RsSHC014 differed from the SHC014 spike protein of concern in the 2015 Baric *et al* warning. If there was no difference between these viruses, then there was no assessment of a known risk. In addition to the potential threat of the RsSHC014 spike, the WIV1 backbone was already known to be potentially dangerous to humans.²⁸ Nevertheless, EcoHealth stated that its research would not be considered GOF because the virus it was using had never previously infected humans:

We believe that this work would not be considered GOF because the pause specifically targeted experiments that related to the pathogenicity or transmissibility of SARS-CoV, MERS CoV and any influenza virus. Our molecular clone is WIV1, which is a group 2b SARS-like bat coronavirus that has never been demonstrated to infect humans or cause human disease.²⁹

EcoHealth also argued that because the virus was ten percent different from the original SARS-CoV, their research did not qualify being subject to the GOF moratorium. EcoHealth continued its justification by explaining that because EcoHealth and/or the WIV would progressively introduce spike proteins that were progressively more distant from the original SARS-CoV, that the research was not subject to the GOF pause. EcoHealth also explained that its theory was supported by the 2015 publication of Dr. Ralph Baric's study:

Moreover, we are introducing progressively more distant S glycoproteins into WIV1 (The RBD of Rs7327 differs from WIV1 in several amino acid residues while RsSHC014 is even more distantly related phylogenetically), so it seems progressively less likely that any of these viruses would be more pathogenic or transmissible than the SARS-CoV. This is further supported by the fact that

²⁶ June 8, 2016, EcoHealth letter to NIH (per notes taken by Minority Committee staff Oct. 5, 2021 during bipartisan *in camera* review).

²⁷ *Id.*

²⁸ Carolyn Korman, The Mysterious Case of the COVID-19 Lab Leak Theory, The New Yorker (October 12, 2021), *available at* <https://www.newyorker.com/science/elements/the-mysterious-case-of-the-covid-19-lab-leak-theory>. (“Shi’s lab developed its own platform for creating chimeric viruses. She crossed another bat coronavirus from Yunnan—named wiv1—with clones of different novel spike proteins and tested the creation in humanized mice. The viruses quickly replicated. One made the mice emaciated, a sign of severe pathogenesis. **What made this work especially risky was that wiv1 was already known to be potentially dangerous to humans.** Baric himself had made this clear in a 2016 study titled ‘SARS-Like WIV1-CoV Poised for Human Emergence.’”) (Emphasis added).

²⁹ June 8, 2016, EcoHealth letter to NIH (per notes taken by Minority Committee staff Oct. 5, 2021, during bipartisan *in camera* review).

Letter to the Honorable Francis Collins

Page 7

Professor Ralph Baric's group (Menachery et al 2015, Nature Medicine 21, 1508-1513...PNAS, 113 (11): 3048-3053) took WIV1 spike and inserted it onto a SARS-CoV backbone and showed reduced pathogenicity in mice with human ACE-2 relative to SARS-CoV (mortality rates were much lower, therefore this is loss of function). This strongly suggests that the chimeric bat spike/bat backbone viruses should not have enhanced pathogenicity in animals.³⁰

NIH Agreed with EcoHealth's Self-Assessment and Added Grant Conditions

In a July 7, 2016, response letter to EcoHealth, NIH replied that NIAID agreed with EcoHealth's determination that its work was not subject to the GOF pause based on its review of the original grant application, and cited two of the justifications provided by EcoHealth as the basis for its agreement:

NIAID is in agreement that the work proposed under Aim 3 to generate MERS-like or SARS-like chimeric coronaviruses (CoVs) is not subject to the GOF research funding pause. This determination is based on the following: (1) the chimeras will contain only S glycoprotein genes from phylogenetically distant bat CoVs; and (2) recently published work demonstrating that similar chimeric viruses exhibited reduced pathogenicity. Therefore, it is not reasonably anticipated that these chimeric viruses will have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route.³¹

As a result, the NIAID added the following award condition, per the grant documents:

NIAID acknowledges that if any of the MERS-like or SARS-like chimeras generated under this grant show **evidence of enhanced virus growth greater than 1 log over the parental backbone strain**, Dr. Daszak will immediately stop all experiments w/ these viruses and provide the NIAID Program Officer and Grants Management Specialist, and Wuhan Institute of Virology Institutional biosafety Committee, with the relevant data and information related to these unanticipated outcomes. (Emphasis added).³²

In a revised grant award notice for Year Three, NIAID added the following in the special terms and conditions section:

Per the letter dated July 7, 2016 to Mr. Aleksei Chmura at EcoHealth Alliance, should any of the MERS-like or SARS-like chimeras generated under this grant show **evidence of enhanced virus growth greater than 1 log over the parental backbone strain** you must stop all experiments with these viruses and provide the NIAID Program Officer and Grants Management Specialist, and Wuhan Institute

³⁰ *Id.*

³¹ *Id.*

³² *Id.*

Letter to the Honorable Francis Collins

Page 8

of Virology Institutional Biosafety Committee with the relevant data and information related to these unanticipated outcomes.³³ (Emphasis added). Neither EcoHealth nor NIAID discussed alternative approaches that could have been less risky but may have been able to achieve the same research goals.

EcoHealth's Progress Report for Year Four Raises Question of Cover-up

EcoHealth submitted a Year Four progress report in September 2020, two years after when the report should have been submitted to receive Year Five funding.³⁴ The original EcoHealth's Year Four progress report that was presumably revised should have been submitted to NIH in spring 2018. However, this report was not included in the production to *The Intercept* or to us.

Sometime during Year Four of the grant (June 1, 2017-May 31, 2018), the humanized mice experiments with the chimeric viruses were carried out.³⁵ The Year Four progress report discussing these experiments are controversial because of the rarity of a progress report being submitted two years late. Given the strict NIH rules regarding the release of grant funds, it is believed that the Year Four progress report may have replaced an earlier version of the Year Four progress report.³⁶ It is highly unusual for a grantee to replace a progress report.

Contrary to Dr. Tabak's stated belief to bipartisan Committee staff during the June 28, 2021, briefing that all of EcoHealth's grant-supported research was published, and thus it was unlikely that EcoHealth would have much unpublished data, Minority Committee staff was unable to find any published studies for EcoHealth's humanized mice experiment discussed in the grant. The humanized mice experiment results EcoHealth reported to NIH, as described in the grant documents, showed that the SHC014S virus seriously infected the mice and caused them to lose 20 percent of their body weight in six days.³⁷ EcoHealth and the WIV infected humanized mice with the WIV1 parental virus and three chimeric viruses containing SHC014S, WIV16S and Rs4231S.³⁸ At two and four days post-infection, "viral loads in lung tissues of mice challenged with all three chimeras reached $>10^6$ genome copies per/g, significantly higher than related WIV1 infection (Fig. 6b). This demonstrates that pathogenicity of SARS-related coronaviruses in humanized mice differs with divergent S proteins, **confirming** the value of this model in assessing novel SARS related coronavirus pathogenicity."³⁹ (Emphasis added).

³³ EcoHealth grant documents at 189, available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

³⁴ Mara Hvistendahl and Sharon Lerner, *NIH Bat Coronavirus Grant Report Was Submitted More Than Two Years Late*, *The Intercept*, (Oct. 1, 2021), available at <https://theintercept.com/2021/10/01/nih-bat-coronavirus-grant-ecohealth-alliance/>.

³⁵ EcoHealth grant documents at 485-486 available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

³⁶ Mara Hvistendahl and Sharon Lerner, *NIH Bat Coronavirus Grant Report Was Submitted More Than Two Years Late*, *The Intercept*, (Oct. 1, 2021), available at <https://theintercept.com/2021/10/01/nih-bat-coronavirus-grant-ecohealth-alliance/>.

³⁷ EcoHealth grant documents at 486, available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

³⁸ *Id.*

³⁹ *Id.* The use of the word "confirming" suggests a previous belief that the experiment would demonstrate increased pathogenicity seen in the experiment's results rather than simply showing reduced pathogenicity, which was the purported justification that the experiment was not GOF.

Letter to the Honorable Francis Collins

Page 9

NIH's Re-Review of EcoHealth Grant Found Research Was Not Subject to the P3CO Risk Analysis Framework Policy

Despite the documents NIH produced to us in which EcoHealth's Year Four progress report, dated September 16, 2020, more than two years after when it should have been submitted, NIH approved EcoHealth's Year Five grant renewal with a Notice of Award dated June 18, 2018.

Even though the proposed humanized mice experiment would have been already conducted during 2016 to 2017, NIH wrote on July 5, 2018, to EcoHealth reaffirming its July 7, 2016, determination that EcoHealth's proposed research was not a GOF experiment under the HHS P3CO framework. In its July 2018 letter, NIH did not cite any new or additional evidence to show the research was not subject to the HHS P3CO framework⁴⁰

The experiments to generate MERS-like or SARS-like chimeric coronaviruses, are not subject to the HHS P3CO framework. The terms and conditions of the award have been revised to indicate that should experiments proposed in this award result in a virus with enhanced growth by more than 1 log compared to wild type strains, you must notify your NIAID Program Officer, and Grants Management specialist immediate and that further research involving the resulting virus(es) may require review by the DHHS in accordance with the HHS PC30 Framework.⁴¹

In its November 5, 2018, progress report to NIH for the period of June 1, 2014 through May 31, 2019, EcoHealth reported that the strains of the viruses it was using in its experiments could represent a significant threat to public health because they could escape existing vaccine and therapeutic treatments.⁴²

Preliminary Observations

Based on the totality of these studies and reports made available so far, we make the following preliminary observations:

- The revised 2017 HHS definition of GOF research appears to be too narrow because it does not capture SARS-like or MERS-like viruses that are very similar to SARS or MERS. On January 23, 2020, Dr. Christian Hassell, the Chair of the HHS P3CO review group, expressed concern about the narrow definition in the most recent meeting of NIH's National Science Advisory Board for Biosecurity (NSABB): "I'll just probably be more frank than may be appropriate - I think that's too narrow. My view on this thing is, don't

⁴⁰ July 5, 2018, NIH letter to EcoHealth (per notes taken by Minority Committee staff Oct. 5, 2021 during bipartisan *in camera* review).

⁴¹ *Id.*

⁴² EcoHealth grant documents at 486, available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

Letter to the Honorable Francis Collins

Page 10

use too fine a filter.”⁴³ No additional meetings or communications have been taken in a year and nine months by NIH to address Dr. Hassell’s concerns.⁴⁴

- Both EcoHealth’s and NIAID’s assessments that the experiment would be expected to show less pathogenesis seem at odds with the stated goals of the research project to look for dangerous viruses with pandemic potential. The assessments also turned out to be wrong. Specifically, the humanized mice experiment with the SARS-like coronaviruses showed more pathogenesis with three of the viruses, especially the one labeled SHC014, which produced a 20 percent weight loss in the humanized mice.⁴⁵ As previously mentioned, Baric *et al* warned about viruses containing SHC014 in their 2015 publication.
- After the results of the 2015 Baric *et al* paper, which showed an increase in pathogenesis with some viruses, EcoHealth and NIAID should have examined the research proposal more closely before reaching the conclusion that the expected results of the experiment would be less pathogenic.
- It seems unlikely that EcoHealth and NIAID were unaware of the findings in the 2015 paper. Thus, we are left with the impression that both chose to document the research as less dangerous so that EcoHealth could continue to receive its funding and NIAID could avoid outside oversight of that research proposal.
- Neither the EcoHealth nor the NIAID assessments reflected the careful weighing of risks and benefits of the proposed potential GOF research.⁴⁶ In particular, NIAID’s assessment in 2016 did not explain the benefits of the proposed research and how such benefits outweighed the risks, nor did NIAID consider any biosafety and risk mitigation measures. The NIAID determination in 2018 that the research was not subject to the HHS P3CO framework lacked any analysis or explanation supporting its determination and failed to address how it concluded that there was no pandemic potential.
- Based on the available documents, EcoHealth violated the terms of its grant. The chimeric virus used in the humanized mice experiment produced more than one log of virus growth compared to the WIV1 parental backbone.⁴⁷ In fact, it appears the experiment with the virus listed as SHC014 produced more than 3 logs of comparative growth. Per their grant terms, EcoHealth was to stop their experiment and notify NIAID.⁴⁸ It does not appear it

⁴³ David Willman and Madison Muller, *A Science in the Shadows*, The Washington Post (Aug. 26, 2021), available at <https://www.washingtonpost.com/nation/interactive/2021/a-science-in-the-shadows/>.

⁴⁴ Confirmed with Dr. Hassell on August 13, 2021 in a bipartisan Committee staff briefing.

⁴⁵ Sharon Lerner and Mara Hvistendahl, *New Details Emerge About Coronavirus Research at Chinese Lab*, The Intercept (Sept. 6, 2021), available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

⁴⁶ June 8, 2016 EcoHealth letter to NIH (per notes taken by Minority Committee staff Oct. 5, 2021 during bipartisan *in camera* review); July 7, 2016 NIH letter to EcoHealth (per notes taken by Minority Committee staff Oct. 5, 2021 during bipartisan *in camera* review).

⁴⁷ See Andrew Kerr, *Fauci-Funded Wuhan Lab Viruses Exhibited Over 10,000 Times Higher Viral Load Than Natural Strain*, Daily Caller (September 9, 2021), available at <https://dailycaller.com/2021/09/09/ecohealth-alliance-gain-of-function-higher-viral-load-anthony-fauci/>.

⁴⁸ There is no evidence that EcoHealth stopped the experiment to notify NIAID as required. In discussing the results of this experiment, EcoHealth never explicitly stated in the text of the progress reports the amount of virus growth of the parental backbone, thereby masking the comparison that might have attracted attention from a NIAID reviewer. However, the bar graph in the grant documents shows that the parental backbone, WIV 1, produced about 4.7 log₁₀ genome copies per gram, two days after

Letter to the Honorable Francis Collins

Page 11

did either. As a result, NIAID's oversight of the grant failed to detect the viral growth issue and, notably, did not hold EcoHealth accountable for violating the terms of its grant.

NIH Funded the EcoHealth Grant After Suspending It

Since April 2020, NIH has suspended all activities for NIAID grant R01AI110964 due to EcoHealth's grant award non-compliance.⁴⁹ Among other infractions, NIH advised EcoHealth in a July 8, 2020, letter that EcoHealth had not satisfied its obligations to monitor the WIV's activities and had not reported its subawards as required. The grant activities remain suspended and, as a result of such suspension, NIH made clear in its letter that "no funds from grant R01AI110964 may be provided to or expended by EcoHealth Alliance" until EcoHealth provides information and materials to NIH's satisfaction.⁵⁰

On July 13, 2020, NIH issued a revised award approval notice to EcoHealth for the sixth year of the suspended project, despite NIH's suspension of all grant activities.⁵¹ Not only did NIH approve the award, but based on a letter from EcoHealth, NIH apparently increased the award amount by an additional \$369,819. Despite NIH's notification to EcoHealth on July 8, 2020, that no funds would be provided, NIH issued the payment of that increase to EcoHealth on July 13, 2020, even though EcoHealth was not allowed to conduct activities under this grant during the suspension. In its revised award notice to EcoHealth issued on the same date as the \$369,819 payment, NIH designated specific allocations of \$76,301 for the WIV, and \$75,600 for the Institute of Pathogen Biology in Beijing, China.⁵²

This raises significant concerns regarding NIH's oversight of grantees. This also raises concerns that NIH funding of a suspended entity is contrary to the Public Health Service Act and is possibly an Anti-Deficiency Act violation.⁵³ At a minimum, this expenditure is inconsistent with competent stewardship of federal funds, and subverts compliance with the NIH suspension letter and the NIH Grant Policy, which states: "Organizations or individuals that are suspended... cannot receive NIH grants, be paid from NIH grant funds, whether under a primary or lower-tier transaction (including trainees on NIH-supported training grants), or otherwise participate during the period of suspension...."⁵⁴

On June 10, 2021, we wrote to you about our concerns that NIH issued a new \$2 million award to EcoHealth in August 2020, while EcoHealth was a noncompliant grantee with a

infection compared to about 8 log₁₀ genome copies per gram produced by the SHC014 strain - more than three logs of growth, much more than one log threshold specified in the grant terms.

⁴⁹ Committee staff have confirmed the grant status on multiple occasions with NIH leadership.

⁵⁰ NIH terminated the grant on April 24, 2020. On July 8, 2020, NIH simultaneously reinstated and suspended the grant activities, pending EcoHealth's cooperation and compliance. Katherine Eban, *The Lab Leak Theory: Inside the Fight to Uncover COVID 19's origins*, Vanity Fair (June 3, 2021), available at <https://www.vanityfair.com/news/2021/06/the-lab-leak-theory-inside-the-fight-to-uncover-covid-19s-origins>.

⁵¹ 2R01AI110964-06 is the renewal number assigned to the sixth year of the NIH R01AI110964 grant project.

⁵² EcoHealth grant documents at 321, available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

⁵³ 31 U.S.C. 1341.

⁵⁴ National Institutes of Health, *Debarment and Suspension*, NIH Grants Policy Statement (Oct. 1, 2020), available at https://grants.nih.gov/grants/policy/nihgps/html5/section_4/4.1.6_debarment_and_suspension.htm.

Letter to the Honorable Francis Collins

Page 12

suspended NIH grant.⁵⁵ In the same letter, we also detailed our concerns that EcoHealth had never met its requirements to report publicly its subawards to the WIV or to the Wuhan University School of Public Health until NIH specifically instructed them to do so during communications between April and July 2020. The effect of EcoHealth withholding its financial reporting is that prior to and at the time of the COVID-19 pandemic outbreak, the financial relationship between EcoHealth, NIH, and the WIV was hidden from the public and not included in USASpending.gov.

After paying an illegible grant recipient in July 2020, the NIH in August 2020 announced its award of two multimillion-dollar grants to EcoHealth for NIAID's \$3.05 million project number U01AI151797, and NIAID's \$1.2 million project number U01AI153420.⁵⁶ Based on available information, NIH has not recovered the \$369,819 payment to EcoHealth. As recently as July 2021, NIH approved a \$574,984 payment to EcoHealth.⁵⁷ Furthermore, over \$23.4 million has been paid to EcoHealth in its status as a potentially ineligible grant recipient, by NIH, USAID, and DoD since the time NIH should have reported its administrative suspension to www.SAM.gov.⁵⁸

In light of our concerns about NIH's grant management and oversight, please respond to the following by November 10, 2021:

1. Does NIH plan to stop funding EcoHealth until it is compliant with NIH's requests? If yes, please identify when you will notify EcoHealth. If not, why not?
2. Does NIH plan to recover the money paid to EcoHealth on its suspended grant? If yes, please identify when you will notify EcoHealth. If not, why not?
3. Please identify who authorized the \$369,819 funding issued to EcoHealth on July 13, 2020, and the specific authority for this funding.
4. Does NIH intend to enter the EcoHealth suspension into the www.SAM.gov database that is intended for agency reporting of temporary or permanent suspensions? If yes, when? If no, why not?
5. Please provide all funded and denied grant applications, progress and final reports for all NIH grants awarded to EcoHealth Alliance as a prime or subgrant recipient in unredacted form.
6. Please provide the following documents related to grant award R01AI110964:

⁵⁵ U.S. House of Representatives Energy and Commerce Committee Republicans, Letter to NIH, Spotlight on COVID-19 Origin Investigation, (June 10, 2021), *available at* <https://republicans-energycommerce.house.gov/wp-content/uploads/2021/06/06.10.21-Letter-to-NIH-Director-Collins.pdf>.

⁵⁶ National Institutes of Health, *NIH establishes Center for Research in Emerging Infectious Diseases*, News Releases (Aug. 27, 2020), *available at* <https://www.nih.gov/news-events/news-releases/nih-establishes-centers-research-emerging-infectious-diseases>.

⁵⁷ USA Spending.gov, *EcoHealth Alliance*, Advanced Recipient Search (Oct. 13, 2021) *available at* https://www.usaspending.gov/award/ASST_NON_U01AI153420_7529.

⁵⁸ U.S. House of Representatives Energy and Commerce Committee Republicans, Letter to NIH, Spotlight on COVID-19 Origin Investigation, (June 10, 2021), *available at* <https://republicans-energycommerce.house.gov/wp-content/uploads/2021/06/06.10.21-Letter-to-NIH-Director-Collins.pdf>.

Letter to the Honorable Francis Collins

Page 13

- a. all documents that were not provided to *The Intercept*, including the letter from EcoHealth on which NIH based its decision to increase the award,
 - b. EcoHealth's original application, and
 - c. all other original documents for which only the revised versions were produced.
7. Please provide all correspondence between EcoHealth and NIH, including any letter exchanges about NIH's identification of EcoHealth research that potentially included GOF experiments and EcoHealth's response, dated in May, June, and July of 2016 and July 2018. Please also provide all correspondence between EcoHealth and NIH, including any letter exchanges about humanized mice experiments conducted during Year Five of the grant. Please also include another missing letter from EcoHealth to NIH that was used as the basis to increase the award amount by \$369,819.
8. Please provide an accounting of all EcoHealth subawards, including contracts or any other agreements, to all organizations and scientists located in or sponsored by China from the year 2000 to the present.
9. Please facilitate access for Committee staff and the undersigned to EcoHealth's genomic sequence data and/or database of unpublished and published sequences.
10. Please provide all documentation regarding NIH's resource coordination with USAID, EcoHealth, DoD, and any other communications in which NIH took steps to ensure no overlap of U.S. Government agency funds for the same research was occurring.
11. Please provide EcoHealth's original Year Four progress report for the period of June 1, 2017 to May 31, 2018, that would have been submitted in 2018.
12. Please provide the list of all NIH personnel involved in the development of the HHS P3CO framework with an explanation of each individual's role.
13. What would be the purpose of conducting humanized mice experiments other than to test whether a virus could infect human cells?
14. Please make appropriate NIAID personnel available to Committee staff to address questions about the handling of the EcoHealth grant.
15. When did NIAID first learn that EcoHealth had conducted the humanized mice experiment proposed in 2016?
16. Why did NIAID conduct an HHS P3CO review of the EcoHealth research proposal if the experiment was already conducted?
17. Why were less risky alternative approaches to EcoHealth's proposed experiment not considered and discussed?


Letter to the Honorable Francis Collins

Page 14

18. Please explain why NIAID concluded that the EcoHealth grant was not subject to the HHS P3CO framework.

If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff.


Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Brett Guthrie
Republican Leader
Subcommittee on Health



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and Investigations

cc: The Honorable Frank Pallone, Chairman
The Honorable Anna Eshoo, Chair, Subcommittee on Health
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations
Ms. Christi Grimm, Principal Deputy Inspector General, U.S. Department of Health and Human Services

FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

February 14, 2022

Dr. Francis Collins
National Human Genome Research Institute
National Institutes of Health
31 Center Drive MSC 2152
9000 Rockville Pike
Bethesda, MD 20892-2152

Dr. Collins,

Recently disclosed emails revealed that in January 2020, virology experts told you and Dr. Anthony Fauci that they believed COVID-19 had lab-made features and that the virus may have escaped from a lab.¹ However, those same email communications, particularly when viewed in light of other publicly available information, demonstrate an apparent effort by you and Dr. Fauci not only to cover-up the concerns those virologists raised, but to suppress scientific debate about the origins of COVID-19. It appears you and Dr. Fauci may have done so to protect China and avoid criticism about incredibly risky research that the National Institute of Allergy and Infectious Diseases (NIAID) was funding at the Wuhan lab.

According to emails released by House Oversight and Reform Republicans, there was significant concern among virology experts that COVID-19 may have originated from a lab.² One scientist told you he was “bothered by the furin site” and had a “hard time explain[ing] that as an event outside the lab,” which led him to opine it was “70:30” that the virus came from a lab; another scientist told you he “can’t think of a plausible natural scenario”; a different scientist claimed that “some of the features (potentially) look engineered”; and yet another said the “furin cleavage site” struck him as unusual as it related to natural evolution and that “if evolutionary origins...were to be discussed...only people with sufficient information or access to samples to address it would be the teams working in Wuhan.”³

¹ Correspondence posted by House Oversight and Government Reform Republicans (Jan. 11, 2022) *available at* <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/Letter-Re-Feb-1-Emails-011122.pdf>

² *Id.*

³ *Id.*

Letter to Dr. Francis Collins

Page 2

Rather than allow for scientific review and robust debate, communications in these emails show that you and Dr. Fauci appeared more concerned about protecting certain relationships and institutional interests in collaborations in China. In fact, the NIAID has had a full-time official, Dr. Ping Chen, stationed at the U.S. Embassy in Beijing for several years to oversee and promote NIAID's interests in China and the emails show that your immediate concern was how discussion of the lab leak theory would do "great potential harm to science and international harmony." Specifically, you were responding to an email chain that included this statement from Dr. Ron Fouchier: "However, further debate about such accusations would unnecessarily distract top researchers from their active duties and do unnecessary harm to science in general and science in China in particular." You even went a step further and asked how NIH could work to "help put down this very destructive conspiracy." In contrast, there is no evidence from the available emails nor has NIH provided any information to us that indicates Dr. Fauci or you took action to investigate further the possible lab origins of the pandemic.

Instead of alerting national security experts to the potential threat that scientists were questioning the origin of the SARS2 virus, you shut down debate about the COVID-19 origin.⁴ We are deeply concerned about your decision to suppress highly relevant information when you received the early alert that the SARS2 virus could be a potential threat. As the then Director of the NIH that includes NIAID's multibillion dollar biodefense program and the NIAID as an advocate for global sampling and surveillance to detect *potential* pandemics, when the alert was in your hands, you remained silent and worse, propagated a counter narrative that may have hurt our government's response in the early days of the pandemic.

We oversee public health and are seeking the truth about how this pandemic started so we can better prepare and hopefully prevent future pandemics. We have significant concerns that your conduct, which appears to have been designed to protect China and, in furtherance of that, to suppress certain scientific information, occurred at a time when it was critical for government leaders and decisionmakers to be aware of all relevant information and may have hurt our COVID-19 response.

Accordingly, in light of these concerns, please provide written responses to the following questions by February 28, 2022:

1. Regarding your January 2020 communications with the virology experts referenced above:
 - a. How were the communications with the virology experts initiated?
 - i. Did you initiate the communications with the virology experts or did they?
 - ii. When were these communications initiated? Please identify all parties to these communications and the specific subject matters addressed in these communications.

⁴ *Id.*

Letter to Dr. Francis Collins

Page 3

- b. What was the purpose for your communications with these virology experts?
 - c. Please identify additional individuals you consulted with about the origins of COVID-19 in January and February 2020.
 - d. How did you select the virology experts to contact?
 - e. When did your communications with these virology experts about the origins of COVID-19 end and why?
2. Did you brief anyone at the White House, the U.S. Department of Health and Human Services (HHS), or anyone else involved in the COVID-19 response about the communications with the virology experts?
 - a. If you did, please identify who you notified, when you notified them, and what information you provided to them.
 - b. If you did not, why did you withhold such relevant information?
3. To what extent did preserving international harmony (especially with China) affect your advice to the White House, HHS, or anyone else involved in the COVID-19 response?
4. What is the purpose of having an NIAID official posted at the U.S. embassy in China?
5. Please identify any NIAID collaborations in China from January 1 to June 30, 2020.
6. During January 2020, were you in contact with Chinese scientists about SARS CoV-2?
 - a. If so, how have these contacts influenced you in the performance of your COVID-19 response duties?
7. Prior to the January 31, 2020, email, did you know about the pangolin coronavirus sequence with a receptor binding domain (RBD) similar to the one in SARS CoV-2?
8. Did the publication of pangolin virus RBD impact your assessment on the origins of the COVID-19 pandemic? If so, why?
9. Did the publication on February 3, 2020, of the RaTG-13 bat coronavirus sequence that was 96 percent similar to SARS CoV-2 impact your assessment on the origins of COVID-19 pandemic? If so, why?

Letter to Dr. Francis Collins

Page 4

10. Were you involved with the February 4, 2020, emergency meeting at the National Academies of Science, Engineering, and Medicine (NASEM) convened at the request of the White House?
- a. If so, did you attend, what was your role, and what was discussed?
 - b. Did the NASEM emergency meeting influence your assessment of the origins of COVID-19?
 - c. Did you and/or the virology experts discuss the NASEM emergency meeting in the communications?
11. Did you edit, make suggestions, or influence in any way the publication of the proximal origin paper?
12. In a February 2, 2022, letter to HHS Secretary Xavier Becerra and NIH Acting Director Lawrence Tabak, the House Committee on Oversight and Reform Republicans noted that NIH forced an NIH advisor to shred notes and other documents pertaining to the Wuhan Institute of Virology (WIV) grants as early as 2014. That committee pointed to a November 5, 2021, email from a redacted source, which stated:

I signed a confidentiality agreement in which I agreed not to discuss any grant with anyone except with other members of the study section, and - once the meeting was over - that I would destroy any notes that I had taken during the meeting (we did this by tossing them in shred box in the meeting room).

This email suggests that this redacted source served on a peer review panel for the NIAID, and that the practice of shredding documents was not limited to grants related to EcoHealth Alliance or the WIV. It may have been systemic.

What are NIAID's document retention rules for peer review panels scoring grant proposals? Please provide the legal justification for any document shredding practices at NIAID, and specifically NIAID peer review panels.

Sincerely,




Cathy McMorris Rodgers
Ranking Member
Committee on Energy and Commerce



Brett Guthrie
Ranking Member
Subcommittee on Health

Letter to Dr. Francis Collins

Page 5

A handwritten signature in black ink, appearing to read "H. Morgan Griffith", is written over a horizontal line.

H. Morgan Griffith
Ranking Member
Subcommittee on Oversight and
Investigations

EXHIBIT

EXHIBIT

FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

February 24, 2022

Lawrence A. Tabak, D.D.S., PhD.
Acting Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dr. Tabak,

We write to continue our oversight of National Institutes of Health (NIH) grant awards to EcoHealth Alliance (EcoHealth). On January 6, 2022, the NIH sent two letters to EcoHealth related to its failure to comply with terms agreed upon for its NIH grants.¹ While we appreciate the NIH's current enforcement efforts to obtain EcoHealth's compliance, new information from recently disclosed information included in the recent NIH letters raises troubling concerns about EcoHealth's conduct upon which the NIH is either overlooking or taking insufficient action. Those concerns include withheld data and possible double billing, missing laboratory notebooks and electronic files related to humanized mice research at the Wuhan lab, and EcoHealth's private donations that may not have been reported to NIH. These concerns raise the prospect of possible fraud that require the NIH's heightened attention.

Withheld Data and Potential Double Billing

In June 2014 and during the gain-of-function research pause in the United States, NIH awarded grant R01AI110964 to EcoHealth for bat coronavirus research. EcoHealth then entered into a subaward agreement with scientists at the Wuhan Institute of Virology (WIV) for research assistance. During that time, EcoHealth also received awards from other U.S. agencies, including as a subgrant recipient from the U.S. Agency for International Development (USAID) to support scientific collaboration at the WIV.²

¹ Letters to EcoHealth Alliance (Jan. 11, 2022) *available at* <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/January-2022-EHA-SAC-CAP-letter-final1.pdf>.

² Energy and Commerce Republicans, Letter to USAID (June 28, 2021) *available at* <https://republicans-energycommerce.house.gov/wp-content/uploads/2021/06/2021.06.22-USAID-Origins-Letter.pdf>.

Letter to Dr. Lawrence A. Tabak

Page 2

Through its USAID project work, EcoHealth catalogued human and bat genomic sequence findings into a database used to create predictive maps of potential disease outbreaks and reported finding a high number of SARS-like coronaviruses in bats sampled in China.³ EcoHealth identified several novel bat coronaviruses.⁴ USAID also supported sampling by EcoHealth and its collaborative partners of more than 7,300 humans and animals in China.⁵ The human specimens were obtained from individuals with symptoms of an infectious disease meeting criteria that the most-likely cause had been ruled out through laboratory tests and supporting data was available.⁶

Research accomplishments in USAID PREDICT reports very closely resemble those reported by EcoHealth to NIH in its progress reports. The similarities are striking and include similar charts, graphics, sampling locations, and research discoveries. For example, virus detection was described in the USAID-China PREDICT report as, “Working in collaboration with NIAID-funded partners, we demonstrated that some of the newly discovered bat-CoVs were able to bind to human cells, infect them in vitro, and cause SARS-like disease in a lab animal model.”⁷ This is a research accomplishment EcoHealth also reported in its NIH progress reports.⁸ EcoHealth reported having access to tens of thousands of wildlife samples as a result of its NIH project and from a large multi-year contract from USAID for the PREDICT project.⁹

Recently published email documents show that Dr. Daszak worked to ensure that the USAID-catalogued sequences were not attributed to the USAID work in GenBank, the NIH genetic sequence database of all publicly available DNA sequences.¹⁰ In emails acquired by U.S. Right to Know, an EcoHealth USAID collaborator at Metabiota advised an EcoHealth staff member on April 20, 2020, that virus sequences detected in China as part of the USAID project were submitted to GenBank and scheduled for release in 10 days.¹¹ The EcoHealth staff member replied to delay uploading the sequences because **some** of the sequences were ready for

³ USAID, *PREDICT-Advancing Global Health Security at the Frontiers of Disease Emergence*, (June 5, 2021) available at https://ohi.vetmed.ucdavis.edu/sites/g/files/dgvnsk5251/files/inline-files/PREDICT%20LEGACY%20-%20FINAL%20FOR%20WEB%20-compressed_0.pdf.

⁴ Kirsten V.K. Gilardi, Jonna A.K. Mazet, *The United States Agency for International Development Emerging Pandemic Threat PREDICT Project – Global Detection of Emerging Wildlife Viral Zoonoses*, Fowler's Zoo and Wild Animal Medicine Current Therapy, Volume 9, Pages 110-116 (Sep. 28, 2018) available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152072/>.

⁵ USAID, *PREDICT-Advancing Global Health Security at the Frontiers of Disease Emergence*, (June 5, 2021) available at https://ohi.vetmed.ucdavis.edu/sites/g/files/dgvnsk5251/files/inline-files/PREDICT%20LEGACY%20-%20FINAL%20FOR%20WEB%20-compressed_0.pdf.

⁶ *Id.*

⁷ USAID Predict China, One Health in Action (2009-2020) available at <https://static1.squarespace.com/static/5c7d60a711f7845f734d4a73/t/5f5fe4e59eeb3f245097cbac/1600120064528/FINAL+REPORT+COUNTRY-CHINA-FULL.pdf>.

⁸ EcoHealth grant documents available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>.

⁹ *Id.*

¹⁰ U.S. Right to Know, EcoHealth Alliance wanted to block disclosure of Covid-19 relevant virus data from China (Jan. 10, 2022) available at <https://usrtk.org/biohazards-blog/ecohealth-alliance-wanted-to-block-disclosure-of-covid-19-relevant-virus-data-from-china/>.

¹¹ *Id.*

Letter to Dr. Lawrence A. Tabak

Page 3

publication and time was needed to check the data, and also because the China institution must approve publication.¹²

Dr. Daszak then wrote, “All - It’s extremely important that we don’t have these sequences as part of our PREDICT release to Genbank at this point. As you may have heard, these were part of a grant just terminated by NIH...Having them as part of PREDICT will bring [sic] very unwelcome attention to UC Davis, PREDICT and USAID.”¹³ Dr. Daszak’s response raises questions about project funding he received from NIH and USAID for his work in China and the potential that both agencies were funding the same research. Suspicions of potential duplication of funding are further raised by the collaborator and staff logging the sequences as belonging to the USAID project.

On January 10, 2022, Dr. Daszak tweeted that sequences were discovered under NIH funding and that all SARSr-CoVs were uploaded into GenBank then publicized in the *Nature Communications* article referenced earlier that also identified EcoHealth’s private and anonymous funding sources.¹⁴ Dr. Daszak wrote, “All sequences of SARS-related coronaviruses discovered by EcoHealth Alliance in China were sequenced using NIH funding and have been made public in peer-reviewed scientific papers and via the publicly available Genbank database. The Genbank accession numbers for over 600 sequences can be found in the attached paper.” [Emphasis added].¹⁵ Dr. Daszak’s tweet representing that “all sequences...have been made public” contradicts the EcoHealth employee’s email stating that only some of the USAID-funded sequences from China would be published. We question if Dr. Daszak reported those sequences in the sequence data he reported as an accomplishment under USAID funding. It is imperative for NIH to make available all genomic sequencing data from Dr. Daszak and EcoHealth and compare EcoHealth documentation submitted to USAID.

Questions of grant coordination with another federal agency are also raised. In March 2018, EcoHealth submitted a bat coronavirus research proposal to Defense Advanced Research Projects Agency (DARPA), entitled “Project DEFUSE: Defusing the Threat of Bat-borne Coronaviruses.” The proposal included detailed plans to fund research that, among other risky experiment techniques, would insert a furin cleavage site into a bat coronavirus genetic sequence. The SARS-CoV-2 virus is a betacoronavirus that features a furin cleavage site in the spike protein, a characteristic that has never previously been detected in this family of coronaviruses. The function of the furin cleavage site in SARS-CoV-2 is significant because it is the essential mechanism for the virus entry into human lungs. DARPA ultimately rejected the proposal later in 2018.

However, in its Year Four NIH progress report submitted in April 2018, covering activities between June 2017 and May 2018, EcoHealth reported that Peter Daszak and WIV co-investigator Zhengli Shi introduced this project and discussed new opportunities about predicting and preventing zoonoses with NIAID and the Defense Advanced Research Projects Agency

¹² *Id.*

¹³ *Id.*

¹⁴ Daszak, Peter@PaterDaszak Twitter, Jan 10, 2022 9:52 pm available at <https://twitter.com/PeterDaszak/status/1480734382558224388?s=20>.

¹⁵ *Id.*

Letter to Dr. Lawrence A. Tabak

Page 4

(DARPA), the National Academies of Science, Engineering and Medicine Forum on Microbial Threats and with organizations in China.¹⁶ The reference to DARPA in the Year Four progress report suggests that EcoHealth saw linkage between the DARPA proposal and its NIAID research grant. It is unclear whether the rejected DARPA proposal was funded elsewhere, and to what extent this proposal or any other ideas EcoHealth discussed with DARPA informed any EcoHealth communications with NIAID and/or any research activity funded by NIAID.

Missing Laboratory Notebooks and Electronic Files

In a January 6, 2022, letter to EcoHealth, the NIH reiterated its request for the laboratory notebooks and electronic files that led to the generation of bar figures and accompanying texts portraying weight loss and death in humanized mice experiments.¹⁷ The NIH letter confirmed that EcoHealth reported to NIH that notebooks or files created and retained by the sub-grantee, WIV, were not in EcoHealth's possession.¹⁸ EcoHealth claimed it had forwarded the NIH's request for those records to the WIV.¹⁹ Given the Chinese government's lack of cooperation with global public health requests and its known punishment of Chinese scientific institutions and scientists for cooperating with others outside China, there is little reason to believe that the WIV will actually provide these notebooks and files. EcoHealth's inability to substantiate these research experiments calls into question the validity of the entire research effort with the WIV, in addition to violating the terms of its NIH agreement. Because EcoHealth has received over \$16.8 million from NIH since 2005²⁰ and Dr. Daszak has worked as an NIH peer reviewer, the NIH grant requirements were well known to them, so the deliberateness of their noncompliance should be questioned.

Further, EcoHealth's admission that it did not have copies of the notebooks or the files raises new troubling issues that need to be resolved by the NIH.²¹ Since EcoHealth did not have notebooks or the files, the NIH needs to find out how EcoHealth was able to certify the validity of all figures and texts of the humanized mice experiment results reported in progress reports for Year Four and Year Five.²² The NIH needs to protect the integrity of the NIH grant oversight program and sponsored research. Since EcoHealth claims the WIV created and retained these records, presumably EcoHealth received documentation from the WIV to complete its progress reports.²³ To dispel the notion of research cover-ups or fabrication and to prove how EcoHealth

¹⁶ EcoHealth grant documents at page 273 *available at*

<https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

¹⁷ Letters to EcoHealth Alliance (Jan. 11, 2022) *available at* <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/January-2022-EHA-SAC-CAP-letter-final1.pdf>.

¹⁸ *Id.*

¹⁹ *Id.*

²⁰ NIH Reporter, Query results for *EcoHealth Alliance* (Jan. 13, 2022) *available at* https://reporter.nih.gov/search/z_bHgzk69kCqeyiCfy-7fA/projects.

²¹ Letters to EcoHealth Alliance (Jan. 11, 2022) *available at* <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/January-2022-EHA-SAC-CAP-letter-final1.pdf>.

²² EcoHealth grant documents *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

EcoHealth grant documents *available at* https://s3.documentcloud.org/documents/21089573/priority-grants-for-foia-request-55058-first-look-institute-2_redacted.pdf.

²³ Letters to EcoHealth Alliance (Jan. 11, 2022) *available at* <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/January-2022-EHA-SAC-CAP-letter-final1.pdf>.

Letter to Dr. Lawrence A. Tabak

Page 5

prepared its certified progress reports, NIH should request that EcoHealth produce all documentation relied upon to validate its progress reports.

Finally, it is highly suspicious that EcoHealth and the WIV reported results from a single risky experiment conducted in one year into two separate progress reports for two different years. The research involved bat coronaviruses and humanized mice. During the Year Four reporting period between June 2017 and May 2018, EcoHealth conducted one experiment that caused some ACE2 Receptor humanized mice to get sick within six days after infection and die within two weeks of infection. However, EcoHealth reported the sick mice in its Year Four report (the first six days) and saved the lethal results (the full two weeks) to report in Year Five, in a delayed submission that was not received by the NIH until August 2021. The Year Five report covered experiments between June 2018 through May 2019.²⁴ The reporting of the humanized mice fatalities to NIH was delayed for three years.²⁵ Bifurcating the reporting of experiment results raises the question of whether EcoHealth and the WIV were covering up the deadly pathogenic results of risky research by concealing the mice deaths for an extended period of time (especially during the time of the grant renewal in mid-2019).

Further, EcoHealth represented in its Year Five report that the experiments were conducted between June 2018 and May 2019, evidenced by the statement, “In Year 5, we **continued** with *in vivo* infection experiments of diverse bat SARS-CoVs on transgenic mice expressing human ACE2.”²⁶ [Emphasis added]. EcoHealth’s questionable representation of the experiment dates raises questions about whether the humanized mice experiment results were stretched out into another year’s progress report to provide filler in the report and divert NIH’s attention away from the possibility of undisclosed research conducted in Year Five (2019). Questions about the possibility of undisclosed Year Five research are heightened because laboratory analysis was the only project activity EcoHealth planned during its final year of the five-year grant award. In the grant research strategy timeline and management plan section, EcoHealth reported that the duration of its lab data analysis and modeling activities would span the final four years of the project and conclude at the end of the award. No other research activities were planned during the final project year.²⁷

Other discrepancies in EcoHealth’s Year Five progress report heightens concerns arising from the missing substantiation of research. A close examination of the Year Five progress report dated August 3, 2021, covering the June 1, 2018 to May 30, 2019, project period shows that the chart examples are not in sequential order.²⁸ The report contains two different charts that

²⁴ Ecohealth Oct. 26, 2021 letter to NIH *available at* <https://www.documentcloud.org/documents/21097880-ecohealth-letter-contesting-claims>.

²⁵ EcoHealth grant documents *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

²⁶ *Id.* The wording suggests that EcoHealth was continuing to conduct experiments, instead of organizing follow-up analysis of an experiment already conducted in the previous award year.

²⁷ EcoHealth grant documents at page 126 posted by *The Intercept* (Sept. 8, 2021) *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

²⁸ EcoHealth grant documents posted by *The Intercept* (Oct. 21, 2021) *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

Letter to Dr. Lawrence A. Tabak

Page 6

are both labeled *Figure 2*, one on page 6 and the other on page 9.²⁹ The *Figure 2* on page six is also missing letters from some sampling site locations. For example, spaces are evident where the letter “P” should be in Jinning, Yunnan and instead reads, “J nn ng, Yunnan.”³⁰ On Year Five report page 11, the chart examples skip from from *Figure 4* directly to *Figure 8*.³¹ Another example from the Year Five report is how *Figure 13* is followed by *Figure 7*. The contents of some of the figures do not match what is described in the text. For example, the text states *Figure 7* shows rates of evolutionary transitions among alphacoronavirus families during evolution, but the actual figure shows immunofluorescence measurements for MERS-like CoVs.³² There are other similar inconsistencies between the figure numbers and what the text says and what the figures show. For example, there are also two different graphics that are labeled “Figure 1.”³³

Finally, there are inconsistencies in EcoHealth’s explanation surrounding the delayed submission of the Year Five progress report to the NIH. In his letter to the NIH of October 26, 2021, EcoHealth president Peter Daszak wrote that he did not submit the Year Five progress report because he was locked out of the system “starting” on July 24, 2019.³⁴ However, documents released under FOIA show Peter Daszak sent an email to the NIH that said he “is” now able to submit the Year Five progress report on July 24, 2019, and is about to do so.³⁵

Private Funding

With respect to private funding, documents show that EcoHealth has been receiving private donations that may not have been disclosed to the NIH.³⁶ On August 25, 2020, Nature Communications published *Origin and cross-species transmission of bat coronaviruses in China*, authored by EcoHealth president Peter Daszak and others.³⁷ Research funding sources are acknowledged as: award number R01AI110964 from the NIH National Institute of Allergy and Infectious Diseases (NIAID); cooperative agreement number GHN-A-OO-09-00010-00

²⁹ EcoHealth grant documents, page 6 and page 9, posted by *The Intercept* (Oct. 21, 2021) available at https://www.documentcloud.org/documents/21089573-priority-grants-for-foia-request-55058-first-look-institute-2_redacted.

³⁰ *Id.*

³¹ EcoHealth grant documents, page 11, posted by *The Intercept* (Oct. 21, 2021) available at https://www.documentcloud.org/documents/21089573-priority-grants-for-foia-request-55058-first-look-institute-2_redacted.

³² EcoHealth grant documents, page 17, posted by *The Intercept* (Oct. 21, 2021) available at https://www.documentcloud.org/documents/21089573-priority-grants-for-foia-request-55058-first-look-institute-2_redacted.

³³ EcoHealth grant documents, posted by *The Intercept* (Oct. 21, 2021) available at https://www.documentcloud.org/documents/21089573-priority-grants-for-foia-request-55058-first-look-institute-2_redacted.

³⁴ EcoHealth letter posted by *The Intercept* (Nov. 3, 2021) available at <https://www.documentcloud.org/documents/21097880-ecohealth-letter-contesting-claims>.

³⁵ Emails posted by White Coat Waste Project at 302, Andrew Kerr, Gain of Function Communications Between EcoHealth Alliance and NIAID, White Coat Waste Project (Nov. 4, 2021) available at <https://www.scribd.com/document/537027808/GainOf-Function-Communications-Between-EcoHealth-Alliance-And-NIAID>.

³⁶ Latinne, A., Hu, B., Olival, K.J. et al., *Origin and cross-species transmission of bat coronaviruses in China*, Nature Communications (Aug. 25, 2020) available at <https://www.nature.com/articles/s41467-020-17687-3>.

³⁷ *Id.*

Letter to Dr. Lawrence A. Tabak

Page 7

from the USAID Emerging Pandemic Threats PREDICT project, the Chinese Academy of Sciences (XDB29010101), and National Natural Science Foundation of China (31770175, 31830096).³⁸ The funding description for EcoHealth continues: “All work conducted by EcoHealth Alliance staff after April 24th 2020 was supported by generous funding from The Samuel Freeman Charitable Trust, Pamela Thye, The Wallace Fund, & an Anonymous Donor c/o Schwab Charitable.”³⁹

In our review of available EcoHealth grant documents for NIH award R01AI11964, EcoHealth did not disclose the three named or anonymous financial sources.⁴⁰ However, because NIH has refused to cooperate fully with Congressional oversight and mostly released records under Freedom of Information Act (FOIA) requests to private entities, our review may be limited.

NIH terminated EcoHealth’s award R01AI110964 in April 2020 due to noncompliance. The award was later reinstated and then immediately suspended on July 8, 2020. On May 29, 2020, EcoHealth board member Randy Schekman of the Li Ka Shing Center, University of California at Berkeley, emailed EcoHealth president Peter Daszak that Schekman would be the intermediary for a \$500,000 donation to EcoHealth from an anonymous source to make up for the terminated NIH award:

Dear Peter,

I am part of the Rich Roberts group and helped to line-up more Laureates to join the petition to Azar and Collins. We don’t expect a response from them but we wish to make a constructive contribution to your essential work and have resolved to help find private funds to offset your loss. Our first success is with a foundation that makes anonymous contributions to various causes including in support of biomedical science. I am pleased to report that this group will provide the Ecohealth Alliance a grant of \$500,000 to at least partially offset the NIH funds that were withdrawn from your program. Since they wish to remain anonymous, I will be happy to serve as the intermediary in transfer of funds to your program. We can communicate about how to proceed.⁴¹

Instead of trying to cooperate with the NIH to get back into compliance, EcoHealth exploited the NIH’s grant suspension to boost fundraising and get donations from private sources. We do not know the amount of private funding provided to, or used by, EcoHealth to continue work on its suspended NIH grant, but the notification of private funding in May 2020 and citation of private funding sources in the August 25, 2020, Nature Communications indicates resources were available to EcoHealth in lieu of the suspended grant award. Another recent

³⁸ *Id.*

³⁹ *Id.*

⁴⁰ EcoHealth grant documents *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

EcoHealth grant documents *available at* https://s3.documentcloud.org/documents/21089573/priority-grants-for-foia-request-55058-first-look-institute-2_redacted.pdf.

⁴¹ U.S. Right to Know, *EcoHealth Alliance emails: University of Maryland* page 422 (Nov. 18, 2020) *available at* https://usrtk.org/wp-content/uploads/2020/11/Biohazard_FOIA_Maryland_Emails_11.6.20.pdf.

Letter to Dr. Lawrence A. Tabak

Page 8

example of EcoHealth private funding is referenced in an August 31, 2020, publication that cites the Ford Foundation, the David and Lucile Packard Foundation, and Johnson & Johnson as additional private funding sources of EcoHealth.⁴²

Additionally, an email from EcoHealth spokesperson Robert Kessler to EcoHealth board members noted how Dr. Daszak appearing on CNN with Chris Cuomo and on CBS “60 Minutes” resulted in private donations:

P.S. An unexpected reaction to the 60 Minutes story has been an outpouring of support in my personal favorite form: donations. We’ve picked up more than \$3,000 today alone with the donations still coming in. A couple dozen people have created Facebook fundraisers in our name, as well. While most of these donations are only small amounts, each represents a new supporter that the development team can cultivate and a new advocate for our work. Overall, a really exciting day for EcoHealth Alliance.⁴³

Pursuant to the NIH grants financial conflict of interest policy, in alignment with 42 C.F.R. Part 50, each participating researcher is required “to submit an updated disclosure of significant financial interests within thirty days of discovering or acquiring (e.g., through purchase, marriage, or inheritance) a new significant financial interest.”⁴⁴ Significant financial interest is defined as the aggregated value within the twelve months preceding the disclosure that exceeds \$5,000.⁴⁵ EcoHealth is responsible for ensuring that all individual investigators, including subaward recipients, make all appropriate disclosures regarding other support, affiliations, and financial interests.⁴⁶ Likewise, NIH is responsible for ensuring that its grant recipients comply with all record and data retention requirements, including submission of records and data to NIH.

By virtue of funding EcoHealth’s research without considering undisclosed private donations, NIH would have over-funded EcoHealth’s award and thus, would have not funded other worthy research applications. The NIH needs to determine whether EcoHealth complied with these requirements for private donations. Any undisclosed conflict of interest also calls into question the scientific integrity and objectivity of EcoHealth’s research.

In light of our concerns, please provide written responses to the following questions and copies of the following documents by March 24, 2022:

1. Will NIH investigate whether EcoHealth’s research funded by NIH was also funded by USAID? If not, why not?

⁴² Roche, et al, *Was the COVID-19 pandemic avoidable? A call for a “solution-oriented” approach in pathogen evolutionary ecology to prevent future outbreaks* (Aug. 31, 2020) available at <https://doi.org/10.1111/ele.13586>

⁴³ U.S. Right to Know, *EcoHealth Alliance emails: University of Maryland* page 443 (Nov. 18, 2020) available at https://usrtk.org/wp-content/uploads/2020/11/Biohazard_FOIA_Maryland_Emails_11.6.20.pdf.

⁴⁴ C.F.R. Part 50

⁴⁵ 42 CFR § 50.603 Definitions, [https://www.ecfr.gov/current/title-42/chapter-I/subchapter-D/part-50#p-50.605\(b\)](https://www.ecfr.gov/current/title-42/chapter-I/subchapter-D/part-50#p-50.605(b))

⁴⁶ NIH Grants Policy Statement, *Section 2.5.1 Just-in-Time Procedures* (last accessed January 10, 2022) available at https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.5.1_just-in-time_procedures.htm,


Letter to Dr. Lawrence A. Tabak

Page 9

2. Please provide copies of all NIH correspondence to and from EcoHealth Alliance since the July 8, 2020, grant suspension.
3. Is NIH seeking a copy of the Year 6 progress report for the EcoHealth grant (covering the 2019 -2020 timeframe)? If not, why not? If so, please provide.
4. Please describe the NIAID's understanding of the DARPA proposal referenced in EcoHealth's Year Four progress report.
5. Please provide all emails, correspondence, or any documents related to the EcoHealth's discussions with the NIAID about research proposals or ideas with DARPA.
6. We are troubled that research sponsored by NIH must first be reviewed and approved by an institution in China before NIH receives the data. Is this process a special arrangement NIH authorized for EcoHealth? When did NIH become aware that a foreign institution was intervening in the contractual relationship between NIH and an NIH grant recipient? Before sponsoring research to be conducted in a foreign country, does the NIH evaluate the likelihood that the government of such country will prohibit the NIH from obtaining any materials or data related to such research?
7. Will NIH investigate how EcoHealth was able to report the humanized mice experiment results in the Year 4 and Year 5 progress reports since (1) EcoHealth admitted it does not have copies of the laboratory notebooks and electronic files; and (2) EcoHealth did not create or retain these records? If not, why not?
8. Did EcoHealth provide the WIV with access to the NIH eraCommons system for grantees?
9. How did NIH assess the conflicts of interest in EcoHealth's research involving its anonymous financial source and the private financial sources referenced on page two of this letter?
10. Did EcoHealth disclose the private donations to NIH? If not, what actions will NIH take to obtain this reporting? If yes, how did NIH assess the conflicts of interest?

If you have questions about this correspondence, please contact Alan Slobodin of the Minority Committee Staff.

Sincerely,



Cathy McMorris Rodgers
Ranking Member
Committee on Energy and Commerce



Brett Guthrie
Ranking Member
Subcommittee on Health

Letter to Dr. Lawrence A. Tabak

Page 10



H. Morgan Griffith
Ranking Member
Subcommittee on Oversight and
Investigations

EXHIBIT

EXHIBIT

FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

April 25, 2022

Lawrence A. Tabak, D.D.S., PhD.
Acting Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dr. Tabak,

Our review of EcoHealth Alliance's reports about its humanized mice experiments at the Wuhan Institute of Virology (WIV) using funds from the National Institutes of Health (NIH) shows pervasive discrepancies, inconsistencies, and omissions in its progress reports and renewal application that raise serious questions about scientific and ethical misconduct, violations of NIH policies and regulations, and possible false statements and fraud. Accordingly, we request the NIH investigate Dr. Peter Daszak, the Principal Investigator of R01A110964, and other EcoHealth officials to determine whether certain data related to mice deaths and other material information were intentionally withheld during the peer review process for EcoHealth's grant renewal application.

A. History of Grant R01A110964

EcoHealth's National Institute of Allergy and Infectious Diseases (NIAID) grant R01A110964 was funded for June 2014 to May 2019. During this five-year term, EcoHealth was required to submit annual progress reports to the NIAID. Such submissions typically occurred around mid-April and were required before funding for the following year was provided. On or around November 5, 2018,¹ EcoHealth prepared and submitted a renewal application to NIAID, and the grant was renewed for another five years in May 2019. This renewal award was for \$3.7 million plus a \$369,819 increase over the first award.² At that point, EcoHealth received its funding for Year 6, the first year of its renewal grant. However, the renewal and funding

¹ This is based on what looks like a time stamp at the bottom of the first few pages of the renewal application.

² Letter from NIH Deputy Director for Extramural Research Michael Lauer, MD to Drs. Aleksei Chmura and Peter Daszak, EcoHealth Alliance (July 8, 2020) http://downloads.vanityfair.com/lab-leak-theory/Daszak_7_8_20_Reactivation_and_Suspension.pdf

Letter to Dr. Lawrence Tabak

Page 2

occurred before EcoHealth attempted to submit its Year 5 progress report in late July 2019. EcoHealth claimed that it was locked out of the NIH system for submitting its Year 5 progress report, which remained unsubmitted until 2021.³ In April 2020, concerns emerged about EcoHealth-funded research at the WIV, and NIH suspended the grant on July 8, 2020, which appears to remain suspended.⁴

B. Peer Review Process

Our concerns over EcoHealth's reporting of the humanized mice experiments and how it affected review of its grant must be seen in the context of the NIH peer review process. Unlike the general review of progress reports by the grant officer, the goal of peer reviewers is to perform an in-depth look at the data to see what the grant would accomplish over the next five years. All NIH grant, fellowship, and cooperative agreement applications undergo review through a two-tiered system of peer review, a competitive and committee-based process to evaluate the applications.⁵ The required peer review system was established pursuant to section 492 of the Public Health Service Act (42 U.S.C. §289a), and federal regulations (42 C.F.R. §52).⁶

In the first stage, the applications are received by the NIH Center for Scientific Review (CSR), who then assigns each application that meets basic requirements to both a potential awarding IC and an associated Scientific Review Group (SRG) of the IC.⁷ The potential awarding IC (Institutes and Centers) is the one whose mission best aligns with the objectives of the research project.⁸ An SRG is a peer-review committee composed of 12 to 22 scientists who are experts in the relevant fields of research. No more than one-fourth of the members of any SRG may be federal employees.⁹ The SRG is responsible for evaluating a grant proposal on the basis of scientific merit and potential impact of the research. After discussing the application, each member gives the application a final score, and an overall impact score is determined from the average of members' final scores. The application is also given a percentile ranking, based on how the overall impact score compares to other applications reviewed by the SRG in the past year.¹⁰

In the second stage, the funding decisions are refined by the National Advisory Councils or Boards of the potential awarding ICs. Advisory Councils and Boards are composed of scientific and lay representatives. These groups examine applications recommended for funding,

³ EcoHealth's explanation for the delayed submission of the Year 5 report does not make sense. Dr. Daszak claimed that EcoHealth was ready to submit its Year 5 progress report at the end of July 2019, but EcoHealth was locked out by the NIH's data system. However, even if this were true, the question remains: Why didn't EcoHealth simply submit its Year 5 progress report by email to its grant officer? Even though it would not have been in the eraCommons system used by grantees, EcoHealth at least would have gotten its submission to the NIAID until submission into the eraCommons system could be figured out.

⁴ Letter from Dr. Michael Lauer, NIH to Dr. Peter Daszak, EcoHealth Alliance (July 8, 2020).

⁵ NIH, Report of the Director of the National Institutes of Health: Fiscal Years 2014 & 2015, p. 25, https://report.nih.gov/biennialreport/NIH_Biennial_Report_2014-15_non508.pdf.

⁶ NIH, Peer Review," at <https://grants.nih.gov/grants/peer-review.htm> (accessed April 4, 2022).

⁷ NIH, Peer Review," at <https://grants.nih.gov/grants/peer-review.htm> (accessed April 4, 2022).

⁸ *Id.*

⁹ NIH, Peer Review," at <https://grants.nih.gov/grants/peer-review.htm> (accessed April 4, 2022).

¹⁰ NIH, "Peer Review-Scoring," at <https://grants.nih.gov/grants/peer-review.htm#scoring>

Letter to Dr. Lawrence Tabak

Page 3

place their impact scores and percentile rankings in the context of the IC's research priorities, and then make recommendations for final funding decisions.¹¹

C. EcoHealth's proposed humanized mice experiment

As noted in our October 30, 2021, letter to NIH, EcoHealth first proposed testing chimeric SARS-like viruses in a humanized mice experiment to evaluate pathogenicity in the spring of 2016. The NIH approved this research in July 2016 with the condition that EcoHealth immediately stop its experiments and report to the NIH if there was more than one log of virus growth in any of mice groups infected with one of the chimeric viruses. Peculiarly, EcoHealth did not specify in its proposal to NIH how pathogenicity would be evaluated in an animal experiment, and NIH did not follow-up to ask for such information.¹²

In addition to gain-of-function research concerns, it appears NIH approved an animal experiment without knowing the number of animals that would be involved and potentially harmed. Despite EcoHealth and NIH's conclusion that there was no potential gain-of-function concern (which seems counter to the purpose of the grant),¹³ the results of the experiments showed all three chimeric viruses were more lethal compared to the WIV-1 virus.

Notably, one condition that NIAID did impose on the research proposal related to enhanced virus growth, per the grant documents:

NIAID acknowledges that if any of the MERS-like or SARS-like chimeras generated under this grant show **evidence of enhanced virus growth greater than 1 log over the parental backbone strain**, Dr. Daszak will immediately stop all experiments w/ these viruses and provide the NIAID Program Officer and Grants Management Specialist, and Wuhan Institute of Virology Institutional biosafety Committee, with the relevant data and information related to these unanticipated outcomes. (Emphasis added).

However, NIAID requested that EcoHealth clarify the location of the experiment since EcoHealth previously indicated that the experiment would be conducted at the University of North Carolina (UNC). However, on June 27, 2016, Dr. Daszak clarified that the experiment

¹¹ NIH, Peer Review," at <https://grants.nih.gov/grants/peer-review.htm> (accessed April 4, 2022).

¹² This is contrary to animal research reporting guidelines that state, "Clearly define all outcome measures assessed (e.g., cell death, molecular markers, or behavioural changes)." Nathalie Percie du Sert, *et al*, Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0, PLOS Biology (July 14, 2020) available at <https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000411>

¹³ "Moreover, we are introducing progressively more distant S glycoproteins into WIV1 (The RBD of Rs7327 differs from WIV1 in several amino acid residues while RsSHC014 is even more distantly related phylogenetically), so it seems progressively less likely that any of these viruses would be more pathogenic or transmissible than the SARS-CoV." June 8, 2016, EcoHealth letter to NIH (per notes taken by Minority Committee staff Oct. 5, 2021, during bipartisan *in camera* review).

Letter to Dr. Lawrence Tabak

Page 4

would be conducted at the WIV, and he assured NIH that the WIV would immediately notify EcoHealth of such enhanced virus growth:

You are correct to identify a mistake in our letter. UNC has no oversight of the chimera work, all of which will be conducted at the **Wuhan Institute of Virology**.... We will clarify tonight with Prof. Zhengli Shi¹⁴ exactly who will be notified if we see enhanced replication...**my understanding is that I will be notified straight away**, as [principal investigator], and that I can then notify you at NIAID. Apologies for the error! (Emphasis added).¹⁵

Even though EcoHealth received approval for the risky research from NIAID in the early weeks of Year 3, EcoHealth and the WIV did not report the experiment until the Year 4 report. It appears that during Year 3, EcoHealth arranged to get the humanized mice for the experiment imported to China. More transgenic mice were then constructed and bred before the experiment was conducted.¹⁶

D. EcoHealth's Descriptions of Humanized Mice Experiment

As far as we are aware, neither EcoHealth nor the WIV published the details of these experiments in scientific literature, nor are there indications that such publication was even intended. Thus, available details of the experiment are limited to three key documents that described aspects of the mice experiment: the Year 4 progress report, the renewal application for NIAID grant R01A110964, and the Year 5 progress report.

i. The Year 4 progress report (June 2017-May 2018)

The experiment involved infecting four groups of humanized mice with different SARS-like bat viruses, with three groups getting infected with chimeric SARS-like viruses. During the Year 4 reporting period between June 2017 and May 2018, the WIV conducted one experiment that caused some Angiotensin-Converting Enzyme 2 (ACE2) Receptor humanized mice to get sick within six days after infection, and some to die within two weeks. However, EcoHealth split the disclosure of the experiment's data into two parts: (1) weight loss data and viral load in lung tissue in the Year 4 report and the renewal application; and (2) the deaths, viral load in brain tissue, and two photos of lung tissue in the Year 5 report.

As we stated in our February 24 letter, EcoHealth claimed in October 2021 that it conducted a single risky virus infection experiment in one year, but split up the reporting into two different years. The wording of the reports and the renewal application can be read as if there were two experiments. The report stated, "we continued with in vivo infection experiments."¹⁷ If the report accurately reflected Dr. Daszak's claim, then the report should have

¹⁴ Dr. Shi leads bat coronavirus research at the WIV.

¹⁵ Katherine Eban, "This Shouldn't Happen": Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy, Vanity Fair (March 31, 2022), [Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy | Vanity Fair](#)

¹⁶ Year 3 Report, at 253.

¹⁷ EcoHealth Alliance Year 5 progress report at 15.

Letter to Dr. Lawrence Tabak

Page 5

read “we continued data analysis of in vivo infection experiments.” The plain meaning of the text does not support Dr. Daszak’s assertion.

Further, the term “experiments” is plural, incorrectly suggesting more than one experiment. In the Year 4 progress report, the experiment was characterized as “preliminary,” but, interestingly, the word “preliminary” does not appear in the Year 5 progress report description. Yet, more significantly, the Year 5 report makes no mention of the weight loss data from the Year 4 report that would show it was a continuation of the same study.¹⁸

According to the Year 4 progress report:

In Year 4, we performed **preliminary** in vivo infection of SARSr-CoVs on transgenic mice that express hACE2. Mice were infected with 10^5 pfu of full-length recombinant virus of WIV1 (rWIV1) and the three chimeric viruses with different spikes. Pathogenesis of the 4 SARSr-CoVs was then determined in a 2-week course. Mice challenged with rW IV1-SHC014S have experienced about 20% body weight loss by the 6th day post infection, while rWIV1 and rWIV-4231 S produced less body weight loss. In the mice infected with rWIV1-WIV16S, no body weight loss was observed (Fig. 35a).¹⁹ (Emphasis added).

The Year 4 (2017-2018) progress report disclosed weight loss results in the infected mice (Figure 35(a) included below) and a graph showing virus growth in mice lung tissue for the first few days during the two-weeks and then from the “dead point” (Figure 35(b) included below). However, the graph showing the weight loss results only showed results up to 6 days post-infection, even though it was a two-week experiment. Notably, it was on the sixth day of the experiment that the first mouse death occurred according to Figure 13(a) in the Year 5 report. For example, there is no weight loss data for days 8, 10, 12, and 14 post-infection.²⁰

The graph showing the viral load in lung tissue also only showed measurements up to six days (again without data for days 8, 10, 12, and 14) but then included measurements at the “dead point.” However, the “dead point” was not defined or explained. Most significantly, the lung graph did not imply mice deaths from the virus. The mice deaths could have reflected the sacrificed mice made either to obtain the lung tissue samples or to prevent further suffering from the mice during the experiment in accordance with animal welfare requirements.

¹⁸ The Year 5 report included two photographs of lung tissue sections to showcase the difference in pathogenicity between the most lethal virus and the least lethal virus. However, such a visual would have attracted more attention at the study panel review into the extent of the virulence that EcoHealth appeared to be trying to conceal. EcoHealth should have linked this photographic evidence with the viral load in the lung tissue graph in the Year 4 report, but no linkage was made between the photographs in the Year 5 report and the graph in the Year 4 report.

¹⁹ HHS docs at 297, Year 4 report at 24. EcoHealth grant documents *available at* <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

²⁰ EcoHealth may have chosen not to report additional weight loss results because the mice were dying at such a high rate, the data would be biased toward the heavier, healthier mice that survived. On the other hand, if the mice mounted an immune response to the virus, then that data was not shared.

Letter to Dr. Lawrence Tabak

Page 6

Additionally, Figure 35(b) showed viral growth in the experiment that implicated the NIH policy of stopping the experiment if more than one log of viral growth occurred. There is no evidence that EcoHealth complied with NIH's condition to stop this experiment since it continued past the point of excessive viral growth and there was no evidence of stoppage or any notification to NIAID. EcoHealth apparently reported the experiment in the Year 4 progress report well after the experiment was completed. Overall, EcoHealth vaguely characterized the experiment: "These results demonstrate varying pathogenicity of SARSr-COVs with different spike proteins in humanized mice."

ii. EcoHealth's renewal application (November 2018).

EcoHealth's application for competitive renewal sent later in 2018 for its grant included the same Year 4 report data but conspicuously omitted the word "dead" from the lung tissue graph. But this time EcoHealth provided some interpretation. EcoHealth pointed out that the results demonstrated that "pathogenicity of SARSr-CoVs in humanized mice differs with divergent S proteins, thus confirming the value of this model in assessing novel SARSr-COV pathogenicity."²¹ In addition, EcoHealth mentioned that the WIV had vaccinated the humanized mice infected with the SHC014 chimeric virus and the WIV-1 virus. The renewal application stated that the vaccine did not reduce clinical symptoms in the SHC014-infected mice, but the vaccine cross-neutralized two out of the four monoclonal antibodies in the WIV-1-infected mice. However, none of this data was actually shown nor any other substantiating details provided.²²

Most significantly, EcoHealth used the experiment results to help make the case for grant renewal. EcoHealth asserted that its humanized mice work had three implications for its R01 renewal:

(1) some SARS related CoVs currently circulating in bats in southern China **are likely able to infect and replicate within people**; (2) clinical outcomes of infection may include SARS-like illness that is **not treatable with monoclonal antibodies nor preventable with experimental vaccines**; (3) SARS related coronavirus ability to bind human ACE2 is lost with S protein divergence between 10 and 24 percent. **Although no viruses within this range have so far been described, these strains likely used hACE2 but could escape existing vaccines and immunotherapeutics and represent significant public health threats.** In our R01 renewal proposal, we will actively seek to identify viruses with this level of S protein divergence, characterize their binding targets in vitro, and their capacity to produce SARS-like disease that evade immunotherapy and vaccination in vivo. (Bolded in original).

²¹ EcoHealth Alliance grant renewal application at 162 available at [Understanding the Risk of Bat Coronavirus Emergence - The Intercept](#)

²² Again, since there has been no publication of the experiment and publication does not appear to have been intended. EcoHealth could make these assertions in NIH documents without substantiation.

Letter to Dr. Lawrence Tabak

Page 7

iii. Year 5 progress report (June 2018 – May 2019).

The Year 5 progress report disclosed death data, a graph of virus load in brains of infected mice, and two photographs of viral load impact on lung tissue of infected mice.²³ However, the submission of EcoHealth's progress report for Year 5 that included the mice death data was delayed and not received by the NIH until August 2021.²⁴ The Year 5 progress report (due in September 2019, but submitted to NIH in August 2021) stated:

In Year 5, we **continued** with in vivo infection **experiments** of diverse bat SARSr-CoVs on transgenic mice expressing human ACE2. Mice were infected with 4 strains of SARSr-CoVs with different S protein, including the full-length recombinant virus of SARSr-CoV WIV1 and three chimeric viruses with the backbone of WIV1 and S proteins of SHC014, WIV16 and Rs4231, respectively. Pathogenicity of the 4 SARSr-CoVs was evaluated by recording the survival rate of challenged mice in a 2-week course. All of the 4 SARSr-CoVs caused lethal infection in hACE2 transgenic mice, but the mortality rate vary among 4 groups of infected mice (Fig. 13a). 14 days post infection, 5 out of 7 mice infected with WIV1 remained alive (71.4%), while only 2 of 8 mice infected with rWIV1-SHC014 S survived (25%). The survival rate of mice infected with rWIV1-WIV16S and rWIV1-4231S were 50%. (Emphasis added).

E. Dr. Daszak Claimed There Was Only a Single Experiment

The wording in the progress reports and the renewal application appeared to show two experiments in different reporting years.²⁵ As a result, in October 2021, NIH wrote to EcoHealth mentioning the experiment discussed in the Year 5 progress report and informed EcoHealth that the research violated the one log virus growth policy.

In its defense, EcoHealth claimed that it complied with the policy because EcoHealth now claimed it was a single experiment conducted in Year 4 in which some of the results were reported in the Year 4 progress report, with the deaths results reported in the Year 5 progress report. In his October 26, 2021, response,²⁶ Dr. Daszak claimed the humanized mice experiment discussed in both progress reports was one study:

²³ EcoHealth grant documents available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-ofbat-coronavirus-emergence/>.

²⁴ *Id.*

²⁵ According to one expert contacted by staff who is familiar with such studies, two different experiments would have been standard practice. The Year 4 experiment would have been a preliminary small study assessing weight loss (probably with four or fewer mice per group, which is a number of mice sufficient to provide interpretable weight-loss data but not sufficient to provide interpretable survival-rate data), and a follow-up large study (perhaps with 10 or more mice per group). However, this experiment was conducted in China, not in the U.S.

²⁶ EcoHealth Oct. 26, 2021, letter to NIH available at <https://www.documentcloud.org/documents/21097880-ecohealth-letter-contesting-claims>.

Letter to Dr. Lawrence Tabak

Page 8

Firstly, Dr. Tabak's letter appears to refer to our year 5 report, and we note that in your email accompanying you also refer to a Figure 13 from that year 5 report. However, as is visible in the pattern of viral genome measurements, this figure closely resembles Figure 35 from our year 4 report, but with follow-up histopathological and survival data added (both are inserted, below).²⁷ The reason for this is that both figures are from the same experiment – conducted in 2018 and, as noted above, reported rapidly to NIH on 13th April 2018 in our Year 4 report.²⁸

In his March 2022 interview with *The Intercept*, Dr. Daszak further explained how there was only one humanized mice experiment.²⁹ First, he stated that EcoHealth Alliance essentially cut and pasted the report section sent by the WIV on the experiment:

Here's what happens, it's a very standard procedure: We are subcontracting to a lab in China to do some work. Every year we have to file a report to NIH to tell them what we've done for the year, how we've spent the money, and whether we've achieved the goals of the grant. So, we contact our subcontractees and we say, 'Send us the information. Let us know what successes you've had this year and whether you've had problems and issues. Put it all in a report and send it to us.' And then we use that to produce a report for NIH. That's why there are some editing issues around that. We move them around a bit, and we send a final report.

He then detailed how the reporting of one humanized mice experiment was split between two progress reports:

This is a simple issue of Chinese nationals writing a report and then us drafting our report to NIH. So there's a word in there where they say we continued the studies. That doesn't mean they continued infecting mice with new viruses. No. What it means is they continued doing the research on the one experiment that they've done. And that continuation is a lot of work. So they did all the pathology, which means at the end of the experiment, you take all the mice, and you look at every organ in the body. You

²⁷ While Dr. Daszak depicted the "pattern of viral genome measurements" and the results in Figure 35 in the Year 4 report and in Figure 13 in the Year 5 report as "closely" resembling each other, a closer examination revealing data discrepancies shows otherwise. This is discussed in a latter section of the letter.

²⁸ EcoHealth grant documents posted by *The Intercept* (Oct. 21, 2021) available at <https://theintercept.com/document/2021/09/08/understanding-the-risk-of-bat-coronavirus-emergence/>. As we noted in a previous letter, EcoHealth was not in compliance with the NIH policy even with the Year 4 progress report because the experiment was not stopped when the excessive virus growth occurred while it was being conducted. Instead, EcoHealth reported the experiment after it had been completed.

²⁹ Sharon Lerner and Mara Hvistendahl, Peter Daszak Answers Critics and Defends Coronavirus Research, *The Intercept* (March 11, 2022), [Peter Daszak Answers His Critics, Defends EcoHealth Alliance \(theintercept.com\)](https://theintercept.com/peter-daszak-answers-his-critics-defends-ecohealth-alliance/)

Letter to Dr. Lawrence Tabak

Page 9

do detailed microscopical analysis. It takes months. So that's why it dragged on because you've got months of after-the-experiment analysis. And we included the mortality data as part of the pathology data. That's completely normal."³⁰

F. Financial Pressures on EcoHealth

As recently reported by *Vanity Fair*,³¹ EcoHealth faced a "brewing financial crisis" in 2017 and 2018 leading up to the time EcoHealth submitted its grant renewal application to the NIAID in 2018. Ninety-one percent of EcoHealth's funding came from the federal government, with 71 percent of that funding from the PREDICT grant from the U.S. Agency for International Development. The renewed PREDICT II grant was scheduled to end in two years. EcoHealth did not know if this grant would be reauthorized. This looming possibility was known within EcoHealth as the "PREDICT cliff." These financial concerns consumed EcoHealth in meeting after meeting.³²

To offset this potential loss of funding, EcoHealth sought a grant with the Defense Advanced Research Projects Agency (DARPA) in March 2018, which was ultimately declined. However, at a March 29, 2018, EcoHealth staff meeting, Dr. Daszak expressed his concerns about the amateur nature of the DARPA submission, calling it "a major failure on all accounts"³³ and he demanded a "change in culture" as "part of [a] mentality [sic] to get money."³⁴ Notably, it was during this time of financial urgency and the push for a culture "to get money" that EcoHealth submitted its Year 4 progress report on April 13, 2018, and its grant renewal application in November 2018.

³⁰ Dr. Daszak's statement is contradicted by the Year 4 report that included the lung pathology data but not the mortality data.

³¹ Katherine Eban, "This Shouldn't Happen": Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy, *Vanity Fair* (March 31, 2022), [Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy | Vanity Fair](#)

³² *Id.*

³³ *Id.*

³⁴ *Id.*

Letter to Dr. Lawrence Tabak

Page 10

G. The mice death cover-up

The renewal application for the EcoHealth grant concealed the mice deaths by reproducing the two figures from the Year 4 report, but deleting the word “dead” from the term “dead point” in the lung tissue graph:

Figure 35 – Year 4 Report (with “dead point”)




Figure 35. *In vivo* infection of SARSr-CoVs in hACE2-expressing mice. (a, left) Body weight change after infection; (b, right) Viral load in lung tissues

However, the renewal application for the EcoHealth grant shows that the word “dead” was defaced and deleted, but still includes the DPI line for the weight loss graph (Figure 6(b) is reproduced and enlarged for readability):

Figure 6 – Renewal Application (with defaced and deleted “dead” from “dead point”)




Fig. 6: *In vivo* infection of SARSr-CoVs in hACE2 transgenic mice. **6a (left)** Body weight change after infection; **6b (right)** Viral load in lung tissues.


Infection of rWIV1-SHC014S caused mild SARS-like clinical signs in the transgenic hACE2 mouse model **that weren't**

Letter to Dr. Lawrence Tabak

Page 11

In the Year 5 report, EcoHealth has no problem including the word “dead” under the brain tissue graph:

Figure 35 – Year 5 Report (with “dead point”)



There is no apparent reason why EcoHealth was able to include the word “dead” in the Year 4 and Year 5 report graphs, but not in the graph in the renewal application. Without the word “dead” with Figure 6(b), the lung tissue graph would not have implied mice deaths; it would have implied only increasing viral loads. As such, this looks suspiciously tailored to delete this word in a document that would be reviewed by subject matter experts in the peer review process who were independent of NIAID.

Further, the renewal application, unlike the Year 4 report, stated that the presented information showed that the mice infected with SHC014 only had “mild” SARS-like clinical signs that were not reduced by immune-therapeutic monoclonals that reduce SARS pathogenicity or by vaccines. However, the Year 5 report with the mice death data showed that the SHC014 produced a staggering 75 percent death rate. Thus, the portrayal of the SHC014 infected mice as having mild symptoms when EcoHealth would have known of the 75 percent death rate strongly suggests EcoHealth intended to deceive the peer reviewers.

Finally, the deletion of the word “dead” in Figure 35(b) suggests that EcoHealth believed including “dead point” would have triggered questions from the peer reviewers about the deaths. It appears the word “dead” was taken out to conceal the deaths from the peer reviewers, which raises scientific and ethical concerns.³⁵

H. Why Concealing the Mice Deaths Mattered

EcoHealth found itself with unpleasant choices. It could admit that it was doing gain-of-function research, or risk losing money it desperately needed from NIAID. Given the financial pressures it was facing and the culture of “getting money” created by Dr. Daszak, the presentation of the humanized mice data in the renewal application appears intentional.

³⁵S. Moran and R. Huneke, The Role of IACUCs in Responsible Animal Research, ILAR Journal (November 2019), <https://academic.oup.com/ilarjournal/article/60/1/43/5618668>

Letter to Dr. Lawrence Tabak

Page 12

If the mice deaths had been disclosed, it is reasonable to expect that the peer reviewers would have noted these results and the discrepancies in the data when the data of both Year 4 and Year 5 reports are combined. Had the peer reviewers seen the mice death data from the survival rate graph held back for the Year 5 report, they would have known mice were dying at high rates from the chimeric viruses in a risky experiment. There was a significant probability that reviewers would have wanted to stop such risky research and not continue EcoHealth's funding.

I. Dr. Daszak's Explanation for the Delayed Mice Death Reporting is Suspect

In his March 2022 interview with *The Intercept*, Dr. Daszak stated that the reporting of the mice deaths was delayed because months of pathology work needed to be done. This explanation does not make sense because EcoHealth was able to include lung pathology work in the Year 4 progress report. The renewal application, which appears to have been submitted to the NIH in early November 2018, was seven months after the April 2018 submission of the Year 4 report data, presumably more than enough time to have done pathology work.

Additionally, Dr. Daszak's claims about the length of time needed for pathology work appear dubious. Minority committee staff consulted with scientific experts who are either board-certified in pathology or have conducted humanized mice experiments with coronaviruses and staff found no support for the notion that such pathology work would take months. In fact, two experts indicated that pathology takes a week or so since tissues need to be fixed for 24 hours and then processed and stained. One expert told staff that EcoHealth's assertion that reporting of survival data would need to be deferred until pathology work was done was comical.

Even if Dr. Daszak's assertion were true, there is no basis that we are aware of that justifies holding back the death data that EcoHealth already had. In fact, animal welfare regulations suggest that it would be unethical to withhold or delay reporting the death data. The WIV and EcoHealth could have, and should have, reported the death data and told NIH that the pathology work was continuing.

Using the mice death data generated during Year 4 for the Year 5 report also raises questions about how EcoHealth and the WIV actually spent the Year 5 funds for laboratory research since no new mice experiments were apparently conducted in Year 5 given EcoHealth's claim of a single experiment conducted in Year 4. It does not make sense that the pathology work for the lung tissue up to the "dead point" was done in time for inclusion in the Year 4 report, but the pathology work for the viral load in brain tissue up to the "dead point" could not be done in time for the Year 4 report and/or the renewal application. It does not explain why the death data could not have been included in the Year 4 report since lung tissue data with a "dead point" were also submitted in the Year 4 report.

Dr. Daszak's explanation does not explain why the Year 4 report data submitted in April 2018 were not updated with death data for the renewal application that was sent months later in 2018. If Dr. Daszak's statement about the delay in reporting the deaths because of the time needed to do pathology work were true, then there should have been no lung measurements up to

Letter to Dr. Lawrence Tabak

Page 13

the “dead point” of the experiment included in the Year 4 report. Nor did Dr. Daszak make any distinctions between the lung work and brain work on the length of time to do the pathology work.

J. Discrepancies and Omissions in EcoHealth’s Reports

i. “Dead point” Not Defined

As we noted in our previous letter, EcoHealth’s Year 5 progress report was riddled with errors, such as mislabeled graphs.³⁶ Our further examination of the Year 4 and Year 5 reports on the humanized mice research shows the results of the experiment(s) have many discrepancies and omissions. As already noted, the so-called “dead point” in the experiment was not defined or explained.

ii. No Mention of Sample Size

In addition, none of EcoHealth’s descriptions of the experiment mention the sample size. For the Year 4 report and renewal application, there is no mention of sample size of any kind, and the Year 5 report only noted that there were 9 mice in the control group and 7 mice in the group that had the most deaths.³⁷ However, neither the number of mice in the other two groups nor the overall number of mice in the study are mentioned. This is contrary to animal research reporting guidelines that state “Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.”³⁸ By omitting or keeping the mice number vague, EcoHealth was able to hide additional mice deaths resulting from sacrifices made to obtain tissue samples or to mitigate suffering.

iii. Discrepancies in Pathogenicity Results

In the Year 4 report, the WIV 16S infected-mice group had no weight loss, an indication of no pathogenicity. In the Year 5 report, the 16S infected group had a 50 percent death rate while the WIV 1 infected control group had a 29 percent death rate. Thus, for the group infected with the 16S chimeric virus, the experiment in the Year 4 report showed no pathogenesis in terms of weight loss, but the full two-week study in the Year 5 report showed a 50 percent death rate, evidence of pathogenesis. The WIV 1 group had a 29 percent death rate, even though this group had more weight loss (more pathogenesis) than the 16S group had.

³⁶ Letter from House Energy and Commerce Committee Republican Leader Cathy McMorris Rodgers, Republican Health Subcommittee Leader Brett Guthrie, and Republican Oversight and Investigations Subcommittee Leader Morgan Griffith to Dr. Lawrence A. Tabak, Acting Director of the NIH (February 24, 2022).

³⁷ Assuming the other two mice groups were of similar number, the total number of mice used in a single study would have been more than 30, not the typical number in a preliminary in vivo infection study. Given the expense of mice and minimizing the number of mice sacrificed, the number in a preliminary study would be much smaller, according to an expert consulted by staff.

³⁸ Nathalie Percie du Sert, *et al*, Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0, PLOS Biology (July 14, 2020) available at <https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000411>

Letter to Dr. Lawrence Tabak

Page 14

The lung tissue results were not consistent with the weight loss findings. The group with no weight loss and the group with the highest weight loss had nearly the same number of logs of virus growth at the “dead point” of the experiment.³⁹

In the Year 4 report, in Figure 35(b), there is no bar for the 4231-infected group at the dead point in the bar graph on the viral loads in lung tissue, although the bar for the 4231 group is represented in measurements taken 2, 4, and 6 days post-infection. As noted before, during the time that mice deaths were accruing, there were no results for days 8, 10, and 12, and it is inexplicable why the 4231-infected mice data for the “dead point” would be missing in Figure 35(b).

The viral load in brain results in Figure 13b were not consistent with the death results in Figure 13a. The group infected with SHC014 that had the highest death rate (75 percent) had less virus growth in the brain than the amount of virus growth in the brain in the two groups that had a 50 percent death rate. Groups with different death rates had similar viral loads in the brain suggesting that the viral loads in brain tissue may not have been as pertinent as viral loads in lung tissues in its association with pathogenicity. But this issue was not distinguished or pursued.

iv. Missing Data

The Year 5 report stated, “Viral replication was confirmed by quantitative PCR in spleen, lung, intestine, and brain of infected mice.” However, the PCR viral replication data for the spleen and intestine were not included in the report. Perhaps if EcoHealth and the WIV had published the experiment in scientific literature, complete data sets would have been provided. However, it has been more than four years since the experiment was conducted and we have been unable to find any publication about this experiment. Notably, even Dr. Daszak admitted EcoHealth did not have the lab notebooks or the electronic files for the experiment and claimed that such records were in China.⁴⁰

K. EcoHealth Also Masked Its Violation of NIH Policy on Virus Growth

Even with the Year 4 report’s focus on mice weight loss, EcoHealth violated the NIH grant policy that required experiment stoppage when more than one log of viral growth occurred

³⁹ EcoHealth’s Year 4 report description of the mice experiment only focused on the early lung viral loads that were consistent with its assertion that the chimeric virus-infected mice had greater pathogenicity than the WIV1-infected mice. However, EcoHealth’s description did not include the later results in the experiment that were inconsistent with this pattern. EcoHealth wrote, “2 and 4 days post infection, the viral load in lung tissues of mice challenged with rWIV1-SHC014S, rWIV1-WIV16S and rWIV1-Rs4231 S reached more than 10 to the 6 genome copies/g and were significantly higher than that in rWIV1-infected mice (Fig. 35b). These results demonstrate varying pathogenicity of SARSr-CoVs with different spike proteins in humanized mice.” However, Fig. 35b also showed that 6 days post infection the rWIV1-infected mice had viral loads only slightly less than the other infected mice. In fact, at the dead point, rWIV1-infected mice had higher viral loads in lung tissue than the load in the 4231 S group and almost the same viral load as the SHC014S group.

⁴⁰ Letters to EcoHealth Alliance (Jan. 11, 2022) available at <https://republicans-oversight.house.gov/wp-content/uploads/2022/01/January-2022-EHA-SAC-CAP-letter-final1.pdf>.

Letter to Dr. Lawrence Tabak

Page 15

with the one of the chimera-infected mice groups compared to the viral growth in the control group. The violation is supported by the bar graph in Figure 35(b) showing the excessive viral growth in lung tissue. However, the text of the report does not discuss mice deaths nor quantify the extent of viral growth.⁴¹ Moreover, the weight loss graph stops at 6 days and not for the full two-week period. In contrast, the survival graph in the Year 5 report covered the full 14 days.

It is now apparent how this violation occurred. Contrary to its assurance to NIAID in 2016 about the WIV reporting to Dr. Daszak “right away,” EcoHealth had no real-time knowledge of this experiment. It appears EcoHealth simply benefited financially by being a pass-through for the WIV.⁴² Based on Dr. Daszak’s statement to *The Intercept* about cutting and pasting the WIV excerpts into progress reports, EcoHealth did not know about the virus growth until the WIV sent in its report section for the Year 4 report about the experiment that was already completed.

The concerns raised here have profound implications on the integrity of the peer review process. More investigation needs to be conducted to obtain more complete and accurate information about the humanized mice experiment. In addition to investigating the above concerns, please respond to the following by May 16, 2022:

1. Why did NIAID provide renewal grant funding to EcoHealth before EcoHealth filed its Year 5 Progress Report?
2. Why did NIAID neglect or willfully ignore EcoHealth’s missing Year 5 progress report for nearly two years?
3. Why would NIAID fund a study that does not report its sample size? What are the scientific standards for these studies to meet on detailing sample size?
4. Animal experiments are highly regulated, and EcoHealth and the WIV should have very detailed records about the mice experiments. Did NIAID monitor this grant for compliance with animal welfare regulations or ABSL3 (Animal Biosafety Level 3) regulations? Why or why not?
5. When NIAID reviewed EcoHealth’s research proposal to study pathogenesis of SARS-related viruses in humanized mice, did the NIAID approve only one experiment? Was EcoHealth authorized by NIH to conduct as many as experiments as it wanted pursuant to the proposal submitted to NIH? Other than the viral growth policy, were there any other restrictions or conditions on EcoHealth’s authority in conducting the humanized mice experiment?

⁴¹ EcoHealth only stated that the viral load in mice infected with the three chimeras had “significantly higher” growth than that in the WIV-1 infected mice.

⁴² EcoHealth would receive the financial benefit by charging the grant for the WIV overhead and would hold some of that overhead charge for itself.


Letter to Dr. Lawrence Tabak

Page 16

6. Is it permissible for an NIH grantee to withhold and delay reporting of data on deaths in an animal experiment? If so, under what circumstances?
7. What animal welfare regulations applied to the humanized mice experiment, and was EcoHealth in compliance with those regulations?
8. If a grantee submits a research plan involving an animal experiment on pathogenicity for NIH's review, does the grantee need to specify how pathogenicity is evaluated? Or can the grantee evaluate pathogenicity through a survival study that could result in animal deaths without explicitly informing the NIH?
9. Why did NIAID not seek details on the kind of pathogenicity study that EcoHealth wanted to pursue with the WIV?
10. When was the EcoHealth application reviewed by the SRG for renewal? When did NIAID finalize the decision?
11. What are the implications of grant applicants selectively sharing data that may be material to the funding decision? What is NIH policy in this area?

If you have questions about this correspondence, please contact Alan Slobodin of the Minority Committee Staff.


Sincerely,



Cathy McMorris Rodgers
Ranking Member
Committee on Energy and Commerce



Brett Guthrie
Ranking Member
Subcommittee on Health



H. Morgan Griffith
Ranking Member
Subcommittee on Oversight and
Investigations

Letter to Dr. Lawrence Tabak

Page 17

Cc: The Honorable Frank Pallone, Chair, House Energy and Commerce Committee
The Honorable Anna Eshoo, Chair, Subcommittee on Health
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations
The Honorable Christi Grimm, HHS Inspector General
Elena Fuentes-Afflick, M.D., M.P.H., Home Secretary, National Academy of Medicine

EXHIBIT 32

EXHIBIT 32

FRANK PALLONE, JR., NEW JERSEY
CHAIRMANCATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States**House of Representatives****COMMITTEE ON ENERGY AND COMMERCE**

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

July 21, 2021

The Honorable Francis Collins, M.D., Ph.D.
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Dear Dr. Collins,

According to its mission statement, a goal of the National Institutes of Health (NIH) is “to exemplify . . . the highest level of scientific integrity and public accountability.”¹ However, under your leadership, the NIH is falling short of that goal. On March 18, 2021, we sent NIH a detailed, eleven-page request for information about origins of the COVID-19 pandemic, which the public deserves to see. Three months later, the NIH has refused to cooperate with that request. The NIH has not provided a single document to us or made any document available to the public that responds directly to the paramount question of whether NIH funding played a role in risky research in China that could have started the pandemic.

We specifically requested documents related to National Institute of Allergy and Infectious Diseases (NIAID) grant R01AI110964, “Understanding the Risk of Bat Coronavirus Emergence” to EcoHealth Alliance that in part funded the Wuhan Institute of Virology (WIV) research into bat coronaviruses. The NIH has not provided the documents and did not provide written responses to any of the 29 questions in the March 18th letter. Instead, the NIH only provided a one-hour oral briefing to bipartisan committee staff with no documents to address any of the topics covered by the 29 questions in the March 18th letter. Additionally, no subject matter experts from the NIAID were included in the briefing, even though we specifically requested to hear from NIAID, which is the NIH institute responsible for issuing this grant. The only written response provided by the NIH was a two-page May 21, 2021, letter signed by NIH Principal Deputy Director Lawrence Tabak that did not address any of the questions in the March 18th letter, but instead stated:

¹ National Institutes of Health, *Mission and Goals*, What We Do (accessed July 14, 2021) available at <https://www.nih.gov/about-nih/what-we-do/mission-goals>.

Letter to The Honorable Francis Collins

Page 2

The application [from EcoHealth Alliance] was subjected to rigorous peer review and did not propose research to enhance any coronavirus to be more transmissible or virulent. The research proposed in the grant application sought to understand how bat coronaviruses evolve naturally in the environment to become transmissible to the human population. This included studying viral diversity in bat reservoirs, surveying people who work in live animal markets or other jobs with high exposure to wildlife for evidence of bat-coronavirus infection, and analyzing data to predict which newly discovered viruses pose the greatest threat to human health. To support its work, EcoHealth made sub-awards to the Wuhan Institute of Virology and other institutions based in East Asia where coronaviruses tend to emerge and are prevalent. NIH is not currently funding the Wuhan Institute of Virology.²

In addition, the NIH has denied supporting “gain-of-function” research at the WIV through this NIAID grant. For example, NIAID Director Dr. Anthony Fauci testified, “The NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology.”³ You also stated: “Let me be very clear, we never approved any grant that would have supported gain of function research on dangerous coronaviruses to see if they could be more transmissible or lethal for individuals in the human species.”⁴ Yet, the NIH has declined to produce the underlying grant documents and records to substantiate these assertions. Importantly, the NIH has not provided complete information about exactly what the NIH did support at the WIV.

Based on published reports over the last few months and the NIH’s June 28, 2021, briefing with bipartisan committee staff, we have reason to believe that the NIH may have funded humanized mice experiments at the WIV, and that such experiments may have had the potential to start the pandemic. This recent information seems contrary to NIH’s characterizations of the EcoHealth grant and WIV research at issue.

Further, recent documents obtained under the Freedom of Information Act (FOIA) reveal that an NIAID official visited the WIV in 2017, and that NIAID had familiarity with the WIV research on bat coronaviruses and that some of these viruses could be transmissible to humans.

² NIH did not identify by name the “other institutions based in East Asia where coronaviruses tend to emerge and are prevalent” in its letter. The only institution (singular) other than the WIV reported by EcoHealth Alliance as a sub-grant recipient for this grant is the Wuhan University, the same institution from which a researcher requested NIH to remove its submissions to the NIH Sequence Read Archive (SRA) database and NIH removed them. Dr. Jesse Bloom of the Fred Hutchinson Cancer Center recovered some of the removed sequence data and determined that the sequences related to the SARS CoV-2 early Chinese COVID-19 patients.

³ Lori Robertson, *The Wuhan Lab and the Gain-of-Function Disagreement*, FactCheck.org (July 1, 2021) available at <https://www.factcheck.org/2021/05/the-wuhan-lab-and-the-gain-of-function-disagreement/>. We note collaborative projects between Dr. Ralph Baric of the University of North Carolina at Chapel Hill and the WIV, have produced research articles that describe Gain-of-Function research experiments when the WIV was technically funded through a USAID cooperative agreement facilitated by a consortium that included EcoHealth Alliance.

⁴ Samuel Chamberlain, NIH head accuses Rand Paul of ‘misinformation’ about US ties to Wuhan lab New York Post (May 14, 2021) available at <https://nypost.com/2021/05/14/nih-head-accuses-rand-paul-of-misinformation-about-us-ties-to-wuhan-lab/>.

Letter to The Honorable Francis Collins

Page 3

NIAID indirectly continued to fund the WIV research despite concerns about biosafety practices at the WIV raised in 2018 State Department cables, which were based in part on the NIAID visit in 2017.

First, we note that the FY 2018 abstract for the EcoHealth Alliance NIAID “Understanding the Risk of Bat Coronavirus Emergence” grant renewal openly discussed experiments with humanized mice. The abstract for the project declared that aim number three of the research project was to: “3. Test predictions of CoV inter-species transmission. Predictive models of host range (i.e. emergence potential) will be tested experimentally using reverse genetics, pseudovirus and receptor binding assays, and virus infection experiments across a range of cell cultures from different species and **humanized mice**.” (emphasis added).⁵ As noted by science writer Nicholas Wade, in such experiments, “laboratory mice, a cheap and ethical stand-in for human subjects, are genetically engineered to carry the human version of a protein called ACE2 that studs the surface of cells that line the airways.”⁶

Second, a recent article in Vanity Fair reported that the WIV and its bat coronavirus research director, Dr. Shi Zhengli, were involved with experiments in humanized mice in recent years. The article stated that “Shi’s own comments to a science journal, and grant information available on a Chinese government database, suggest that in the past three years her team has tested two novel but undisclosed bat coronaviruses on humanized mice, to gauge their infectiousness.”⁷

Third, such experiments have pandemic potential. As the EcoHealth Alliance wrote in the FY 2019 abstract for this same NIH grant, “We will use S protein sequence data, infectious clone technology, in vitro and in vivo infection experiments and analysis of receptor binding to test the hypothesis that % divergence thresholds in S protein sequences predict spillover potential.”⁸ Mr. Wade further explained the implications of this research:

What this means, in non-technical language, is that Shi set out to create novel coronaviruses with the highest possible infectivity for human cells. Her plan was to take genes that coded for spike proteins possessing a variety of measured affinities for human cells, ranging from high to low. She would insert these spike genes one by one into the backbone of a number of viral genomes (“reverse genetics” and “infectious clone technology”), creating a series of chimeric viruses. These chimeric viruses would then be tested for their ability to attack human cell cultures (“in vitro”) and humanized mice (“in vivo”). And this information would help

⁵ Grantome NIH, Abstract for Understanding the Risk of Bat Coronavirus Emergence, EcoHealth Alliance Inc. FY 2018 available at <https://grantome.com/grant/NIH/R01-AI110964-05>.

⁶ Nicholas Wade, *The origin of COVID: Did people or nature open Pandora’s box at Wuhan?*, Bulletin of the Atomic Scientists, (May 5, 2021), available at <https://thebulletin.org/2021/05/the-origin-of-covid-did-people-or-nature-open-pandoras-box-at-wuhan/>.

⁷ Katherine Eban, *The Lab Leak Theory: Inside the Fight to Uncover COVID 19’s origins*, Vanity Fair (June 3, 2021), available at <https://www.vanityfair.com/news/2021/06/the-lab-leak-theory-inside-the-fight-to-uncover-covid-19s-origins>.

⁸ Grantome NIH, Abstract for Understanding the Risk of Bat Coronavirus Emergence, EcoHealth Alliance Inc. FY 2019 available at <https://grantome.com/grant/NIH/R01-AI110964-05>.

Letter to The Honorable Francis Collins

Page 4

predict the likelihood of “spillover,” the jump of a coronavirus from bats to people.

The methodical approach was designed to find the best combination of coronavirus backbone and spike protein for infecting human cells. The approach could have generated SARS2-like viruses, and indeed may have created the SARS2 virus itself with the right combination of virus backbone and spike protein.⁹

From his review of WIV research, Dr. Richard Ebright, a molecular biologist and biosafety expert at Rutgers University, stated, “It is clear that the Wuhan Institute of Virology was systematically constructing novel chimeric coronaviruses and was assessing their ability to infect human cells and human-ACE2-expressing mice.”¹⁰ He further stated, “It is also clear that, depending on the constant genomic contexts chosen for analysis, this work could have produced SARS-CoV-2 or a proximal progenitor of SARS-CoV-2.”¹¹

Even Dr. Peter Daszak, the President of EcoHealth Alliance, noted the humanized mice and the risks of this research in a December 2019 interview.¹² Around minute 28 of the interview, Dr. Daszak stated:

And we have now found, you know, after 6 or 7 years of doing this, over 100 new SARS-related coronaviruses, very close to SARS. Some of them get into human cells in the lab, some of them can cause SARS disease in humanized mice models and are untreatable with therapeutic monoclonals and you can’t vaccinate against them with a vaccine. So, these are a clear and present danger....¹³

Likewise, Dr. Steven Quay noted the unique characteristic of efficient human-to-human transmission of SARS-CoV-2 in his testimony before the June 29, 2021, House Republican Forum that the SARS CoV-2 virus was “highly adapted for infection of humans from the start, unlike prior natural zoonoses. And growth in humanized mice would allow this lab [adaptation],”¹⁴ like in a March 2020 published paper by Dr. Ralph Baric of University of North Carolina and Dr. Shi of the WIV.

Fourth, the NIH in the June 28, 2021, staff briefing acknowledged that the NIH-funded research at the WIV involved mice. One of the two NIH briefers, Dr. Tabak stated that the only animals that were used in this NIH-funded research at the WIV were mice. However, to date, the

⁹ Wade, note 5.

¹⁰ *Id.*

¹¹ *Id.*

¹² Vincent Racaniello, *TWiV 615: Peter Daszak of EcoHealth Alliance - YouTube*, This Week in Virology, (May 19, 2020), available at https://www.youtube.com/watch?app=desktop&v=IdYDL_RK--w.

¹³ *Id.*

¹⁴ Led By Science: The COVID-19 Origin Story: Forum Before Select Subcomm. on the Coronavirus Crisis, H. Comm. on Oversight & Reform, 117th Cong. (June 29, 2021) (statement by Dr. Steven Quay).

Letter to The Honorable Francis Collins

Page 5

NIH has not clarified to the Committee whether the mice used in the NIH-supported research were *humanized* mice.

Fifth, humanized mice have not been ruled out as an intermediate animal host. According to the World Health Organization joint study with China, more than 80,000 animal samples were tested with no positive results for either SARS CoV-2 antibodies or for the virus itself in an attempt to identify the intermediate animal host to support the zoonotic origins theory.¹⁵ There is no evidence that any of these samples included samples of humanized mice at the WIV.

Finally, on October 26, 2017, Dr. Ping Chen, the Director of the NIAID office in China located in the U.S. embassy in Beijing, wrote to several NIAID officials stating that earlier in the week she had visited the P4 lab at the WIV and that her contact who helped arrange the visit was Dr. Zhengli Shi, “who is a Chinese collaborator on a NIAID grant to EcoHealth for SARS like corona virus project.”¹⁶

Unfortunately, the rest of this email and the trip report were redacted. But, in an April 15, 2020, email sent to Gray Handley of the NIAID with the subject “FW: 2018 Cable” with the January 2018 State Department cable attached, Dr. Chen stated: “Rick forwarded the cable. I was listed as a drafter. About half of the content was taken from my summary.”¹⁷ The January 2018 State Department cable discussed the BSL-4 lab at the WIV, China investing in infectious disease control, unclear guidelines on virus access, the lack of trained talent impeding research, and despite limitations, WIV researchers produce SARS discoveries. For the last topic, the cable noted the WIV research finding “strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like disease.”¹⁸ These redacted documents provide a reason to believe that the NIH – or at least the NIAID – had a much higher level of engagement and familiarity with the EcoHealth Alliance grant and WIV bat coronavirus research than just reading press reports during April-July 2020 as NIH suggested at the June 28, 2021, briefing with bipartisan Committee staff.¹⁹

Over 600,000 Americans have died from COVID-19 and more than 4 million people worldwide. We need answers to some basic questions about the origin of the virus, and yet, the NIH continues to frustrate our efforts to get answers. The stakes are too high to operate on an

¹⁵ World Health Organization, *WHO-convened Global Study of the Origins of SARS-CoV-2* (March 30, 2021) available at <https://www.who.int/health-topics/coronavirus/origins-of-the-virus>.

¹⁶ Judicial Watch, *Judicial Watch: New Documents Show Wuhan Lab Asked NIH Official for Information on Disinfectants; Nine Fauci Agency Grants for EcoHealth Bat Coronavirus Research*, Press Releases (July 8, 2021) available at <https://www.judicialwatch.org/press-releases/wuhan-lab-fauci-grants/>.

¹⁷ *Id.*

¹⁸ Josh Rogin, *Opinion: State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses*, The Washington Post (April 14, 2020) available at <https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/>.

¹⁹ Based on the questions the NIH Office of Extramural Research asked EcoHealth Alliance, it is unclear that NIH maintained control, oversight or responsibility of EcoHealth Alliance as its grantee. For example, in an April 2020 email to EcoHealth Alliance, the NIH Deputy Director of Extramural Research, Dr. Michael Lauer, asked EcoHealth Alliance for information about this same grant, to include, “...it would be helpful for us to know about *all* China-based participants in this work since the Type 1 grant started in 2014 - who they were and how much money they received.”

Letter to The Honorable Francis Collins


Page 6

honor system. This not only undermines NIH's mission goals, but also Congress' and the public's trust in the NIH. It is time for the NIH to share all information and documents that it has related to NIAID grant R01AI110964 with the public and the scientific community.

Therefore, we request that the NIH provide all documents related to the October 2017 visit to the WIV, all documents related to NIAID grant R01AI110964, and the identities of the "other institutions" referenced in NIH's May letter by July 28, 2021. In addition, we request staff briefings immediately and no later than July 28, 2021, with the following officials from NIAID: Dr. Ping Chen and Dr. Erik Stemmy, the program officer for NIAID grant R01AI110964.

If you have any questions, please contact Alan Slobodin or Diane Cutler of the Minority Committee staff.


Sincerely,



Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce



Brett Guthrie
Republican Leader
Subcommittee on Health



H. Morgan Griffith
Republican Leader
Subcommittee on Oversight and Investigations

CC: The Honorable Frank Pallone, Chairman
The Honorable Anna Eshoo, Chair, Subcommittee on Health
The Honorable Diana DeGette, Chair, Subcommittee on Oversight and Investigations

EXHIBIT 33

EXHIBIT 33

DEPARTMENT OF STATE HEALTH SERVICES
VITAL STATISTICS

TEXAS DEPARTMENT OF STATE HEALTH SERVICES - VITAL STATISTICS

Dec 10 2020

STATE OF TEXAS

CERTIFICATE OF DEATH

STATE FILE NUMBER

142-20-224265

1. LEGAL NAME OF DECEASED (Include AKA's, if any) (First, Middle, Last)				(Before Marriage)		2. DATE OF DEATH - ACTUAL OR PRESUMED (mm-dd-yyyy)	
PATRICIA MARIE CADDOD				GAARDER		DECEMBER 9, 2020	
3. SEX	4. DATE OF BIRTH (mm-dd-yyyy)	5. AGE-Last Birthday (Years)	IF UNDER 1 YR Mo Days		IF UNDER 1 DAY Hours Min		6. BIRTHPLACE (City & State or Foreign Country)
FEMALE	MAY 22, 1935	85					YONKERS, NY
7. SOCIAL SECURITY NUMBER		8. MARITAL STATUS AT TIME OF DEATH			9. SURVIVING SPOUSE'S NAME (If spouse, give name prior to first marriage)		
		<input type="checkbox"/> Married <input checked="" type="checkbox"/> Widowed (but not remarried) <input type="checkbox"/> Divorced (but not remarried) <input type="checkbox"/> Never Married <input type="checkbox"/> Unknown					
10a. RESIDENCE STREET ADDRESS				10b. APT. NO.		10c. CITY OR TOWN	
2043 BISCAYNE DRIVE						LEWISVILLE	
10d. COUNTY		10e. STATE		10f. ZIP CODE		10g. INSIDE CITY LIMITS?	
DENTON		TEXAS		75067-7420		<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
11. FATHER/PARENT 2 NAME PRIOR TO FIRST MARRIAGE				12. MOTHER/PARENT 1 NAME PRIOR TO FIRST MARRIAGE			
OSCAR EARL GAARDER				CARMELLA DENICOLA			
13. PLACE OF DEATH (CHECK ONLY ONE)							
IF DEATH OCCURRED IN A HOSPITAL: <input type="checkbox"/> Inpatient <input type="checkbox"/> ER/Outpatient <input type="checkbox"/> DOA <input type="checkbox"/> Hospice Facility <input checked="" type="checkbox"/> Nursing Home <input type="checkbox"/> Decedent's Home <input type="checkbox"/> Other (Specify)							
14. COUNTY OF DEATH		15. CITY/TOWN, ZIP (IF OUTSIDE CITY LIMITS, GIVE PRECINCT NO)			16. FACILITY NAME (If not institution, give street address)		
DENTON		LEWISVILLE, 75067			INSPIRED LIVING OF LEWISVILLE		
17. INFORMANT'S NAME & RELATIONSHIP TO DECEASED				18. MAILING ADDRESS OF INFORMANT (Street and Number, City, State, Zip Code)			
DAVID ANDREW CADDOD - SON				2043 BISCAYNE DRIVE, LEWISVILLE, TX 75067-7420			
19. METHOD OF DISPOSITION		20. SIGNATURE AND LICENSE NUMBER OF FUNERAL DIRECTOR OR PERSON ACTING AS SUCH			21. <input checked="" type="checkbox"/> Unknown		
<input type="checkbox"/> Burial <input checked="" type="checkbox"/> Cremation <input type="checkbox"/> Donation <input type="checkbox"/> Entombment <input type="checkbox"/> Removal from state <input type="checkbox"/> Mausoleum <input type="checkbox"/> Other (Specify)		BRADLEY SUTTON, BY ELECTRONIC SIGNATURE - 11079			Section _____ Block _____ Lot _____ Space _____		
22. PLACE OF DISPOSITION (Name of cemetery, crematory, other place)				23. LOCATION (City/Town, and State)			
METRO MORTUARY AND CREMATORY				SACHSE, TX			
24. NAME OF FUNERAL FACILITY				25. COMPLETE ADDRESS OF FUNERAL FACILITY (Street and Number, City, State, Zip Code)			
DALTON AND SON FUNERAL HOME				1550 N STEMMONS FRWY, LEWISVILLE, TX 75067			
26. CERTIFIER (Check only one)							
<input checked="" type="checkbox"/> Certifying physician-To the best of my knowledge, death occurred due to the cause(s) and manner stated.							
<input type="checkbox"/> Medical Examiner/Justice of the Peace - On the basis of examination, and/or investigation, in my opinion, death occurred at the time, date and place, and due to the cause(s) and manner stated.							
27. SIGNATURE OF CERTIFIER				28. DATE CERTIFIED (mm-dd-yyyy)		29. LICENSE NUMBER	
ROSALINE SHARIFI, BY ELECTRONIC SIGNATURE				DECEMBER 9, 2020		N6656	
30. TIME OF DEATH (Actual or presumed)				31. PRINTED NAME, ADDRESS OF CERTIFIER (Street and Number, City, State, Zip Code)			
01:30 PM				ROSALINE SHARIFI 800 W. RANDOL MILL RD, ARLINGTON, TX 76012			
32. TITLE OF CERTIFIER				33. PART 1. ENTER THE CHAIN OF EVENTS - DISEASES, INJURIES, OR COMPLICATIONS - THAT DIRECTLY CAUSED THE DEATH. DO NOT ENTER TERMINAL EVENTS SUCH AS CARDIAC ARREST, RESPIRATORY ARREST, OR VENTRICULAR FIBRILLATION WITHOUT SHOWING THE ETIOLOGY. DO NOT ABBREVIATE. ENTER ONLY ONE CAUSE ON EACH.			
DO				Approximate interval Onset to death			
CAUSE OF DEATH				DAYS			
IMMEDIATE CAUSE (Final disease or condition resulting in death)				WEEK			
a. COVID 19 PNEUMONIA				Due to (or as a consequence of):			
b. COVID 19 VIRUS				Due to (or as a consequence of):			
c.				Due to (or as a consequence of):			
d.				Due to (or as a consequence of):			
PART 2. ENTER OTHER CAUSE GIVEN IN PART 1							
DIABETES MELLITUS, DEMENTIA, HISTORY BREAST CANCER							
34. WAS AN AUTOPSY PERFORMED?		35. WERE AUTOPSY FINDINGS AVAILABLE TO COMPLETE THE CAUSE OF DEATH?					
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		<input type="checkbox"/> Yes <input type="checkbox"/> No					
36. MANNER OF DEATH		37. DID TOBACCO USE CONTRIBUTE TO DEATH?		38. IF FEMALE:		39. IF TRANSPORTATION INJURY, SPECIFY:	
<input checked="" type="checkbox"/> Natural <input type="checkbox"/> Accident <input type="checkbox"/> Suicide <input type="checkbox"/> Homicide <input type="checkbox"/> Pending Investigation <input type="checkbox"/> Could not be determined		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Previously <input type="checkbox"/> Probably <input type="checkbox"/> Unknown		<input type="checkbox"/> Not pregnant within past year <input type="checkbox"/> Pregnant at time of death <input type="checkbox"/> Not pregnant, but pregnant within 42 days of death <input type="checkbox"/> Not pregnant, but pregnant 43 days to one year before death <input type="checkbox"/> Unknown if pregnant within the past year		<input type="checkbox"/> Driver/Operator <input type="checkbox"/> Passenger <input type="checkbox"/> Pedestrian <input type="checkbox"/> Other (Specify)	
40a. DATE OF INJURY (mm-dd-yyyy)		40b. TIME OF INJURY		40c. INJURY AT WORK?		40d. PLACE OF INJURY (e.g., Decedent's home, construction site, restaurant, wooded area)	
				<input type="checkbox"/> Yes <input type="checkbox"/> No			
40e. LOCATION (Street and Number, City, State, Zip Code)				40f. COUNTY OF INJURY			
41. DESCRIBE HOW INJURY OCCURRED							
42a. REGISTRAR FILE NO.		42b. DATE RECEIVED BY LOCAL REGISTRAR		42c. REGISTRAR			
				Tara Das			

EDR NUMBER 00004444895193

This is a true and correct copy of the record as registered in the State of Texas. Issued under the authority of Section 191.051, Health and Safety Code.

ISSUED Dec 16 2020

WARNING: THIS DOCUMENT HAS A DARK BLUE BORDER AND A COLORED BACKGROUND

ANY ALTERATION OR ERASURE VOIDS THIS CERTIFICATE



EXHIBIT 34

EXHIBIT 34

Family Members-Surviving Spouse's Middle Name- amended on Dec-15-2021; formerly blank; , Family Members-Last(Entire birth name of spouse if married or separated)- amended on Dec-15-2021; , formerly Smith, , Family Members-Mother's Maiden Last Name- amended on Dec-15-2021; , Informant Middle Name- amended on Dec-15-2021; , formerly Smith, , formerly Smith, Amended on Mar-10-2022 - Cause of Death-Line D Description was CHRONIC OBSTRUCTIVE PULMONARY DISEASE

[illegible]



NY3520440

Ver. 09/2020

This is to certify that the within copy has been compared by me with the original thereof on file in the Bureau of Vital Records, New York State Department of Health, Albany, NY and that it is a correct copy of the original record and of the whole thereof.

New York State Registrar
Stephanie E. Ostrowski

JUL 27 2022

N. B. Do not accept this copy unless the raised seal of the New York State Department of Health is affixed, thereon.
Albany, New York




EXHIBIT 35

EXHIBIT 35

NYSCEF DOC. NO. 9401

RECEIVED NYSCEF: 02/04/2023

131-2022-00005246

RECORDED DISTRICT		NEW YORK STATE		DEPARTMENT OF HEALTH		STATE FILE NUMBER			
REGISTER NUMBER 0269		CERTIFICATE OF DEATH							
1. NAME: FIRST MIDDLE LAST Robert F Lewis Jr.				2. SEX: MALE <input checked="" type="checkbox"/> 1 FEMALE <input type="checkbox"/> 2		3A. DATE OF DEATH: MONTH DAY YEAR 01 15 2022			
4A. PLACE OF DEATH: (Check one) HOSPITAL DOA ER <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> HOSPITAL OUTPATIENT <input type="checkbox"/> HOSPITAL INPATIENT <input checked="" type="checkbox"/> NURSING HOME <input type="checkbox"/> PRIVATE RESIDENCE <input type="checkbox"/> HOSPICE FACILITY <input type="checkbox"/> OTHER (Specify): <input type="checkbox"/>				4B. IF FACILITY, DATE ADMITTED: MONTH DAY YEAR 12 28 2021		38. HOUR: Approx 07:30 PM			
4C. NAME OF FACILITY: (If not facility, give address) Mercy Hospital				4D. LOCALITY: (Check one and specify) CITY VILLAGE TOWN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Buffalo		4E. COUNTY OF DEATH: Erie			
4F. MEDICAL RECORD NO.		4G. WAS DECEDENT TRANSFERRED FROM ANOTHER INSTITUTION? (If yes, specify institution name, city or town, county and state) NO <input type="checkbox"/> YES <input type="checkbox"/>							
5. DATE OF BIRTH: MONTH DAY YEAR 04 24 1961		6A. AGE IN YEARS: 60 yrs		6B. IF UNDER 1 YEAR ENTER: months days		6C. IF UNDER 1 DAY ENTER: hours minutes			
7A. CITY AND STATE OF BIRTH: (If not USA, Country and Region/Province) Baltimore, Maryland				7B. IF AGE UNDER 1 YEAR, NAME OF HOSPITAL OF BIRTH:					
8. SERVED IN U.S. ARMED FORCES? (Specify years) NO <input checked="" type="checkbox"/> YES <input type="checkbox"/> 0 <input type="checkbox"/> 1		9. DECEDENT OF HISPANIC ORIGIN? Check the boxes that best describe whether the decedent is Spanish/Hispanic/Latino. A <input checked="" type="checkbox"/> No, not Spanish/Hispanic/Latino B <input type="checkbox"/> Yes, Mexican, Mexican American, Chicano C <input type="checkbox"/> Yes, Puerto Rican D <input type="checkbox"/> Yes, Cuban E <input type="checkbox"/> Yes, Other Spanish/Hispanic/Latino (Specify)				10. DECEDENT'S RACE: Check one or more races to indicate what the decedent considered himself or herself to be: A <input checked="" type="checkbox"/> White/Caucasian B <input type="checkbox"/> Black or African American C <input type="checkbox"/> Asian Indian D <input type="checkbox"/> Chinese E <input type="checkbox"/> Filipino F <input type="checkbox"/> Japanese G <input type="checkbox"/> Korean H <input type="checkbox"/> Vietnamese J <input type="checkbox"/> Native Hawaiian K <input type="checkbox"/> Guamanian or Chamorro M <input type="checkbox"/> Samoan N <input type="checkbox"/> American Indian or Alaska Native (Specify) P <input type="checkbox"/> Other Asian (Specify) R <input type="checkbox"/> Other Pacific Islander (Specify) S <input type="checkbox"/> Other (Specify)			
11. DECEDENT'S EDUCATION: Check the box that best describes the highest degree or level of school completed at the time of death. 1 <input type="checkbox"/> < 8th grade 2 <input type="checkbox"/> 9th-12th grade: no diploma 3 <input type="checkbox"/> High school graduate or GED 4 <input type="checkbox"/> Some college credit, but no degree 5 <input type="checkbox"/> Associate's degree 6 <input checked="" type="checkbox"/> Bachelor's degree 7 <input type="checkbox"/> Master's degree 8 <input type="checkbox"/> Doctorate/Professional degree		12. SOCIAL SECURITY NUMBER: [REDACTED]				13. MARITAL STATUS: NEVER MARRIED <input type="checkbox"/> 1 MARRIED <input checked="" type="checkbox"/> 2 WIDOWED <input type="checkbox"/> 3 DIVORCED <input type="checkbox"/> 4 SEPARATED <input type="checkbox"/> 5			
14. SURVIVING SPOUSE: Enter birth name of spouse if married or separated. Kimberly Lewis									
15A. USUAL OCCUPATION: (Do not enter retired) Computer Programmer		15B. KIND OF BUSINESS OR INDUSTRY: Hospital Supplies		15C. NAME AND LOCALITY OF COMPANY OR FIRM: Buffalo Hospital Supply - Buffalo, NY					
16A. RESIDENCE: (State or Country if not USA) NY		16B. County or Region/Province if not USA: Erie		16C. LOCALITY: (Check one and specify) CITY VILLAGE TOWN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Alden Village		16F. IF CITY OR VILLAGE, IS RESIDENCE WITHIN CITY OR VILLAGE LIMITS? <input type="checkbox"/> YES <input type="checkbox"/> NO IF NO, SPECIFY TOWN:			
16D. STREET AND NUMBER OF RESIDENCE: 13014 Broadway				16E. ZIP CODE: 14004					
17. BIRTH NAME OF FATHER / PARENT: FIRST MI LAST Robert Lewis Sr.		18. BIRTH NAME OF MOTHER / PARENT: FIRST MI LAST Dorothy Gebhart							
19A. NAME OF INFORMANT: Kimberly Lewis		19B. MAILING ADDRESS: (include zip code) 13014 Broadway, Alden Village, NY 14004							
20A. 1 <input type="checkbox"/> BURIAL 2 <input checked="" type="checkbox"/> CREMATION 3 <input type="checkbox"/> REMOVAL MONTH DAY YEAR 6 <input type="checkbox"/> ENTOMBMENT 01 18 2022		20B. PLACE OF BURIAL, CREMATION, REMOVAL OR OTHER DISPOSITION: Cutler Cremation Co		20C. LOCATION: (City or town and state) Buffalo, New York					
21A. NAME AND ADDRESS OF FUNERAL HOME: Charles Meyer Funeral Home 13228 Broadway, Alden, NY 14004		21B. REGISTRATION NUMBER: 00316							
22A. NAME OF FUNERAL DIRECTOR: Tracey L Golding		22B. SIGNATURE OF FUNERAL DIRECTOR: Tracey L Golding Electronically Signed				22C. REGISTRATION NUMBER: 11378			
23A. SIGNATURE OF REGISTRAR: Tianna M Marks Electronically Signed		23B. DATE FILED: MONTH DAY YEAR 01 18 2022		24A. BURIAL OR REMOVAL PERMIT ISSUED BY: Dwyane Buchanan		24B. DATE ISSUED: MONTH DAY YEAR 01 18 2022			
ITEMS 25 THRU 33 COMPLETED BY CERTIFYING PHYSICIAN -- OR -- CORONER/CORONER'S PHYSICIAN OR MEDICAL EXAMINER									
25A. CERTIFICATION: To the best of my knowledge, death occurred at the time, date and place and due to the causes stated. Certifier's Name: Chelsea Lynn Stoeckl, PA License No.: 019649 Signature: Chelsea Lynn Stoeckl, PA Electronically Signed Month Day Year 01 16 2022 Certifier's Title: 0 <input type="checkbox"/> Attending Physician 0 <input type="checkbox"/> Physician acting on behalf of Attending Physician Address: 565 Abbott Road, Buffalo, NY 14220 1 <input type="checkbox"/> Coroner 2 <input type="checkbox"/> Medical Examiner / Deputy Medical Examiner									
25B. If coroner is not a physician, enter Coroner's Physician's name & title:		License No.:		Signature:		Month Day Year			
25C. If certifier is not attending physician, enter Attending Physician's name & title:		License No.:		Address:					
26A. Attending physician attended deceased: FROM Month Day Year 12 28 2021 TO Month Day Year 01 12 2022		26B. Deceased last seen alive by attending physician: Month Day Year 01 12 2022		26C. Pronounced Dead ON Month Day Year 01 15 2022 AT Time 07:30 PM					
27. MANNER OF DEATH: NATURAL CAUSE <input checked="" type="checkbox"/> 1 ACCIDENT <input type="checkbox"/> 2 HOMICIDE <input type="checkbox"/> 3 SUICIDE <input type="checkbox"/> 4 UNDETERMINED CIRCUMSTANCES <input type="checkbox"/> 5 PENDING INVESTIGATION <input type="checkbox"/> 6		28. WAS CASE REFERRED TO CORONER OR MEDICAL EXAMINER? 0 <input checked="" type="checkbox"/> NO 1 <input type="checkbox"/> YES		29A. AUTOPSY? NO <input checked="" type="checkbox"/> 0 YES <input type="checkbox"/> 1 REFUSED <input type="checkbox"/> 2		29B. IF YES, WERE FINDINGS USED TO DETERMINE CAUSE OF DEATH? 0 <input type="checkbox"/> NO 1 <input type="checkbox"/> YES			
CONFIDENTIAL SEE INSTRUCTION SHEET FOR COMPLETING CAUSE OF DEATH CONFIDENTIAL									
30. DEATH WAS CAUSED BY: (ENTER ONLY ONE CAUSE PER LINE FOR (A), (B), AND (C).) PART I. IMMEDIATE CAUSE: (A) COVID-19 DUE TO OR AS A CONSEQUENCE OF: (B) Acute Respiratory Failure with Hypoxia DUE TO OR AS A CONSEQUENCE OF: (C) Deep Vein Thrombosis PART II. OTHER SIGNIFICANT CONDITIONS CONTRIBUTING TO DEATH BUT NOT RELATED TO CAUSE GIVEN IN PART I (A): <<<>>>> DID TOBACCO USE CONTRIBUTE TO DEATH? 0 <input checked="" type="checkbox"/> NO 1 <input type="checkbox"/> YES 2 <input type="checkbox"/> PROBABLY 3 <input type="checkbox"/> UNKNOWN									
31A. IF INJURY, DATE: MONTH DAY YEAR HOUR:		31B. INJURY LOCALITY: (City or town and county and state)		31C. DESCRIBE HOW INJURY OCCURRED:		31D. PLACE OF INJURY:			
31E. IF TRANSPORTATION INJURY, SPECIFY: 1 <input type="checkbox"/> Driver/Operator 2 <input type="checkbox"/> Passenger 3 <input type="checkbox"/> Pedestrian 4 <input type="checkbox"/> OTHER (specify)		32. WAS DECEDENT HOSPITALIZED IN LAST 2 MONTHS? NO <input type="checkbox"/> 0 YES <input type="checkbox"/> 1		33A. IF FEMALE: 0 <input type="checkbox"/> Not pregnant within last year 1 <input type="checkbox"/> Pregnant at time of death 2 <input type="checkbox"/> Not pregnant, but pregnant within 42 days of death 4 <input type="checkbox"/> Unknown if pregnant within past year		33B. DATE OF DELIVERY: MONTH DAY YEAR			

EXHIBIT 36

EXHIBIT 36

NYSCEF DOC. NO. 60

RECEIVED NYSCEF: 02/04/2023

NEW YORK STATE DEPARTMENT OF HEALTH		131-2021-00110717 STATE FILE NUMBER	
CERTIFICATE OF DEATH			
1. NAME: FIRST MIDDLE LAST Patricia A Chislett		2. SEX: MALE <input type="checkbox"/> FEMALE <input checked="" type="checkbox"/>	3A. DATE OF DEATH: MONTH DAY YEAR 12 18 2021
4A. PLACE OF DEATH: (Check one) HOSPITAL DDA ER <input type="checkbox"/> HOSPITAL OUTPATIENT <input type="checkbox"/> HOSPITAL INPATIENT <input checked="" type="checkbox"/> NURSING HOME <input type="checkbox"/> PRIVATE RESIDENCE <input type="checkbox"/> HOSPICE FACILITY <input type="checkbox"/> OTHER (Specify): <input type="checkbox"/>		3B. HOUR: 10:20 AM	
4C. NAME OF FACILITY: (If not facility, give address) Sisters Of Charity Hospital		4B. IF FACILITY, DATE ADMITTED: MONTH DAY YEAR 12 18 2021	
4F. MEDICAL RECORD NO. 285159846		4E. COUNTY OF DEATH: Erie	
5. DATE OF BIRTH: MONTH DAY YEAR 06 11 1946		6A. AGE IN YEARS: 75 yrs.	
6B. IF UNDER 1 YEAR ENTER: months days		6C. IF UNDER 1 DAY ENTER: hours minutes	
7A. CITY AND STATE OF BIRTH: (If not USA, Country and Region/Province) Buffalo, New York		7B. IF AGE UNDER 1 YEAR, NAME OF HOSPITAL OF BIRTH:	
8. SERVED IN U.S. ARMED FORCES? (Specify years) NO YES <input checked="" type="checkbox"/> 0 <input type="checkbox"/> 1		9. DECEDENT OF HISPANIC ORIGIN? Check the boxes that best describe whether the decedent is Spanish/Hispanic/Latino. A <input checked="" type="checkbox"/> No, not Spanish/Hispanic/Latino B <input type="checkbox"/> Yes, Mexican, Mexican American, Chicano C <input type="checkbox"/> Yes, Puerto Rican D <input type="checkbox"/> Yes, Cuban E <input type="checkbox"/> Yes, Other Spanish/Hispanic/Latino (Specify)	
10. DECEDENT'S RACE: Check one or more races to indicate what the decedent considered himself or herself to be: A <input checked="" type="checkbox"/> White/Caucasian B <input type="checkbox"/> Black or African American C <input type="checkbox"/> Asian Indian D <input type="checkbox"/> Chinese E <input type="checkbox"/> Filipino F <input type="checkbox"/> Japanese G <input type="checkbox"/> Korean H <input type="checkbox"/> Vietnamese J <input type="checkbox"/> Native Hawaiian K <input type="checkbox"/> Guamanian or Chamorro M <input type="checkbox"/> Samoan N <input type="checkbox"/> American Indian or Alaska Native (specify) P <input type="checkbox"/> Other Asian (specify) R <input type="checkbox"/> Other Pacific Islander (specify) S <input type="checkbox"/> Other (specify)		11. DECEDENT'S EDUCATION: Check the box that best describes the highest degree or level of school completed at the time of death. 1 <input type="checkbox"/> < 8th grade 2 <input type="checkbox"/> 9th-12th grade; no diploma 3 <input checked="" type="checkbox"/> High school graduate or GED 4 <input type="checkbox"/> Some college credit, but no degree 5 <input type="checkbox"/> Associate's degree 6 <input type="checkbox"/> Bachelor's degree 7 <input type="checkbox"/> Master's degree 8 <input type="checkbox"/> Doctorate/Professional degree	
12. SOCIAL SECURITY NUMBER: [REDACTED]		13. MARITAL STATUS: NEVER MARRIED <input type="checkbox"/> 1 MARRIED <input checked="" type="checkbox"/> 2 WIDOWED <input type="checkbox"/> 3 DIVORCED <input type="checkbox"/> 4 SEPARATED <input type="checkbox"/> 5	
14. SURVIVING SPOUSE: Enter birth name of spouse if married or separated. James A Chislett		15A. USUAL OCCUPATION: (Do not enter retired) home maker	
15B. KIND OF BUSINESS OR INDUSTRY: own home		15C. NAME AND LOCALITY OF COMPANY OR FIRM:	
16A. RESIDENCE: (State or Country if not USA) NY		16B. County or Region/Province if not USA: Erie	
16C. LOCALITY: (Check one and specify) CITY VILLAGE TOWN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Elma Town		16F. IF CITY OR VILLAGE, IS RESIDENCE WITHIN CITY OR VILLAGE LIMITS? <input type="checkbox"/> YES <input type="checkbox"/> NO IF NO, SPECIFY TOWN:	
16D. STREET AND NUMBER OF RESIDENCE: 3680 Bullis Road		16E. ZIP CODE: 14059	
17. BIRTH NAME OF FATHER / PARENT: FIRST MI LAST E. William Carey		18. BIRTH NAME OF MOTHER / PARENT: FIRST MI LAST Evelyn Mangus	
19A. NAME OF INFORMANT: James A Chislett		19B. MAILING ADDRESS: (include zip code) 3680 Bullis Road, Elma Town, NY 14059	
20A. 1 <input type="checkbox"/> BURIAL 2 <input checked="" type="checkbox"/> CREMATION 3 <input type="checkbox"/> REMOVAL 4 <input type="checkbox"/> HOLD DAY 5 <input type="checkbox"/> DONATION YEAR 6 <input type="checkbox"/> ENTOMBMENT 12 29 2021		20B. PLACE OF BURIAL, CREMATION, REMOVAL OR OTHER DISPOSITION: Cutler Cremation Co	
20C. LOCATION: (City or town and state) Buffalo, New York		21A. NAME AND ADDRESS OF FUNERAL HOME: Charles Meyer Funeral Home 13228 Broadway, Alden, NY 14004	
21B. REGISTRATION NUMBER: 00316		22A. NAME OF FUNERAL DIRECTOR: Tracey L. Golding	
22B. SIGNATURE OF FUNERAL DIRECTOR: Tracey L. Golding Electronically Signed		22C. REGISTRATION NUMBER: 11378	
23A. SIGNATURE OF REGISTRAR: Tanna M Marks Electronically Signed		23B. DATE FILED: MONTH DAY YEAR 12 21 2021	
24A. BURIAL OR REMOVAL PERMIT ISSUED BY: Dwyane Buchanan		24B. DATE ISSUED: MONTH DAY YEAR 12 21 2021	
ITEMS 25 THRU 33 COMPLETED BY CERTIFYING PHYSICIAN -- OR -- CORONER/CORONER'S PHYSICIAN OR MEDICAL EXAMINER			
25A. CERTIFICATION: To the best of my knowledge, death occurred at the time, date and place and due to the causes stated. Certifier's Name: Nashat Rabadi, MD License No.: 186923 Signature: Nashat Rabadi, MD Electronically Signed Month Day Year 12 20 2021			
Certifier's Title: 0 <input checked="" type="checkbox"/> Attending Physician 0 <input type="checkbox"/> Physician acting on behalf of Attending Physician 1 <input type="checkbox"/> Coroner 2 <input type="checkbox"/> Medical Examiner / Deputy Medical Examiner Address: 2157 Main St, Buffalo, NY 14214			
25B. If coroner is not a physician, enter Coroner's Physician's name & title: License No.: Signature: Month Day Year			
25C. If certifier is not attending physician, enter Attending Physician's name & title: License No.: Signature: Address: Month Day Year			
26A. Attending physician attended deceased: FROM Month Day Year TO Month Day Year 12 13 2021 TO 12 18 2021			
26B. Deceased last seen alive by attending physician: Month Day Year 12 17 2021			
26C. Pronounced: Month Day Year 12 18 2021 AT 10:20 AM			
27. MANNER OF DEATH: NATURAL CAUSE <input checked="" type="checkbox"/> 1 ACCIDENT <input type="checkbox"/> 2 HOMICIDE <input type="checkbox"/> 3 SUICIDE <input type="checkbox"/> 4 UNDETERMINED CIRCUMSTANCES <input type="checkbox"/> 5 PENDING INVESTIGATION <input type="checkbox"/> 6			
28. WAS CASE REFERRED TO CORONER OR MEDICAL EXAMINER? 0 <input checked="" type="checkbox"/> NO 1 <input type="checkbox"/> YES			
29A. AUTOPSY? NO YES REFUSED <input checked="" type="checkbox"/> 0 <input type="checkbox"/> 1 <input type="checkbox"/> 2			
29B. IF YES, WERE FINDINGS USED TO DETERMINE CAUSE OF DEATH? 0 <input type="checkbox"/> NO 1 <input type="checkbox"/> YES			
30. DEATH WAS CAUSED BY: (ENTER ONLY ONE CAUSE PER LINE FOR (A), (B), AND (C).) PART I. IMMEDIATE CAUSE: (A) COVID 19 PNEUMONIA DAYS DUE TO OR AS A CONSEQUENCE OF: (B) HYPOXIC RESPIRATORY FAILURE DAYS DUE TO OR AS A CONSEQUENCE OF: (C) ACUTE RENAL FAILURE (D) HOSPITAL ACQUIRED PNEUMONIA DAYS, (D) DAYS PART II. OTHER SIGNIFICANT CONDITIONS CONTRIBUTING TO DEATH BUT NOT RELATED TO CAUSE GIVEN IN PART I (A): <<<>>>> DID TOBACCO USE CONTRIBUTE TO DEATH? 0 <input checked="" type="checkbox"/> NO 1 <input type="checkbox"/> YES 2 <input type="checkbox"/> PROBABLY 3 <input type="checkbox"/> UNKNOWN			
31A. IF INJURY, DATE: MONTH DAY YEAR HOUR:		31B. INJURY LOCALITY: (City or town and county and state)	
31C. DESCRIBE HOW INJURY OCCURRED:		31D. PLACE OF INJURY:	
31E. INJURY AT WORK? NO YES <input type="checkbox"/> 0 <input type="checkbox"/> 1		31F. DATE OF DELIVERY: MONTH DAY YEAR	
31G. IF TRANSPORTATION INJURY, SPECIFY: 1 <input type="checkbox"/> Driver/Operator 2 <input type="checkbox"/> Passenger 3 <input type="checkbox"/> Pedestrian 4 <input type="checkbox"/> OTHER (specify)		32. WAS DECEDENT HOSPITALIZED IN LAST 2 MONTHS? NO YES <input type="checkbox"/> 0 <input type="checkbox"/> 1	
33A. IF FEMALE: 0 <input checked="" type="checkbox"/> Not pregnant within last year 1 <input type="checkbox"/> Pregnant at time of death 2 <input type="checkbox"/> Not pregnant, but pregnant within 42 days of death 3 <input type="checkbox"/> Not pregnant, but pregnant 43 days to 1 year before death 4 <input type="checkbox"/> Unknown if pregnant within past year		33B. DATE OF DELIVERY: MONTH DAY YEAR	

EXHIBIT 37

EXHIBIT 37

REGISTER NUMBER
3747

131-2021-00075592

31F. IF TRANSPORTATION INJURY, SPECIFY: 1 <input type="checkbox"/> Driver/Operator 2 <input type="checkbox"/> Passenger 3 <input type="checkbox"/> Pedestrian 4 <input type="checkbox"/> OTHER (specify) _____		32. WAS DECEDENT HOSPITALIZED IN LAST 2 MONTHS? NO <input checked="" type="checkbox"/> YES <input type="checkbox"/>		33A. IF FEMALE: 0 <input type="checkbox"/> Not pregnant within last year 1 <input type="checkbox"/> Pregnant at time of death 3 <input type="checkbox"/> Not pregnant, but pregnant 43 days to 1 year before death 4 <input type="checkbox"/> Unknown if pregnant within past year		33B. DATE OF DELIVERY: MONTH _____ DAY _____ YEAR _____	
---	--	---	--	---	--	---	--